[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"\"}":3,"_public_publisher_byId_6923c4fb-d265-4349-b8bf-a665ac6340dd":656,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"totalCitation\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:6923c4fb-d265-4349-b8bf-a665ac6340dd,\"}":748},{"meta":4,"data":6},{"total":5},"117",[7,60,176,207,299,413,445,480,543,572],{"id":8,"createTime":9,"updateTime":10,"relativeEntities":11,"slug":12,"properties":13,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":27,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":29,"subjectFields":30,"manageAffiliations":31,"indexDatabases":32,"url":33,"thumbnailPath":34,"statistic":35,"gsStatistic":26,"type":26,"analyzePriority":26},"5a09599f-54d1-44c3-8f16-3847ac552024","2023-08-17T04:28:50.832+00:00","2025-10-13T23:58:52.517+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Truy%E1%BB%81n-nhi%E1%BB%85m-Vi%E1%BB%87t-Nam",{"country":14,"issn":16,"introduce":18,"title":21},{"VOID":15},"VN",{"VOID":17},"08667829",{"EN":19,"VI":20},"{\"ops\":[{\"insert\":\"Vietnam Journal of Infectious Diseases is a social - professional forum of the Vietnam Society for Infectious Diseases, whose responsibility is to introduce the researches, the scientific advances in Vietnam and from the world; to contribute to the improvement of knowledges for health care staffs about clinic, treatment, guideline, prevention, epidemiology for infectious diseases, HIV\u002FAIDS and community health care; to provide, exchange and publish scientific information to the public accurately and promptly.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Vietnam Journal of Infectious Diseases publishes in the whole country; serves the professional work for researchers, clinical staffs, administrators, undergraduate and postgraduate students who are working and studying in the infections, tropical diseases and HIV\u002FAIDS from central to local levels, also organizations and individuals in the world who are interested in infectious and tropical diseases and prevention for HIV\u002FAIDS.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Editor in Chief:\"},{\"attributes\":{\"header\":4},\"insert\":\"\\n\"},{\"insert\":\"Prof. Dr. Nguyen Van Kinh. - Chairman of Editorial Board\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"insert\":\"Prof. Dr. Nguyen Van Mui.\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Headquarter:\"},{\"attributes\":{\"header\":4},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Address:\"},{\"insert\":\" Level 6, National Hospital for Tropical Diseases, No. 78 Giai Phong Street, Dong Da District, Hanoi city, Vietnam.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Tel:\"},{\"insert\":\" \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:02435765464\"},\"insert\":\"02435765464\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:0913552672\"},\"insert\":\"0913552672\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:0913228072\"},\"insert\":\"0913228072\"},{\"insert\":\".\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Email\"},{\"insert\":\": \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Findex\u002Fadmin\u002Fcontexts\u002Fmailto:tungphamvan52@gmail.com\"},\"insert\":\"tungphamvan52@gmail.com\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Fmailto:tapchitruyennhiem@gmail.com\"},\"insert\":\"tapchitruyennhiem@gmail.com\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Bank account:\"},{\"insert\":\" 0021000275119, Vietcombank Hanoi Branch. Transaction office No. 7, 402 Tran Khat Chan, Hai Ba Trung District, Hanoi city, Vietnam.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"\\n\"}]}","{\"ops\":[{\"insert\":\"Tạp chí Truyền nhiễm Việt Nam là cơ quan ngôn luận của Hội Truyền nhiễm Việt Nam, chịu sự lãnh đạo, chỉ đạo trực tiếp của Thường vụ Ban Chấp hành Hội Truyền nhiễm Việt Nam; sự kiểm tra, giám sát về nghiệp vụ báo chí của các cơ quan chức năng quản lý báo chí thuộc Bộ Thông tin và Truyền thông và Ban Tuyên giáo Trung ương Đảng.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Tạp chí có trách nhiệm giới thiệu các công trình nghiên cứu khoa học, những tiến bộ khoa học trên thế giới và trong nước, góp phần nâng cao kiến thức khoa học cho cán bộ y tế về lâm sàng, điều trị, hướng dẫn, dự phòng, dịch tễ học các bệnh truyền nhiễm, HIV\u002FAIDS và chăm sóc sức khỏe cộng đồng; cung cấp, trao đổi, phổ biến các thông tin khoa học tới công chúng chính xác và kịp thời.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Tạp chí xuất bản 03 tháng\u002F01 kỳ và được phát hành qua Bưu điện và tự phát hành trong phạm vi toàn quốc.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Lãnh đạo Tạp chí: \"},{\"attributes\":{\"header\":4},\"insert\":\"\\n\"},{\"insert\":\"Tổng Biên tập: ThS.BSCKII Nguyễn Trung Cấp\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"insert\":\"Phó Tổng Biên tập:\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"insert\":\"            TS.BSCKII Phạm Ngọc Thạch\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Trụ sở tòa soạn:\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Địa chỉ: Tầng 6, Bệnh viện Bệnh Nhiệt đới Trung ương, 78 đường Giải Phóng, phường Phương Mai, quận Đống Đa, thành phố Hà Nội.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Điện thoại:\"},{\"insert\":\" \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:02435765464\"},\"insert\":\"02435765464\"},{\"insert\":\" - \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:0913228072\"},\"insert\":\"0913228072\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Email\"},{\"insert\":\": \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Findex\u002Fadmin\u002Fcontexts\u002Fmailto:tungphamvan52@gmail.com\"},\"insert\":\"tungphamvan52@gmail.com\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Fmailto:tapchitruyennhiem@gmail.com\"},\"insert\":\"tapchitruyennhiem@gmail.com\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Tài khoản:\"},{\"insert\":\" Số 0021000275119 Ngân hàng Ngoại thương Việt Nam, chi nhánh Hà Nội (Vietcombank Hà Nội). Phòng giao dịch số 7, 402 Trần Khát Chân, quận Hai Bà Trưng, Thành phố Hà Nội.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"\\n\"}]}",{"EN":22,"VI":23},"Vietnam Journal of Infectious Diseases","Tạp chí Truyền nhiễm Việt Nam","PUBLISHER","VERIFIED",null,"Admin update database","PENDING",51,[],[],[],"https:\u002F\u002Ftruyennhiemvietnam.vn\u002Findex.php\u002Fvjid","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F5a09599f-54d1-44c3-8f16-3847ac552024\u002Fadb0e52bf25e0de580fd4289519cb8bf.jpg",{"impactFactor":36,"impactFactorByYear":37,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":41,"totalPublicationByYear":42,"totalCitation":48,"totalCitationByYear":49,"totalCitationPerPublication":54,"totalCitationPerPublicationByYear":55,"hindexLast5Year":59,"hindex":59},0,{"2022":38,"2023":39,"2024":40},0.01,0.03,0.13,315,{"2020":43,"2021":44,"2022":45,"2023":46,"2024":47},63,58,57,65,72,43,{"2020":50,"2021":51,"2022":52,"2023":53},8,15,9,11,0.14,{"2020":40,"2021":56,"2022":57,"2023":58},0.26,0.16,0.17,3,{"id":61,"createTime":62,"updateTime":63,"relativeEntities":64,"slug":65,"properties":66,"entityType":24,"verifyStatus":25,"verifyTime":78,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":79,"subjectFields":80,"manageAffiliations":81,"indexDatabases":136,"url":137,"thumbnailPath":26,"statistic":138,"gsStatistic":155,"type":175,"analyzePriority":26},"25b6bd10-676c-40c0-8dc3-356d1679a284","2023-05-19T02:22:33.430+00:00","2026-06-18T23:33:57.141+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Y-D%C6%B0%E1%BB%A3c-h%E1%BB%8Dc-C%E1%BA%A7n-Th%C6%A1",{"country":67,"issn":68,"introduce":70,"title":73,"gsId":76},{"VOID":15},{"VOID":69},"23541210",{"EN":71,"VI":72},"\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">04\u002F10\u002F2015 Ministry of Information and Communications allowed Can Tho journal of medicine and pharmacy to operate (102 \u002FGP-BTTTT)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">07\u002F16\u002F2015 Can Tho journal of medicine and pharmacy is internationally recognized: ISSN 2354-1210\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">In 2016, The journal has been included in the list of medical science journals by The State Council for professorship which is awarded a work score of 0-0.5 points for a published article.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Can Tho Journal of Medicine and Pharmacy welcome original works that haven’t been submitted or published in other medical journals. Posts must contain content related to one of the journal’s categories.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The content published\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The journal is divided into 3 categories:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Scientific research article: are valuable scientific works, which have been researched and accepted.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Overview of medicine, biology and pharmacy: serving the objective of continuing training in the fields of medicine, biology and pharmacy; to systematize classical and modern knowledge.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Update information on new knowledge about medicine, biology, pharmacy in the country and in the world.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Scope\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Publication and introduction of scientific research in the fields:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Medicine (internal medicine, surgery, pediatrics, obstetrics and gynecology, odonto-stomatology, laboratory, oncology, traditional medicine, nursing).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Biology (genetics, biotechnology).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Pharmacology (pharmaceutics, drug quality analysis-control, synthetic pharmaceutical chemistry, biochemistry, pharmacognosy, botany, clinical pharmacy).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- To enhance the quality of undergraduate, postgraduate education, scientifically researching and meet the necessary treatment in hospital.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Introducing the updated domestic and oversea information about science technology to promote scientific research and exchanging technology in local, other universities.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Exchanging pharmaceutical and medical information for social health developing in the Mekong Delta and Vietnam.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The object\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Postgraduate students, student of Can Tho University of Medicine and Pharmacy, scientists from schools, research institutes, hospitals, health centers, pharmaceutical companies of the Mekong Delta; other provinces and regions in Vietnam and other country.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Address\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Headquarters of Can Tho Journal of Medicine and Pharmacy, located Scientific Research and International Cooperation Office: 179 Nguyen Van Cu Street, An Khanh Ward, Ninh Kieu District, Can Tho City, Vietnam.\u003C\u002Fspan>\u003C\u002Fp>","\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Ngày 16\u002F7\u002F2015, Tạp chí Y Dược học Cần Thơ được cấp chỉ số quốc tế: ISSN 2354-1210.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Từ tháng 4\u002F2016, Tạp chí đã được Hội đồng Giáo sư ngành Y đưa vào danh sách các tạp chí khoa học Y học được tính điểm công trình 0-0,5 điểm cho một bài báo đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Năm 2020 Tạp chí Y Dược học Cần Thơ đã được phê duyệt vào danh mục của các Hội đồng Giáo sư ngành Dược học được tính điểm công trình 0-0,5 điểm cho một bài báo đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ ra 12 số\u002Fnăm, 180-200 trang\u002Fsố.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Từ tháng 12\u002F2022 Tạp chí Y Dược học Cần Thơ là thành viên của hệ thống Crossref và từ tháng 01\u002F2023 tạp chí thực hiện bình duyệt online kín 2 chiều nhằm tăng tính minh bạch, tin cậy của các công trình nghiên cứu khoa học và đảm bảo tốt nhất chất lượng khoa học của bài viết.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tôn chỉ, mục đích và phạm vi của tạp chí\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tôn chỉ và mục đích hoạt động của tạp chí: xuất bản nhằm mục đích phổ biến kết quả từ các đề tài nghiên cứu khoa học; giao lưu trao đổi khoa học, chia sẻ kinh nghiệm, học tập, đồng thời cập nhật thông tin khoa học mới trong các lĩnh vực y, sinh, dược học trong và ngoài nước.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Phạm vi của tạp chí: Tạp chí xuất bản được chia thành 3 chuyên mục: (i) Bài báo nghiên cứu khoa học là kết quả công trình nghiên cứu khoa học có giá trị đã được triển khai nghiên cứu, (ii) Bài tổng quan y, sinh, dược học: phục vụ mục tiêu đào tạo liên tục trong lĩnh vực y, sinh, dược học; nhằm hệ thống hóa những kiến thức kinh điển và hiện đại; (iii) Thông tin cập nhật kiến thức mới về y, sinh, dược học trong nước và trên thế giới.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Chính sách truy cập mở\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ áp dụng chính sách truy cập mở đối với các bài báo đã xuất bản đến với độc giả, nhằm mở rộng cơ hội tiếp cận các kết quả nghiên cứu chất lượng cao và tăng cường trao đổi kiến thức. Tạp chí đăng tải trực tuyến (miễn phí) toàn văn các bài báo được công bố trên website của Tạp chí (https:\u002F\u002Ftapchi.ctump.edu.vn).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đạo đức xuất bản\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ cam kết tuân thủ đạo đức xuất bản phù hợp với các hướng dẫn và tiêu chuẩn của the Committee on Publication Ethics (COPE), tuân thủ các nguyên tắc của COPE’s Core Practices, Best Practices Guidelines for Journal Editors và Guidelines on Good Publication Practices.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Bản thảo bài báo chỉ được chấp nhận khi được tác giả chịu trách nhiệm chính cam kết các nội dung sau: Các nội dung của bản thảo chưa được đăng tải toàn bộ hoặc một phần ở các tạp chí khác; Tất cả các tác giả đều có đóng góp một cách đáng kể vào quá trình nghiên cứu hoặc chuẩn bị bản thảo và cùng chịu trách nhiệm về các nội dung của bản thảo; Tuân thủ các biện pháp đảm bảo đạo đức nghiên cứu (ví dụ thỏa thuận đồng ý tham gia nghiên cứu).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Cam kết bảo mật\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí cam kết thực hiện và tuân thủ các quy định của luật và các văn bản hướng dẫn liên quan đến bảo mật thông tin cá nhân trên không gian mạng. Các thông tin mà người dùng (tác giả, độc giả, biên tập viên, người phản biện) nhập vào các biểu mẫu trên Hệ thống Quản lý xuất bản trực tuyến của tạp chí chỉ được sử dụng vào các mục đích đã được tuyên bố rõ ràng và sẽ không được cung cấp cho bất kỳ bên thứ ba nào khác, hay dùng vào bất kỳ mục đích nào khác.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Phí gửi bài\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Lệ phí gửi đăng bài: 1.000.000đ\u002Fbài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Lệ phí gửi đăng nhanh: 1.500.000đ\u002Fbài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đối với tác giả là cán bộ viên chức thuộc Trường Đại học Y Dược Cần Thơ thì được hỗ trợ 50% lệ phí gửi đăng bài.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đối với sinh viên thực hiện đề tài nghiên cứu khoa học cấp trường được hỗ trợ 100% lệ phí đăng bài ( Tác giả gửi đính kèm “ Quyết định về việc giao tổ chức thực hiện đề tài nghiên cứu khoa học cấp Trường của sinh viên”).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Hình thức nộp lệ phí:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Tiền mặt:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Nộp trực tiếp tại Phòng Tài chính - Kế toán, Trường Đại học Y Dược Cần Thơ, số 179 Nguyễn Văn Cừ, P. An Khánh, Q. Ninh Kiều, thành phố Cần Thơ.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Chuyển khoản:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tên Tài khoản: Trường ĐHYD Cần Thơ, Số TK: 0111000115668, tại ngân hàng Vietcombank chi nhánh Cần Thơ.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Thời gian: Áp dụng từ ngày 01\u002F02\u002F2023.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">* Phí gửi bài không được hoàn trả khi bài viết bị từ chối hoặc tác giả xin rút bài viết.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Quy trình phản biện bài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ thực hiện quy trình phản biện kín hai chiều nghiêm ngặt. Danh tính của những người phản biện không được tiết lộ cho các tác giả và ngược lại. Quy trình thẩm định bài báo đăng gồm các bước sau:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tiếp nhận bản thảo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tác giả liên hệ gửi bản thảo đến Tạp chí qua hệ thống trực tuyến tại website: https:\u002F\u002Ftapchi.ctump.edu.vn. Hướng dẫn về cách đăng ký, gửi bài và chuẩn bị bản thảo được cung cấp trên website của Tạp chí.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Sàng lọc sơ bộ\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Sau khi Tòa soạn nhận được bài báo của tác giả, Ban Thư ký sẽ tiến hành kiểm tra sơ bộ bài báo (các yêu cầu về nội dung và hình thức). Những bài báo không đúng quy cách hoặc có nội dung không phù hợp hoặc vi phạm bản quyền sẽ bị từ chối (Ban Thư ký thông báo phản hồi đến tác giả trong vòng 1 tuần). Những bài báo đủ điều kiện, được Ban Thư ký tòa soạn chuyển đến Ban Biên tập có cùng chuyên môn với nội dung bài báo để đề xuất người phản biện. Thời gian kể từ khi Ban Biên tập nhận bài báo đến khi đề xuất người phản biện bài báo chậm nhất là 5 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Vòng phản biện\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Ban Thư ký gửi bài và yêu cầu phản biện đến 02 phản biện độc lập.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Các phản biện gởi nhận xét cho Ban Thư ký. Thời gian từ khi gửi bài cho phản biện đến khi nhận ý kiến của phản biện tối đa là 20 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Xử ký kết quả phản biện\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Nếu ý kiến đồng ý cho đăng và không cần chỉnh sửa, Ban Thư ký tiếp tục đăng bài theo qui trình.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Nếu ý kiến đồng ý đăng và cần chỉnh sửa, Ban Thư ký sẽ thông tin đến tác giả chỉnh sửa theo yêu cầu của người phản biện. Thời gian chỉnh sửa và gửi lại kéo dài không quá 2 tuần, từ khi tác giả bài báo nhận được thông tin (Quá trình này có thể lặp lại tối đa 2 lần\u002F1 bài báo). Khi có sự thống nhất, đồng ý của người phản biện; bài báo được tiếp tục đăng theo qui trình.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">3. Những bài báo có chất lượng không đạt yêu cầu, cả 2 phản biện không đồng ý cho đăng sẽ bị Tòa soạn từ chối đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Xuất bản\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Ban Thư ký tổng hợp các bản thảo đã được tác giả hoàn thiện sau thẩm định trình Ban Biên tập xem xét, Tổng Biên tập phê duyệt, quyết định bài đăng theo các tiêu chí: sự phù hợp nội dung với tôn chỉ và mục đích, thể loại bài viết (ưu tiên các bài có bài có nghiên cứu chuyên sâu, hàm lượng khoa học cao), đóng góp mới bài báo, bài báo được ưu tiên đăng trong số gần nhất của Tạp chí theo thứ tự: tính thời sự, chất lượng bài báo và thời gian gửi bài.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Ban Biên tập và Ban Thư ký biên tập bản thảo, chế bản, đọc rà soát lỗi. Thời gian hoàn thành từ 10-15 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">3. Ban Thư ký có trách nhiệm thông báo cho tác giả bài báo (bằng e-mail) về tình hình phê duyệt bài báo, thời gian, số kỳ, tập xuất bản bài báo theo qui định.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">4. Danh sách bài báo theo số Tạp chí được in ấn và phát hành trong năm định kỳ được công bố chính thức trên website: https:\u002F\u002Ftapchi.ctump.edu.vn\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>",{"EN":74,"VI":75},"Cantho Journal of Medicine and Pharmacy","Tạp chí Y Dược học Cần Thơ",{"VOID":77},"wcQ1uqwAAAAJ","2023-05-30T08:17:21.868+00:00",32,[],[82],{"id":83,"createTime":84,"updateTime":85,"relativeEntities":86,"slug":87,"properties":88,"entityType":98,"verifyStatus":25,"verifyTime":99,"verifyNote":26,"syncStatus":28,"languages":100,"translateLanguages":26,"viewCount":103,"url":104,"parentIds":105,"statistic":106},"6413896b-eca9-442b-a73f-182a58a0ce40","2023-06-12T14:59:13.446+00:00","2026-06-19T02:29:32.871+00:00",[],"Tr%C6%B0%E1%BB%9Dng-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Y-D%C6%B0%E1%BB%A3c-C%E1%BA%A7n-Th%C6%A1",{"country":89,"title":90,"address":93,"abbreviation":96},{"VOID":15},{"EN":91,"VI":92},"Can Tho University of Medicine and Pharmacy","Trường Đại học Y Dược Cần Thơ",{"VI":94,"EN":95},"Số 179, đường Nguyễn Văn Cừ, phường An Khánh, quận Ninh Kiều, thành phố Cần Thơ, Việt Nam","No 179, Nguyen Van Cu street, An Khanh ward, Ninh Kieu district, Can Tho city, Vietnam",{"VOID":97},"ctump","AFFILIATION","2023-08-01T14:07:27.977+00:00",[101,102],"VI","EN",12,"http:\u002F\u002Fwww.ctump.edu.vn\u002F",[],{"impactFactor":36,"impactFactorByYear":107,"i10Index":111,"i10IndexLast5Year":59,"totalPublication":112,"totalPublicationByYear":113,"totalCitation":122,"totalCitationByYear":123,"totalCitationPerPublication":128,"totalCitationPerPublicationByYear":129,"hindexLast5Year":135,"hindex":135},{"2022":108,"2023":109,"2024":110,"2025":38},0.1,0.05,0.07,4,1489,{"2013":114,"2014":115,"2015":115,"2016":111,"2017":115,"2018":59,"2019":114,"2020":116,"2021":117,"2022":118,"2023":119,"2024":120,"2025":121,"2026":111},2,1,10,84,281,680,260,156,313,{"2013":59,"2014":114,"2018":124,"2021":125,"2022":126,"2023":127},17,36,123,132,0.21,{"2013":130,"2014":114,"2018":131,"2021":132,"2022":133,"2023":134},1.5,5.67,0.43,0.44,0.19,6,[],"https:\u002F\u002Ftapchi.ctump.edu.vn\u002Findex.php\u002Fctump",{"impactFactor":36,"impactFactorByYear":139,"i10Index":114,"i10IndexLast5Year":114,"totalPublication":140,"totalPublicationByYear":141,"totalCitation":147,"totalCitationByYear":148,"totalCitationPerPublication":151,"totalCitationPerPublicationByYear":152,"hindexLast5Year":135,"hindex":135},{"2022":38,"2023":36,"2024":39,"2025":38},1956,{"0":114,"2019":114,"2020":50,"2021":142,"2022":143,"2023":144,"2024":145,"2025":146},76,403,789,305,371,524,{"0":114,"2019":135,"2021":124,"2022":149,"2023":150,"2024":111,"2025":114},287,206,0.27,{"0":115,"2019":59,"2021":153,"2022":154,"2023":56,"2024":38,"2025":38},0.22,0.71,{"impactFactor":26,"impactFactorByYear":26,"i10Index":114,"i10IndexLast5Year":114,"totalPublication":156,"totalPublicationByYear":157,"totalCitation":163,"totalCitationByYear":164,"totalCitationPerPublication":169,"totalCitationPerPublicationByYear":170,"hindexLast5Year":135,"hindex":135},461,{"0":158,"2019":114,"2021":159,"2022":160,"2023":161,"2024":158,"2025":162},7,37,296,107,5,419,{"2021":59,"2022":59,"2023":165,"2024":166,"2025":167,"2026":168},71,126,171,41,0.91,{"2021":171,"2022":38,"2023":172,"2024":173,"2025":174},0.08,0.66,18,34.2,"JOURNAL",{"id":177,"createTime":178,"updateTime":179,"relativeEntities":180,"slug":181,"properties":182,"entityType":24,"verifyStatus":25,"verifyTime":193,"verifyNote":26,"syncStatus":28,"languages":194,"translateLanguages":26,"viewCount":36,"subjectFields":195,"manageAffiliations":196,"indexDatabases":197,"url":198,"thumbnailPath":26,"statistic":26,"gsStatistic":199,"type":175,"analyzePriority":26},"f8d0bf97-8d89-482e-b58c-2fc481a0b79b","2025-10-27T06:27:08.591+00:00","2026-06-18T23:33:41.667+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Khoa-h%E1%BB%8Dc-v%C3%A0-C%C3%B4ng-ngh%E1%BB%87-nhi%E1%BB%87t-%C4%91%E1%BB%9Bi",{"country":183,"introduce":184,"gsId":186,"title":188,"issn":191},{"VOID":15},{"EN":185},"\u003Cp style=\"text-align:justify;\">     Journal of Tropical Science and Engineering (JTSE) is a multidisciplinary scientific journal, licensed to operate as a print journal in 2012 and an electronic journal in 2024 (License No.1479\u002FGP-BTTTT dated August 20, 2012 and No.91\u002FGP-BTTTT dated April 9, 2024 issued by the Ministry of Information and Communications of Vietnam). The JTSE is headquartered in Hanoi.\u003C\u002Fp>\u003Cp style=\"text-align:justify;\">        The JTSE is published every 3 months (4 issues\u002Fyear), publishing research results and overview articles in 3 groups of fields: Tropical Ecology and Environment; Chemistry and Material Sciences; Biomedicine and Pharmacy. In 2022, the JTSE registered the international identifier Digital Object Identifier (DOI): 10.58334\u002Fvrtc.jtst and assigned DOI codes to all articles of the journal. The members of the Editorial Board of the JTSE are prestigious scientists and leading scientists from Vietnam and many countries in the world. The JTSE has been recognized by the Vietnam State Council for Professorship to score scientific articles in Chemistry, Medicine and Biology with scores ranging from 0-0.75 points.\u003C\u002Fp>\u003Cp style=\"text-align:justify;\">      Currently, the JTSE is building and perfecting a set of criteria and making efforts to join the List of prestigious  international journals with a roadmap to enter Scopus and SCIE in the coming time.\u003C\u002Fp>",{"VOID":187},"MS2_GJQAAAAJ",{"VI":189,"EN":190},"Tạp chí Khoa học và Công nghệ nhiệt đới","Journal of Tropical Science and Engineering",{"VOID":192},"08667535","2025-10-27T06:27:25.058+00:00",[101,102],[],[],[],"https:\u002F\u002Ftapchikhcnnd.com.vn",{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":200,"totalPublicationByYear":201,"totalCitation":161,"totalCitationByYear":203,"totalCitationPerPublication":153,"totalCitationPerPublicationByYear":205,"hindexLast5Year":114,"hindex":114},481,{"0":115,"2020":115,"2021":115,"2022":114,"2024":115,"2025":202,"2026":115},474,{"2017":114,"2018":115,"2019":111,"2020":162,"2021":162,"2022":116,"2023":50,"2024":162,"2025":204,"2026":52},52,{"2020":162,"2021":162,"2022":162,"2024":162,"2025":206,"2026":52},0.11,{"id":208,"createTime":209,"updateTime":210,"relativeEntities":211,"slug":212,"properties":213,"entityType":24,"verifyStatus":25,"verifyTime":221,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":222,"subjectFields":223,"manageAffiliations":224,"indexDatabases":225,"url":226,"thumbnailPath":26,"statistic":227,"gsStatistic":276,"type":175,"analyzePriority":26},"a3d1e82a-57e2-40f9-940e-f5fa8b9ef64a","2023-06-01T07:11:26.039+00:00","2026-06-18T23:33:28.573+00:00",[],"VNU-Journal-of-Science-Earth-and-Environmental-Sciences",{"issn":214,"title":216,"country":218,"gsId":219},{"VOID":215},"26159279",{"EN":217},"VNU Journal of Science: Earth and Environmental Sciences",{"VOID":15},{"VOID":220},"UmXD8vEAAAAJ","2023-06-01T07:17:59.210+00:00",27,[],[],[],"https:\u002F\u002Fjs.vnu.edu.vn\u002FEES",{"impactFactor":36,"impactFactorByYear":228,"i10Index":234,"i10IndexLast5Year":36,"totalPublication":235,"totalPublicationByYear":236,"totalCitation":246,"totalCitationByYear":247,"totalCitationPerPublication":261,"totalCitationPerPublicationByYear":262,"hindexLast5Year":103,"hindex":103},{"2010":229,"2012":40,"2013":230,"2014":230,"2015":231,"2016":54,"2017":171,"2018":109,"2019":110,"2020":57,"2021":232,"2022":233,"2023":151,"2024":58},0.02,0.04,0.09,0.31,0.4,19,656,{"2008":237,"2009":238,"2010":239,"2011":238,"2012":240,"2013":241,"2014":239,"2015":242,"2016":243,"2017":244,"2018":245,"2019":165,"2020":125,"2021":168,"2022":125,"2023":222,"2024":111},23,24,22,28,25,20,146,29,78,1038,{"2008":248,"2009":249,"2010":250,"2011":251,"2012":252,"2013":253,"2014":254,"2015":255,"2016":256,"2017":257,"2018":161,"2019":258,"2020":259,"2021":29,"2022":260},119,64,66,86,38,73,59,31,129,39,97,53,26,1.58,{"2008":263,"2009":264,"2010":59,"2011":265,"2012":266,"2013":267,"2014":268,"2015":269,"2016":270,"2017":271,"2018":272,"2019":272,"2020":273,"2021":274,"2022":275},5.17,2.67,3.58,1.36,2.92,2.68,1.55,0.88,1.34,1.37,1.47,1.24,0.72,{"impactFactor":26,"impactFactorByYear":26,"i10Index":173,"i10IndexLast5Year":135,"totalPublication":277,"totalPublicationByYear":278,"totalCitation":279,"totalCitationByYear":280,"totalCitationPerPublication":288,"totalCitationPerPublicationByYear":289,"hindexLast5Year":158,"hindex":298},113,{"2007":114,"2008":103,"2009":173,"2010":116,"2011":51,"2012":239,"2013":103,"2014":162,"2015":53,"2016":135},616,{"2009":162,"2010":114,"2011":52,"2012":124,"2013":222,"2014":255,"2015":48,"2016":44,"2017":281,"2018":282,"2019":259,"2020":283,"2021":284,"2022":285,"2023":286,"2024":257,"2025":287,"2026":59},54,60,49,47,34,44,33,5.45,{"2009":290,"2010":291,"2011":292,"2012":293,"2013":294,"2014":295,"2015":296,"2016":297},0.28,0.2,0.6,0.77,2.25,6.2,3.91,9.67,14,{"id":300,"createTime":301,"updateTime":302,"relativeEntities":303,"slug":304,"properties":305,"entityType":24,"verifyStatus":25,"verifyTime":316,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":234,"subjectFields":317,"manageAffiliations":318,"indexDatabases":388,"url":389,"thumbnailPath":390,"statistic":391,"gsStatistic":409,"type":175,"analyzePriority":26},"a7166325-6c9e-4db3-8a59-7c879701a372","2023-07-31T04:28:49.231+00:00","2026-06-18T23:33:22.428+00:00",[],"VNU-Journal-of-Science-Policy-and-Management-Studies",{"country":306,"issn":307,"eissn":309,"title":311,"gsId":314},{"VOID":15},{"VOID":308},"26159295",{"VOID":310},"25881116",{"EN":312,"VI":313},"VNU Journal of Science: Policy and Management Studies","Tạp chí Nghiên cứu Chính sách và Quản lý",{"VOID":315},"xKW2E_cAAAAJ","2023-08-01T03:23:46.688+00:00",[],[319],{"id":320,"createTime":321,"updateTime":322,"relativeEntities":323,"slug":324,"properties":325,"entityType":98,"verifyStatus":25,"verifyTime":335,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":336,"url":337,"parentIds":338,"statistic":339},"12466116-8f60-4b01-8faf-2411483a0977","2023-05-30T09:37:38.472+00:00","2026-06-19T02:14:28.352+00:00",[],"Vietnam-National-University",{"country":326,"title":327,"abbreviation":330,"address":332},{"VOID":15},{"EN":328,"VI":329},"Vietnam National University, Hanoi","Đại học Quốc gia Hà Nội",{"VOID":331},"VNU",{"VI":333,"EN":334},"Số 144 Xuân Thủy, Phường Dịch Vọng Hậu, Quận Cầu Giấy, Hà Nội, Việt Nam","No. 144 Xuan Thuy Street, Dich Vong Hau Ward, Cau Giay District, Hanoi, Vietnam","2023-08-02T13:58:17.029+00:00",16,"http:\u002F\u002Fwww.vnu.edu.vn\u002F",[],{"impactFactor":36,"impactFactorByYear":340,"i10Index":285,"i10IndexLast5Year":162,"totalPublication":344,"totalPublicationByYear":345,"totalCitation":354,"totalCitationByYear":355,"totalCitationPerPublication":368,"totalCitationPerPublicationByYear":369,"hindexLast5Year":336,"hindex":336},{"2014":109,"2015":231,"2016":231,"2017":206,"2018":341,"2019":110,"2020":342,"2021":343,"2022":171,"2023":231,"2024":110,"2025":39},0.06,0.18,0.35,1247,{"2003":115,"2004":115,"2005":114,"2006":59,"2007":111,"2008":162,"2009":59,"2010":50,"2011":124,"2012":336,"2013":260,"2014":244,"2015":250,"2016":281,"2017":346,"2018":347,"2019":348,"2020":349,"2021":350,"2022":351,"2023":352,"2024":353,"2025":255,"2026":50},94,88,83,67,176,185,187,93,1644,{"2004":111,"2005":115,"2006":52,"2007":298,"2008":356,"2009":298,"2010":286,"2011":357,"2012":244,"2013":358,"2014":359,"2015":360,"2016":361,"2017":362,"2018":363,"2019":364,"2020":365,"2021":366,"2022":367,"2023":367,"2024":162},13,81,48,70,151,115,109,259,174,181,121,101,1.32,{"2004":111,"2005":370,"2006":59,"2007":371,"2008":372,"2009":373,"2010":374,"2011":375,"2012":376,"2013":377,"2014":378,"2015":379,"2016":380,"2017":381,"2018":382,"2019":383,"2020":384,"2021":385,"2022":386,"2023":387,"2024":109},0.5,3.5,2.6,4.67,5.5,4.76,1.81,1.85,2.41,2.29,2.13,1.16,2.94,2.1,2.7,0.69,0.55,0.54,[],"https:\u002F\u002Fjs.vnu.edu.vn\u002FPaM","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002Fa7166325-6c9e-4db3-8a59-7c879701a372\u002Fecfe83f4bcc60c7023ae04d8900fe0ac.jpg",{"impactFactor":36,"impactFactorByYear":392,"i10Index":111,"i10IndexLast5Year":36,"totalPublication":394,"totalPublicationByYear":395,"totalCitation":399,"totalCitationByYear":400,"totalCitationPerPublication":293,"totalCitationPerPublicationByYear":403,"hindexLast5Year":158,"hindex":158},{"2018":109,"2019":171,"2020":393,"2021":108,"2022":54,"2023":206,"2024":54},0.23,320,{"2015":50,"2016":239,"2017":286,"2018":396,"2019":397,"2020":159,"2021":398,"2022":168,"2023":79,"2024":255},30,35,40,247,{"2015":115,"2016":242,"2017":401,"2018":222,"2019":402,"2020":79,"2021":239,"2022":50,"2023":116},77,50,{"2015":404,"2016":169,"2017":405,"2018":406,"2019":407,"2020":408,"2021":386,"2022":291,"2023":232},0.12,1.75,0.9,1.43,0.86,{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":103,"totalPublicationByYear":410,"totalCitation":234,"totalCitationByYear":411,"totalCitationPerPublication":261,"totalCitationPerPublicationByYear":412,"hindexLast5Year":114,"hindex":59},{"2015":114,"2016":116},{"2016":115,"2017":114,"2018":114,"2019":59,"2020":114,"2021":59,"2022":114,"2023":114,"2024":115,"2026":115},{"2016":108},{"id":414,"createTime":415,"updateTime":416,"relativeEntities":417,"slug":418,"properties":419,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":238,"subjectFields":428,"manageAffiliations":429,"indexDatabases":430,"url":431,"thumbnailPath":26,"statistic":432,"gsStatistic":438,"type":175,"analyzePriority":26},"16e65a3f-d274-47dd-8691-56d76eb58c3d","2023-05-30T09:10:06.062+00:00","2026-06-18T23:33:17.679+00:00",[],"Vietnam-Journal-of-Otorhinolaryngology-Head-and-Neck-Surgery",{"country":420,"issn":421,"title":423,"gsId":426},{"VOID":15},{"VOID":422},"18593704",{"EN":424,"VI":425},"Vietnam Journal of Otorhinolaryngology - Head and Neck Surgery","Tạp chí Tai Mũi Họng Việt Nam",{"VOID":427},"L78B_eIAAAAJ",[],[],[],"https:\u002F\u002Ftapchitaimuihong.vn\u002Findex.php\u002Ftmh",{"impactFactor":36,"impactFactorByYear":433,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":434,"totalPublicationByYear":435,"totalCitation":111,"totalCitationByYear":436,"totalCitationPerPublication":230,"totalCitationPerPublicationByYear":437,"hindexLast5Year":115,"hindex":115},{"2024":229},95,{"2022":52,"2023":286,"2024":255,"2025":53},{"2023":111},{"2023":231},{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":240,"totalPublicationByYear":439,"totalCitation":234,"totalCitationByYear":440,"totalCitationPerPublication":441,"totalCitationPerPublicationByYear":442,"hindexLast5Year":114,"hindex":114},{"2023":53,"2024":116,"2025":135,"2026":115},{"2024":59,"2025":298,"2026":114},0.68,{"2024":443,"2025":444,"2026":114},0.3,2.33,{"id":446,"createTime":447,"updateTime":448,"relativeEntities":449,"slug":450,"properties":451,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":396,"subjectFields":460,"manageAffiliations":461,"indexDatabases":462,"url":463,"thumbnailPath":464,"statistic":465,"gsStatistic":472,"type":175,"analyzePriority":26},"25988add-c322-4eda-afda-63b1559bb824","2023-04-07T03:49:55.817+00:00","2026-06-18T23:32:23.776+00:00",[],"T%E1%BA%A1p%20ch%C3%AD%20Y%20-%20D%C6%B0%E1%BB%A3c%20h%E1%BB%8Dc%20qu%C3%A2n%20s%E1%BB%B1",{"country":452,"issn":453,"title":455,"gsId":458},{"VOID":15},{"VOID":454},"18590748",{"EN":456,"VI":457},"Journal of Military Pharmaco-medicine","Tạp chí Y - Dược học quân sự",{"VOID":459},"_pmQ8IEAAAAJ",[],[],[],"https:\u002F\u002Fjmpm.vn\u002Findex.php\u002Fjmpm","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F25988add-c322-4eda-afda-63b1559bb824\u002F09c6bc42157cf5ece95edc971ccddb52.jpg",{"impactFactor":36,"impactFactorByYear":466,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":467,"totalPublicationByYear":468,"totalCitation":135,"totalCitationByYear":470,"totalCitationPerPublication":38,"totalCitationPerPublicationByYear":471,"hindexLast5Year":115,"hindex":115},{"2023":229,"2024":38},475,{"2022":168,"2023":365,"2024":469,"2025":124},236,{"2022":114,"2023":111},{"2022":109,"2023":229},{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":277,"totalPublicationByYear":473,"totalCitation":401,"totalCitationByYear":474,"totalCitationPerPublication":441,"totalCitationPerPublicationByYear":475,"hindexLast5Year":59,"hindex":59},{"2015":115,"2018":114,"2019":115,"2020":115,"2021":59,"2022":103,"2023":159,"2024":287,"2025":237},{"2020":115,"2021":115,"2022":115,"2023":52,"2024":237,"2025":79,"2026":116},{"2020":115,"2021":476,"2022":171,"2023":477,"2024":478,"2025":479},0.33,0.24,0.7,1.39,{"id":481,"createTime":482,"updateTime":483,"relativeEntities":484,"slug":485,"properties":486,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":27,"syncStatus":28,"languages":496,"translateLanguages":26,"viewCount":45,"subjectFields":497,"manageAffiliations":498,"indexDatabases":525,"url":526,"thumbnailPath":527,"statistic":528,"gsStatistic":26,"type":26,"analyzePriority":26},"2b8d7b12-2d20-4777-be98-077f44f03c69","2023-09-07T07:40:58.286+00:00","2025-07-13T21:21:00.542+00:00",[],"VNU-Journal-of-Social-Sciences-and-Humanities",{"country":487,"issn":488,"introduce":490,"title":493},{"VOID":15},{"VOID":489},"23541172",{"EN":491,"VI":492},"{\"ops\":[{\"insert\":\"VNU Journal of Social Sciences and Humanities (ISSN 2354-1172) is a double-blind peer-reviewed journal published by University of Social Sciences and Humanities, Vietnam National University, Hanoi, Vietnam, under the publication permit no. 155\u002FGP-BTTTT, issued on 11\"},{\"attributes\":{\"script\":\"super\"},\"insert\":\"th \"},{\"insert\":\"May, 2015 by Ministry of Information and Communications. The journal publishes four Vietnamese issues and two English issues per year.\\nCurrently, there are 35 reputable professors in the editorial board. The main objectives of the journal include: providing an intellectual platform for Vietnamese and international scholars; promoting interdisciplinary studies in social sciences and humanities; becoming the leading journal in social sciences and humanities in Vietnam; being indexed by worldwide databases and having academic recognition internationally in the near future.\\nThe journal is currently indexed by Google Scholar, WorldCat, Open Archives, Cosmos Impact Factor, Advanced Sciences Index, Scientific Indexing Services, CrossRef, EBSCO Information Services and Vietnam National University’s digital archive.\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Journal of Social Sciences and Humanities-Vietnam\"},{\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"ISSN 2354-1172, email: tapchikhxhnv@gmail.com, tckhxhnv@vnu.edu.vn\"},{\"insert\":\"\\n\"}]}","{\"ops\":[{\"insert\":\"Được thành lập ngày 31\u002F8\u002F2015 (giấy phép hoạt động số 155\u002FGP-BVHTT ngày 11 tháng 5 năm 2015 của Bộ Thông tin và Truyền thông, mã số tiêu chuẩn quốc tế ISSN 2354-1172), Tạp chí Khoa học Xã hội và Nhân văn (Journal of Social Sciences and Humanities) là ấn phẩm khoa học chính thức, duy nhất của Trường Đại học Khoa học Xã hội và Nhân văn, ĐHQG Hà Nội, phát triển và kế thừa Chuyên san Khoa học Xã hội và Nhân văn, Tạp chí Khoa học, ĐHQG Hà Nội.\\nTạp chí xuất bản định kỳ (04 số tiếng Việt\u002Fnăm và 02 số tiếng Anh\u002Fnăm), có nhiệm vụ \"},{\"attributes\":{\"italic\":true},\"insert\":\"công bố, giới thiệu các công trình nghiên cứu khoa học khoa học xã hội và nhân văn của các tác giả là các nhà khoa học trong và ngoài nước, phục vụ giảng dạy, học tập và nghiên cứu khoa học\"},{\"insert\":\". Hội đồng biên tập của Tạp chí hiện bao gồm 33 nhà khoa học có uy tín trong nước và quốc tế. Tạp chí tập trung và ưu tiên đăng tải những bài báo theo định hướng của tinh thần cởi mở, sáng tạo, nhanh chóng vươn lên để tiếp cận và sánh ngang với các tạp chí có uy tín hàng đầu của khu vực và trên thế giới. Nội dung chính của Tạp chí bao gồm các Bài nghiên cứu (khoảng 6000 đến 15000 từ), các bài điểm sách, thông tin khoa học (khoảng 300 đến 1500 từ) được trình bày theo đúng cấu trúc và chuẩn mực của một tạp chí khoa học.\\nCác bài viết của Tạp chí hiện đang được trích dẫn bởi Google Scholar, WorldCat, Open Archives, Cosmos Impact Factor, Advanced Sciences Index, Scientific Indexing Services, CrossRef, EBSCO Information Services.\\nMọi thông tin xin liên hệ: \"},{\"attributes\":{\"italic\":true},\"insert\":\"Phòng Tạp chí, 701 - E, Trường Đại học Khoa học Xã hội và Nhân văn, 336 Nguyễn Trãi, Thanh Xuân, Hà Nội. ĐT: 024.35581984; email: tckhxhnv@vnu.edu.vn \"},{\"insert\":\"hoặc \"},{\"attributes\":{\"italic\":true},\"insert\":\"tapchikhxhnv@gmail.com \"},{\"insert\":\"\\n\"}]}",{"EN":494,"VI":495},"VNU Journal of Social Sciences and Humanities","Tạp chí Khoa học Xã hội và Nhân văn",[101,102],[],[499],{"id":500,"createTime":501,"updateTime":502,"relativeEntities":503,"slug":504,"properties":505,"entityType":98,"verifyStatus":25,"verifyTime":509,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":222,"url":26,"parentIds":510,"statistic":511},"8b6e349b-0daf-4895-9c3f-85f30f1bfd42","2023-07-31T12:55:58.430+00:00","2026-06-19T02:30:07.899+00:00",[],"Tr%C6%B0%E1%BB%9Dng-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Khoa-h%E1%BB%8Dc-X%C3%A3-h%E1%BB%99i-v%C3%A0-Nh%C3%A2n-v%C4%83n-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Qu%E1%BB%91c-gia-H%C3%A0-N%E1%BB%99i",{"title":506},{"EN":507,"VI":508},"VNU University of Social Sciences and Humanities","Trường Đại học Khoa học Xã hội và Nhân văn, Đại học Quốc gia Hà Nội","2023-08-02T15:28:49.057+00:00",[],{"impactFactor":36,"impactFactorByYear":512,"i10Index":59,"i10IndexLast5Year":115,"totalPublication":514,"totalPublicationByYear":515,"totalCitation":518,"totalCitationByYear":519,"totalCitationPerPublication":520,"totalCitationPerPublicationByYear":521,"hindexLast5Year":162,"hindex":162},{"2016":229,"2017":230,"2018":229,"2021":230,"2022":58,"2023":513,"2024":38},0.15,365,{"2013":115,"2014":158,"2015":125,"2016":252,"2017":44,"2018":516,"2019":286,"2020":396,"2021":259,"2022":517,"2023":396,"2024":115,"2025":59,"2026":115},21,42,169,{"2015":283,"2016":135,"2017":52,"2018":50,"2019":298,"2020":53,"2021":359,"2022":115,"2023":115},0.46,{"2015":266,"2016":57,"2017":57,"2018":522,"2019":523,"2020":524,"2021":368,"2022":229,"2023":39},0.38,0.32,0.37,[],"http:\u002F\u002Fjournal.ussh.vnu.edu.vn\u002Findex.php\u002Fvjossh","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F2b8d7b12-2d20-4777-be98-077f44f03c69\u002F0bd0751202944a4b4165b482e6e623e4.png",{"impactFactor":36,"impactFactorByYear":529,"i10Index":162,"i10IndexLast5Year":115,"totalPublication":530,"totalPublicationByYear":531,"totalCitation":537,"totalCitationByYear":538,"totalCitationPerPublication":343,"totalCitationPerPublicationByYear":540,"hindexLast5Year":135,"hindex":135},{"2016":341,"2017":39,"2018":229,"2019":38,"2020":110,"2021":231,"2022":231,"2023":341,"2024":39},764,{"2015":255,"2016":245,"2017":532,"2018":259,"2019":533,"2020":534,"2021":535,"2022":536,"2023":534,"2024":254,"2025":50},111,106,68,92,89,265,{"2015":539,"2016":241,"2017":168,"2018":51,"2019":349,"2020":260,"2021":244,"2022":298,"2023":114},46,{"2015":541,"2016":523,"2017":524,"2018":290,"2019":542,"2020":522,"2021":523,"2022":57,"2023":39},1.48,0.63,{"id":544,"createTime":545,"updateTime":546,"relativeEntities":547,"slug":548,"properties":549,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":558,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":50,"subjectFields":559,"manageAffiliations":560,"indexDatabases":561,"url":562,"thumbnailPath":563,"statistic":564,"gsStatistic":26,"type":26,"analyzePriority":26},"6ec01bd0-15c0-469a-86ac-41339076ae0a","2023-08-10T07:08:33.153+00:00","2026-01-31T21:19:06.362+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Da-li%E1%BB%85u-h%E1%BB%8Dc-Vi%E1%BB%87t-Nam",{"country":550,"issn":551,"introduce":553,"title":555},{"VOID":15},{"VOID":552},"18594824",{"VI":554},"{\"ops\":[{\"insert\":\"Tạp chí “Da liễu học Việt Nam” (Tiếng Anh: Vietnamese Journal of Dermatology and Venereology) thuộc Hội Da liễu Việt Nam, xuất bản 4 số mỗi năm bằng tiếng Việt hoặc tiếng Anh.\\nTạp chí Da liễu học Việt Nam hoạt động với mục đích, tôn chỉ là phổ biến, trao đổi thông tin trong lĩnh vực chuyên ngành da liễu; đăng tải các công trình nghiên cứu khoa học; chuyển giao công nghệ - kinh tế và khoa học kỹ thuật liên quan đến lĩnh vực da liễu.\\nPhạm vi của tạp chí là tất cả các bài báo khoa học, bài tổng quan, giới thiệu ca lâm sàng, … có liên quan tới chuyên ngành da liễu trong và ngoài nước. Tạp chí công bố các công trình nghiên cứu liên quan đến mô hình bệnh tật, các phương pháp chẩn đoán, điều trị, dự phòng và phục hồi chức năng các bệnh thuộc chuyên ngành da liễu. Ngoài ra, tạp chí còn đăng tải các bài tổng quan, cập nhật thông tin, kiến thức, hướng dẫn chẩn đoán, điều trị trong chuyên ngành da liễu trong nước và quốc tế; đăng tải các bài ca lâm sàng đặc biệt trong chuyên ngành da liễu.\\nTạp chí Da liễu học Việt Nam được biết tới là một tạp chí chuyên ngành có uy tín trong lĩnh vực da liễu. Các bài báo về nghiên cứu khoa học đăng trong Tạp chí được bình duyệt một cách nghiêm ngặt bởi ít nhất 2 chuyên gia. Hội đồng biên tập tạp chí bao gồm các nhà khoa học có uy tín (Giáo sư, Phó Giáo sư, Tiến sĩ, Bác sĩ…) trong chuyên ngành da liễu nhằm đảm bảo chất lượng và tính khách quan, khoa học cho các bài viết đăng trên Tạp chí.\\n\"}]}",{"EN":556,"VI":557},"Vietnamese Journal of Dermatology and Venereology","Tạp chí Da liễu học Việt Nam","Admin Import",[],[],[],"https:\u002F\u002Fvjdv.vn\u002Findex.php\u002Fvjdv","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F6ec01bd0-15c0-469a-86ac-41339076ae0a\u002F3cbc81720e58429dc7b1c4d7ab1935ca.jpg",{"impactFactor":36,"impactFactorByYear":565,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":566,"totalPublicationByYear":567,"totalCitation":116,"totalCitationByYear":570,"totalCitationPerPublication":109,"totalCitationPerPublicationByYear":571,"hindexLast5Year":115,"hindex":115},{"2023":38,"2024":230},182,{"2022":568,"2023":45,"2024":569},69,56,{"2022":52,"2023":115},{"2022":40,"2023":229},{"id":573,"createTime":574,"updateTime":575,"relativeEntities":576,"slug":577,"properties":578,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":27,"syncStatus":28,"languages":587,"translateLanguages":26,"viewCount":283,"subjectFields":588,"manageAffiliations":589,"indexDatabases":647,"url":648,"thumbnailPath":649,"statistic":650,"gsStatistic":26,"type":26,"analyzePriority":26},"19221551-7519-47ff-a892-331d1139c64b","2023-09-12T07:03:05.744+00:00","2026-01-24T20:54:40.144+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Khoa-h%E1%BB%8Dc-S%E1%BB%A9c-kho%E1%BA%BB-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Qu%E1%BB%91c-gia-Th%C3%A0nh-ph%E1%BB%91-H%E1%BB%93-Ch%C3%AD-Minh",{"country":579,"issn":580,"introduce":582,"title":584},{"VOID":15},{"VOID":581},"27349446",{"EN":583},"{\"ops\":[{\"attributes\":{\"bold\":true},\"insert\":\"1. History\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Science and Technology Development Journal\"},{\"insert\":\" (STDJ) (ISSN 2734-9446), Vietnam National University - Ho Chi Minh City (VNU-HCM) was established in 1997. And the first issue was published in January 1998 with ISSN 1859-0128. Since then, STDJ has become the most important scientific forum of scientists from VNU-HCM as well as other universities. The magazine has undergone 20 years of development and has become a bridge for scientific exchanges, as well as enriching reference materials for the faculty, doctoral students, students of VNU-HCM in particular and other universities, institutes...\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Science and Technology Development Journal - Health Sciences (STDJ-HS) is a subjournal of Science and Technology Development Journal since 2020.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\" \"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"2. Focus and Scope\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Publishing articles with contents on healthcare, research projects in the field of health, advanced directions in health education and management. Therefore, STDJ-HS will accept articles from doctors, administrators, teachers, researchers, graduate students and fellows. The authors will be responsible for the accuracy of the data, opinions, opinions and material cited in the article.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Facilitating the exchange of scientific and technological information and act as a bridge between theory and practice in the community of educators, scientists, managers, policy makers and enterprises in and out of the country.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"\\n\"}]}",{"EN":585,"VI":586},"VNUHCM JOURNAL OF HEALTH SCIENCES","Tạp chí Khoa học Sức khoẻ Đại học Quốc gia Thành phố Hồ Chí Minh",[101,102],[],[590],{"id":591,"createTime":592,"updateTime":593,"relativeEntities":594,"slug":595,"properties":596,"entityType":98,"verifyStatus":25,"verifyTime":606,"verifyNote":26,"syncStatus":28,"languages":607,"translateLanguages":26,"viewCount":608,"url":609,"parentIds":610,"statistic":611},"fc4c2560-868c-4677-acb1-8686bef88727","2023-06-26T04:48:23.774+00:00","2026-06-19T01:46:17.248+00:00",[],"%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Qu%E1%BB%91c-gia-Th%C3%A0nh-ph%E1%BB%91-H%E1%BB%93-Ch%C3%AD-Minh",{"country":597,"title":598,"abbreviation":601,"address":603},{"VOID":15},{"EN":599,"VI":600},"Vietnam National University Ho Chi Minh City","Đại học Quốc gia Thành phố Hồ Chí Minh",{"VOID":602},"VNUHCM",{"VI":604,"EN":605},"khu phố 6, Phường Linh Trung, Thành phố Thủ Đức, Thành phố Hồ Chí Minh, Việt Nam","Quarter 6, Linh Trung Ward, Thu Duc City, Ho Chi Minh City, Vietnam","2023-08-16T14:13:07.134+00:00",[101,102],45,"https:\u002F\u002Fvnuhcm.edu.vn\u002F",[],{"impactFactor":36,"impactFactorByYear":612,"i10Index":285,"i10IndexLast5Year":51,"totalPublication":613,"totalPublicationByYear":614,"totalCitation":624,"totalCitationByYear":625,"totalCitationPerPublication":634,"totalCitationPerPublicationByYear":635,"hindexLast5Year":124,"hindex":124},{"2014":36,"2015":38,"2016":109,"2017":39,"2018":229,"2019":38,"2020":110,"2021":171,"2022":110,"2023":110,"2024":171,"2025":229},3708,{"2005":115,"2006":115,"2007":115,"2008":135,"2009":111,"2010":53,"2011":52,"2012":568,"2013":615,"2014":351,"2015":616,"2016":469,"2017":617,"2018":127,"2019":618,"2020":619,"2021":620,"2022":621,"2023":622,"2024":623,"2025":159,"2026":50},164,266,177,226,603,931,314,246,74,2399,{"2006":115,"2008":50,"2010":162,"2011":242,"2012":222,"2013":43,"2014":626,"2015":627,"2016":628,"2017":629,"2018":258,"2019":630,"2020":631,"2021":632,"2022":633,"2023":353,"2024":115},250,124,157,162,152,385,559,128,0.65,{"2006":115,"2008":636,"2010":637,"2011":638,"2012":639,"2013":522,"2014":640,"2015":641,"2016":642,"2017":643,"2018":644,"2019":642,"2020":645,"2021":292,"2022":646,"2023":522,"2024":38},1.33,0.45,2.22,0.39,1.35,0.47,0.67,0.92,0.73,0.64,0.41,[],"http:\u002F\u002Fstdjhs.scienceandtechnology.com.vn\u002Findex.php\u002Fstdjhs","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F19221551-7519-47ff-a892-331d1139c64b\u002F2e10768b7d1e380c36a25ed0c714dd7e.png",{"impactFactor":36,"impactFactorByYear":651,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":652,"totalPublicationByYear":653,"totalCitation":516,"totalCitationByYear":654,"totalCitationPerPublication":151,"totalCitationPerPublicationByYear":655,"hindexLast5Year":59,"hindex":59},{"2022":57,"2023":108,"2024":39},79,{"2020":116,"2021":240,"2022":239,"2023":52,"2024":162,"2025":162},{"2020":59,"2021":51,"2022":59},{"2020":443,"2021":387,"2022":54},{"code":657,"data":658,"meta":26},"SUCCESS",{"id":659,"createTime":660,"updateTime":661,"relativeEntities":662,"slug":663,"properties":664,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":674,"manageAffiliations":691,"indexDatabases":702,"url":742,"thumbnailPath":26,"statistic":743,"gsStatistic":26,"type":26,"analyzePriority":26},"6923c4fb-d265-4349-b8bf-a665ac6340dd","2023-05-29T10:26:39.288+00:00","2025-11-21T10:05:31.921+00:00",[],"Frontiers-in-Oncology",{"country":665,"issn":667,"introduce":669,"eissn":671,"title":672},{"VOID":666},"CH",{"VOID":668},"2234943X",{"EN":670},"Frontiers in Oncology publishes rigorously peer-reviewed research across the entire field of cancer research. Field Chief Editor Giuseppe Giaccone at Georgetown University is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. The journal welcomes outstanding contributions in any domain of cancer research: from basic laboratory research to clinical investigation, from prevention to treatment, and from imaging studies to novel treatment strategies.",{"VOID":668},{"EN":673},"Frontiers in Oncology",[675,683],{"id":676,"createTime":677,"updateTime":678,"relativeEntities":679,"label":680,"description":682,"parentId":26,"standard":26,"scholarHubFieldId":26},"d9687dc3-fd83-46ff-aef4-1925044c24eb","2023-05-29T10:24:05.052+00:00","2023-11-21T05:08:37.643+00:00",[],{"EN":681},"Oncology",{},{"id":684,"createTime":685,"updateTime":686,"relativeEntities":687,"label":688,"description":690,"parentId":26,"standard":26,"scholarHubFieldId":26},"740fbbd4-0204-4499-bc5d-be3ba61fc9be","2023-05-29T10:24:05.032+00:00","2023-11-21T05:08:37.653+00:00",[],{"EN":689},"Cancer Research",{},[692],{"id":693,"createTime":694,"updateTime":695,"relativeEntities":696,"slug":697,"properties":698,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":162,"url":26,"parentIds":701,"statistic":26},"57a1b006-1eeb-4af3-bad6-598ed57cbdc4","2023-05-29T10:24:21.833+00:00","2024-02-09T17:22:19.223+00:00",[],"Frontiers-Media-S-A-",{"title":699},{"EN":700},"Frontiers Media S.A.",[],[703,722],{"id":704,"indexDatabase":705,"url":719,"indexYears":26,"academicFieldIds":720,"indexDatabaseRanking":26},"6e6a4db6-688a-485e-ae97-e6a71b7ff0b4",{"id":706,"createTime":707,"updateTime":708,"relativeEntities":709,"label":710,"description":712,"key":715,"publicationTags":716,"standard":26},"a4921856-b128-4d9f-8f1f-e80813d3bbd4","2023-05-22T09:59:31.026+00:00","2025-11-21T10:07:52.153+00:00",[],{"EN":711,"VI":711},"ISI\u002FSCIE - Science Citation Index Expanded",{"VI":713,"EN":714},"Cơ sở dữ liệu SCIE","SCIE database","scie",[717,718],"SCIE","ISI","https:\u002F\u002Fmjl.clarivate.com\u002Fsearch-results?issn=2234-943X",[721],"248e54de-c562-4c06-8a10-d7f8a37c06fe",{"id":723,"indexDatabase":724,"url":736,"indexYears":737,"academicFieldIds":738,"indexDatabaseRanking":741},"e722276e-ba0c-421a-a828-2711c33ec291",{"id":725,"createTime":726,"updateTime":727,"relativeEntities":728,"label":729,"description":731,"key":733,"publicationTags":734,"standard":26},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9","2023-05-22T09:57:18.509+00:00","2025-11-21T10:07:52.274+00:00",[],{"EN":730,"VI":730},"Scopus - Elsevier",{"EN":730,"VI":732},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[735],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F21100275443","2011-2025",[739,740],"ee505398-b96f-423d-82ed-9f73f07d49d4","462e3fe4-4fc0-4c02-80d6-8d2af4fc74ea","SCOPUS__Q1","https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Foncology",{"impactFactor":36,"impactFactorByYear":744,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":115,"totalPublicationByYear":745,"totalCitation":158,"totalCitationByYear":746,"totalCitationPerPublication":158,"totalCitationPerPublicationByYear":747,"hindexLast5Year":115,"hindex":115},{},{"2021":115},{"2021":158},{"2021":158},{"meta":749,"data":751},{"total":750},"124",[752,1391,1549,2024,3172,4290,4387,5430,6475,7433],{"id":753,"createTime":754,"updateTime":754,"relativeEntities":755,"slug":756,"properties":757,"entityType":772,"verifyStatus":25,"verifyTime":754,"verifyNote":773,"syncStatus":28,"languages":774,"translateLanguages":26,"viewCount":36,"primaryUrl":775,"fullTextUrl":26,"authors":776,"publicationType":843,"publisherRelationship":844,"citationCount":878,"citationInfo":879,"publishDate":26,"publishYear":26,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":885,"isForceReanalyzing":1390},"d753e86c-caa4-41a1-8b72-3505fbe38d7a","2024-10-10T11:01:42.826+00:00",[],"Anti-PD-1-and-Anti-CTLA-4-Therapies-in-Cancer-Mechanisms-of-Action-Efficacy-and-Limitations",{"mag":758,"keywords":760,"pmc":761,"openalex":763,"abstract":765,"title":766,"pm":768,"doi":770},{"VOID":759},"2794612508",{},{"VOID":762},"5883082",{"VOID":764},"W2794612508",{},{"EN":767},"Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations",{"VOID":769},"29644214",{"VOID":771},"10.3389\u002Ffonc.2018.00086","PUBLICATION","Auto Verify",[102],"http:\u002F\u002Fjournal.frontiersin.org\u002Farticle\u002F10.3389\u002Ffonc.2018.00086\u002Ffull",[777,799,816],{"id":778,"sortIndex":115,"researcher":26,"roles":779,"affiliations":780,"properties":792},"54986c7d-191c-4b80-b2ed-184373f0a7cd",[],[781],{"id":782,"sortIndex":36,"affiliation":783,"properties":26},"946fcc54-fe36-4c08-a0ba-5689bbd6d495",{"id":784,"createTime":785,"updateTime":786,"relativeEntities":787,"slug":788,"properties":789,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"99eff58c-6f17-4be0-8c7b-60c4ad1f2520","2024-01-29T00:06:27.719+00:00","2025-02-01T18:53:37.579+00:00",[],"Department-of-Dermatology-Kyoto-University-Graduate-School-of-Medicine-Kyoto-Japan",{"title":790},{"VI":791},"Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan",{"openalex":793,"orcid":795,"title":797},{"VOID":794},"A5005685966",{"VOID":796},"https:\u002F\u002Forcid.org\u002F0000-0001-7365-947X",{"EN":798},"Atsushi Otsuka",{"id":800,"sortIndex":36,"researcher":26,"roles":801,"affiliations":802,"properties":809},"aaa9a912-adf3-415a-9b18-865e09648f80",[],[803],{"id":804,"sortIndex":36,"affiliation":805,"properties":26},"01eefc9f-2c96-45eb-a31d-6edaa4d3b9bf",{"id":784,"createTime":785,"updateTime":786,"relativeEntities":806,"slug":788,"properties":807,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":808},{"VI":791},{"openalex":810,"orcid":812,"title":814},{"VOID":811},"A5024608308",{"VOID":813},"https:\u002F\u002Forcid.org\u002F0000-0001-6116-9246",{"EN":815},"Judith A. Seidel",{"id":817,"sortIndex":114,"researcher":26,"roles":818,"affiliations":819,"properties":836},"ea233e7e-3144-4e5b-8a68-d64d4dc5a410",[],[820,830],{"id":821,"sortIndex":115,"affiliation":822,"properties":26},"af31033f-e031-433a-bd22-fce16e1f4bd1",{"id":823,"createTime":824,"updateTime":824,"relativeEntities":825,"slug":826,"properties":827,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"6b373efd-1b8d-4e72-9060-85187a4dd15d","2024-10-10T11:01:42.868+00:00",[],"Singapore-Immunology-Network-SIgN-Institute-of-Medical-Biology-Agency-for-Science-Technology-and-Research-A-STAR-Biopolis-Singapore-Singapore",{"title":828},{"EN":829},"Singapore Immunology Network (SIgN), Institute of Medical Biology, Agency for Science, Technology and Research (A*STAR), Biopolis, Singapore, Singapore",{"id":831,"sortIndex":36,"affiliation":832,"properties":26},"f28fb52b-8b8b-4863-a683-c5a6f68ea718",{"id":784,"createTime":785,"updateTime":786,"relativeEntities":833,"slug":788,"properties":834,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":835},{"VI":791},{"openalex":837,"orcid":839,"title":841},{"VOID":838},"A5023533946",{"VOID":840},"https:\u002F\u002Forcid.org\u002F0000-0002-0773-0554",{"EN":842},"Kenji Kabashima","ARTICLE",{"url":26,"publisher":845,"properties":875},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":846,"slug":663,"properties":847,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":853,"manageAffiliations":854,"indexDatabases":855,"url":742,"thumbnailPath":26,"statistic":870,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"country":848,"issn":849,"introduce":850,"eissn":851,"title":852},{"VOID":666},{"VOID":668},{"EN":670},{"VOID":668},{"EN":673},[],[],[856,863],{"id":704,"indexDatabase":857,"url":719,"indexYears":26,"academicFieldIds":862,"indexDatabaseRanking":26},{"id":706,"createTime":707,"updateTime":708,"relativeEntities":858,"label":859,"description":860,"key":715,"publicationTags":861,"standard":26},[],{"EN":711,"VI":711},{"VI":713,"EN":714},[717,718],[721],{"id":723,"indexDatabase":864,"url":736,"indexYears":737,"academicFieldIds":869,"indexDatabaseRanking":741},{"id":725,"createTime":726,"updateTime":727,"relativeEntities":865,"label":866,"description":867,"key":733,"publicationTags":868,"standard":26},[],{"EN":730,"VI":730},{"EN":730,"VI":732},[735],[739,740],{"impactFactor":36,"impactFactorByYear":871,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":115,"totalPublicationByYear":872,"totalCitation":158,"totalCitationByYear":873,"totalCitationPerPublication":158,"totalCitationPerPublicationByYear":874,"hindexLast5Year":115,"hindex":115},{},{"2021":115},{"2021":158},{"2021":158},{"volume":876},{"VOID":877},"8",1093,{"total":878,"publishYear":26,"statisticByYear":880},{"2013":115,"2018":234,"2019":366,"2020":881,"2021":351,"2022":882,"2023":883,"2024":884},203,208,205,149,[886,890,894,898,902,906,910,914,918,922,926,930,934,938,942,946,950,954,958,962,966,970,974,978,982,986,990,994,998,1002,1006,1010,1014,1018,1022,1026,1030,1034,1038,1042,1046,1050,1054,1058,1062,1066,1070,1074,1078,1082,1086,1090,1094,1098,1102,1106,1110,1114,1118,1122,1126,1130,1134,1138,1142,1146,1150,1154,1158,1162,1166,1170,1174,1178,1182,1186,1190,1194,1198,1202,1206,1210,1214,1218,1222,1226,1230,1234,1238,1242,1246,1250,1254,1258,1262,1266,1270,1274,1278,1282,1286,1290,1294,1298,1302,1306,1310,1314,1318,1322,1326,1330,1334,1338,1342,1346,1350,1354,1358,1362,1366,1370,1374,1378,1382,1386],{"id":26,"text":887,"url":26,"identifiers":888},"Lawrence, 2013, Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature, 499, 214, 10.1038\u002Fnature12213",{"doi":889},"10.1038\u002Fnature12213",{"id":26,"text":891,"url":26,"identifiers":892},"Pennock, 2013, T cell responses: naïve to memory and everything in between, Adv Physiol Educ, 37, 273, 10.1152\u002Fadvan.00066.2013",{"doi":893},"10.1152\u002Fadvan.00066.2013",{"id":26,"text":895,"url":26,"identifiers":896},"Teng, 2015, From mice to humans: developments in cancer immunoediting, J Clin Invest, 125, 3338, 10.1172\u002FJCI80004",{"doi":897},"10.1172\u002FJCI80004",{"id":26,"text":899,"url":26,"identifiers":900},"Otsuka, 2015, Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma, Clin Cancer Res, 21, 1289, 10.1158\u002F1078-0432.CCR-14-2110",{"doi":901},"10.1158\u002F1078-0432.CCR-14-2110",{"id":26,"text":903,"url":26,"identifiers":904},"Otsuka, 2015, Hedgehog signaling in basal cell carcinoma, J Dermatol Sci, 78, 95, 10.1016\u002Fj.jdermsci.2015.02.007",{"doi":905},"10.1016\u002Fj.jdermsci.2015.02.007",{"id":26,"text":907,"url":26,"identifiers":908},"Zaretsky, 2016, Mutations associated with acquired resistance to PD-1 blockade in melanoma, N Engl J Med, 375, 819, 10.1056\u002FNEJMoa1604958",{"doi":909},"10.1056\u002FNEJMoa1604958",{"id":26,"text":911,"url":26,"identifiers":912},"Vinay, 2015, Immune evasion in cancer: mechanistic basis and therapeutic strategies, Semin Cancer Biol, 35, S185, 10.1016\u002Fj.semcancer.2015.03.004",{"doi":913},"10.1016\u002Fj.semcancer.2015.03.004",{"id":26,"text":915,"url":26,"identifiers":916},"Sarvaria, 2017, B cell regulation in cancer and anti-tumor immunity, Cell Mol Immunol, 14, 662, 10.1038\u002Fcmi.2017.35",{"doi":917},"10.1038\u002Fcmi.2017.35",{"id":26,"text":919,"url":26,"identifiers":920},"Parry, 2005, CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms, Mol Cell Biol, 25, 9543, 10.1128\u002FMCB.25.21.9543-9553.2005",{"doi":921},"10.1128\u002FMCB.25.21.9543-9553.2005",{"id":26,"text":923,"url":26,"identifiers":924},"Blackburn, 2009, Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection, Nat Immunol, 10, 29, 10.1038\u002Fni.1679",{"doi":925},"10.1038\u002Fni.1679",{"id":26,"text":927,"url":26,"identifiers":928},"Anderson, 2016, Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation, Immunity, 44, 989, 10.1016\u002Fj.immuni.2016.05.001",{"doi":929},"10.1016\u002Fj.immuni.2016.05.001",{"id":26,"text":931,"url":26,"identifiers":932},"Day, 2006, PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression, Nature, 443, 350, 10.1038\u002Fnature05115",{"doi":933},"10.1038\u002Fnature05115",{"id":26,"text":935,"url":26,"identifiers":936},"Baitsch, 2011, Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients, J Clin Invest, 121, 2350, 10.1172\u002FJCI46102",{"doi":937},"10.1172\u002FJCI46102",{"id":26,"text":939,"url":26,"identifiers":940},"Wherry, 2011, T cell exhaustion, Nat Immunol, 12, 492, 10.1038\u002Fni.2035",{"doi":941},"10.1038\u002Fni.2035",{"id":26,"text":943,"url":26,"identifiers":944},"Jin, 2011, Role of PD-1 in regulating T-cell immunity, Curr Top Microbiol Immunol, 350, 17, 10.1007\u002F82_2010_116",{"doi":945},"10.1007\u002F82_2010_116",{"id":26,"text":947,"url":26,"identifiers":948},"Gardner, 2014, Understanding the CD28\u002FCTLA-4 (CD152) pathway and its implications for costimulatory blockade, Am J Transplant, 14, 1985, 10.1111\u002Fajt.12834",{"doi":949},"10.1111\u002Fajt.12834",{"id":26,"text":951,"url":26,"identifiers":952},"Speiser, 2014, T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?, Nat Rev Immunol, 14, 768, 10.1038\u002Fnri3740",{"doi":953},"10.1038\u002Fnri3740",{"id":26,"text":955,"url":26,"identifiers":956},"Erickson, 2012, Viral acute lower respiratory infections impair CD8+ T cells through PD-1, J Clin Invest, 122, 2967, 10.1172\u002FJCI62860",{"doi":957},"10.1172\u002FJCI62860",{"id":26,"text":959,"url":26,"identifiers":960},"Hodi, 2003, Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients, Proc Natl Acad Sci U S A, 100, 4712, 10.1073\u002Fpnas.0830997100",{"doi":961},"10.1073\u002Fpnas.0830997100",{"id":26,"text":963,"url":26,"identifiers":964},"Phan, 2003, Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma, Proc Natl Acad Sci U S A, 100, 8372, 10.1073\u002Fpnas.1533209100",{"doi":965},"10.1073\u002Fpnas.1533209100",{"id":26,"text":967,"url":26,"identifiers":968},"Chan, 2014, Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation, Genes Immun, 15, 25, 10.1038\u002Fgene.2013.57",{"doi":969},"10.1038\u002Fgene.2013.57",{"id":26,"text":971,"url":26,"identifiers":972},"Leung, 1995, Cytotoxic T lymphocyte-associated molecule-4, a high avidity receptor for CD80 and CD86, contains an intracellular localization motif in its cytoplasmic tail, J Biol Chem, 270, 25107, 10.1074\u002Fjbc.270.42.25107",{"doi":973},"10.1074\u002Fjbc.270.42.25107",{"id":26,"text":975,"url":26,"identifiers":976},"Rudd, 2009, CD28 and CTLA-4 coreceptor expression and signal transduction, Immunol Rev, 229, 12, 10.1111\u002Fj.1600-065X.2009.00770.x",{"doi":977},"10.1111\u002Fj.1600-065X.2009.00770.x",{"id":26,"text":979,"url":26,"identifiers":980},"Qureshi, 2011, Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4, Science, 332, 600, 10.1126\u002Fscience.1202947",{"doi":981},"10.1126\u002Fscience.1202947",{"id":26,"text":983,"url":26,"identifiers":984},"Wing, 2008, CTLA-4 control over Foxp3+ regulatory T cell function, Science, 322, 271, 10.1126\u002Fscience.1160062",{"doi":985},"10.1126\u002Fscience.1160062",{"id":26,"text":987,"url":26,"identifiers":988},"Waterhouse, 1995, Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4, Science, 270, 985, 10.1126\u002Fscience.270.5238.985",{"doi":989},"10.1126\u002Fscience.270.5238.985",{"id":26,"text":991,"url":26,"identifiers":992},"Gough, 2005, CTLA4 gene polymorphism and autoimmunity, Immunol Rev, 204, 102, 10.1111\u002Fj.0105-2896.2005.00249.x",{"doi":993},"10.1111\u002Fj.0105-2896.2005.00249.x",{"id":26,"text":995,"url":26,"identifiers":996},"Nakamoto, 2009, Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1\u002FCTLA-4 blockade, PLoS Pathog, 5, e1000313, 10.1371\u002Fjournal.ppat.1000313",{"doi":997},"10.1371\u002Fjournal.ppat.1000313",{"id":26,"text":999,"url":26,"identifiers":1000},"Curran, 2010, PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors, Proc Natl Acad Sci U S A, 107, 4275, 10.1073\u002Fpnas.0915174107",{"doi":1001},"10.1073\u002Fpnas.0915174107",{"id":26,"text":1003,"url":26,"identifiers":1004},"Ishida, 1992, Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death, EMBO J, 11, 3887, 10.1002\u002Fj.1460-2075.1992.tb05481.x",{"doi":1005},"10.1002\u002Fj.1460-2075.1992.tb05481.x",{"id":26,"text":1007,"url":26,"identifiers":1008},"Nishimura, 1999, Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor, Immunity, 11, 141, 10.1016\u002FS1074-7613(00)80089-8",{"doi":1009},"10.1016\u002FS1074-7613(00)80089-8",{"id":26,"text":1011,"url":26,"identifiers":1012},"Sage, 2013, The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood, Nat Immunol, 14, 152, 10.1038\u002Fni.2496",{"doi":1013},"10.1038\u002Fni.2496",{"id":26,"text":1015,"url":26,"identifiers":1016},"Agata, 1996, Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes, Int Immunol, 8, 765, 10.1093\u002Fintimm\u002F8.5.765",{"doi":1017},"10.1093\u002Fintimm\u002F8.5.765",{"id":26,"text":1019,"url":26,"identifiers":1020},"Kinter, 2008, The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands, J Immunol, 181, 6738, 10.4049\u002Fjimmunol.181.10.6738",{"doi":1021},"10.4049\u002Fjimmunol.181.10.6738",{"id":26,"text":1023,"url":26,"identifiers":1024},"Peña-Cruz, 2010, PD-1 on immature and PD-1 ligands on migratory human Langerhans cells regulate antigen-presenting cell activity, J Invest Dermatol, 130, 2222, 10.1038\u002Fjid.2010.127",{"doi":1025},"10.1038\u002Fjid.2010.127",{"id":26,"text":1027,"url":26,"identifiers":1028},"Thibult, 2013, PD-1 is a novel regulator of human B-cell activation, Int Immunol, 25, 129, 10.1093\u002Fintimm\u002Fdxs098",{"doi":1029},"10.1093\u002Fintimm\u002Fdxs098",{"id":26,"text":1031,"url":26,"identifiers":1032},"Lim, 2016, PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity, Oncoimmunology, 5, e1085146, 10.1080\u002F2162402X.2015.1085146",{"doi":1033},"10.1080\u002F2162402X.2015.1085146",{"id":26,"text":1035,"url":26,"identifiers":1036},"Rodrigues, 2016, Tolerogenic IDO+ dendritic cells are induced by PD-1-expressing mast cells, Front Immunol, 7, 9, 10.3389\u002Ffimmu.2016.00009",{"doi":1037},"10.3389\u002Ffimmu.2016.00009",{"id":26,"text":1039,"url":26,"identifiers":1040},"Latchman, 2001, PD-L2 is a second ligand for PD-1 and inhibits T cell activation, Nat Immunol, 2, 261, 10.1038\u002F85330",{"doi":1041},"10.1038\u002F85330",{"id":26,"text":1043,"url":26,"identifiers":1044},"Freeman, 2006, Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade, J Exp Med, 203, 2223, 10.1084\u002Fjem.20061800",{"doi":1045},"10.1084\u002Fjem.20061800",{"id":26,"text":1047,"url":26,"identifiers":1048},"Brown, 2003, Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production, J Immunol, 170, 1257, 10.4049\u002Fjimmunol.170.3.1257",{"doi":1049},"10.4049\u002Fjimmunol.170.3.1257",{"id":26,"text":1051,"url":26,"identifiers":1052},"Patsoukis, 2012, Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation, Sci Signal, 5, ra46, 10.1126\u002Fscisignal.2002796",{"doi":1053},"10.1126\u002Fscisignal.2002796",{"id":26,"text":1055,"url":26,"identifiers":1056},"Chemnitz, 2004, SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation, J Immunol, 173, 945, 10.4049\u002Fjimmunol.173.2.945",{"doi":1057},"10.4049\u002Fjimmunol.173.2.945",{"id":26,"text":1059,"url":26,"identifiers":1060},"Sheppard, 2004, PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70\u002FCD3ζ signalosome and downstream signaling to PKCθ, FEBS Lett, 574, 37, 10.1016\u002Fj.febslet.2004.07.083",{"doi":1061},"10.1016\u002Fj.febslet.2004.07.083",{"id":26,"text":1063,"url":26,"identifiers":1064},"Hui, 2017, T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition, Science, 355, 1428, 10.1126\u002Fscience.aaf1292",{"doi":1065},"10.1126\u002Fscience.aaf1292",{"id":26,"text":1067,"url":26,"identifiers":1068},"Carter, 2002, PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2, Eur J Immunol, 32, 634, 10.1002\u002F1521-4141(200203)32:3\u003C634:AID-IMMU634>3.0.CO;2-9",{"doi":1069},"10.1002\u002F1521-4141(200203)32:3\u003C634:AID-IMMU634>3.0.CO;2-9",{"id":26,"text":1071,"url":26,"identifiers":1072},"Nurieva, 2006, T-cell tolerance or function is determined by combinatorial costimulatory signals, EMBO J, 25, 2623, 10.1038\u002Fsj.emboj.7601146",{"doi":1073},"10.1038\u002Fsj.emboj.7601146",{"id":26,"text":1075,"url":26,"identifiers":1076},"Freeman, 2000, Engagement of the Pd-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J Exp Med, 192, 1027, 10.1084\u002Fjem.192.7.1027",{"doi":1077},"10.1084\u002Fjem.192.7.1027",{"id":26,"text":1079,"url":26,"identifiers":1080},"Nishimura, 1998, Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses, Int Immunol, 10, 1563, 10.1093\u002Fintimm\u002F10.10.1563",{"doi":1081},"10.1093\u002Fintimm\u002F10.10.1563",{"id":26,"text":1083,"url":26,"identifiers":1084},"Salama, 2003, Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis, J Exp Med, 198, 71, 10.1084\u002Fjem.20022119",{"doi":1085},"10.1084\u002Fjem.20022119",{"id":26,"text":1087,"url":26,"identifiers":1088},"Nielsen, 2003, Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes, Tissue Antigens, 62, 492, 10.1046\u002Fj.1399-0039.2003.00136.x",{"doi":1089},"10.1046\u002Fj.1399-0039.2003.00136.x",{"id":26,"text":1091,"url":26,"identifiers":1092},"Velázquez-Cruz, 2007, Association of PDCD1 polymorphisms with childhood-onset systemic lupus erythematosus, Eur J Hum Genet, 15, 336, 10.1038\u002Fsj.ejhg.5201767",{"doi":1093},"10.1038\u002Fsj.ejhg.5201767",{"id":26,"text":1095,"url":26,"identifiers":1096},"Salvi, 2012, Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer, Cancer Immunol Immunother, 61, 1463, 10.1007\u002Fs00262-012-1211-y",{"doi":1097},"10.1007\u002Fs00262-012-1211-y",{"id":26,"text":1099,"url":26,"identifiers":1100},"Huang, 2016, Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma, Oncotarget, 7, 13060, 10.18632\u002Foncotarget.7421",{"doi":1101},"10.18632\u002Foncotarget.7421",{"id":26,"text":1103,"url":26,"identifiers":1104},"Ahmadzadeh, 2009, Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired, Blood, 114, 1537, 10.1182\u002Fblood-2008-12-195792",{"doi":1105},"10.1182\u002Fblood-2008-12-195792",{"id":26,"text":1107,"url":26,"identifiers":1108},"Chapon, 2011, Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes, J Invest Dermatol, 131, 1300, 10.1038\u002Fjid.2011.30",{"doi":1109},"10.1038\u002Fjid.2011.30",{"id":26,"text":1111,"url":26,"identifiers":1112},"Saito, 2013, Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer, J Surg Oncol, 107, 517, 10.1002\u002Fjso.23281",{"doi":1113},"10.1002\u002Fjso.23281",{"id":26,"text":1115,"url":26,"identifiers":1116},"Xiao, 2016, PD-1hi identifies a novel regulatory b-cell population in human hepatoma that promotes disease progression, Cancer Discov, 6, 546, 10.1158\u002F2159-8290.CD-15-1408",{"doi":1117},"10.1158\u002F2159-8290.CD-15-1408",{"id":26,"text":1119,"url":26,"identifiers":1120},"Gordon, 2017, PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity, Nature, 545, 495, 10.1038\u002Fnature22396",{"doi":1121},"10.1038\u002Fnature22396",{"id":26,"text":1123,"url":26,"identifiers":1124},"Honda, 2016, Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma, Oncoimmunology, 6, e1253657, 10.1080\u002F2162402X.2016.1253657",{"doi":1125},"10.1080\u002F2162402X.2016.1253657",{"id":26,"text":1127,"url":26,"identifiers":1128},"Hino, 2010, Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma, Cancer, 116, 1757, 10.1002\u002Fcncr.24899",{"doi":1129},"10.1002\u002Fcncr.24899",{"id":26,"text":1131,"url":26,"identifiers":1132},"Hamanishi, 2015, Safety and antitumor activity of anti–PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer, J Clin Oncol, 33, 4015, 10.1200\u002FJCO.2015.62.3397",{"doi":1133},"10.1200\u002FJCO.2015.62.3397",{"id":26,"text":1135,"url":26,"identifiers":1136},"Inman, 2007, PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata, Cancer, 109, 1499, 10.1002\u002Fcncr.22588",{"doi":1137},"10.1002\u002Fcncr.22588",{"id":26,"text":1139,"url":26,"identifiers":1140},"Kim, 2016, Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer, Gastric Cancer, 19, 42, 10.1007\u002Fs10120-014-0440-5",{"doi":1141},"10.1007\u002Fs10120-014-0440-5",{"id":26,"text":1143,"url":26,"identifiers":1144},"Zhang, 2015, Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) expression in epithelial-originated cancer: a meta-analysis, Medicine, 94, e515, 10.1097\u002FMD.0000000000000515",{"doi":1145},"10.1097\u002FMD.0000000000000515",{"id":26,"text":1147,"url":26,"identifiers":1148},"Ribas, 2016, Association of pembrolizumab with tumor response and survival among patients with advanced melanoma, JAMA, 315, 1600, 10.1001\u002Fjama.2016.4059",{"doi":1149},"10.1001\u002Fjama.2016.4059",{"id":26,"text":1151,"url":26,"identifiers":1152},"Larkin, 2015, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, N Engl J Med, 373, 23, 10.1056\u002FNEJMoa1504030",{"doi":1153},"10.1056\u002FNEJMoa1504030",{"id":26,"text":1155,"url":26,"identifiers":1156},"Motzer, 2015, Nivolumab versus everolimus in advanced renal-cell carcinoma, N Engl J Med, 373, 1803, 10.1056\u002FNEJMoa1510665",{"doi":1157},"10.1056\u002FNEJMoa1510665",{"id":26,"text":1159,"url":26,"identifiers":1160},"Ansell, 2015, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma, N Engl J Med, 372, 311, 10.1056\u002FNEJMoa1411087",{"doi":1161},"10.1056\u002FNEJMoa1411087",{"id":26,"text":1163,"url":26,"identifiers":1164},"Ferris, 2016, Nivolumab for recurrent squamous-cell carcinoma of the head and neck, N Engl J Med, 375, 1856, 10.1056\u002FNEJMoa1602252",{"doi":1165},"10.1056\u002FNEJMoa1602252",{"id":26,"text":1167,"url":26,"identifiers":1168},"Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 373, 1627, 10.1056\u002FNEJMoa1507643",{"doi":1169},"10.1056\u002FNEJMoa1507643",{"id":26,"text":1171,"url":26,"identifiers":1172},"Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer, N Engl J Med, 373, 123, 10.1056\u002FNEJMoa1504627",{"doi":1173},"10.1056\u002FNEJMoa1504627",{"id":26,"text":1175,"url":26,"identifiers":1176},"Robert, 2015, Pembrolizumab versus ipilimumab in advanced melanoma, N Engl J Med, 372, 2521, 10.1056\u002FNEJMoa1503093",{"doi":1177},"10.1056\u002FNEJMoa1503093",{"id":26,"text":1179,"url":26,"identifiers":1180},"Nghiem, 2016, PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma, N Engl J Med, 374, 2542, 10.1056\u002FNEJMoa1603702",{"doi":1181},"10.1056\u002FNEJMoa1603702",{"id":26,"text":1183,"url":26,"identifiers":1184},"Garon, 2015, Pembrolizumab for the treatment of non–small-cell lung cancer, N Engl J Med, 372, 2018, 10.1056\u002FNEJMoa1501824",{"doi":1185},"10.1056\u002FNEJMoa1501824",{"id":26,"text":1187,"url":26,"identifiers":1188},"Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer, N Engl J Med, 375, 1823, 10.1056\u002FNEJMoa1606774",{"doi":1189},"10.1056\u002FNEJMoa1606774",{"id":26,"text":1191,"url":26,"identifiers":1192},"Herbst, 2016, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, 387, 1540, 10.1016\u002FS0140-6736(15)01281-7",{"doi":1193},"10.1016\u002FS0140-6736(15)01281-7",{"id":26,"text":1195,"url":26,"identifiers":1196},"Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, 372, 2509, 10.1056\u002FNEJMoa1500596",{"doi":1197},"10.1056\u002FNEJMoa1500596",{"id":26,"text":1199,"url":26,"identifiers":1200},"Armand, 2013, Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial, J Clin Oncol, 31, 4199, 10.1200\u002FJCO.2012.48.3685",{"doi":1201},"10.1200\u002FJCO.2012.48.3685",{"id":26,"text":1203,"url":26,"identifiers":1204},"Westin, 2014, Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial, Lancet Oncol, 15, 69, 10.1016\u002FS1470-2045(13)70551-5",{"doi":1205},"10.1016\u002FS1470-2045(13)70551-5",{"id":26,"text":1207,"url":26,"identifiers":1208},"Rittmeyer, 2016, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet, 389, 255, 10.1016\u002FS0140-6736(16)32517-X",{"doi":1209},"10.1016\u002FS0140-6736(16)32517-X",{"id":26,"text":1211,"url":26,"identifiers":1212},"Balar, 2017, Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial, Lancet, 389, 67, 10.1016\u002FS0140-6736(16)32455-2",{"doi":1213},"10.1016\u002FS0140-6736(16)32455-2",{"id":26,"text":1215,"url":26,"identifiers":1216},"Robert, 2011, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, N Engl J Med, 364, 2517, 10.1056\u002FNEJMoa1104621",{"doi":1217},"10.1056\u002FNEJMoa1104621",{"id":26,"text":1219,"url":26,"identifiers":1220},"Ribas, 2013, Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma, J Clin Oncol, 31, 616, 10.1200\u002FJCO.2012.44.6112",{"doi":1221},"10.1200\u002FJCO.2012.44.6112",{"id":26,"text":1223,"url":26,"identifiers":1224},"Antonia, 2016, Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\u002F2 trial, Lancet Oncol, 17, 883, 10.1016\u002FS1470-2045(16)30098-5",{"doi":1225},"10.1016\u002FS1470-2045(16)30098-5",{"id":26,"text":1227,"url":26,"identifiers":1228},"Rizvi, 2015, Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer, Science, 348, 124, 10.1126\u002Fscience.aaa1348",{"doi":1229},"10.1126\u002Fscience.aaa1348",{"id":26,"text":1231,"url":26,"identifiers":1232},"Snyder, 2014, Genetic basis for clinical response to CTLA-4 blockade in melanoma, N Engl J Med, 371, 2189, 10.1056\u002FNEJMoa1406498",{"doi":1233},"10.1056\u002FNEJMoa1406498",{"id":26,"text":1235,"url":26,"identifiers":1236},"Tumeh, 2014, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, 515, 568, 10.1038\u002Fnature13954",{"doi":1237},"10.1038\u002Fnature13954",{"id":26,"text":1239,"url":26,"identifiers":1240},"Peng, 2012, PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines, Cancer Res, 72, 5209, 10.1158\u002F0008-5472.CAN-12-1187",{"doi":1241},"10.1158\u002F0008-5472.CAN-12-1187",{"id":26,"text":1243,"url":26,"identifiers":1244},"Anegawa, 2016, Upregulation of granzyme B and interferon-γ MRNA in responding lesions by treatment with nivolumab for metastatic melanoma: a case report, J Eur Acad Dermatol Venereol, 30, e231, 10.1111\u002Fjdv.13567",{"doi":1245},"10.1111\u002Fjdv.13567",{"id":26,"text":1247,"url":26,"identifiers":1248},"Nonomura, 2017, ADAMTSL5 Is upregulated in melanoma tissues in patients with idiopathic psoriasis vulgaris induced by nivolumab, J Eur Acad Dermatol Venereol, 31, e100, 10.1111\u002Fjdv.13818",{"doi":1249},"10.1111\u002Fjdv.13818",{"id":26,"text":1251,"url":26,"identifiers":1252},"Nonomura, 2016, Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients, Oncoimmunology, 5, e1248327, 10.1080\u002F2162402X.2016.1248327",{"doi":1253},"10.1080\u002F2162402X.2016.1248327",{"id":26,"text":1255,"url":26,"identifiers":1256},"Appay, 2008, Phenotype and function of human T lymphocyte subsets: consensus and issues, Cytometry A, 73, 975, 10.1002\u002Fcyto.a.20643",{"doi":1257},"10.1002\u002Fcyto.a.20643",{"id":26,"text":1259,"url":26,"identifiers":1260},"Im, 2016, Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy, Nature, 537, 417, 10.1038\u002Fnature19330",{"doi":1261},"10.1038\u002Fnature19330",{"id":26,"text":1263,"url":26,"identifiers":1264},"Kamphorst, 2017, Rescue of exhausted CD8 T cells by PD-1–targeted therapies Is CD28-dependent, Science, 355, 1423, 10.1126\u002Fscience.aaf0683",{"doi":1265},"10.1126\u002Fscience.aaf0683",{"id":26,"text":1267,"url":26,"identifiers":1268},"Hugo, 2017, Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma, Cell, 168, 542, 10.1016\u002Fj.cell.2017.01.010",{"doi":1269},"10.1016\u002Fj.cell.2017.01.010",{"id":26,"text":1271,"url":26,"identifiers":1272},"Vétizou, 2015, Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota, Science, 350, 1079, 10.1126\u002Fscience.aad1329",{"doi":1273},"10.1126\u002Fscience.aad1329",{"id":26,"text":1275,"url":26,"identifiers":1276},"Routy, 2018, Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors, Science, 359, 91, 10.1126\u002Fscience.aan3706",{"doi":1277},"10.1126\u002Fscience.aan3706",{"id":26,"text":1279,"url":26,"identifiers":1280},"Abdel-Rahman, 2016, A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors, Immunotherapy, 8, 665, 10.2217\u002Fimt-2015-0020",{"doi":1281},"10.2217\u002Fimt-2015-0020",{"id":26,"text":1283,"url":26,"identifiers":1284},"Kato, 2016, Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma, J Eur Acad Dermatol Venereol, 30, e89, 10.1111\u002Fjdv.13336",{"doi":1285},"10.1111\u002Fjdv.13336",{"id":26,"text":1287,"url":26,"identifiers":1288},"Chae, 2016, A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes, Cancer Immunol Immunother, 66, 25, 10.1007\u002Fs00262-016-1913-7",{"doi":1289},"10.1007\u002Fs00262-016-1913-7",{"id":26,"text":1291,"url":26,"identifiers":1292},"Zou, 2016, PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations, Sci Transl Med, 8, 328rv4, 10.1126\u002Fscitranslmed.aad7118",{"doi":1293},"10.1126\u002Fscitranslmed.aad7118",{"id":26,"text":1295,"url":26,"identifiers":1296},"Freeman-Keller, 2016, Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes, Clin Cancer Res, 22, 886, 10.1158\u002F1078-0432.CCR-15-1136",{"doi":1297},"10.1158\u002F1078-0432.CCR-15-1136",{"id":26,"text":1299,"url":26,"identifiers":1300},"Diem, 2016, Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma, Br J Cancer, 114, 256, 10.1038\u002Fbjc.2015.467",{"doi":1301},"10.1038\u002Fbjc.2015.467",{"id":26,"text":1303,"url":26,"identifiers":1304},"Sharma, 2017, Primary, adaptive, and acquired resistance to cancer immunotherapy, Cell, 168, 707, 10.1016\u002Fj.cell.2017.01.017",{"doi":1305},"10.1016\u002Fj.cell.2017.01.017",{"id":26,"text":1307,"url":26,"identifiers":1308},"Calapre, 2017, Circulating tumour DNA (CtDNA) as a liquid biopsy for melanoma, Cancer Lett, 404, 62, 10.1016\u002Fj.canlet.2017.06.030",{"doi":1309},"10.1016\u002Fj.canlet.2017.06.030",{"id":26,"text":1311,"url":26,"identifiers":1312},"Lee, 2017, Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma, Ann Oncol, 28, 1130, 10.1093\u002Fannonc\u002Fmdx026",{"doi":1313},"10.1093\u002Fannonc\u002Fmdx026",{"id":26,"text":1315,"url":26,"identifiers":1316},"Topalian, 2012, Safety, activity, and immune correlates of anti–PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056\u002FNEJMoa1200690",{"doi":1317},"10.1056\u002FNEJMoa1200690",{"id":26,"text":1319,"url":26,"identifiers":1320},"Weide, 2016, Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab, Clin Cancer Res, 22, 5487, 10.1158\u002F1078-0432.CCR-16-0127",{"doi":1321},"10.1158\u002F1078-0432.CCR-16-0127",{"id":26,"text":1323,"url":26,"identifiers":1324},"Giacomo, 2013, Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 Mg\u002FKg within an expanded access programme, Cancer Immunol Immunother, 62, 1021, 10.1007\u002Fs00262-013-1418-6",{"doi":1325},"10.1007\u002Fs00262-013-1418-6",{"id":26,"text":1327,"url":26,"identifiers":1328},"Ishida, 2017, HLA-A*26 is correlated with response to nivolumab in Japanese melanoma patients, J Invest Dermatol, 137, 2443, 10.1016\u002Fj.jid.2017.06.023",{"doi":1329},"10.1016\u002Fj.jid.2017.06.023",{"id":26,"text":1331,"url":26,"identifiers":1332},"Gao, 2017, VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer, Nat Med, 23, 551, 10.1038\u002Fnm.4308",{"doi":1333},"10.1038\u002Fnm.4308",{"id":26,"text":1335,"url":26,"identifiers":1336},"Koyama, 2016, Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints, Nat Commun, 7, 10501, 10.1038\u002Fncomms10501",{"doi":1337},"10.1038\u002Fncomms10501",{"id":26,"text":1339,"url":26,"identifiers":1340},"Arlauckas, 2017, In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy, Sci Transl Med, 9, eaal3604, 10.1126\u002Fscitranslmed.aal3604",{"doi":1341},"10.1126\u002Fscitranslmed.aal3604",{"id":26,"text":1343,"url":26,"identifiers":1344},"Lines, 2014, VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy, Cancer Immunol Res, 2, 510, 10.1158\u002F2326-6066.CIR-14-0072",{"doi":1345},"10.1158\u002F2326-6066.CIR-14-0072",{"id":26,"text":1347,"url":26,"identifiers":1348},"Blake, 2016, Molecular pathways: targeting CD96 and TIGIT for cancer immunotherapy, Clin Cancer Res, 22, 5183, 10.1158\u002F1078-0432.CCR-16-0933",{"doi":1349},"10.1158\u002F1078-0432.CCR-16-0933",{"id":26,"text":1351,"url":26,"identifiers":1352},"Glen, 2016, TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection, PLoS Pathog, 12, e1005349, 10.1371\u002Fjournal.ppat.1005349",{"doi":1353},"10.1371\u002Fjournal.ppat.1005349",{"id":26,"text":1355,"url":26,"identifiers":1356},"Spranger, 2014, Mechanism of tumor rejection with doublets of CTLA-4, PD-1\u002FPD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment, J Immunother Cancer, 2, 3, 10.1186\u002F2051-1426-2-3",{"doi":1357},"10.1186\u002F2051-1426-2-3",{"id":26,"text":1359,"url":26,"identifiers":1360},"Antonios, 2017, Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1\u002FPD-L1 mechanism in glioblastoma, Neuro Oncol, 19, 796, 10.1093\u002Fneuonc\u002Fnow287",{"doi":1361},"10.1093\u002Fneuonc\u002Fnow287",{"id":26,"text":1363,"url":26,"identifiers":1364},"Chamoto, 2017, Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity, Proc Natl Acad Sci U S A, 114, E761, 10.1073\u002Fpnas.1620433114",{"doi":1365},"10.1073\u002Fpnas.1620433114",{"id":26,"text":1367,"url":26,"identifiers":1368},"Quezada, 2006, CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells, J Clin Invest, 116, 1935, 10.1172\u002FJCI27745",{"doi":1369},"10.1172\u002FJCI27745",{"id":26,"text":1371,"url":26,"identifiers":1372},"Sorensen, 2010, Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model, Vaccine, 28, 6757, 10.1016\u002Fj.vaccine.2010.07.066",{"doi":1373},"10.1016\u002Fj.vaccine.2010.07.066",{"id":26,"text":1375,"url":26,"identifiers":1376},"Chesney, 2016, Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma, Ann Oncol, 27, 379, 10.1093\u002Fannonc\u002Fmdw379.04",{"doi":1377},"10.1093\u002Fannonc\u002Fmdw379.04",{"id":26,"text":1379,"url":26,"identifiers":1380},"Ribas, 2017, Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy, Cell, 170, 1109.e, 10.1016\u002Fj.cell.2017.08.027",{"doi":1381},"10.1016\u002Fj.cell.2017.08.027",{"id":26,"text":1383,"url":26,"identifiers":1384},"Sivan, 2015, Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy, Science, 350, 1084, 10.1126\u002Fscience.aac4255",{"doi":1385},"10.1126\u002Fscience.aac4255",{"id":26,"text":1387,"url":26,"identifiers":1388},"Gopalakrishnan, 2018, Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients, Science, 359, 97, 10.1126\u002Fscience.aan4236",{"doi":1389},"10.1126\u002Fscience.aan4236",false,{"id":1392,"createTime":1393,"updateTime":1393,"relativeEntities":1394,"slug":1395,"properties":1396,"entityType":772,"verifyStatus":25,"verifyTime":1393,"verifyNote":773,"syncStatus":28,"languages":1411,"translateLanguages":26,"viewCount":36,"primaryUrl":1412,"fullTextUrl":26,"authors":1413,"publicationType":843,"publisherRelationship":1510,"citationCount":1544,"citationInfo":1545,"publishDate":26,"publishYear":26,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":1548,"isForceReanalyzing":1390},"bcd34f6b-9a1b-4baf-a159-728d3995e1a1","2024-09-25T20:02:36.063+00:00",[],"Radiation-induced-brain-injury-A-review",{"mag":1397,"keywords":1399,"pmc":1400,"openalex":1402,"abstract":1404,"title":1405,"pm":1407,"doi":1409},{"VOID":1398},"2094522722",{},{"VOID":1401},"3400082",{"VOID":1403},"W2094522722",{},{"EN":1406},"Radiation-induced brain injury: A review",{"VOID":1408},"22833841",{"VOID":1410},"10.3389\u002Ffonc.2012.00073",[102],"http:\u002F\u002Fjournal.frontiersin.org\u002Farticle\u002F10.3389\u002Ffonc.2012.00073\u002Fabstract",[1414,1433,1448,1465,1480,1495],{"id":1415,"sortIndex":115,"researcher":26,"roles":1416,"affiliations":1417,"properties":1428},"7380d44e-8bb5-476a-ac28-b66ad33bb4f3",[],[1418],{"id":1419,"sortIndex":36,"affiliation":1420,"properties":26},"fc39e0b5-4742-4b6f-8128-854bfd58cb06",{"id":1421,"createTime":1422,"updateTime":1422,"relativeEntities":1423,"slug":1424,"properties":1425,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"ff8f6299-522b-40dd-9dac-d80dee4b4f50","2024-09-25T20:02:36.077+00:00",[],"Wake-Forest-School-of-Medicine-Radiation-Oncology-Medical-Center-Blvd-Winston-Salem-27157-North-Carolina-United-States",{"title":1426},{"EN":1427},"Wake Forest School of Medicine, Radiation Oncology, Medical Center Blvd, Winston-Salem, 27157, North Carolina, United States",{"openalex":1429,"title":1431},{"VOID":1430},"A5053671289",{"EN":1432},"Mike E. Robbins",{"id":1434,"sortIndex":36,"researcher":26,"roles":1435,"affiliations":1436,"properties":1443},"a74f9269-76aa-4181-9031-5dc7fe840ff1",[],[1437],{"id":1438,"sortIndex":36,"affiliation":1439,"properties":26},"2909b821-f004-496e-a611-d9254f8db477",{"id":1421,"createTime":1422,"updateTime":1422,"relativeEntities":1440,"slug":1424,"properties":1441,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1442},{"EN":1427},{"openalex":1444,"title":1446},{"VOID":1445},"A5018720713",{"EN":1447},"Dana Greene-Schloesser",{"id":1449,"sortIndex":162,"researcher":26,"roles":1450,"affiliations":1451,"properties":1458},"46b0b58a-b788-4b89-b699-92022a0f665a",[],[1452],{"id":1453,"sortIndex":36,"affiliation":1454,"properties":26},"2c5bca84-f0ad-42a9-a303-fdc044f54239",{"id":1421,"createTime":1422,"updateTime":1422,"relativeEntities":1455,"slug":1424,"properties":1456,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1457},{"EN":1427},{"openalex":1459,"orcid":1461,"title":1463},{"VOID":1460},"A5053414244",{"VOID":1462},"https:\u002F\u002Forcid.org\u002F0000-0002-5278-6709",{"EN":1464},"Michael D. Chan",{"id":1466,"sortIndex":59,"researcher":26,"roles":1467,"affiliations":1468,"properties":1475},"27985a15-dbd8-42e8-b20b-08ec5af041e2",[],[1469],{"id":1470,"sortIndex":36,"affiliation":1471,"properties":26},"5f781b56-7081-4b0a-9a44-72c8e9f5f051",{"id":1421,"createTime":1422,"updateTime":1422,"relativeEntities":1472,"slug":1424,"properties":1473,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1474},{"EN":1427},{"openalex":1476,"title":1478},{"VOID":1477},"A5103415116",{"EN":1479},"Edward G. Shaw",{"id":1481,"sortIndex":111,"researcher":26,"roles":1482,"affiliations":1483,"properties":1490},"ed7f5806-eb74-48b0-8a89-684a49ea82d9",[],[1484],{"id":1485,"sortIndex":36,"affiliation":1486,"properties":26},"d2300ed6-47af-4257-8cab-c1a490be9b0c",{"id":1421,"createTime":1422,"updateTime":1422,"relativeEntities":1487,"slug":1424,"properties":1488,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1489},{"EN":1427},{"openalex":1491,"title":1493},{"VOID":1492},"A5007729863",{"EN":1494},"Kenneth T. Wheeler",{"id":1496,"sortIndex":114,"researcher":26,"roles":1497,"affiliations":1498,"properties":1505},"1f11ee4d-a72c-4787-a02e-f6db26bb07f9",[],[1499],{"id":1500,"sortIndex":36,"affiliation":1501,"properties":26},"de06302e-2857-4b3d-a5de-fe0fa5364f53",{"id":1421,"createTime":1422,"updateTime":1422,"relativeEntities":1502,"slug":1424,"properties":1503,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1504},{"EN":1427},{"openalex":1506,"title":1508},{"VOID":1507},"A5067450066",{"EN":1509},"Ann M. Peiffer",{"url":26,"publisher":1511,"properties":1541},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":1512,"slug":663,"properties":1513,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":1519,"manageAffiliations":1520,"indexDatabases":1521,"url":742,"thumbnailPath":26,"statistic":1536,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"country":1514,"issn":1515,"introduce":1516,"eissn":1517,"title":1518},{"VOID":666},{"VOID":668},{"EN":670},{"VOID":668},{"EN":673},[],[],[1522,1529],{"id":704,"indexDatabase":1523,"url":719,"indexYears":26,"academicFieldIds":1528,"indexDatabaseRanking":26},{"id":706,"createTime":707,"updateTime":708,"relativeEntities":1524,"label":1525,"description":1526,"key":715,"publicationTags":1527,"standard":26},[],{"EN":711,"VI":711},{"VI":713,"EN":714},[717,718],[721],{"id":723,"indexDatabase":1530,"url":736,"indexYears":737,"academicFieldIds":1535,"indexDatabaseRanking":741},{"id":725,"createTime":726,"updateTime":727,"relativeEntities":1531,"label":1532,"description":1533,"key":733,"publicationTags":1534,"standard":26},[],{"EN":730,"VI":730},{"EN":730,"VI":732},[735],[739,740],{"impactFactor":36,"impactFactorByYear":1537,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":115,"totalPublicationByYear":1538,"totalCitation":158,"totalCitationByYear":1539,"totalCitationPerPublication":158,"totalCitationPerPublicationByYear":1540,"hindexLast5Year":115,"hindex":115},{},{"2021":115},{"2021":158},{"2021":158},{"volume":1542},{"VOID":1543},"2",590,{"total":1544,"publishYear":26,"statisticByYear":1546},{"2012":162,"2013":124,"2014":285,"2015":287,"2016":358,"2017":283,"2018":1547,"2019":539,"2020":254,"2021":359,"2022":1547,"2023":165,"2024":252},55,[],{"id":1550,"createTime":1551,"updateTime":1551,"relativeEntities":1552,"slug":1553,"properties":1554,"entityType":772,"verifyStatus":25,"verifyTime":1551,"verifyNote":773,"syncStatus":28,"languages":1569,"translateLanguages":26,"viewCount":36,"primaryUrl":1570,"fullTextUrl":26,"authors":1571,"publicationType":843,"publisherRelationship":1610,"citationCount":163,"citationInfo":1644,"publishDate":26,"publishYear":26,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":1646,"isForceReanalyzing":1390},"5a30acf7-cd58-471c-873f-d2be35963564","2024-11-27T13:35:56.365+00:00",[],"The-KEAP1-NRF2-System-in-Cancer",{"mag":1555,"keywords":1557,"pmc":1558,"openalex":1560,"abstract":1562,"title":1563,"pm":1565,"doi":1567},{"VOID":1556},"2611475096",{},{"VOID":1559},"5415577",{"VOID":1561},"W2611475096",{},{"EN":1564},"The KEAP1–NRF2 System in Cancer",{"VOID":1566},"28523248",{"VOID":1568},"10.3389\u002Ffonc.2017.00085",[102],"http:\u002F\u002Fjournal.frontiersin.org\u002Farticle\u002F10.3389\u002Ffonc.2017.00085\u002Ffull",[1572,1593],{"id":1573,"sortIndex":36,"researcher":26,"roles":1574,"affiliations":1575,"properties":1586},"66e6e98a-538f-4487-99fc-bd3e63249afb",[],[1576],{"id":1577,"sortIndex":36,"affiliation":1578,"properties":26},"c5874caa-4132-40f4-9efe-976fb5cb4562",{"id":1579,"createTime":1580,"updateTime":1580,"relativeEntities":1581,"slug":1582,"properties":1583,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"322cee92-31ee-4f4a-ab58-c5ba30b74180","2024-11-27T13:35:56.386+00:00",[],"Department-of-Medical-Biochemistry-Graduate-School-of-Medicine-Tohoku-University-Japan",{"title":1584},{"EN":1585},"Department of Medical Biochemistry, Graduate School of Medicine, Tohoku University, Japan",{"openalex":1587,"orcid":1589,"title":1591},{"VOID":1588},"A5075296882",{"VOID":1590},"https:\u002F\u002Forcid.org\u002F0000-0002-5798-0076",{"EN":1592},"Keiko Taguchi",{"id":1594,"sortIndex":115,"researcher":26,"roles":1595,"affiliations":1596,"properties":1603},"7a4914d8-d8e9-4eaa-bf6d-92a6b096c3ac",[],[1597],{"id":1598,"sortIndex":36,"affiliation":1599,"properties":26},"887b7d44-345c-451d-8c7b-a3ce167f4d50",{"id":1579,"createTime":1580,"updateTime":1580,"relativeEntities":1600,"slug":1582,"properties":1601,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1602},{"EN":1585},{"openalex":1604,"orcid":1606,"title":1608},{"VOID":1605},"A5102992059",{"VOID":1607},"https:\u002F\u002Forcid.org\u002F0000-0002-9073-9436",{"EN":1609},"Masayuki Yamamoto",{"url":26,"publisher":1611,"properties":1641},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":1612,"slug":663,"properties":1613,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":1619,"manageAffiliations":1620,"indexDatabases":1621,"url":742,"thumbnailPath":26,"statistic":1636,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"country":1614,"issn":1615,"introduce":1616,"eissn":1617,"title":1618},{"VOID":666},{"VOID":668},{"EN":670},{"VOID":668},{"EN":673},[],[],[1622,1629],{"id":704,"indexDatabase":1623,"url":719,"indexYears":26,"academicFieldIds":1628,"indexDatabaseRanking":26},{"id":706,"createTime":707,"updateTime":708,"relativeEntities":1624,"label":1625,"description":1626,"key":715,"publicationTags":1627,"standard":26},[],{"EN":711,"VI":711},{"VI":713,"EN":714},[717,718],[721],{"id":723,"indexDatabase":1630,"url":736,"indexYears":737,"academicFieldIds":1635,"indexDatabaseRanking":741},{"id":725,"createTime":726,"updateTime":727,"relativeEntities":1631,"label":1632,"description":1633,"key":733,"publicationTags":1634,"standard":26},[],{"EN":730,"VI":730},{"EN":730,"VI":732},[735],[739,740],{"impactFactor":36,"impactFactorByYear":1637,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":115,"totalPublicationByYear":1638,"totalCitation":158,"totalCitationByYear":1639,"totalCitationPerPublication":158,"totalCitationPerPublicationByYear":1640,"hindexLast5Year":115,"hindex":115},{},{"2021":115},{"2021":158},{"2021":158},{"volume":1642},{"VOID":1643},"7",{"total":163,"publishYear":26,"statisticByYear":1645},{"2017":116,"2018":159,"2019":240,"2020":46,"2021":253,"2022":165,"2023":253,"2024":282},[1647,1651,1654,1658,1662,1666,1670,1674,1678,1682,1686,1690,1694,1698,1702,1706,1710,1714,1718,1722,1726,1729,1733,1737,1741,1745,1749,1753,1757,1761,1765,1769,1773,1777,1781,1785,1789,1793,1797,1801,1805,1809,1813,1817,1821,1824,1827,1831,1835,1839,1843,1847,1851,1855,1859,1863,1867,1871,1875,1879,1883,1887,1891,1895,1899,1903,1907,1911,1915,1919,1923,1927,1931,1935,1939,1943,1947,1951,1955,1959,1963,1966,1970,1974,1977,1981,1985,1989,1993,1997,2001,2005,2008,2012,2016,2020],{"id":26,"text":1648,"url":26,"identifiers":1649},"Itoh, 1997, An Nrf2\u002Fsmall Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements, Biochem Biophys Res Commun, 236, 313, 10.1006\u002Fbbrc.1997.6943",{"doi":1650},"10.1006\u002Fbbrc.1997.6943",{"id":26,"text":1652,"url":26,"identifiers":1653},"McMahon, 2001, The Cap’n’Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes, Cancer Res, 61, 3299",{},{"id":26,"text":1655,"url":26,"identifiers":1656},"Kobayashi, 2004, Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2, Mol Cell Biol, 24, 7130, 10.1128\u002FMCB.24.16.7130-7139.2004",{"doi":1657},"10.1128\u002FMCB.24.16.7130-7139.2004",{"id":26,"text":1659,"url":26,"identifiers":1660},"Tong, 2006, Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model, Mol Cell Biol, 26, 2887, 10.1128\u002FMCB.26.8.2887-2900.2006",{"doi":1661},"10.1128\u002FMCB.26.8.2887-2900.2006",{"id":26,"text":1663,"url":26,"identifiers":1664},"Kim, 2016, NRF2, a key regulator of antioxidants with two faces towards cancer, Oxid Med Cell Longev, 2016, 2746457, 10.1155\u002F2016\u002F2746457",{"doi":1665},"10.1155\u002F2016\u002F2746457",{"id":26,"text":1667,"url":26,"identifiers":1668},"Iso, 2016, Absolute amounts and status of the Nrf2-Keap1-Cul3 complex within cells, Mol Cell Biol, 36, 3100, 10.1128\u002FMCB.00389-16",{"doi":1669},"10.1128\u002FMCB.00389-16",{"id":26,"text":1671,"url":26,"identifiers":1672},"Itoh, 2001, Nrf2 activation by electrophiles is mediated by the inhibition of proteasomal degradation of Nrf2 protein in activated macrophages, FASEB J, 15, A899, 10.1128\u002FMCB.26.1.221-229.2006",{"doi":1673},"10.1128\u002FMCB.26.1.221-229.2006",{"id":26,"text":1675,"url":26,"identifiers":1676},"McMahon, 2003, Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression, J Biol Chem, 278, 21592, 10.1074\u002Fjbc.M300931200",{"doi":1677},"10.1074\u002Fjbc.M300931200",{"id":26,"text":1679,"url":26,"identifiers":1680},"Zhang, 2004, Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex, Mol Cell Biol, 24, 10941, 10.1128\u002FMCB.24.24.10941-10953.2004",{"doi":1681},"10.1128\u002FMCB.24.24.10941-10953.2004",{"id":26,"text":1683,"url":26,"identifiers":1684},"Fukutomi, 2014, Kinetic, thermodynamic, and structural characterizations of the association between Nrf2-DLGex degron and Keap1, Mol Cell Biol, 34, 832, 10.1128\u002FMCB.01191-13",{"doi":1685},"10.1128\u002FMCB.01191-13",{"id":26,"text":1687,"url":26,"identifiers":1688},"Itoh, 1999, Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain, Genes Dev, 13, 76, 10.1101\u002Fgad.13.1.76",{"doi":1689},"10.1101\u002Fgad.13.1.76",{"id":26,"text":1691,"url":26,"identifiers":1692},"Dinkova-Kostova, 2005, Keap1, the sensor for electrophiles and oxidants that regulates the phase 2 response, is a zinc metalloprotein, Biochemistry, 44, 6889, 10.1021\u002Fbi047434h",{"doi":1693},"10.1021\u002Fbi047434h",{"id":26,"text":1695,"url":26,"identifiers":1696},"Zhang, 2003, Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress, Mol Cell Biol, 23, 8137, 10.1128\u002FMCB.23.22.8137-8151.2003",{"doi":1697},"10.1128\u002FMCB.23.22.8137-8151.2003",{"id":26,"text":1699,"url":26,"identifiers":1700},"Takaya, 2012, Validation of the multiple sensor mechanism of the Keap1-Nrf2 system, Free Radic Biol Med, 53, 817, 10.1016\u002Fj.freeradbiomed.2012.06.023",{"doi":1701},"10.1016\u002Fj.freeradbiomed.2012.06.023",{"id":26,"text":1703,"url":26,"identifiers":1704},"Saito, 2015, Characterizations of three major cysteine sensors of Keap1 in stress response, Mol Cell Biol, 36, 271, 10.1128\u002FMCB.00868-15",{"doi":1705},"10.1128\u002FMCB.00868-15",{"id":26,"text":1707,"url":26,"identifiers":1708},"Eggler, 2007, Identification of the highly reactive cysteine 151 in the chemopreventive agent-sensor Keap1 protein is method-dependent, Chem Res Toxicol, 20, 1878, 10.1021\u002Ftx700217c",{"doi":1709},"10.1021\u002Ftx700217c",{"id":26,"text":1711,"url":26,"identifiers":1712},"Taguchi, 2011, Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution, Genes Cells, 16, 123, 10.1111\u002Fj.1365-2443.2010.01473.x",{"doi":1713},"10.1111\u002Fj.1365-2443.2010.01473.x",{"id":26,"text":1715,"url":26,"identifiers":1716},"Ishii, 2000, Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages, J Biol Chem, 275, 16023, 10.1074\u002Fjbc.275.21.16023",{"doi":1717},"10.1074\u002Fjbc.275.21.16023",{"id":26,"text":1719,"url":26,"identifiers":1720},"Rachakonda, 2008, Covalent modification at Cys151 dissociates the electrophile sensor Keap1 from the ubiquitin ligase CUL3, Chem Res Toxicol, 21, 705, 10.1021\u002Ftx700302s",{"doi":1721},"10.1021\u002Ftx700302s",{"id":26,"text":1723,"url":26,"identifiers":1724},"Abiko, 2011, Participation of covalent modification of Keap1 in the activation of Nrf2 by tert-butylbenzoquinone, an electrophilic metabolite of butylated hydroxyanisole, Toxicol Appl Pharmacol, 255, 32, 10.1016\u002Fj.taap.2011.05.013",{"doi":1725},"10.1016\u002Fj.taap.2011.05.013",{"id":26,"text":1727,"url":26,"identifiers":1728},"Kobayashi, 2006, Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1, Mol Cell Biol, 26, 221, 10.1128\u002FMCB.26.1.221-229.2006",{"doi":1673},{"id":26,"text":1730,"url":26,"identifiers":1731},"Watai, 2007, Subcellular localization and cytoplasmic complex status of endogenous Keap1, Genes Cells, 12, 1163, 10.1111\u002Fj.1365-2443.2007.01118.x",{"doi":1732},"10.1111\u002Fj.1365-2443.2007.01118.x",{"id":26,"text":1734,"url":26,"identifiers":1735},"Kang, 2004, Scaffolding of Keap1 to the actin cytoskeleton controls the function of Nrf2 as key regulator of cytoprotective phase 2 genes, Proc Natl Acad Sci U S A, 101, 2046, 10.1073\u002Fpnas.0308347100",{"doi":1736},"10.1073\u002Fpnas.0308347100",{"id":26,"text":1738,"url":26,"identifiers":1739},"Rada, 2012, Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3\u002Fbeta-TrCP axis, Mol Cell Biol, 32, 3486, 10.1128\u002FMCB.00180-12",{"doi":1740},"10.1128\u002FMCB.00180-12",{"id":26,"text":1742,"url":26,"identifiers":1743},"Chowdhry, 2013, Nrf2 is controlled by two distinct beta-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity, Oncogene, 32, 3765, 10.1038\u002Fonc.2012.388",{"doi":1744},"10.1038\u002Fonc.2012.388",{"id":26,"text":1746,"url":26,"identifiers":1747},"Mitsuishi, 2012, Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming, Cancer Cell, 22, 66, 10.1016\u002Fj.ccr.2012.05.016",{"doi":1748},"10.1016\u002Fj.ccr.2012.05.016",{"id":26,"text":1750,"url":26,"identifiers":1751},"Taguchi, 2014, Nrf2 enhances cholangiocyte expansion in Pten-deficient livers, Mol Cell Biol, 34, 900, 10.1128\u002FMCB.01384-13",{"doi":1752},"10.1128\u002FMCB.01384-13",{"id":26,"text":1754,"url":26,"identifiers":1755},"Cheng, 2013, Regulation of the Nrf2 antioxidant pathway by microRNAs: new players in micromanaging redox homeostasis, Free Radic Biol Med, 64, 4, 10.1016\u002Fj.freeradbiomed.2013.07.025",{"doi":1756},"10.1016\u002Fj.freeradbiomed.2013.07.025",{"id":26,"text":1758,"url":26,"identifiers":1759},"Yang, 2011, MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism, Breast Cancer Res Treat, 129, 983, 10.1007\u002Fs10549-011-1604-1",{"doi":1760},"10.1007\u002Fs10549-011-1604-1",{"id":26,"text":1762,"url":26,"identifiers":1763},"Eades, 2011, miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells, J Biol Chem, 286, 40725, 10.1074\u002Fjbc.M111.275495",{"doi":1764},"10.1074\u002Fjbc.M111.275495",{"id":26,"text":1766,"url":26,"identifiers":1767},"Singh, 2013, Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis, J Clin Invest, 123, 2921, 10.1172\u002FJCI66353",{"doi":1768},"10.1172\u002FJCI66353",{"id":26,"text":1770,"url":26,"identifiers":1771},"Rushmore, 1990, Transcriptional regulation of the rat glutathione S-transferase Ya subunit gene. Characterization of a xenobiotic-responsive element controlling inducible expression by phenolic antioxidants, J Biol Chem, 265, 14648, 10.1016\u002FS0021-9258(18)77351-1",{"doi":1772},"10.1016\u002FS0021-9258(18)77351-1",{"id":26,"text":1774,"url":26,"identifiers":1775},"Friling, 1990, Xenobiotic-inducible expression of murine glutathione S-transferase Ya subunit gene is controlled by an electrophile-responsive element, Proc Natl Acad Sci U S A, 87, 6258, 10.1073\u002Fpnas.87.16.6258",{"doi":1776},"10.1073\u002Fpnas.87.16.6258",{"id":26,"text":1778,"url":26,"identifiers":1779},"Hirotsu, 2012, Nrf2-MafG heterodimers contribute globally to antioxidant and metabolic networks, Nucleic Acids Res, 40, 10228, 10.1093\u002Fnar\u002Fgks827",{"doi":1780},"10.1093\u002Fnar\u002Fgks827",{"id":26,"text":1782,"url":26,"identifiers":1783},"Mignotte, 1990, The extinction of erythroid genes after tetradecanoylphorbol acetate treatment of erythroleukemic cells correlates with down-regulation of the tissue-specific factors NF-E1 and NF-E2, J Biol Chem, 265, 22090, 10.1016\u002FS0021-9258(18)45673-6",{"doi":1784},"10.1016\u002FS0021-9258(18)45673-6",{"id":26,"text":1786,"url":26,"identifiers":1787},"Sykiotis, 2008, Keap1\u002FNrf2 signaling regulates oxidative stress tolerance and lifespan in Drosophila, Dev Cell, 14, 76, 10.1016\u002Fj.devcel.2007.12.002",{"doi":1788},"10.1016\u002Fj.devcel.2007.12.002",{"id":26,"text":1790,"url":26,"identifiers":1791},"Otsuki, 2016, Unique cistrome defined as CsMBE is strictly required for Nrf2-sMaf heterodimer function in cytoprotection, Free Radic Biol Med, 91, 45, 10.1016\u002Fj.freeradbiomed.2015.12.005",{"doi":1792},"10.1016\u002Fj.freeradbiomed.2015.12.005",{"id":26,"text":1794,"url":26,"identifiers":1795},"Malhotra, 2010, Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis, Nucleic Acids Res, 38, 5718, 10.1093\u002Fnar\u002Fgkq212",{"doi":1796},"10.1093\u002Fnar\u002Fgkq212",{"id":26,"text":1798,"url":26,"identifiers":1799},"Chorley, 2012, Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha, Nucleic Acids Res, 40, 7416, 10.1093\u002Fnar\u002Fgks409",{"doi":1800},"10.1093\u002Fnar\u002Fgks409",{"id":26,"text":1802,"url":26,"identifiers":1803},"Suzuki, 2013, Toward clinical application of the Keap1-Nrf2 pathway, Trends Pharmacol Sci, 34, 340, 10.1016\u002Fj.tips.2013.04.005",{"doi":1804},"10.1016\u002Fj.tips.2013.04.005",{"id":26,"text":1806,"url":26,"identifiers":1807},"Padmanabhan, 2006, Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer, Mol Cell, 21, 689, 10.1016\u002Fj.molcel.2006.01.013",{"doi":1808},"10.1016\u002Fj.molcel.2006.01.013",{"id":26,"text":1810,"url":26,"identifiers":1811},"Ohta, 2008, Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth, Cancer Res, 68, 1303, 10.1158\u002F0008-5472.CAN-07-5003",{"doi":1812},"10.1158\u002F0008-5472.CAN-07-5003",{"id":26,"text":1814,"url":26,"identifiers":1815},"Leinonen, 2015, Dysregulation of the Keap1-Nrf2 pathway in cancer, Biochem Soc Trans, 43, 645, 10.1042\u002FBST20150048",{"doi":1816},"10.1042\u002FBST20150048",{"id":26,"text":1818,"url":26,"identifiers":1819},"Ramos-Gomez, 2003, Interactive effects of nrf2 genotype and oltipraz on benzo[a]pyrene-DNA adducts and tumor yield in mice, Carcinogenesis, 24, 461, 10.1093\u002Fcarcin\u002F24.3.461",{"doi":1820},"10.1093\u002Fcarcin\u002F24.3.461",{"id":26,"text":1822,"url":26,"identifiers":1823},"Solt, 1977, Rapid emergence of carcinogen-induced hyperplastic lesions in a new model for the sequential analysis of liver carcinogenesis, Am J Pathol, 88, 595",{},{"id":26,"text":1825,"url":26,"identifiers":1826},"Kartner, 1983, Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein, Cancer Res, 43, 4413",{},{"id":26,"text":1828,"url":26,"identifiers":1829},"Singh, 2006, Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer, PLoS Med, 3, e420, 10.1371\u002Fjournal.pmed.0030420",{"doi":1830},"10.1371\u002Fjournal.pmed.0030420",{"id":26,"text":1832,"url":26,"identifiers":1833},"Ooi, 2013, CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma, Cancer Res, 73, 2044, 10.1158\u002F0008-5472.CAN-12-3227",{"doi":1834},"10.1158\u002F0008-5472.CAN-12-3227",{"id":26,"text":1836,"url":26,"identifiers":1837},"Menegon, 2016, The dual roles of NRF2 in cancer, Trends Mol Med, 22, 578, 10.1016\u002Fj.molmed.2016.05.002",{"doi":1838},"10.1016\u002Fj.molmed.2016.05.002",{"id":26,"text":1840,"url":26,"identifiers":1841},"Wang, 2008, Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues, Biochem Biophys Res Commun, 373, 151, 10.1016\u002Fj.bbrc.2008.06.004",{"doi":1842},"10.1016\u002Fj.bbrc.2008.06.004",{"id":26,"text":1844,"url":26,"identifiers":1845},"Komatsu, 2010, The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1, Nat Cell Biol, 12, 213, 10.1038\u002Fncb2021",{"doi":1846},"10.1038\u002Fncb2021",{"id":26,"text":1848,"url":26,"identifiers":1849},"Chen, 2009, Direct interaction between Nrf2 and p21(Cip1\u002FWAF1) upregulates the Nrf2-mediated antioxidant response, Mol Cell, 34, 663, 10.1016\u002Fj.molcel.2009.04.029",{"doi":1850},"10.1016\u002Fj.molcel.2009.04.029",{"id":26,"text":1852,"url":26,"identifiers":1853},"Adam, 2011, Renal cyst formation in Fh1-deficient mice is independent of the Hif\u002FPhd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling, Cancer Cell, 20, 524, 10.1016\u002Fj.ccr.2011.09.006",{"doi":1854},"10.1016\u002Fj.ccr.2011.09.006",{"id":26,"text":1856,"url":26,"identifiers":1857},"Ooi, 2011, An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma, Cancer Cell, 20, 511, 10.1016\u002Fj.ccr.2011.08.024",{"doi":1858},"10.1016\u002Fj.ccr.2011.08.024",{"id":26,"text":1860,"url":26,"identifiers":1861},"Taguchi, 2008, Redox cycling of 9,10-phenanthraquinone to cause oxidative stress is terminated through its monoglucuronide conjugation in human pulmonary epithelial A549 cells, Free Radic Biol Med, 44, 1645, 10.1016\u002Fj.freeradbiomed.2008.01.024",{"doi":1862},"10.1016\u002Fj.freeradbiomed.2008.01.024",{"id":26,"text":1864,"url":26,"identifiers":1865},"Shibata, 2011, NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer, Neoplasia, 13, 864, 10.1593\u002Fneo.11750",{"doi":1866},"10.1593\u002Fneo.11750",{"id":26,"text":1868,"url":26,"identifiers":1869},"Li, 2013, SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer, Cancer Cell, 24, 738, 10.1016\u002Fj.ccr.2013.10.025",{"doi":1870},"10.1016\u002Fj.ccr.2013.10.025",{"id":26,"text":1872,"url":26,"identifiers":1873},"Probst, 2015, Cancer cell growth is differentially affected by constitutive activation of NRF2 by KEAP1 deletion and pharmacological activation of NRF2 by the synthetic triterpenoid, RTA 405, PLoS One, 10, e0135257, 10.1371\u002Fjournal.pone.0135257",{"doi":1874},"10.1371\u002Fjournal.pone.0135257",{"id":26,"text":1876,"url":26,"identifiers":1877},"Hong, 2010, Nuclear factor (erythroid-derived 2)-like 2 regulates drug resistance in pancreatic cancer cells, Pancreas, 39, 463, 10.1097\u002FMPA.0b013e3181c31314",{"doi":1878},"10.1097\u002FMPA.0b013e3181c31314",{"id":26,"text":1880,"url":26,"identifiers":1881},"Arlt, 2013, Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity, Oncogene, 32, 4825, 10.1038\u002Fonc.2012.493",{"doi":1882},"10.1038\u002Fonc.2012.493",{"id":26,"text":1884,"url":26,"identifiers":1885},"Lister, 2011, Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy, Mol Cancer, 10, 37, 10.1186\u002F1476-4598-10-37",{"doi":1886},"10.1186\u002F1476-4598-10-37",{"id":26,"text":1888,"url":26,"identifiers":1889},"Ichimura, 2013, Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy, Mol Cell, 51, 618, 10.1016\u002Fj.molcel.2013.08.003",{"doi":1890},"10.1016\u002Fj.molcel.2013.08.003",{"id":26,"text":1892,"url":26,"identifiers":1893},"2012, Comprehensive genomic characterization of squamous cell lung cancers, Nature, 489, 519, 10.1038\u002Fnature11404",{"doi":1894},"10.1038\u002Fnature11404",{"id":26,"text":1896,"url":26,"identifiers":1897},"Schulze, 2015, Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets, Nat Genet, 47, 505, 10.1038\u002Fng.3252",{"doi":1898},"10.1038\u002Fng.3252",{"id":26,"text":1900,"url":26,"identifiers":1901},"Lee, 2003, Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis, J Biol Chem, 278, 12029, 10.1074\u002Fjbc.M211558200",{"doi":1902},"10.1074\u002Fjbc.M211558200",{"id":26,"text":1904,"url":26,"identifiers":1905},"Wu, 2011, Beneficial role of Nrf2 in regulating NADPH generation and consumption, Toxicol Sci, 123, 590, 10.1093\u002Ftoxsci\u002Fkfr183",{"doi":1906},"10.1093\u002Ftoxsci\u002Fkfr183",{"id":26,"text":1908,"url":26,"identifiers":1909},"Saito, 2016, p62\u002FSqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming, Nat Commun, 7, 12030, 10.1038\u002Fncomms12030",{"doi":1910},"10.1038\u002Fncomms12030",{"id":26,"text":1912,"url":26,"identifiers":1913},"Liu, 2015, Hepatitis B virus stimulates G6PD expression through HBx-mediated Nrf2 activation, Cell Death Dis, 6, e1980, 10.1038\u002Fcddis.2015.322",{"doi":1914},"10.1038\u002Fcddis.2015.322",{"id":26,"text":1916,"url":26,"identifiers":1917},"Zhang, 1992, A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure, Proc Natl Acad Sci U S A, 89, 2399, 10.1073\u002Fpnas.89.6.2399",{"doi":1918},"10.1073\u002Fpnas.89.6.2399",{"id":26,"text":1920,"url":26,"identifiers":1921},"Balogun, 2003, Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element, Biochem J, 371, 887, 10.1042\u002Fbj20021619",{"doi":1922},"10.1042\u002Fbj20021619",{"id":26,"text":1924,"url":26,"identifiers":1925},"Satoh, 2008, Carnosic acid, a catechol-type electrophilic compound, protects neurons both in vitro and in vivo through activation of the Keap1\u002FNrf2 pathway via S-alkylation of targeted cysteines on Keap1, J Neurochem, 104, 1116, 10.1111\u002Fj.1471-4159.2007.05039.x",{"doi":1926},"10.1111\u002Fj.1471-4159.2007.05039.x",{"id":26,"text":1928,"url":26,"identifiers":1929},"Krajka-Kuzniak, 2016, The Nrf2-ARE signaling pathway: an update on its regulation and possible role in cancer prevention and treatment, Pharmacol Rep, 69, 393, 10.1016\u002Fj.pharep.2016.12.011",{"doi":1930},"10.1016\u002Fj.pharep.2016.12.011",{"id":26,"text":1932,"url":26,"identifiers":1933},"Zhu, 2016, An overview of chemical inhibitors of the Nrf2-ARE signaling pathway and their potential applications in cancer therapy, Free Radic Biol Med, 99, 544, 10.1016\u002Fj.freeradbiomed.2016.09.010",{"doi":1934},"10.1016\u002Fj.freeradbiomed.2016.09.010",{"id":26,"text":1936,"url":26,"identifiers":1937},"Lee, 1982, Antitumor agents XLV: bisbrusatolyl and brusatolyl esters and related compounds as novel potent antileukemic agents, J Pharm Sci, 71, 338, 10.1002\u002Fjps.2600710320",{"doi":1938},"10.1002\u002Fjps.2600710320",{"id":26,"text":1940,"url":26,"identifiers":1941},"Willingham, 1981, Mechanism of eukaryotic protein synthesis inhibition by brusatol, Biochim Biophys Acta, 654, 169, 10.1016\u002F0005-2787(81)90168-4",{"doi":1942},"10.1016\u002F0005-2787(81)90168-4",{"id":26,"text":1944,"url":26,"identifiers":1945},"Hall, 1982, Antitumor agents XLVI: in vitro effects of esters of brusatol, bisbrusatol, and related compounds on nucleic acid and protein synthesis of P-388 lymphocytic leukemia cells, J Pharm Sci, 71, 345, 10.1002\u002Fjps.2600710229",{"doi":1946},"10.1002\u002Fjps.2600710229",{"id":26,"text":1948,"url":26,"identifiers":1949},"Liou, 1982, Antitumor agents XLVIII: structure-activity relationships of quassinoids as in vitro protein synthesis inhibitors of P-388 lymphocytic leukemia tumor cell metabolism, J Pharm Sci, 71, 430, 10.1002\u002Fjps.2600711208",{"doi":1950},"10.1002\u002Fjps.2600711208",{"id":26,"text":1952,"url":26,"identifiers":1953},"Ren, 2011, Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism, Proc Natl Acad Sci U S A, 108, 1433, 10.1073\u002Fpnas.1014275108",{"doi":1954},"10.1073\u002Fpnas.1014275108",{"id":26,"text":1956,"url":26,"identifiers":1957},"Vartanian, 2016, Application of mass spectrometry profiling to establish brusatol as an inhibitor of global protein synthesis, Mol Cell Proteomics, 15, 1220, 10.1074\u002Fmcp.M115.055509",{"doi":1958},"10.1074\u002Fmcp.M115.055509",{"id":26,"text":1960,"url":26,"identifiers":1961},"Singh, 2016, Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-deficient NSCLC tumors, ACS Chem Biol, 11, 3214, 10.1021\u002Facschembio.6b00651",{"doi":1962},"10.1021\u002Facschembio.6b00651",{"id":26,"text":1964,"url":26,"identifiers":1965},"Coatney, 1950, Studies in human malaria. XXV. Trial of febrifugine, an alkaloid obtained from Dichroa febrifuga lour., against the Chesson strain of Plasmodium vivax, J Natl Malar Soc, 9, 183",{},{"id":26,"text":1967,"url":26,"identifiers":1968},"Pines, 1997, Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis, J Hepatol, 27, 391, 10.1016\u002FS0168-8278(97)80186-9",{"doi":1969},"10.1016\u002FS0168-8278(97)80186-9",{"id":26,"text":1971,"url":26,"identifiers":1972},"Keller, 2012, Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase, Nat Chem Biol, 8, 311, 10.1038\u002Fnchembio.790",{"doi":1973},"10.1038\u002Fnchembio.790",{"id":26,"text":1975,"url":26,"identifiers":1976},"Elkin, 1999, Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone, Cancer Res, 59, 4111",{},{"id":26,"text":1978,"url":26,"identifiers":1979},"Pines, 2003, Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma, Biol Blood Marrow Transplant, 9, 417, 10.1016\u002FS1083-8791(03)00151-4",{"doi":1980},"10.1016\u002FS1083-8791(03)00151-4",{"id":26,"text":1982,"url":26,"identifiers":1983},"Nevo, 2010, Fibrosis inhibition and muscle histopathology improvement in laminin-alpha2-deficient mice, Muscle Nerve, 42, 218, 10.1002\u002Fmus.21706",{"doi":1984},"10.1002\u002Fmus.21706",{"id":26,"text":1986,"url":26,"identifiers":1987},"Tsuchida, 2016, Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation, Free Radic Biol Med, 103, 236, 10.1016\u002Fj.freeradbiomed.2016.12.041",{"doi":1988},"10.1016\u002Fj.freeradbiomed.2016.12.041",{"id":26,"text":1990,"url":26,"identifiers":1991},"Gao, 2013, Chrysin enhances sensitivity of BEL-7402\u002FADM cells to doxorubicin by suppressing PI3K\u002FAkt\u002FNrf2 and ERK\u002FNrf2 pathway, Chem Biol Interact, 206, 100, 10.1016\u002Fj.cbi.2013.08.008",{"doi":1992},"10.1016\u002Fj.cbi.2013.08.008",{"id":26,"text":1994,"url":26,"identifiers":1995},"Tang, 2011, Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2\u002FARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs, Free Radic Biol Med, 50, 1599, 10.1016\u002Fj.freeradbiomed.2011.03.008",{"doi":1996},"10.1016\u002Fj.freeradbiomed.2011.03.008",{"id":26,"text":1998,"url":26,"identifiers":1999},"Johnson, 2014, Complete protection against aflatoxin B1-induced liver cancer with a triterpenoid: DNA adduct dosimetry, molecular signature, and genotoxicity threshold, Cancer Prev Res (Phila), 7, 658, 10.1158\u002F1940-6207.CAPR-13-0430",{"doi":2000},"10.1158\u002F1940-6207.CAPR-13-0430",{"id":26,"text":2002,"url":26,"identifiers":2003},"Iida, 2004, Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis, Cancer Res, 64, 6424, 10.1158\u002F0008-5472.CAN-04-1906",{"doi":2004},"10.1158\u002F0008-5472.CAN-04-1906",{"id":26,"text":2006,"url":26,"identifiers":2007},"Kelloff, 1994, Clinical development plan: oltipraz, J Cell Biochem Suppl, 20, 205",{},{"id":26,"text":2009,"url":26,"identifiers":2010},"Kensler, 1995, Oltipraz: clinical opportunities for cancer chemoprevention. p, J Cell Biochem Suppl, 22, 101, 10.1002\u002Fjcb.240590813",{"doi":2011},"10.1002\u002Fjcb.240590813",{"id":26,"text":2013,"url":26,"identifiers":2014},"Dinkova-Kostova, 2002, Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants, Proc Natl Acad Sci U S A, 99, 11908, 10.1073\u002Fpnas.172398899",{"doi":2015},"10.1073\u002Fpnas.172398899",{"id":26,"text":2017,"url":26,"identifiers":2018},"Kensler, 2005, Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People’s Republic of China, Cancer Epidemiol Biomarkers Prev, 14, 2605, 10.1158\u002F1055-9965.EPI-05-0368",{"doi":2019},"10.1158\u002F1055-9965.EPI-05-0368",{"id":26,"text":2021,"url":26,"identifiers":2022},"Kowalik, 2016, Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis, Oncotarget, 7, 32375, 10.18632\u002Foncotarget.8632",{"doi":2023},"10.18632\u002Foncotarget.8632",{"id":2025,"createTime":2026,"updateTime":2026,"relativeEntities":2027,"slug":2028,"properties":2029,"entityType":772,"verifyStatus":25,"verifyTime":2026,"verifyNote":773,"syncStatus":28,"languages":2044,"translateLanguages":26,"viewCount":36,"primaryUrl":2045,"fullTextUrl":26,"authors":2046,"publicationType":843,"publisherRelationship":2112,"citationCount":2145,"citationInfo":2146,"publishDate":26,"publishYear":26,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":2148,"isForceReanalyzing":1390},"86d0f6f3-977a-4135-a02a-43e8af84c70d","2024-08-09T04:56:20.731+00:00",[],"Multifaceted-Role-of-the-Urokinase-Type-Plasminogen-Activator-uPA-and-Its-Receptor-uPAR-Diagnostic-Prognostic-and-Therapeutic-Applications",{"mag":2030,"keywords":2032,"pmc":2033,"openalex":2035,"abstract":2037,"title":2038,"pm":2040,"doi":2042},{"VOID":2031},"2791482536",{},{"VOID":2034},"5816037",{"VOID":2036},"W2791482536",{},{"EN":2039},"Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications",{"VOID":2041},"29484286",{"VOID":2043},"10.3389\u002Ffonc.2018.00024",[102],"http:\u002F\u002Fjournal.frontiersin.org\u002Farticle\u002F10.3389\u002Ffonc.2018.00024\u002Ffull",[2047,2078,2095],{"id":2048,"sortIndex":114,"researcher":26,"roles":2049,"affiliations":2050,"properties":2071},"4bc35958-8acb-4ff2-8de2-475f2c697c0e",[],[2051,2061],{"id":2052,"sortIndex":115,"affiliation":2053,"properties":26},"0276e275-70d3-46dc-bbd9-bc7bba6be8e4",{"id":2054,"createTime":2055,"updateTime":2055,"relativeEntities":2056,"slug":2057,"properties":2058,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"9983b90f-6024-45b3-b695-1bd8ca9ec47d","2024-08-09T04:56:20.755+00:00",[],"Department-of-Oncology-McGill-University-Health-Centre-Canada",{"title":2059},{"EN":2060},"Department of Oncology, McGill University Health Centre, Canada",{"id":2062,"sortIndex":36,"affiliation":2063,"properties":26},"8ca009f5-404f-4f85-820c-7f12c6948ea4",{"id":2064,"createTime":2065,"updateTime":2065,"relativeEntities":2066,"slug":2067,"properties":2068,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"94fc2e8e-e969-46bc-bad7-5df3af848dee","2024-08-09T04:56:20.742+00:00",[],"Department-of-Medicine-McGill-University-Health-Centre-Canada",{"title":2069},{"EN":2070},"Department of Medicine, McGill University Health Centre, Canada",{"openalex":2072,"orcid":2074,"title":2076},{"VOID":2073},"A5051435795",{"VOID":2075},"https:\u002F\u002Forcid.org\u002F0000-0001-5594-3899",{"EN":2077},"Shafaat A. Rabbani",{"id":2079,"sortIndex":115,"researcher":26,"roles":2080,"affiliations":2081,"properties":2088},"49673ba9-5640-4e3e-a1db-cd2dc8a84b7d",[],[2082],{"id":2083,"sortIndex":36,"affiliation":2084,"properties":26},"948c67ff-3f24-4d70-b256-1858098c9e25",{"id":2054,"createTime":2055,"updateTime":2055,"relativeEntities":2085,"slug":2057,"properties":2086,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2087},{"EN":2060},{"openalex":2089,"orcid":2091,"title":2093},{"VOID":2090},"A5055921357",{"VOID":2092},"https:\u002F\u002Forcid.org\u002F0000-0003-4010-2012",{"EN":2094},"Catalin Mihalcioiu",{"id":2096,"sortIndex":36,"researcher":26,"roles":2097,"affiliations":2098,"properties":2105},"3277f29d-d331-4827-865e-263c6a57184f",[],[2099],{"id":2100,"sortIndex":36,"affiliation":2101,"properties":26},"ae2cc229-148e-41ac-a075-e26518103966",{"id":2064,"createTime":2065,"updateTime":2065,"relativeEntities":2102,"slug":2067,"properties":2103,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2104},{"EN":2070},{"openalex":2106,"orcid":2108,"title":2110},{"VOID":2107},"A5014954056",{"VOID":2109},"https:\u002F\u002Forcid.org\u002F0000-0003-4018-5516",{"EN":2111},"Ani Arakelian",{"url":26,"publisher":2113,"properties":2143},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":2114,"slug":663,"properties":2115,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":2121,"manageAffiliations":2122,"indexDatabases":2123,"url":742,"thumbnailPath":26,"statistic":2138,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"country":2116,"issn":2117,"introduce":2118,"eissn":2119,"title":2120},{"VOID":666},{"VOID":668},{"EN":670},{"VOID":668},{"EN":673},[],[],[2124,2131],{"id":704,"indexDatabase":2125,"url":719,"indexYears":26,"academicFieldIds":2130,"indexDatabaseRanking":26},{"id":706,"createTime":707,"updateTime":708,"relativeEntities":2126,"label":2127,"description":2128,"key":715,"publicationTags":2129,"standard":26},[],{"EN":711,"VI":711},{"VI":713,"EN":714},[717,718],[721],{"id":723,"indexDatabase":2132,"url":736,"indexYears":737,"academicFieldIds":2137,"indexDatabaseRanking":741},{"id":725,"createTime":726,"updateTime":727,"relativeEntities":2133,"label":2134,"description":2135,"key":733,"publicationTags":2136,"standard":26},[],{"EN":730,"VI":730},{"EN":730,"VI":732},[735],[739,740],{"impactFactor":36,"impactFactorByYear":2139,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":115,"totalPublicationByYear":2140,"totalCitation":158,"totalCitationByYear":2141,"totalCitationPerPublication":158,"totalCitationPerPublicationByYear":2142,"hindexLast5Year":115,"hindex":115},{},{"2021":115},{"2021":158},{"2021":158},{"volume":2144},{"VOID":877},366,{"total":2145,"publishYear":26,"statisticByYear":2147},{"2018":116,"2019":48,"2020":517,"2021":251,"2022":347,"2023":254,"2024":252},[2149,2153,2157,2161,2165,2169,2173,2177,2181,2185,2189,2193,2197,2201,2205,2209,2212,2216,2219,2223,2227,2231,2235,2239,2243,2246,2250,2253,2257,2261,2264,2268,2272,2276,2280,2284,2288,2292,2296,2300,2304,2308,2311,2315,2319,2323,2327,2331,2335,2339,2343,2347,2351,2355,2359,2363,2367,2371,2375,2379,2383,2387,2391,2395,2399,2403,2407,2411,2415,2419,2423,2427,2430,2434,2438,2442,2445,2449,2453,2457,2461,2465,2469,2473,2477,2481,2485,2489,2493,2497,2501,2505,2509,2513,2517,2521,2525,2529,2533,2537,2541,2545,2548,2552,2556,2560,2563,2567,2571,2575,2579,2583,2587,2591,2595,2599,2602,2606,2609,2613,2617,2621,2625,2629,2633,2637,2641,2645,2649,2653,2657,2661,2665,2669,2673,2677,2681,2685,2689,2693,2697,2701,2705,2708,2712,2715,2719,2723,2727,2731,2735,2739,2743,2746,2750,2754,2758,2761,2765,2768,2772,2776,2780,2784,2787,2790,2794,2798,2802,2805,2809,2813,2817,2821,2825,2829,2833,2837,2841,2844,2848,2852,2856,2860,2864,2868,2872,2876,2880,2884,2888,2892,2896,2900,2903,2906,2909,2913,2917,2921,2925,2929,2933,2937,2941,2945,2949,2953,2957,2961,2964,2968,2972,2975,2979,2982,2986,2990,2994,2998,3002,3005,3008,3012,3015,3019,3023,3027,3031,3035,3039,3043,3047,3050,3054,3058,3062,3066,3070,3074,3078,3081,3085,3089,3093,3097,3101,3105,3108,3112,3116,3120,3124,3128,3132,3136,3140,3144,3148,3152,3156,3160,3164,3168],{"id":26,"text":2150,"url":26,"identifiers":2151},"Barkan, 2010, Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth, Eur J Cancer, 46, 1181, 10.1016\u002Fj.ejca.2010.02.027",{"doi":2152},"10.1016\u002Fj.ejca.2010.02.027",{"id":26,"text":2154,"url":26,"identifiers":2155},"Mehlen, 2006, Metastasis: a question of life or death, Nat Rev Cancer, 6, 449, 10.1038\u002Fnrc1886",{"doi":2156},"10.1038\u002Fnrc1886",{"id":26,"text":2158,"url":26,"identifiers":2159},"Weigelt, 2005, Breast cancer metastasis: markers and models, Nat Rev Cancer, 5, 591, 10.1038\u002Fnrc1670",{"doi":2160},"10.1038\u002Fnrc1670",{"id":26,"text":2162,"url":26,"identifiers":2163},"Rabbani, 2007, Evaluating distant metastases in breast cancer: from biology to outcomes, Cancer Metastasis Rev, 26, 663, 10.1007\u002Fs10555-007-9085-8",{"doi":2164},"10.1007\u002Fs10555-007-9085-8",{"id":26,"text":2166,"url":26,"identifiers":2167},"Pillay, 2007, The urokinase plasminogen activator receptor as a gene therapy target for cancer, Trends Biotechnol, 25, 33, 10.1016\u002Fj.tibtech.2006.10.011",{"doi":2168},"10.1016\u002Fj.tibtech.2006.10.011",{"id":26,"text":2170,"url":26,"identifiers":2171},"Duffy, 2004, The urokinase plasminogen activator system: role in malignancy, Curr Pharm Des, 10, 39, 10.2174\u002F1381612043453559",{"doi":2172},"10.2174\u002F1381612043453559",{"id":26,"text":2174,"url":26,"identifiers":2175},"Su, 2016, The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies, Expert Opin Ther Targets, 20, 551, 10.1517\u002F14728222.2016.1113260",{"doi":2176},"10.1517\u002F14728222.2016.1113260",{"id":26,"text":2178,"url":26,"identifiers":2179},"Duffy, 2004, The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer, Clin Biochem, 37, 541, 10.1016\u002Fj.clinbiochem.2004.05.013",{"doi":2180},"10.1016\u002Fj.clinbiochem.2004.05.013",{"id":26,"text":2182,"url":26,"identifiers":2183},"Duffy, 2002, Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies, Clin Chem, 48, 1194, 10.1093\u002Fclinchem\u002F48.8.1194",{"doi":2184},"10.1093\u002Fclinchem\u002F48.8.1194",{"id":26,"text":2186,"url":26,"identifiers":2187},"Shin, 2005, Expression of E-cadherin and uPA and their association with the prognosis of pancreatic cancer, Jpn J Clin Oncol, 35, 342, 10.1093\u002Fjjco\u002Fhyi154",{"doi":2188},"10.1093\u002Fjjco\u002Fhyi154",{"id":26,"text":2190,"url":26,"identifiers":2191},"Taubert, 2010, Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients, Br J Cancer, 102, 731, 10.1038\u002Fsj.bjc.6605520",{"doi":2192},"10.1038\u002Fsj.bjc.6605520",{"id":26,"text":2194,"url":26,"identifiers":2195},"Pappot, 2006, The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis, Lung Cancer, 51, 193, 10.1016\u002Fj.lungcan.2005.10.002",{"doi":2196},"10.1016\u002Fj.lungcan.2005.10.002",{"id":26,"text":2198,"url":26,"identifiers":2199},"Sperl, 2001, The uPA\u002FuPA receptor system as a target for tumor therapy, Drug News Perspect, 14, 401, 10.1358\u002Fdnp.2001.14.7.858423",{"doi":2200},"10.1358\u002Fdnp.2001.14.7.858423",{"id":26,"text":2202,"url":26,"identifiers":2203},"Muehlenweg, 2001, Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours, Expert Opin Biol Ther, 1, 683, 10.1517\u002F14712598.1.4.683",{"doi":2204},"10.1517\u002F14712598.1.4.683",{"id":26,"text":2206,"url":26,"identifiers":2207},"McMahon, 2015, Components of the plasminogen-plasmin system as biologic markers for cancer, Adv Exp Med Biol, 867, 145, 10.1007\u002F978-94-017-7215-0_10",{"doi":2208},"10.1007\u002F978-94-017-7215-0_10",{"id":26,"text":2210,"url":26,"identifiers":2211},"Stoppelli, 2013, The Plasminogen Activation System in Cell Invasion",{},{"id":26,"text":2213,"url":26,"identifiers":2214},"O’Rourke, 2005, Distribution of sympathetic tissue plasminogen activator (tPA) to a distant microvasculature, J Neurosci Res, 79, 727, 10.1002\u002Fjnr.20366",{"doi":2215},"10.1002\u002Fjnr.20366",{"id":26,"text":2217,"url":26,"identifiers":2218},"Leurer, 2015, Chapter 6: Plasminogen activator system—diagnostic, prognostic and therapeutic implications in breast cancer, A Concise Review of Molecular Pathology of Breast Cancer",{},{"id":26,"text":2220,"url":26,"identifiers":2221},"Mekkawy, 2014, Involvement of urokinase-type plasminogen activator system in cancer: an overview, Med Res Rev, 34, 918, 10.1002\u002Fmed.21308",{"doi":2222},"10.1002\u002Fmed.21308",{"id":26,"text":2224,"url":26,"identifiers":2225},"Mazar, 2011, Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic, Curr Pharm Des, 17, 1970, 10.2174\u002F138161211796718152",{"doi":2226},"10.2174\u002F138161211796718152",{"id":26,"text":2228,"url":26,"identifiers":2229},"Cianfrocca, 2006, Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours, Br J Cancer, 94, 1621, 10.1038\u002Fsj.bjc.6603171",{"doi":2230},"10.1038\u002Fsj.bjc.6603171",{"id":26,"text":2232,"url":26,"identifiers":2233},"Guo, 2000, A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo, FASEB J, 14, 1400, 10.1096\u002Ffj.14.10.1400",{"doi":2234},"10.1096\u002Ffj.14.10.1400",{"id":26,"text":2236,"url":26,"identifiers":2237},"Choong, 2003, Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis, Clin Orthop Relat Res, 415, S46, 10.1097\u002F01.blo0000093845.72468.bd",{"doi":2238},"10.1097\u002F01.blo0000093845.72468.bd",{"id":26,"text":2240,"url":26,"identifiers":2241},"MacFarlane, 1947, Fibrinolytic activity of normal urine, Nature, 159, 779, 10.1038\u002F159779a0",{"doi":2242},"10.1038\u002F159779a0",{"id":26,"text":2244,"url":26,"identifiers":2245},"Sobel, 1952, Urokinase-an activator of plasma profibrinolysin extracted from urine, Am J Physiol, 171, 768",{},{"id":26,"text":2247,"url":26,"identifiers":2248},"Danø, 1985, Plasminogen activators, tissue degradation, and cancer, Adv Cancer Res, 44, 139, 10.1016\u002FS0065-230X(08)60028-7",{"doi":2249},"10.1016\u002FS0065-230X(08)60028-7",{"id":26,"text":2251,"url":26,"identifiers":2252},"Wang, 1995, Structure of the human urokinase receptor gene and its similarity to CD59 and the Ly-6 family, FEBS J, 227, 116",{},{"id":26,"text":2254,"url":26,"identifiers":2255},"Appella, 1987, The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases, J Biol Chem, 262, 4437, 10.1016\u002FS0021-9258(18)61211-6",{"doi":2256},"10.1016\u002FS0021-9258(18)61211-6",{"id":26,"text":2258,"url":26,"identifiers":2259},"Kristensen, 1984, Human endothelial cells contain one type of plasminogen activator, FEBS Lett, 168, 33, 10.1016\u002F0014-5793(84)80201-X",{"doi":2260},"10.1016\u002F0014-5793(84)80201-X",{"id":26,"text":2262,"url":26,"identifiers":2263},"Schmitt, 1990, Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer, Biomed Biochim Acta, 50, 731",{},{"id":26,"text":2265,"url":26,"identifiers":2266},"Petersen, 1988, One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity, J Biol Chem, 263, 11189, 10.1016\u002FS0021-9258(18)37940-7",{"doi":2267},"10.1016\u002FS0021-9258(18)37940-7",{"id":26,"text":2269,"url":26,"identifiers":2270},"Stack, 1994, Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase), J Biol Chem, 269, 9416, 10.1016\u002FS0021-9258(17)36896-5",{"doi":2271},"10.1016\u002FS0021-9258(17)36896-5",{"id":26,"text":2273,"url":26,"identifiers":2274},"Van Veldhuizen, 1996, Urokinase-type plasminogen activator expression in human prostate carcinomas, Am J Med Sci, 312, 8, 10.1016\u002FS0002-9629(15)41739-2",{"doi":2275},"10.1016\u002FS0002-9629(15)41739-2",{"id":26,"text":2277,"url":26,"identifiers":2278},"Goretzki, 1992, Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L, FEBS Lett, 297, 112, 10.1016\u002F0014-5793(92)80339-I",{"doi":2279},"10.1016\u002F0014-5793(92)80339-I",{"id":26,"text":2281,"url":26,"identifiers":2282},"Koutsilieris, 1987, Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype, J Clin Invest, 80, 941, 10.1172\u002FJCI113186",{"doi":2283},"10.1172\u002FJCI113186",{"id":26,"text":2285,"url":26,"identifiers":2286},"Koutsilieris, 1987, Effects of human prostatic mitogens on rat bone cells and fibroblasts, J Endocrinol, 115, 447, 10.1677\u002Fjoe.0.1150447",{"doi":2287},"10.1677\u002Fjoe.0.1150447",{"id":26,"text":2289,"url":26,"identifiers":2290},"Rabbani, 1990, An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells, Biochem Biophys Res Commun, 173, 1058, 10.1016\u002FS0006-291X(05)80893-9",{"doi":2291},"10.1016\u002FS0006-291X(05)80893-9",{"id":26,"text":2293,"url":26,"identifiers":2294},"Rabbani, 1992, Structural requirements for the growth factor activity of the amino-terminal domain of urokinase, J Biol Chem, 267, 14151, 10.1016\u002FS0021-9258(19)49691-9",{"doi":2295},"10.1016\u002FS0021-9258(19)49691-9",{"id":26,"text":2297,"url":26,"identifiers":2298},"Ellis, 1991, Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor, J Biol Chem, 266, 12752, 10.1016\u002FS0021-9258(18)98963-5",{"doi":2299},"10.1016\u002FS0021-9258(18)98963-5",{"id":26,"text":2301,"url":26,"identifiers":2302},"Higazi, 1995, Enhancement of the enzymatic activity of single-chain urokinase plasminogen activator by soluble urokinase receptor, J Biol Chem, 270, 17375, 10.1074\u002Fjbc.270.29.17375",{"doi":2303},"10.1074\u002Fjbc.270.29.17375",{"id":26,"text":2305,"url":26,"identifiers":2306},"Xu, 2014, Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM), PLoS One, 9, e85349, 10.1371\u002Fjournal.pone.0085349",{"doi":2307},"10.1371\u002Fjournal.pone.0085349",{"id":26,"text":2309,"url":26,"identifiers":2310},"Mars, 1993, Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA, Am J Pathol, 143, 949",{},{"id":26,"text":2312,"url":26,"identifiers":2313},"Irigoyen, 1999, The plasminogen activator system: biology and regulation, Cell Mol Life Sci, 56, 104, 10.1007\u002FPL00000615",{"doi":2314},"10.1007\u002FPL00000615",{"id":26,"text":2316,"url":26,"identifiers":2317},"Nagamine, 2005, Transcriptional and posttranscriptional regulation of the plasminogen activator system, Thromb Haemost, 93, 661, 10.1160\u002FTH04-12-0814",{"doi":2318},"10.1160\u002FTH04-12-0814",{"id":26,"text":2320,"url":26,"identifiers":2321},"Benasciutti, 2004, MAPK and JNK transduction pathways can phosphorylate Sp1 to activate the uPA minimal promoter element and endogenous gene transcription, Blood, 104, 256, 10.1182\u002Fblood-2003-08-2661",{"doi":2322},"10.1182\u002Fblood-2003-08-2661",{"id":26,"text":2324,"url":26,"identifiers":2325},"D’Orazio, 1997, Cooperation of two PEA3\u002FAP1 sites in uPA gene induction by TPA and FGF-2, Gene, 201, 179, 10.1016\u002FS0378-1119(97)00445-9",{"doi":2326},"10.1016\u002FS0378-1119(97)00445-9",{"id":26,"text":2328,"url":26,"identifiers":2329},"Pakneshan, 2003, Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo, FASEB J, 17, 1081, 10.1096\u002Ffj.02-0973com",{"doi":2330},"10.1096\u002Ffj.02-0973com",{"id":26,"text":2332,"url":26,"identifiers":2333},"Guo, 2002, Regulation of DNA methylation in human breast cancer effect on the urokinase-type plasminogen activator gene production and tumor invasion, J Biol Chem, 277, 41571, 10.1074\u002Fjbc.M201864200",{"doi":2334},"10.1074\u002Fjbc.M201864200",{"id":26,"text":2336,"url":26,"identifiers":2337},"Xing, 1999, Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells: role of DNA methylation, Int J Cancer, 81, 443, 10.1002\u002F(SICI)1097-0215(19990505)81:3\u003C443::AID-IJC19>3.0.CO;2-T",{"doi":2338},"10.1002\u002F(SICI)1097-0215(19990505)81:3\u003C443::AID-IJC19>3.0.CO;2-T",{"id":26,"text":2340,"url":26,"identifiers":2341},"Pakneshan, 2004, Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma, Clin Cancer Res, 10, 3035, 10.1158\u002F1078-0432.CCR-03-0545",{"doi":2342},"10.1158\u002F1078-0432.CCR-03-0545",{"id":26,"text":2344,"url":26,"identifiers":2345},"Fowler, 1998, Binding of human single chain urokinase to Chinese hamster ovary cells and cloning of hamster u-PAR, Thromb Haemost, 80, 148, 10.1055\u002Fs-0037-1615154",{"doi":2346},"10.1055\u002Fs-0037-1615154",{"id":26,"text":2348,"url":26,"identifiers":2349},"Stoppelli, 1985, Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes, Proc Natl Acad Sci U S A, 82, 4939, 10.1073\u002Fpnas.82.15.4939",{"doi":2350},"10.1073\u002Fpnas.82.15.4939",{"id":26,"text":2352,"url":26,"identifiers":2353},"Vassalli, 1985, A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase, J Cell Biol, 100, 86, 10.1083\u002Fjcb.100.1.86",{"doi":2354},"10.1083\u002Fjcb.100.1.86",{"id":26,"text":2356,"url":26,"identifiers":2357},"Ploug, 1991, Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol, J Biol Chem, 266, 1926, 10.1016\u002FS0021-9258(18)52382-6",{"doi":2358},"10.1016\u002FS0021-9258(18)52382-6",{"id":26,"text":2360,"url":26,"identifiers":2361},"Llinas, 2005, Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide, EMBO J, 24, 1655, 10.1038\u002Fsj.emboj.7600635",{"doi":2362},"10.1038\u002Fsj.emboj.7600635",{"id":26,"text":2364,"url":26,"identifiers":2365},"Degryse, 2008, The urokinase receptor and integrins constitute a cell migration signalosome, Cancer Degradome, 451, 10.1007\u002F978-0-387-69057-5_23",{"doi":2366},"10.1007\u002F978-0-387-69057-5_23",{"id":26,"text":2368,"url":26,"identifiers":2369},"Montuori, 2005, Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules, Thromb Haemost, 93, 192, 10.1160\u002FTH04-09-0580",{"doi":2370},"10.1160\u002FTH04-09-0580",{"id":26,"text":2372,"url":26,"identifiers":2373},"O’Halloran, 2013, The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target, Theranostics, 3, 496, 10.7150\u002Fthno.4953",{"doi":2374},"10.7150\u002Fthno.4953",{"id":26,"text":2376,"url":26,"identifiers":2377},"Kugler, 2003, Urokinase receptor and integrin interactions, Curr Pharm Des, 9, 1565, 10.2174\u002F1381612033454658",{"doi":2378},"10.2174\u002F1381612033454658",{"id":26,"text":2380,"url":26,"identifiers":2381},"Hu, 2011, Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells, Proc Natl Acad Sci U S A, 108, 15984, 10.1073\u002Fpnas.1113416108",{"doi":2382},"10.1073\u002Fpnas.1113416108",{"id":26,"text":2384,"url":26,"identifiers":2385},"Webb, 2000, Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and matrigel invasion, J Cell Sci, 113, 123, 10.1242\u002Fjcs.113.1.123",{"doi":2386},"10.1242\u002Fjcs.113.1.123",{"id":26,"text":2388,"url":26,"identifiers":2389},"Rønne, 1995, The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria, Br J Haematol, 89, 576, 10.1111\u002Fj.1365-2141.1995.tb08366.x",{"doi":2390},"10.1111\u002Fj.1365-2141.1995.tb08366.x",{"id":26,"text":2392,"url":26,"identifiers":2393},"Lomholt, 2009, Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer, Br J Cancer, 101, 992, 10.1038\u002Fsj.bjc.6605228",{"doi":2394},"10.1038\u002Fsj.bjc.6605228",{"id":26,"text":2396,"url":26,"identifiers":2397},"Resnati, 2002, The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1\u002FLXA4R, Proc Natl Acad Sci U S A, 99, 1359, 10.1073\u002Fpnas.022652999",{"doi":2398},"10.1073\u002Fpnas.022652999",{"id":26,"text":2400,"url":26,"identifiers":2401},"Nykjaer, 1998, Mannose 6-phosphate\u002Finsulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction, J Cell Biol, 141, 815, 10.1083\u002Fjcb.141.3.815",{"doi":2402},"10.1083\u002Fjcb.141.3.815",{"id":26,"text":2404,"url":26,"identifiers":2405},"Mazar, 2008, Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy, Clin Cancer Res, 14, 5649, 10.1158\u002F1078-0432.CCR-07-4863",{"doi":2406},"10.1158\u002F1078-0432.CCR-07-4863",{"id":26,"text":2408,"url":26,"identifiers":2409},"Gonias, 2015, Urokinase receptor and resistance to targeted anticancer agents, Front Pharmacol, 6, 1, 10.3389\u002Ffphar.2015.00154",{"doi":2410},"10.3389\u002Ffphar.2015.00154",{"id":26,"text":2412,"url":26,"identifiers":2413},"Chandran, 2015, HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer, Oncoscience, 2, 207, 10.18632\u002Foncoscience.146",{"doi":2414},"10.18632\u002Foncoscience.146",{"id":26,"text":2416,"url":26,"identifiers":2417},"Pierga, 2005, Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients, Int J Cancer, 114, 291, 10.1002\u002Fijc.20698",{"doi":2418},"10.1002\u002Fijc.20698",{"id":26,"text":2420,"url":26,"identifiers":2421},"Meng, 2006, uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues, Proc Natl Acad Sci U S A, 103, 17361, 10.1073\u002Fpnas.0608113103",{"doi":2422},"10.1073\u002Fpnas.0608113103",{"id":26,"text":2424,"url":26,"identifiers":2425},"Andreasen, 1990, Plasminogen activator inhibitors: hormonally regulated serpins, Mol Cell Endocrinol, 68, 1, 10.1016\u002F0303-7207(90)90164-4",{"doi":2426},"10.1016\u002F0303-7207(90)90164-4",{"id":26,"text":2428,"url":26,"identifiers":2429},"Thorsen, 1988, Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2, FEBS J, 175, 33",{},{"id":26,"text":2431,"url":26,"identifiers":2432},"Croucher, 2008, Revisiting the biological roles of PAI2 (SERPINB2) in cancer, Nat Rev Cancer, 8, 535, 10.1038\u002Fnrc2400",{"doi":2433},"10.1038\u002Fnrc2400",{"id":26,"text":2435,"url":26,"identifiers":2436},"Harbeck, 2013, Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients, Eur J Cancer, 49, 1825, 10.1016\u002Fj.ejca.2013.01.007",{"doi":2437},"10.1016\u002Fj.ejca.2013.01.007",{"id":26,"text":2439,"url":26,"identifiers":2440},"Halamkova, 2011, Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients, Hepatogastroenterology, 58, 1918, 10.5754\u002Fhge10232",{"doi":2441},"10.5754\u002Fhge10232",{"id":26,"text":2443,"url":26,"identifiers":2444},"Lee, 2005, Plasminogen activator inhibitor-1: the expression, biological functions, and effects on tumorigenesis and tumor cell adhesion and migration, J Cancer Mol, 1, 25",{},{"id":26,"text":2446,"url":26,"identifiers":2447},"Stefansson, 1996, The serpin PAI-1 inhibits cell migration by blocking integrin alphavbeta3 binding to vitronectin, Nature, 383, 441, 10.1038\u002F383441a0",{"doi":2448},"10.1038\u002F383441a0",{"id":26,"text":2450,"url":26,"identifiers":2451},"Plesner, 1997, Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR, Stem Cells, 15, 398, 10.1002\u002Fstem.150398",{"doi":2452},"10.1002\u002Fstem.150398",{"id":26,"text":2454,"url":26,"identifiers":2455},"Naldini, 1992, Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor\u002Fscatter factor, EMBO J, 11, 4825, 10.1002\u002Fj.1460-2075.1992.tb05588.x",{"doi":2456},"10.1002\u002Fj.1460-2075.1992.tb05588.x",{"id":26,"text":2458,"url":26,"identifiers":2459},"Hannocks, 1992, Regulation of proteolytic activity in human bone marrow stromal cells by basic fibroblast growth factor, interleukin-1, and transforming growth factor beta, Blood, 79, 1178, 10.1182\u002Fblood.V79.5.1178.1178",{"doi":2460},"10.1182\u002Fblood.V79.5.1178.1178",{"id":26,"text":2462,"url":26,"identifiers":2463},"Degryse, 1999, Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis and cytoskeleton reorganization in rat smooth muscle cells, Blood, 94, 649, 10.1182\u002Fblood.V94.2.649",{"doi":2464},"10.1182\u002Fblood.V94.2.649",{"id":26,"text":2466,"url":26,"identifiers":2467},"Mukhina, 2000, The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain characterization of interactions and contribution to chemotaxis, J Biol Chem, 275, 16450, 10.1074\u002Fjbc.M909080199",{"doi":2468},"10.1074\u002Fjbc.M909080199",{"id":26,"text":2470,"url":26,"identifiers":2471},"Resnati, 1996, Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect, EMBO J, 15, 1572, 10.1002\u002Fj.1460-2075.1996.tb00502.x",{"doi":2472},"10.1002\u002Fj.1460-2075.1996.tb00502.x",{"id":26,"text":2474,"url":26,"identifiers":2475},"Myöhänen, 1993, Distribution and lateral mobility of the urokinase-receptor complex at the cell surface, J Histochem Cytochem, 41, 1291, 10.1177\u002F41.9.8394852",{"doi":2476},"10.1177\u002F41.9.8394852",{"id":26,"text":2478,"url":26,"identifiers":2479},"Limongi, 1995, Biosynthesis and apical localization of the urokinase receptor in polarized MDCK epithelial cells, FEBS Lett, 369, 207, 10.1016\u002F0014-5793(95)00742-R",{"doi":2480},"10.1016\u002F0014-5793(95)00742-R",{"id":26,"text":2482,"url":26,"identifiers":2483},"Estreicher, 1990, The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes, J Cell Biol, 111, 783, 10.1083\u002Fjcb.111.2.783",{"doi":2484},"10.1083\u002Fjcb.111.2.783",{"id":26,"text":2486,"url":26,"identifiers":2487},"Blasi, 1993, Urokinase and urokinase receptor: a paracrine\u002Fautocrine system regulating cell migration and invasiveness, Bioessays, 15, 105, 10.1002\u002Fbies.950150206",{"doi":2488},"10.1002\u002Fbies.950150206",{"id":26,"text":2490,"url":26,"identifiers":2491},"Mondino, 2004, uPA and uPAR in fibrinolysis, immunity and pathology, Trends Immunol, 25, 450, 10.1016\u002Fj.it.2004.06.004",{"doi":2492},"10.1016\u002Fj.it.2004.06.004",{"id":26,"text":2494,"url":26,"identifiers":2495},"Sanderson-Smith, 2013, A key role for the urokinase plasminogen activator (uPA) in invasive Group A streptococcal infection, PLoS Pathog, 9, e1003469, 10.1371\u002Fjournal.ppat.1003469",{"doi":2496},"10.1371\u002Fjournal.ppat.1003469",{"id":26,"text":2498,"url":26,"identifiers":2499},"Abraham, 2003, Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation, J Immunol, 170, 5644, 10.4049\u002Fjimmunol.170.11.5644",{"doi":2500},"10.4049\u002Fjimmunol.170.11.5644",{"id":26,"text":2502,"url":26,"identifiers":2503},"Cao, 1995, Human urokinase-type plasminogen activator primes neutrophils for superoxide anion release. Possible roles of complement receptor type 3 and calcium, J Immunol, 154, 1817, 10.4049\u002Fjimmunol.154.4.1817",{"doi":2504},"10.4049\u002Fjimmunol.154.4.1817",{"id":26,"text":2506,"url":26,"identifiers":2507},"May, 1998, Urokinase receptor (CD87) regulates leukocyte recruitment via β2 integrins in vivo, J Exp Med, 188, 1029, 10.1084\u002Fjem.188.6.1029",{"doi":2508},"10.1084\u002Fjem.188.6.1029",{"id":26,"text":2510,"url":26,"identifiers":2511},"Gyetko, 1995, Function of the urokinase receptor (CD87) in neutrophil chemotaxis, J Leukoc Biol, 58, 533, 10.1002\u002Fjlb.58.5.533",{"doi":2512},"10.1002\u002Fjlb.58.5.533",{"id":26,"text":2514,"url":26,"identifiers":2515},"Gyetko, 1996, Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model, J Clin Invest, 97, 1818, 10.1172\u002FJCI118611",{"doi":2516},"10.1172\u002FJCI118611",{"id":26,"text":2518,"url":26,"identifiers":2519},"Rijneveld, 2002, Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia, J Immunol, 168, 3507, 10.4049\u002Fjimmunol.168.7.3507",{"doi":2520},"10.4049\u002Fjimmunol.168.7.3507",{"id":26,"text":2522,"url":26,"identifiers":2523},"Gyetko, 2000, Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection, J Immunol, 165, 1513, 10.4049\u002Fjimmunol.165.3.1513",{"doi":2524},"10.4049\u002Fjimmunol.165.3.1513",{"id":26,"text":2526,"url":26,"identifiers":2527},"Nykjaer, 1994, Urokinase receptor. An activation antigen in human T lymphocytes, J Immunol, 152, 505, 10.4049\u002Fjimmunol.152.2.505",{"doi":2528},"10.4049\u002Fjimmunol.152.2.505",{"id":26,"text":2530,"url":26,"identifiers":2531},"Gyetko, 2004, Urokinase-deficient mice fail to generate a type 2 immune response following schistosomal antigen challenge, Infect Immun, 72, 461, 10.1128\u002FIAI.72.1.461-467.2004",{"doi":2532},"10.1128\u002FIAI.72.1.461-467.2004",{"id":26,"text":2534,"url":26,"identifiers":2535},"Gyetko, 2002, Urokinase-type plasminogen activator is required for the generation of a type 1 immune response to pulmonary Cryptococcus neoformans infection, J Immunol, 168, 801, 10.4049\u002Fjimmunol.168.2.801",{"doi":2536},"10.4049\u002Fjimmunol.168.2.801",{"id":26,"text":2538,"url":26,"identifiers":2539},"Gyetko, 1994, The urokinase receptor is required for human monocyte chemotaxis in vitro, J Clin Invest, 93, 1380, 10.1172\u002FJCI117114",{"doi":2540},"10.1172\u002FJCI117114",{"id":26,"text":2542,"url":26,"identifiers":2543},"Gyetko, 2001, Cutting edge: antigen-driven lymphocyte recruitment to the lung is diminished in the absence of urokinase-type plasminogen activator (uPA) receptor, but is independent of uPA, J Immunol, 167, 5539, 10.4049\u002Fjimmunol.167.10.5539",{"doi":2544},"10.4049\u002Fjimmunol.167.10.5539",{"id":26,"text":2546,"url":26,"identifiers":2547},"Zheng, 2001, Source of plasminogen activator in rhesus monkey semen and its possible role in sperm capacitation, Sheng Li Xue Bao, 53, 45",{},{"id":26,"text":2549,"url":26,"identifiers":2550},"Qin, 2015, Urokinase-type plasminogen activator: a new target for male contraception?, Asian J Androl, 17, 269, 10.4103\u002F1008-682X.143316",{"doi":2551},"10.4103\u002F1008-682X.143316",{"id":26,"text":2553,"url":26,"identifiers":2554},"Aguirre-Ghiso, 2001, Urokinase receptor and fibronectin regulate the ERKMAPK to p38MAPK activity ratios that determine carcinoma cell proliferation or dormancy in vivo, Mol Biol Cell, 12, 863, 10.1091\u002Fmbc.12.4.863",{"doi":2555},"10.1091\u002Fmbc.12.4.863",{"id":26,"text":2557,"url":26,"identifiers":2558},"Ulisse, 2009, The urokinase plasminogen activator system: a target for anti-cancer therapy, Curr Cancer Drug Targets, 9, 32, 10.2174\u002F156800909787314002",{"doi":2559},"10.2174\u002F156800909787314002",{"id":26,"text":2561,"url":26,"identifiers":2562},"Shapiro, 1996, Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals, Cancer Res, 56, 3597",{},{"id":26,"text":2564,"url":26,"identifiers":2565},"Bergers, 2000, Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis, Nat Cell Biol, 2, 737, 10.1038\u002F35036374",{"doi":2566},"10.1038\u002F35036374",{"id":26,"text":2568,"url":26,"identifiers":2569},"Chen, 2004, Inhibition of apoptosis and caspase-3 in vascular smooth muscle cells by plasminogen activator inhibitor type-1, J Cell Biochem, 92, 178, 10.1002\u002Fjcb.20058",{"doi":2570},"10.1002\u002Fjcb.20058",{"id":26,"text":2572,"url":26,"identifiers":2573},"Soeda, 2001, Deficient release of plasminogen activator inhibitor-1 from astrocytes triggers apoptosis in neuronal cells, Brain Res Mol Brain Res, 91, 96, 10.1016\u002FS0169-328X(01)00133-4",{"doi":2574},"10.1016\u002FS0169-328X(01)00133-4",{"id":26,"text":2576,"url":26,"identifiers":2577},"Subramanian, 2006, siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells, Int J Oncol, 28, 831, 10.3892\u002Fijo.28.4.831",{"doi":2578},"10.3892\u002Fijo.28.4.831",{"id":26,"text":2580,"url":26,"identifiers":2581},"Kenny, 2011, Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis, Clin Cancer Res, 17, 459, 10.1158\u002F1078-0432.CCR-10-2258",{"doi":2582},"10.1158\u002F1078-0432.CCR-10-2258",{"id":26,"text":2584,"url":26,"identifiers":2585},"Chen, 2008, Plasminogen activator inhibitor-1 inhibits prostate tumor growth through endothelial apoptosis, Mol Cancer Ther, 7, 1227, 10.1158\u002F1535-7163.MCT-08-0051",{"doi":2586},"10.1158\u002F1535-7163.MCT-08-0051",{"id":26,"text":2588,"url":26,"identifiers":2589},"Balsara, 2008, Plasminogen activator inhibitor-1: the double-edged sword in apoptosis, Thromb Haemost, 100, 1029, 10.1160\u002FTH08-07-0427",{"doi":2590},"10.1160\u002FTH08-07-0427",{"id":26,"text":2592,"url":26,"identifiers":2593},"Aguirre-Ghiso, 2007, Models, mechanisms and clinical evidence for cancer dormancy, Nat Rev Cancer, 7, 834, 10.1038\u002Fnrc2256",{"doi":2594},"10.1038\u002Fnrc2256",{"id":26,"text":2596,"url":26,"identifiers":2597},"Ghiso, 1999, Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling, J Cell Biol, 147, 89, 10.1083\u002Fjcb.147.1.89",{"doi":2598},"10.1083\u002Fjcb.147.1.89",{"id":26,"text":2600,"url":26,"identifiers":2601},"Montuori, 2016, Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer, Transl Med UniSa, 15, 15",{},{"id":26,"text":2603,"url":26,"identifiers":2604},"Liu, 2002, EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma, Cancer Cell, 1, 445, 10.1016\u002FS1535-6108(02)00072-7",{"doi":2605},"10.1016\u002FS1535-6108(02)00072-7",{"id":26,"text":2607,"url":26,"identifiers":2608},"Aguirre-Ghiso, 2003, ERKMAPK activity as a determinant of tumor growth and dormancy; regulation by p38SAPK, Cancer Res, 63, 1684",{},{"id":26,"text":2610,"url":26,"identifiers":2611},"Ghiso, 2002, Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo, Oncogene, 21, 2513, 10.1038\u002Fsj.onc.1205342",{"doi":2612},"10.1038\u002Fsj.onc.1205342",{"id":26,"text":2614,"url":26,"identifiers":2615},"Duffy, 1992, The role of proteolytic enzymes in cancer invasion and metastasis, Clin Exp Metastasis, 10, 145, 10.1007\u002FBF00132746",{"doi":2616},"10.1007\u002FBF00132746",{"id":26,"text":2618,"url":26,"identifiers":2619},"Nyberg, 2008, Tumor microenvironment and angiogenesis, Front Biosci, 13, 6537, 10.2741\u002F3173",{"doi":2620},"10.2741\u002F3173",{"id":26,"text":2622,"url":26,"identifiers":2623},"Gerwins, 2000, Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis, Crit Rev Oncol Hematol, 34, 185, 10.1016\u002FS1040-8428(00)00062-7",{"doi":2624},"10.1016\u002FS1040-8428(00)00062-7",{"id":26,"text":2626,"url":26,"identifiers":2627},"Preissner, 2011, Vitronectin in vascular context: facets of a multitalented matricellular protein, Semin Thromb Hemost, 37, 408, 10.1055\u002Fs-0031-1276590",{"doi":2628},"10.1055\u002Fs-0031-1276590",{"id":26,"text":2630,"url":26,"identifiers":2631},"Unseld, 2015, PTEN expression in endothelial cells is down-regulated by uPAR to promote angiogenesis, Thromb Haemost, 114, 379, 10.1160\u002FTH15-01-0016",{"doi":2632},"10.1160\u002FTH15-01-0016",{"id":26,"text":2634,"url":26,"identifiers":2635},"Raghu, 2012, uPA and uPAR shRNA inhibit angiogenesis via enhanced secretion of SVEGFR1 independent of GM-CSF but dependent on TIMP-1 in endothelial and glioblastoma cells, Mol Oncol, 6, 33, 10.1016\u002Fj.molonc.2011.11.008",{"doi":2636},"10.1016\u002Fj.molonc.2011.11.008",{"id":26,"text":2638,"url":26,"identifiers":2639},"Gondi, 2007, Intraperitoneal injection of a hairpin RNA–expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice, Clin Cancer Res, 13, 4051, 10.1158\u002F1078-0432.CCR-06-3032",{"doi":2640},"10.1158\u002F1078-0432.CCR-06-3032",{"id":26,"text":2642,"url":26,"identifiers":2643},"Raghu, 2011, Specific knockdown of uPA\u002FuPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch-1 receptor, Mol Cancer, 10, 130, 10.1186\u002F1476-4598-10-130",{"doi":2644},"10.1186\u002F1476-4598-10-130",{"id":26,"text":2646,"url":26,"identifiers":2647},"Stefansson, 2001, Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1, J Biol Chem, 276, 8135, 10.1074\u002Fjbc.M007609200",{"doi":2648},"10.1074\u002Fjbc.M007609200",{"id":26,"text":2650,"url":26,"identifiers":2651},"Bajou, 1998, Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization, Nat Med, 4, 923, 10.1038\u002Fnm0898-923",{"doi":2652},"10.1038\u002Fnm0898-923",{"id":26,"text":2654,"url":26,"identifiers":2655},"Andreasen, 1997, The urokinase-type plasminogen activator system in cancer metastasis: a review, Int J Cancer, 72, 1, 10.1002\u002F(SICI)1097-0215(19970703)72:1\u003C1::AID-IJC1>3.0.CO;2-Z",{"doi":2656},"10.1002\u002F(SICI)1097-0215(19970703)72:1\u003C1::AID-IJC1>3.0.CO;2-Z",{"id":26,"text":2658,"url":26,"identifiers":2659},"Hsiao, 2013, Surface α-enolase promotes extracellular matrix degradation and tumor metastasis and represents a new therapeutic target, PLoS One, 8, e69354, 10.1371\u002Fjournal.pone.0069354",{"doi":2660},"10.1371\u002Fjournal.pone.0069354",{"id":26,"text":2662,"url":26,"identifiers":2663},"Obermajer, 2009, Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness, Mol Cancer, 8, 88, 10.1186\u002F1476-4598-8-88",{"doi":2664},"10.1186\u002F1476-4598-8-88",{"id":26,"text":2666,"url":26,"identifiers":2667},"Kalluri, 2009, The basics of epithelial-mesenchymal transition, J Clin Invest, 119, 1420, 10.1172\u002FJCI39104",{"doi":2668},"10.1172\u002FJCI39104",{"id":26,"text":2670,"url":26,"identifiers":2671},"Kalluri, 2003, Epithelial-mesenchymal transition and its implications for fibrosis, J Clin Invest, 112, 1776, 10.1172\u002FJCI200320530",{"doi":2672},"10.1172\u002FJCI200320530",{"id":26,"text":2674,"url":26,"identifiers":2675},"Lester, 2007, uPAR induces epithelial–mesenchymal transition in hypoxic breast cancer cells, J Cell Biol, 178, 425, 10.1083\u002Fjcb.200701092",{"doi":2676},"10.1083\u002Fjcb.200701092",{"id":26,"text":2678,"url":26,"identifiers":2679},"Rabbani, 2010, An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo, Neoplasia, 12, 778, 10.1593\u002Fneo.10296",{"doi":2680},"10.1593\u002Fneo.10296",{"id":26,"text":2682,"url":26,"identifiers":2683},"Zhang, 2015, A niche role for cancer exosomes in metastasis, Nat Cell Biol, 17, 709, 10.1038\u002Fncb3181",{"doi":2684},"10.1038\u002Fncb3181",{"id":26,"text":2686,"url":26,"identifiers":2687},"Alderton, 2012, Metastasis: exosomes drive premetastatic niche formation, Nat Rev Cancer, 12, 447, 10.1038\u002Fnrc3304",{"doi":2688},"10.1038\u002Fnrc3304",{"id":26,"text":2690,"url":26,"identifiers":2691},"Min, 2016, The roles and implications of exosomes in sarcoma, Cancer Metastasis Rev, 35, 377, 10.1007\u002Fs10555-016-9630-4",{"doi":2692},"10.1007\u002Fs10555-016-9630-4",{"id":26,"text":2694,"url":26,"identifiers":2695},"Endo-Munoz, 2015, Progression of osteosarcoma from a non-metastatic to a metastatic phenotype is causally associated with activation of an autocrine and paracrine uPA Axis, PLoS One, 10, e0133592, 10.1371\u002Fjournal.pone.0133592",{"doi":2696},"10.1371\u002Fjournal.pone.0133592",{"id":26,"text":2698,"url":26,"identifiers":2699},"Harris, 2015, Exosomes released from breast cancer carcinomas stimulate cell movement, PLoS One, 10, e0117495, 10.1371\u002Fjournal.pone.0117495",{"doi":2700},"10.1371\u002Fjournal.pone.0117495",{"id":26,"text":2702,"url":26,"identifiers":2703},"Dass, 2008, Evolving role of uPA\u002FuPAR system in human cancers, Cancer Treat Rev, 34, 122, 10.1016\u002Fj.ctrv.2007.10.005",{"doi":2704},"10.1016\u002Fj.ctrv.2007.10.005",{"id":26,"text":2706,"url":26,"identifiers":2707},"O’Grady, 1985, Multiple forms of plasminogen activator in human breast tumors, Cancer Res, 45, 6216",{},{"id":26,"text":2709,"url":26,"identifiers":2710},"Duffy, 1988, Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report, Cancer, 62, 531, 10.1002\u002F1097-0142(19880801)62:3\u003C531::AID-CNCR2820620315>3.0.CO;2-B",{"doi":2711},"10.1002\u002F1097-0142(19880801)62:3\u003C531::AID-CNCR2820620315>3.0.CO;2-B",{"id":26,"text":2713,"url":26,"identifiers":2714},"Foekens, 2000, The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients, Cancer Res, 60, 636",{},{"id":26,"text":2716,"url":26,"identifiers":2717},"Jänicke, 2001, Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1, J Natl Cancer Inst, 93, 913, 10.1093\u002Fjnci\u002F93.12.913",{"doi":2718},"10.1093\u002Fjnci\u002F93.12.913",{"id":26,"text":2720,"url":26,"identifiers":2721},"Look, 2002, Pooled analysis of prognostic impact of tumor biological factors uPA and PAI-1 in 8377 breast cancer patients, J Natl Cancer Inst, 94, 116, 10.1093\u002Fjnci\u002F94.2.116",{"doi":2722},"10.1093\u002Fjnci\u002F94.2.116",{"id":26,"text":2724,"url":26,"identifiers":2725},"Harris, 2007, American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer, J Clin Oncol, 25, 5287, 10.1200\u002FJCO.2007.14.2364",{"doi":2726},"10.1200\u002FJCO.2007.14.2364",{"id":26,"text":2728,"url":26,"identifiers":2729},"Jelisavac-Cosic, 2011, Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma-a 7.5-year follow-up study, Tumori, 97, 532, 10.1177\u002F030089161109700419",{"doi":2730},"10.1177\u002F030089161109700419",{"id":26,"text":2732,"url":26,"identifiers":2733},"Paik, 2004, A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer, N Engl J Med, 351, 2817, 10.1056\u002FNEJMoa041588",{"doi":2734},"10.1056\u002FNEJMoa041588",{"id":26,"text":2736,"url":26,"identifiers":2737},"Knauer, 2010, The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer, Breast Cancer Res Treat, 120, 655, 10.1007\u002Fs10549-010-0814-2",{"doi":2738},"10.1007\u002Fs10549-010-0814-2",{"id":26,"text":2740,"url":26,"identifiers":2741},"Nicolini, 2017, Prognostic and predictive biomarkers in breast cancer: past, present and future, Semin Cancer Biol, 10.1016\u002Fj.semcancer.2017.08.010",{"doi":2742},"10.1016\u002Fj.semcancer.2017.08.010",{"id":26,"text":2744,"url":26,"identifiers":2745},"Foekens, 1995, Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer, Cancer Res, 55, 1423",{},{"id":26,"text":2747,"url":26,"identifiers":2748},"Shariat, 2007, Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis, J Clin Oncol, 25, 349, 10.1200\u002FJCO.2006.05.6853",{"doi":2749},"10.1200\u002FJCO.2006.05.6853",{"id":26,"text":2751,"url":26,"identifiers":2752},"Kjellman, 2011, Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening, J Intern Med, 269, 299, 10.1111\u002Fj.1365-2796.2010.02284.x",{"doi":2753},"10.1111\u002Fj.1365-2796.2010.02284.x",{"id":26,"text":2755,"url":26,"identifiers":2756},"Kumano, 2009, Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy, Urol Oncol, 27, 180, 10.1016\u002Fj.urolonc.2008.01.012",{"doi":2757},"10.1016\u002Fj.urolonc.2008.01.012",{"id":26,"text":2759,"url":26,"identifiers":2760},"Sier, 1998, The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients, Cancer Res, 58, 1843",{},{"id":26,"text":2762,"url":26,"identifiers":2763},"Sier, 2004, Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice, Thromb Haemost, 91, 403, 10.1160\u002FTH03-06-0351",{"doi":2764},"10.1160\u002FTH03-06-0351",{"id":26,"text":2766,"url":26,"identifiers":2767},"Sier, 1999, Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance, Lab Invest, 79, 717",{},{"id":26,"text":2769,"url":26,"identifiers":2770},"Ljuca, 2007, Monitoring of chemotherapy successfulness of platina\u002Ftaxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage, Bosn J Basic Med Sci, 7, 113, 10.17305\u002Fbjbms.2007.3063",{"doi":2771},"10.17305\u002Fbjbms.2007.3063",{"id":26,"text":2773,"url":26,"identifiers":2774},"Kuhn, 1999, Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc, Br J Cancer, 79, 1746, 10.1038\u002Fsj.bjc.6690278",{"doi":2775},"10.1038\u002Fsj.bjc.6690278",{"id":26,"text":2777,"url":26,"identifiers":2778},"Hoffmann, 1999, Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters, Clin Chem Lab Med, 37, 47, 10.1515\u002FCCLM.1999.007",{"doi":2779},"10.1515\u002FCCLM.1999.007",{"id":26,"text":2781,"url":26,"identifiers":2782},"Daneri-Navarro, 1998, Urokinase-type plasminogen activator and plasminogen activator inhibitors (PAI-1 and PAI-2) in extracts of invasive cervical carcinoma and precursor lesions, Eur J Cancer, 34, 566, 10.1016\u002FS0959-8049(97)10038-7",{"doi":2783},"10.1016\u002FS0959-8049(97)10038-7",{"id":26,"text":2785,"url":26,"identifiers":2786},"Kobayashi, 1994, Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus, Cancer Res, 54, 6539",{},{"id":26,"text":2788,"url":26,"identifiers":2789},"Koelbl, 1988, Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer, Obstet Gynecol, 72, 252",{},{"id":26,"text":2791,"url":26,"identifiers":2792},"Memarzadeh, 2002, Urokinase plasminogen activator receptor: prognostic biomarker for endometrial cancer, Proc Natl Acad Sci U S A, 99, 10647, 10.1073\u002Fpnas.152127499",{"doi":2793},"10.1073\u002Fpnas.152127499",{"id":26,"text":2795,"url":26,"identifiers":2796},"Riisbro, 2001, Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases, Gynecol Oncol, 82, 523, 10.1006\u002Fgyno.2001.6324",{"doi":2797},"10.1006\u002Fgyno.2001.6324",{"id":26,"text":2799,"url":26,"identifiers":2800},"Dariusz, 2012, A potency of plasminogen activation system in long-term prognosis of endometrial cancer: a pilot study, Eur J Obstet Gynecol Reprod Biol, 163, 193, 10.1016\u002Fj.ejogrb.2012.03.031",{"doi":2801},"10.1016\u002Fj.ejogrb.2012.03.031",{"id":26,"text":2803,"url":26,"identifiers":2804},"Choong, 1997, Urokinase plasminogen activator levels and prognosis in 69 soft tissue sarcomas, J Bone Joint Surg Br Vol, 79, 411",{},{"id":26,"text":2806,"url":26,"identifiers":2807},"de Vries, 1995, Components of the plasminogen activation system in uveal melanoma—a clinico-pathological study, J Pathol, 175, 59, 10.1002\u002Fpath.1711750110",{"doi":2808},"10.1002\u002Fpath.1711750110",{"id":26,"text":2810,"url":26,"identifiers":2811},"Stabuc, 2003, Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma, Oncol Rep, 10, 635, 10.3892\u002For.10.3.635",{"doi":2812},"10.3892\u002For.10.3.635",{"id":26,"text":2814,"url":26,"identifiers":2815},"Riisbro, 2005, Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration, Int J Biol Markers, 20, 93, 10.1177\u002F172460080502000203",{"doi":2816},"10.1177\u002F172460080502000203",{"id":26,"text":2818,"url":26,"identifiers":2819},"Herszényi, 2008, Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer, BMC Cancer, 8, 194, 10.1186\u002F1471-2407-8-194",{"doi":2820},"10.1186\u002F1471-2407-8-194",{"id":26,"text":2822,"url":26,"identifiers":2823},"Papadopoulou, 2002, Significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas, Tumor Biol, 23, 170, 10.1159\u002F000064033",{"doi":2824},"10.1159\u002F000064033",{"id":26,"text":2826,"url":26,"identifiers":2827},"Yang, 2000, Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets, Int J Cancer, 89, 431, 10.1002\u002F1097-0215(20000920)89:5\u003C431::AID-IJC6>3.0.CO;2-V",{"doi":2828},"10.1002\u002F1097-0215(20000920)89:5\u003C431::AID-IJC6>3.0.CO;2-V",{"id":26,"text":2830,"url":26,"identifiers":2831},"Halamkova, 2011, Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients, Neoplasma, 58, 377, 10.4149\u002Fneo_2011_05_377",{"doi":2832},"10.4149\u002Fneo_2011_05_377",{"id":26,"text":2834,"url":26,"identifiers":2835},"Sier, 1994, Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis, Gastroenterology, 107, 1449, 10.1016\u002F0016-5085(94)90549-5",{"doi":2836},"10.1016\u002F0016-5085(94)90549-5",{"id":26,"text":2838,"url":26,"identifiers":2839},"Dubuisson, 2000, Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in human hepatocellular carcinoma, J Pathol, 190, 190, 10.1002\u002F(SICI)1096-9896(200002)190:2\u003C190::AID-PATH511>3.0.CO;2-H",{"doi":2840},"10.1002\u002F(SICI)1096-9896(200002)190:2\u003C190::AID-PATH511>3.0.CO;2-H",{"id":26,"text":2842,"url":26,"identifiers":2843},"Zheng, 1998, Inhibitor of plasminogen activator 1 (PAI-1) in hepatocellular carcinoma, Zhonghua Wai Ke Za Zhi, 36, 474",{},{"id":26,"text":2845,"url":26,"identifiers":2846},"Chen, 2011, Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients, Oncol Lett, 2, 693, 10.3892\u002Fol.2011.302",{"doi":2847},"10.3892\u002Fol.2011.302",{"id":26,"text":2849,"url":26,"identifiers":2850},"Langkilde, 2011, Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancer-free individuals, Cancer Epidemiol Biomarkers Prev, 20, 609, 10.1158\u002F1055-9965.EPI-10-1009",{"doi":2851},"10.1158\u002F1055-9965.EPI-10-1009",{"id":26,"text":2853,"url":26,"identifiers":2854},"Almasi, 2013, The liberated domain I of urokinase plasminogen activator receptor – a new tumour marker in small cell lung cancer, APMIS, 121, 189, 10.1111\u002Fj.1600-0463.2012.02955.x",{"doi":2855},"10.1111\u002Fj.1600-0463.2012.02955.x",{"id":26,"text":2857,"url":26,"identifiers":2858},"Salden, 2000, The urokinase-type plasminogen activator system in resected non-small-cell lung cancer, Ann Oncol, 11, 327, 10.1023\u002FA:1008312801800",{"doi":2859},"10.1023\u002FA:1008312801800",{"id":26,"text":2861,"url":26,"identifiers":2862},"Witkiewicz, 2015, Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets, Nat Commun, 6, 6744, 10.1038\u002Fncomms7744",{"doi":2863},"10.1038\u002Fncomms7744",{"id":26,"text":2865,"url":26,"identifiers":2866},"Harris, 2017, SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer, Oncogene, 36, 4288, 10.1038\u002Fonc.2017.63",{"doi":2867},"10.1038\u002Fonc.2017.63",{"id":26,"text":2869,"url":26,"identifiers":2870},"Chen, 2007, Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration, Int J Cancer, 120, 1511, 10.1002\u002Fijc.22487",{"doi":2871},"10.1002\u002Fijc.22487",{"id":26,"text":2873,"url":26,"identifiers":2874},"Sorio, 2011, Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group, BMC Cancer, 11, 448, 10.1186\u002F1471-2407-11-448",{"doi":2875},"10.1186\u002F1471-2407-11-448",{"id":26,"text":2877,"url":26,"identifiers":2878},"Beyer, 2006, Urokinase system expression in gastric carcinoma, Cancer, 106, 1026, 10.1002\u002Fcncr.21682",{"doi":2879},"10.1002\u002Fcncr.21682",{"id":26,"text":2881,"url":26,"identifiers":2882},"Plebani, 1997, Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role, Clin Exp Metastasis, 15, 418, 10.1023\u002FA:1018454305889",{"doi":2883},"10.1023\u002FA:1018454305889",{"id":26,"text":2885,"url":26,"identifiers":2886},"Luebke, 2006, Is the urokinase-type plasminogen activator system a reliable prognostic factor in gastric cancer?, Int J Biol Markers, 21, 162, 10.5301\u002FJBM.2008.3029",{"doi":2887},"10.5301\u002FJBM.2008.3029",{"id":26,"text":2889,"url":26,"identifiers":2890},"Baker, 2007, Plasminogen activator system in oral squamous cell carcinoma, Br J Oral Maxillofac Surg, 45, 623, 10.1016\u002Fj.bjoms.2007.04.021",{"doi":2891},"10.1016\u002Fj.bjoms.2007.04.021",{"id":26,"text":2893,"url":26,"identifiers":2894},"Hundsdorfer, 2005, Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity—clinical relevance and prognostic value, J Craniomaxillofac Surg, 33, 191, 10.1016\u002Fj.jcms.2004.12.005",{"doi":2895},"10.1016\u002Fj.jcms.2004.12.005",{"id":26,"text":2897,"url":26,"identifiers":2898},"Shiomi, 2000, Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma, Am J Pathol, 156, 567, 10.1016\u002FS0002-9440(10)64761-X",{"doi":2899},"10.1016\u002FS0002-9440(10)64761-X",{"id":26,"text":2901,"url":26,"identifiers":2902},"Zheng, 1998, Urokinase-type plasminogen activator (uPA), uPA receptor (uPA-R) and inhibitors (PA I-1) expression in hepatocellular carcinoma in relation to cancer invasion\u002Fmetastasis and prognosis, Zhonghua Zhong Liu Za Zhi, 20, 57",{},{"id":26,"text":2904,"url":26,"identifiers":2905},"Zhao, 2002, Prognostic value of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx, J Clin Otolaryngol, 16, 599",{},{"id":26,"text":2907,"url":26,"identifiers":2908},"Wang, 2005, Expressions and clinical significance of urokinase-type activator (uPA) and uPA receptor (uPAR) in laryngeal squamous cell carcinoma, J Clin Otolaryngol, 19, 529",{},{"id":26,"text":2910,"url":26,"identifiers":2911},"Strojan, 1998, Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients, Eur J Cancer, 34, 1193, 10.1016\u002FS0959-8049(98)00029-X",{"doi":2912},"10.1016\u002FS0959-8049(98)00029-X",{"id":26,"text":2914,"url":26,"identifiers":2915},"Schmidt, 1999, Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients, Acta Otolaryngol, 119, 949, 10.1080\u002F00016489950180342",{"doi":2916},"10.1080\u002F00016489950180342",{"id":26,"text":2918,"url":26,"identifiers":2919},"Ohba, 2005, Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis, J Urol, 174, 461, 10.1097\u002F01.ju.0000165150.46006.92",{"doi":2920},"10.1097\u002F01.ju.0000165150.46006.92",{"id":26,"text":2922,"url":26,"identifiers":2923},"Span, 2008, Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues, BJU Int, 102, 177, 10.1111\u002Fj.1464-410X.2008.07568.x",{"doi":2924},"10.1111\u002Fj.1464-410X.2008.07568.x",{"id":26,"text":2926,"url":26,"identifiers":2927},"Lanza, 1998, Expression and functional role of urokinase-type plasminogen activator receptor in normal and acute leukaemic cells, Br J Haematol, 103, 110, 10.1046\u002Fj.1365-2141.1998.00932.x",{"doi":2928},"10.1046\u002Fj.1365-2141.1998.00932.x",{"id":26,"text":2930,"url":26,"identifiers":2931},"Mustjoki, 1999, Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy, Thromb Haemost, 81, 705, 10.1055\u002Fs-0037-1614558",{"doi":2932},"10.1055\u002Fs-0037-1614558",{"id":26,"text":2934,"url":26,"identifiers":2935},"Rasch, 2008, Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer, Front Biosci, 13, 6752, 10.2741\u002F3186",{"doi":2936},"10.2741\u002F3186",{"id":26,"text":2938,"url":26,"identifiers":2939},"Li, 2013, Urokinase plasminogen activator receptor (uPAR) targeted nuclear imaging and radionuclide therapy, Theranostics, 3, 507, 10.7150\u002Fthno.5557",{"doi":2940},"10.7150\u002Fthno.5557",{"id":26,"text":2942,"url":26,"identifiers":2943},"Yang, 2016, Antibody-based PET of uPA\u002FuPAR signaling with broad applicability for cancer imaging, Oncotarget, 7, 73912, 10.18632\u002Foncotarget.12528",{"doi":2944},"10.18632\u002Foncotarget.12528",{"id":26,"text":2946,"url":26,"identifiers":2947},"Jänicke, 1989, Urokinase-type plasminogen activator antigen and early relapse in breast cancer, Lancet, 334, 1049, 10.1016\u002FS0140-6736(89)91070-2",{"doi":2948},"10.1016\u002FS0140-6736(89)91070-2",{"id":26,"text":2950,"url":26,"identifiers":2951},"Jänicke, 1991, Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer, Semin Thromb Hemost, 17, 303, 10.1055\u002Fs-2007-1002624",{"doi":2952},"10.1055\u002Fs-2007-1002624",{"id":26,"text":2954,"url":26,"identifiers":2955},"Mengele, 2010, Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1, Expert Rev Mol Diagn, 10, 947, 10.1586\u002Ferm.10.73",{"doi":2956},"10.1586\u002Ferm.10.73",{"id":26,"text":2958,"url":26,"identifiers":2959},"Schmitt, 2008, Assessment of urokinase-type plasminogen activator and its inhibitor PAI-1 in breast cancer tissue: historical aspects and future prospects, Breast Care, 3, 3, 10.1159\u002F000151737",{"doi":2960},"10.1159\u002F000151737",{"id":26,"text":2962,"url":26,"identifiers":2963},"Spyratos, 2002, Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer, Anticancer Res, 22, 2997",{},{"id":26,"text":2965,"url":26,"identifiers":2966},"Lamy, 2007, Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression, Am J Clin Pathol, 128, 404, 10.1309\u002FK4JAF2NMD5EJU67Y",{"doi":2967},"10.1309\u002FK4JAF2NMD5EJU67Y",{"id":26,"text":2969,"url":26,"identifiers":2970},"Al-Janabi, 2014, Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancer, Biomed Res Int, 2014, 972587, 10.1155\u002F2014\u002F972587",{"doi":2971},"10.1155\u002F2014\u002F972587",{"id":26,"text":2973,"url":26,"identifiers":2974},"Mahmood, 2017, DNA methylation and breast cancer: mechanistic and therapeutic applications, Trends Cancer Res, 12, 1",{},{"id":26,"text":2976,"url":26,"identifiers":2977},"Gao, 2005, CpG methylation of the PAI-1 gene 5’ flanking region is inversely correlated with PAI-1 mRNA levels in human cell lines, Thromb Haemostas, 94, 651, 10.1160\u002FTH05-02-0114",{"doi":2978},"10.1160\u002FTH05-02-0114",{"id":26,"text":2980,"url":26,"identifiers":2981},"Rabbani, 2002, Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo, Cancer Res, 62, 2390",{},{"id":26,"text":2983,"url":26,"identifiers":2984},"Baart, 2017, uPAR directed-imaging of head-and-neck cancer, Oncotarget, 8, 20519, 10.18632\u002Foncotarget.16240",{"doi":2985},"10.18632\u002Foncotarget.16240",{"id":26,"text":2987,"url":26,"identifiers":2988},"Persson, 2015, First-in-human uPAR PET: imaging of cancer aggressiveness, Theranostics, 5, 1303, 10.7150\u002Fthno.12956",{"doi":2989},"10.7150\u002Fthno.12956",{"id":26,"text":2991,"url":26,"identifiers":2992},"Boonstra, 2015, uPAR-targeted multimodal tracer for pre-and intraoperative imaging in cancer surgery, Oncotarget, 6, 14260, 10.18632\u002Foncotarget.3680",{"doi":2993},"10.18632\u002Foncotarget.3680",{"id":26,"text":2995,"url":26,"identifiers":2996},"Sidenius, 2003, The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy, Cancer Metastasis Rev, 22, 205, 10.1023\u002FA:1023099415940",{"doi":2997},"10.1023\u002FA:1023099415940",{"id":26,"text":2999,"url":26,"identifiers":3000},"Lund, 2011, uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy, Curr Drug Targets, 12, 1744, 10.2174\u002F138945011797635902",{"doi":3001},"10.2174\u002F138945011797635902",{"id":26,"text":3003,"url":26,"identifiers":3004},"Ossowski, 1991, Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse, Cancer Res, 51, 274",{},{"id":26,"text":3006,"url":26,"identifiers":3007},"Towle, 1993, Inhibition of urokinase by 4-substituted benzo [b] thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor, Cancer Res, 53, 2553",{},{"id":26,"text":3009,"url":26,"identifiers":3010},"Rabbani, 1995, Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA), Int J Cancer, 63, 840, 10.1002\u002Fijc.2910630615",{"doi":3011},"10.1002\u002Fijc.2910630615",{"id":26,"text":3013,"url":26,"identifiers":3014},"Xing, 1997, Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428, Cancer Res, 57, 3585",{},{"id":26,"text":3016,"url":26,"identifiers":3017},"Meyer, 2008, The oral serine protease inhibitor WX-671–first experience in patients with advanced head and neck carcinoma, Breast Care, 3, 20, 10.1159\u002F000151736",{"doi":3018},"10.1159\u002F000151736",{"id":26,"text":3020,"url":26,"identifiers":3021},"Goldstein, 2008, Experience in phase I trials and an upcoming phase II study with uPA inhibitors in metastatic breast cancer, Breast Care, 3, 25, 10.1159\u002F000151733",{"doi":3022},"10.1159\u002F000151733",{"id":26,"text":3024,"url":26,"identifiers":3025},"Schmitt, 2011, Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1, Expert Rev Mol Diagn, 11, 617, 10.1586\u002Ferm.11.47",{"doi":3026},"10.1586\u002Ferm.11.47",{"id":26,"text":3028,"url":26,"identifiers":3029},"Crowley, 1993, Prevention of metastasis by inhibition of the urokinase receptor, Proc Natl Acad Sci U S A, 90, 5021, 10.1073\u002Fpnas.90.11.5021",{"doi":3030},"10.1073\u002Fpnas.90.11.5021",{"id":26,"text":3032,"url":26,"identifiers":3033},"Goodson, 1994, High-affinity urokinase receptor antagonists identified with bacteriophage peptide display, Proc Natl Acad Sci U S A, 91, 7129, 10.1073\u002Fpnas.91.15.7129",{"doi":3034},"10.1073\u002Fpnas.91.15.7129",{"id":26,"text":3036,"url":26,"identifiers":3037},"Ploug, 2001, Peptide-derived antagonists of the urokinase receptor. Affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation, Biochemistry, 40, 12157, 10.1021\u002Fbi010662g",{"doi":3038},"10.1021\u002Fbi010662g",{"id":26,"text":3040,"url":26,"identifiers":3041},"Bürgle, 1997, Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides, Biol Chem, 378, 231, 10.1515\u002Fbchm.1997.378.3-4.231",{"doi":3042},"10.1515\u002Fbchm.1997.378.3-4.231",{"id":26,"text":3044,"url":26,"identifiers":3045},"Franco, 1997, Phosphorylation of human pro-urokinase on Ser138\u002F303 impairs its receptor-dependent ability to promote myelomonocytic adherence and motility, J Cell Biol, 137, 779, 10.1083\u002Fjcb.137.3.779",{"doi":3046},"10.1083\u002Fjcb.137.3.779",{"id":26,"text":3048,"url":26,"identifiers":3049},"Guo, 2002, An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer, Cancer Res, 62, 4678",{},{"id":26,"text":3051,"url":26,"identifiers":3052},"Boyd, 2003, A urokinase-derived peptide (Å6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis, Am J Pathol, 162, 619, 10.1016\u002FS0002-9440(10)63855-2",{"doi":3053},"10.1016\u002FS0002-9440(10)63855-2",{"id":26,"text":3055,"url":26,"identifiers":3056},"Mishima, 2000, A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin, Proc Natl Acad Sci U S A, 97, 8484, 10.1073\u002Fpnas.150239497",{"doi":3057},"10.1073\u002Fpnas.150239497",{"id":26,"text":3059,"url":26,"identifiers":3060},"Piotrowicz, 2011, A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells, Mol Cancer Ther, 10, 2072, 10.1158\u002F1535-7163.MCT-11-0351",{"doi":3061},"10.1158\u002F1535-7163.MCT-11-0351",{"id":26,"text":3063,"url":26,"identifiers":3064},"Finlayson, 2015, Modulation of CD44 activity by A6-peptide, Front Immunol, 6, 135, 10.3389\u002Ffimmu.2015.00135",{"doi":3065},"10.3389\u002Ffimmu.2015.00135",{"id":26,"text":3067,"url":26,"identifiers":3068},"Gold, 2012, A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study, Gynecol Oncol, 125, 635, 10.1016\u002Fj.ygyno.2012.03.023",{"doi":3069},"10.1016\u002Fj.ygyno.2012.03.023",{"id":26,"text":3071,"url":26,"identifiers":3072},"Van Buren, 2009, Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver, Cancer, 115, 3360, 10.1002\u002Fcncr.24371",{"doi":3073},"10.1002\u002Fcncr.24371",{"id":26,"text":3075,"url":26,"identifiers":3076},"D’Alessio, 2004, Antisense oligodeoxynucleotides for urokinase-plasminogen activator receptor have anti-invasive and anti-proliferative effects in vitro and inhibit spontaneous metastases of human melanoma in mice, Int J Cancer, 110, 125, 10.1002\u002Fijc.20077",{"doi":3077},"10.1002\u002Fijc.20077",{"id":26,"text":3079,"url":26,"identifiers":3080},"Mohan, 1999, Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth, Cancer Res, 59, 3369",{},{"id":26,"text":3082,"url":26,"identifiers":3083},"Margheri, 2005, Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases, Gene Ther, 12, 702, 10.1038\u002Fsj.gt.3302456",{"doi":3084},"10.1038\u002Fsj.gt.3302456",{"id":26,"text":3086,"url":26,"identifiers":3087},"Gondi, 2007, Down-regulation of uPAR and uPA activates caspase-mediated apoptosis and inhibits the PI3K\u002FAKT pathway, Int J Oncol, 31, 19, 10.3892\u002Fijo.31.1.19",{"doi":3088},"10.3892\u002Fijo.31.1.19",{"id":26,"text":3090,"url":26,"identifiers":3091},"Karikó, 1994, Lipofectin-aided cell delivery of ribozyme targeted to human urokinase receptor mRNA, FEBS Lett, 352, 41, 10.1016\u002F0014-5793(94)00914-7",{"doi":3092},"10.1016\u002F0014-5793(94)00914-7",{"id":26,"text":3094,"url":26,"identifiers":3095},"Pakneshan, 2004, Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis, J Biol Chem, 279, 31735, 10.1074\u002Fjbc.M401669200",{"doi":3096},"10.1074\u002Fjbc.M401669200",{"id":26,"text":3098,"url":26,"identifiers":3099},"Shukeir, 2006, Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo, Cancer Res, 66, 9202, 10.1158\u002F0008-5472.CAN-06-1954",{"doi":3100},"10.1158\u002F0008-5472.CAN-06-1954",{"id":26,"text":3102,"url":26,"identifiers":3103},"Mahmood, 2018, Methyl donor S-adenosylmethionine (SAM) supplementation attenuates breast cancer growth, invasion, and metastasis in vivo; therapeutic and chemopreventive applications, Oncotarget, 9, 5169, 10.18632\u002Foncotarget.23704",{"doi":3104},"10.18632\u002Foncotarget.23704",{"id":26,"text":3106,"url":26,"identifiers":3107},"Koutsilieris, 1997, Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer, Anticancer Res, 17, 1461",{},{"id":26,"text":3109,"url":26,"identifiers":3110},"Mustjoki, 1998, Interferons and retinoids enhance and dexamethasone suppresses urokinase-mediated plasminogen activation in promyelocytic leukemia cells, Leukemia, 12, 164, 10.1038\u002Fsj.leu.2400918",{"doi":3111},"10.1038\u002Fsj.leu.2400918",{"id":26,"text":3113,"url":26,"identifiers":3114},"Sundaram, 2013, Therapeutic RNA aptamers in clinical trials, Eur J Pharm Sci, 48, 259, 10.1016\u002Fj.ejps.2012.10.014",{"doi":3115},"10.1016\u002Fj.ejps.2012.10.014",{"id":26,"text":3117,"url":26,"identifiers":3118},"Blake, 2009, Antimetastatic potential of PAI-1 – specific RNA aptamers, Oligonucleotides, 19, 117, 10.1089\u002Foli.2008.0177",{"doi":3119},"10.1089\u002Foli.2008.0177",{"id":26,"text":3121,"url":26,"identifiers":3122},"Dupont, 2009, Biochemical properties of plasminogen activator inhibitor-1, Front Biosci, 14, 1337, 10.2741\u002F3312",{"doi":3123},"10.2741\u002F3312",{"id":26,"text":3125,"url":26,"identifiers":3126},"Mathiasen, 2008, A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state, Mol Pharmacol, 74, 641, 10.1124\u002Fmol.108.046417",{"doi":3127},"10.1124\u002Fmol.108.046417",{"id":26,"text":3129,"url":26,"identifiers":3130},"Knör, 2008, Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in α-emitter therapy for disseminated ovarian cancer, Eur J Nucl Med Mol Imaging, 35, 53, 10.1007\u002Fs00259-007-0582-3",{"doi":3131},"10.1007\u002Fs00259-007-0582-3",{"id":26,"text":3133,"url":26,"identifiers":3134},"Vallera, 2002, Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT, J Natl Cancer Inst, 94, 597, 10.1093\u002Fjnci\u002F94.8.597",{"doi":3135},"10.1093\u002Fjnci\u002F94.8.597",{"id":26,"text":3137,"url":26,"identifiers":3138},"Hall, 2006, Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme, Neurosurg Focus, 20, E23, 10.3171\u002Ffoc.2006.20.4.15",{"doi":3139},"10.3171\u002Ffoc.2006.20.4.15",{"id":26,"text":3141,"url":26,"identifiers":3142},"Huang, 2012, Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer, J Neurooncol, 109, 229, 10.1007\u002Fs11060-012-0904-6",{"doi":3143},"10.1007\u002Fs11060-012-0904-6",{"id":26,"text":3145,"url":26,"identifiers":3146},"Rajagopal, 2000, Recombinant toxins that bind to the urokinase receptor are cytotoxic without requiring binding to the α2-macroglobulin receptor, J Biol Chem, 275, 7566, 10.1074\u002Fjbc.275.11.7566",{"doi":3147},"10.1074\u002Fjbc.275.11.7566",{"id":26,"text":3149,"url":26,"identifiers":3150},"Adair, 2010, Nanoparticulate alternatives for drug delivery, ACS Nano, 4, 4967, 10.1021\u002Fnn102324e",{"doi":3151},"10.1021\u002Fnn102324e",{"id":26,"text":3153,"url":26,"identifiers":3154},"Zhang, 2013, Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy, Mol Cancer Ther, 12, 2628, 10.1158\u002F1535-7163.MCT-13-0204",{"doi":3155},"10.1158\u002F1535-7163.MCT-13-0204",{"id":26,"text":3157,"url":26,"identifiers":3158},"Kirpotin, 2012, 7 building and characterizing antibody-targeted lipidic nanotherapeutics, Methods Enzymol, 502, 139, 10.1016\u002FB978-0-12-416039-2.00007-0",{"doi":3159},"10.1016\u002FB978-0-12-416039-2.00007-0",{"id":26,"text":3161,"url":26,"identifiers":3162},"Yang, 2009, Receptor-targeted nanoparticles for in vivo imaging of breast cancer, Clin Cancer Res, 15, 4722, 10.1158\u002F1078-0432.CCR-08-3289",{"doi":3163},"10.1158\u002F1078-0432.CCR-08-3289",{"id":26,"text":3165,"url":26,"identifiers":3166},"Abdalla, 2011, Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy, J Control Release, 149, 314, 10.1016\u002Fj.jconrel.2010.10.030",{"doi":3167},"10.1016\u002Fj.jconrel.2010.10.030",{"id":26,"text":3169,"url":26,"identifiers":3170},"Carriero, 2017, Retro-inverso urokinase receptor antagonists for the treatment of metastatic sarcomas, Sci Rep, 7, 1312, 10.1038\u002Fs41598-017-01425-9",{"doi":3171},"10.1038\u002Fs41598-017-01425-9",{"id":3173,"createTime":3174,"updateTime":3174,"relativeEntities":3175,"slug":3176,"properties":3177,"entityType":772,"verifyStatus":25,"verifyTime":3192,"verifyNote":773,"syncStatus":28,"languages":3193,"translateLanguages":26,"viewCount":36,"primaryUrl":3194,"fullTextUrl":26,"authors":3195,"publicationType":843,"publisherRelationship":3252,"citationCount":3286,"citationInfo":3287,"publishDate":26,"publishYear":26,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":3289,"isForceReanalyzing":1390},"eeb18987-f62c-4081-a803-1c79680f3d81","2024-09-29T01:28:35.382+00:00",[],"Microtubules-and-Their-Role-in-Cellular-Stress-in-Cancer",{"mag":3178,"keywords":3180,"pmc":3181,"openalex":3183,"abstract":3185,"title":3186,"pm":3188,"doi":3190},{"VOID":3179},"2007917102",{},{"VOID":3182},"4061531",{"VOID":3184},"W2007917102",{},{"EN":3187},"Microtubules and Their Role in Cellular Stress in Cancer",{"VOID":3189},"24995158",{"VOID":3191},"10.3389\u002Ffonc.2014.00153","2024-09-29T01:28:35.381+00:00",[102],"http:\u002F\u002Fjournal.frontiersin.org\u002Farticle\u002F10.3389\u002Ffonc.2014.00153\u002Fabstract",[3196,3218,3235],{"id":3197,"sortIndex":36,"researcher":26,"roles":3198,"affiliations":3199,"properties":3211},"ab81ce5c-d607-40d3-9b39-af15ea7d892c",[],[3200],{"id":3201,"sortIndex":36,"affiliation":3202,"properties":26},"474033fc-6ac0-4243-8e35-9a822bf23020",{"id":3203,"createTime":3204,"updateTime":3205,"relativeEntities":3206,"slug":3207,"properties":3208,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"03e3e9ac-caca-4ecf-bf88-1a9c121ff594","2024-09-29T01:28:35.422+00:00","2025-06-11T17:11:58.624+00:00",[],"Tumour-Biology-and-Targeting-Program-Children-s-Cancer-Institute-Australia-Lowy-Cancer-Research-Centre-University-of-New-South-Wales-Australia",{"title":3209},{"EN":3210},"Tumour Biology and Targeting Program, Children’s Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Australia",{"openalex":3212,"orcid":3214,"title":3216},{"VOID":3213},"A5051655023",{"VOID":3215},"https:\u002F\u002Forcid.org\u002F0000-0002-3142-8937",{"EN":3217},"Amelia L. Parker",{"id":3219,"sortIndex":114,"researcher":26,"roles":3220,"affiliations":3221,"properties":3228},"b3691169-51a7-4c2c-8db3-7aa89a6af801",[],[3222],{"id":3223,"sortIndex":36,"affiliation":3224,"properties":26},"65bffa26-0023-4955-9d24-b6c44554bf26",{"id":3203,"createTime":3204,"updateTime":3205,"relativeEntities":3225,"slug":3207,"properties":3226,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3227},{"EN":3210},{"openalex":3229,"orcid":3231,"title":3233},{"VOID":3230},"A5103231153",{"VOID":3232},"https:\u002F\u002Forcid.org\u002F0000-0001-8807-3623",{"EN":3234},"Joshua A. McCarroll",{"id":3236,"sortIndex":115,"researcher":26,"roles":3237,"affiliations":3238,"properties":3245},"7e0d7341-e24c-4d6e-b09e-e674eebddd09",[],[3239],{"id":3240,"sortIndex":36,"affiliation":3241,"properties":26},"ec2b12d5-f1cb-4a06-ad0a-1f1b158a1d7a",{"id":3203,"createTime":3204,"updateTime":3205,"relativeEntities":3242,"slug":3207,"properties":3243,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3244},{"EN":3210},{"openalex":3246,"orcid":3248,"title":3250},{"VOID":3247},"A5026784302",{"VOID":3249},"https:\u002F\u002Forcid.org\u002F0000-0003-2309-898X",{"EN":3251},"Maria Kavallaris",{"url":26,"publisher":3253,"properties":3283},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":3254,"slug":663,"properties":3255,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":3261,"manageAffiliations":3262,"indexDatabases":3263,"url":742,"thumbnailPath":26,"statistic":3278,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"country":3256,"issn":3257,"introduce":3258,"eissn":3259,"title":3260},{"VOID":666},{"VOID":668},{"EN":670},{"VOID":668},{"EN":673},[],[],[3264,3271],{"id":704,"indexDatabase":3265,"url":719,"indexYears":26,"academicFieldIds":3270,"indexDatabaseRanking":26},{"id":706,"createTime":707,"updateTime":708,"relativeEntities":3266,"label":3267,"description":3268,"key":715,"publicationTags":3269,"standard":26},[],{"EN":711,"VI":711},{"VI":713,"EN":714},[717,718],[721],{"id":723,"indexDatabase":3272,"url":736,"indexYears":737,"academicFieldIds":3277,"indexDatabaseRanking":741},{"id":725,"createTime":726,"updateTime":727,"relativeEntities":3273,"label":3274,"description":3275,"key":733,"publicationTags":3276,"standard":26},[],{"EN":730,"VI":730},{"EN":730,"VI":732},[735],[739,740],{"impactFactor":36,"impactFactorByYear":3279,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":115,"totalPublicationByYear":3280,"totalCitation":158,"totalCitationByYear":3281,"totalCitationPerPublication":158,"totalCitationPerPublicationByYear":3282,"hindexLast5Year":115,"hindex":115},{},{"2021":115},{"2021":158},{"2021":158},{"volume":3284},{"VOID":3285},"4",342,{"total":3286,"publishYear":26,"statisticByYear":3288},{"2014":135,"2015":124,"2016":237,"2017":396,"2018":79,"2019":255,"2020":358,"2021":539,"2022":159,"2023":358,"2024":237},[3290,3294,3298,3302,3306,3310,3314,3318,3322,3326,3329,3332,3336,3340,3343,3347,3351,3355,3359,3363,3367,3371,3375,3379,3383,3387,3391,3395,3399,3403,3407,3411,3415,3419,3423,3426,3430,3434,3437,3441,3445,3449,3453,3457,3461,3465,3469,3473,3476,3480,3484,3488,3492,3496,3500,3504,3508,3512,3516,3520,3524,3528,3532,3536,3540,3544,3548,3552,3556,3560,3564,3568,3572,3576,3580,3584,3588,3592,3596,3600,3604,3608,3612,3616,3620,3624,3628,3632,3636,3640,3644,3648,3652,3656,3660,3664,3668,3672,3676,3680,3684,3688,3692,3696,3700,3704,3708,3712,3716,3720,3724,3728,3732,3736,3740,3744,3748,3752,3756,3760,3764,3768,3772,3776,3780,3784,3788,3792,3796,3800,3804,3808,3812,3816,3820,3824,3828,3832,3836,3840,3844,3848,3852,3856,3860,3864,3868,3872,3876,3880,3884,3888,3892,3896,3900,3904,3908,3912,3916,3920,3924,3928,3932,3936,3940,3944,3948,3952,3956,3960,3964,3968,3972,3976,3980,3984,3988,3992,3996,4000,4004,4008,4012,4016,4020,4024,4028,4032,4035,4039,4043,4047,4051,4055,4059,4063,4067,4071,4075,4079,4083,4087,4091,4095,4099,4103,4107,4111,4115,4119,4123,4127,4131,4135,4139,4143,4147,4151,4155,4159,4163,4167,4170,4174,4177,4180,4184,4188,4192,4195,4199,4203,4207,4211,4214,4218,4222,4226,4230,4234,4238,4242,4246,4250,4254,4258,4262,4266,4270,4274,4278,4282,4286],{"id":26,"text":3291,"url":26,"identifiers":3292},"Nogales, 2000, Structural insights into microtubule function, Annu Rev Biochem, 69, 277, 10.1146\u002Fannurev.biochem.69.1.277",{"doi":3293},"10.1146\u002Fannurev.biochem.69.1.277",{"id":26,"text":3295,"url":26,"identifiers":3296},"Downing, 1998, Tubulin structure: insights into microtubule properties and functions, Curr Opin Struct Biol, 8, 785, 10.1016\u002FS0959-440X(98)80099-7",{"doi":3297},"10.1016\u002FS0959-440X(98)80099-7",{"id":26,"text":3299,"url":26,"identifiers":3300},"Jordan, 2004, Microtubules as a target for anticancer drugs, Nat Rev Cancer, 4, 253, 10.1038\u002Fnrc1317",{"doi":3301},"10.1038\u002Fnrc1317",{"id":26,"text":3303,"url":26,"identifiers":3304},"Veldhoen, 2013, The chemotherapeutic agent paclitaxel inhibits autophagy through two distinct mechanisms that regulate apoptosis, Oncogene, 32, 736, 10.1038\u002Fonc.2012.92",{"doi":3305},"10.1038\u002Fonc.2012.92",{"id":26,"text":3307,"url":26,"identifiers":3308},"Wang, 2009, Blockade of GRP78 sensitizes breast cancer cells to microtubules-interfering agents that induce the unfolded protein response, J Cell Mol Med, 13, 3888, 10.1111\u002Fj.1582-4934.2009.00873.x",{"doi":3309},"10.1111\u002Fj.1582-4934.2009.00873.x",{"id":26,"text":3311,"url":26,"identifiers":3312},"Xi, 2011, Autophagy inhibition promotes paclitaxel-induced apoptosis in cancer cells, Cancer Lett, 307, 141, 10.1016\u002Fj.canlet.2011.03.026",{"doi":3313},"10.1016\u002Fj.canlet.2011.03.026",{"id":26,"text":3315,"url":26,"identifiers":3316},"Luduena, 1993, Are tubulin isotypes functionally significant, Mol Biol Cell, 4, 445, 10.1091\u002Fmbc.4.5.445",{"doi":3317},"10.1091\u002Fmbc.4.5.445",{"id":26,"text":3319,"url":26,"identifiers":3320},"Sullivan, 1986, Identification of conserved isotype-defining variable region sequences for 4 vertebrate beta-tubulin polypeptide classes, Proc Natl Acad Sci U S A, 83, 4327, 10.1073\u002Fpnas.83.12.4327",{"doi":3321},"10.1073\u002Fpnas.83.12.4327",{"id":26,"text":3323,"url":26,"identifiers":3324},"Janke, 2011, Post-translational regulation of the microtubule cytoskeleton: mechanisms and functions, Nat Rev Mol Cell Biol, 12, 773, 10.1038\u002Fnrm3227",{"doi":3325},"10.1038\u002Fnrm3227",{"id":26,"text":3327,"url":26,"identifiers":3328},"Kavallaris, 2001, Multiple microtubule alterations are associated with vinca alkaloid resistance in human leukemia cells, Cancer Res, 61, 5803",{},{"id":26,"text":3330,"url":26,"identifiers":3331},"Martello, 2003, Elevated levels of microtubule destabilizing factors in a taxol-resistant\u002Fdependent A549 cell line with an alpha-tubulin mutation, Cancer Res, 63, 1207",{},{"id":26,"text":3333,"url":26,"identifiers":3334},"Verdier-Pinard, 2003, Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry, Biochemistry, 42, 5349, 10.1021\u002Fbi027293o",{"doi":3335},"10.1021\u002Fbi027293o",{"id":26,"text":3337,"url":26,"identifiers":3338},"Mozzetti, 2005, Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients, Clin Cancer Res, 11, 298, 10.1158\u002F1078-0432.298.11.1",{"doi":3339},"10.1158\u002F1078-0432.298.11.1",{"id":26,"text":3341,"url":26,"identifiers":3342},"Sale, 2002, Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers, Mol Cancer Ther, 1, 215",{},{"id":26,"text":3344,"url":26,"identifiers":3345},"Kavallaris, 2010, Microtubules and resistance to tubulin-binding agents, Nat Rev Cancer, 10, 194, 10.1038\u002Fnrc2803",{"doi":3346},"10.1038\u002Fnrc2803",{"id":26,"text":3348,"url":26,"identifiers":3349},"Ferrandina, 2006, Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients, Clin Cancer Res, 12, 2774, 10.1158\u002F1078-0432.CCR-05-2715",{"doi":3350},"10.1158\u002F1078-0432.CCR-05-2715",{"id":26,"text":3352,"url":26,"identifiers":3353},"Lee, 2007, Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia, Histopathology, 51, 539, 10.1111\u002Fj.1365-2559.2007.02792.x",{"doi":3354},"10.1111\u002Fj.1365-2559.2007.02792.x",{"id":26,"text":3356,"url":26,"identifiers":3357},"McCarroll, 2010, Beta III-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer, Cancer Res, 70, 4995, 10.1158\u002F0008-5472.CAN-09-4487",{"doi":3358},"10.1158\u002F0008-5472.CAN-09-4487",{"id":26,"text":3360,"url":26,"identifiers":3361},"Gan, 2011, Specific β-tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung cancer cells, PLoS One, 6, e21717, 10.1371\u002Fjournal.pone.0021717",{"doi":3362},"10.1371\u002Fjournal.pone.0021717",{"id":26,"text":3364,"url":26,"identifiers":3365},"Gan, 2008, Tubulin-targeted drug action: functional significance of class II and class IVb beta-tubulin in vinca alkaloid sensitivity, Cancer Res, 68, 9817, 10.1158\u002F0008-5472.CAN-08-1501",{"doi":3366},"10.1158\u002F0008-5472.CAN-08-1501",{"id":26,"text":3368,"url":26,"identifiers":3369},"Cucchiarelli, 2008, Beta-tubulin isotype classes II and V expression patterns in nonsmall cell lung carcinomas, Cell Motil Cytoskeleton, 65, 675, 10.1002\u002Fcm.20297",{"doi":3370},"10.1002\u002Fcm.20297",{"id":26,"text":3372,"url":26,"identifiers":3373},"Don, 2004, Neuronal-associated microtubule proteins class III beta-tubulin and MAP2c in neuroblastoma: role in resistance to microtubule-targeted drugs, Mol Cancer Ther, 3, 1137, 10.1158\u002F1535-7163.1137.3.9",{"doi":3374},"10.1158\u002F1535-7163.1137.3.9",{"id":26,"text":3376,"url":26,"identifiers":3377},"Bhattacharya, 2004, A ubiquitous beta-tubulin disrupts microtubule assembly and inhibits cell proliferation, Mol Biol Cell, 15, 3123, 10.1091\u002Fmbc.E04-01-0060",{"doi":3378},"10.1091\u002Fmbc.E04-01-0060",{"id":26,"text":3380,"url":26,"identifiers":3381},"Lobert, 2011, Regulation of beta-tubulin isotypes by micro-RNA 100 in MCF7 breast cancer cells, Cytoskeleton (Hoboken), 68, 355, 10.1002\u002Fcm.20517",{"doi":3382},"10.1002\u002Fcm.20517",{"id":26,"text":3384,"url":26,"identifiers":3385},"Verrills, 2003, Proteome analysis of vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations, J Biol Chem, 278, 45082, 10.1074\u002Fjbc.M303378200",{"doi":3386},"10.1074\u002Fjbc.M303378200",{"id":26,"text":3388,"url":26,"identifiers":3389},"Mozzetti, 2008, Molecular mechanisms of patupilone resistance, Cancer Res, 68, 10197, 10.1158\u002F0008-5472.CAN-08-2091",{"doi":3390},"10.1158\u002F0008-5472.CAN-08-2091",{"id":26,"text":3392,"url":26,"identifiers":3393},"Dozier, 2003, Beta class II tubulin predominates in normal and tumor breast tissues, Breast Cancer Res, 5, R157, 10.1186\u002Fbcr631",{"doi":3394},"10.1186\u002Fbcr631",{"id":26,"text":3396,"url":26,"identifiers":3397},"Blade, 1999, Overexpression of class I, II or IVb beta-tubulin isotypes in CHO cells is insufficient to confer resistance to paclitaxel, J Cell Sci, 112, 2213, 10.1242\u002Fjcs.112.13.2213",{"doi":3398},"10.1242\u002Fjcs.112.13.2213",{"id":26,"text":3400,"url":26,"identifiers":3401},"Ranganathan, 2001, Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III) cDNA transfection into prostate carcinoma cells, Br J Cancer, 85, 735, 10.1054\u002Fbjoc.2001.1956",{"doi":3402},"10.1054\u002Fbjoc.2001.1956",{"id":26,"text":3404,"url":26,"identifiers":3405},"Hari, 2003, Expression of class III β-tubulin reduces microtubule assembly and confers resistance to paclitaxel, Cell Motil Cytoskeleton, 56, 45, 10.1002\u002Fcm.10132",{"doi":3406},"10.1002\u002Fcm.10132",{"id":26,"text":3408,"url":26,"identifiers":3409},"Levallet, 2012, High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway, Mol Cancer Ther, 11, 1203, 10.1158\u002F1535-7163.MCT-11-0899",{"doi":3410},"10.1158\u002F1535-7163.MCT-11-0899",{"id":26,"text":3412,"url":26,"identifiers":3413},"Cochrane, 2009, MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents, Mol Cancer Ther, 8, 1055, 10.1158\u002F1535-7163.MCT-08-1046",{"doi":3414},"10.1158\u002F1535-7163.MCT-08-1046",{"id":26,"text":3416,"url":26,"identifiers":3417},"Leskela, 2011, The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients, Endocr Relat Cancer, 18, 85, 10.1677\u002FERC-10-0148",{"doi":3418},"10.1677\u002FERC-10-0148",{"id":26,"text":3420,"url":26,"identifiers":3421},"Akasaka, 2009, Loss of class III beta-tubulin induced by histone deacetylation is associated with chemosensitivity to paclitaxel in malignant melanoma cells, J Invest Dermatol, 129, 1516, 10.1038\u002Fjid.2008.406",{"doi":3422},"10.1038\u002Fjid.2008.406",{"id":26,"text":3424,"url":26,"identifiers":3425},"Izutsu, 2008, Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells, Int J Oncol, 32, 1227",{},{"id":26,"text":3427,"url":26,"identifiers":3428},"Tsourlakis, 2014, βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion, Am J Pathol, 184, 609, 10.1016\u002Fj.ajpath.2013.11.007",{"doi":3429},"10.1016\u002Fj.ajpath.2013.11.007",{"id":26,"text":3431,"url":26,"identifiers":3432},"Ranganathan, 1998, Cloning and sequencing of human betaIII-tubulin cDNA: induction of betaIII isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents, Biochim Biophys Acta, 1395, 237, 10.1016\u002FS0167-4781(97)00168-1",{"doi":3433},"10.1016\u002FS0167-4781(97)00168-1",{"id":26,"text":3435,"url":26,"identifiers":3436},"Saussede-Aim, 2009, Vinorelbine induces beta 3-tubulin gene expression through an AP-1 site, Anticancer Res, 29, 3003",{},{"id":26,"text":3438,"url":26,"identifiers":3439},"Raspaglio, 2008, Hypoxia induces class III beta-tubulin gene expression by HIF-1 alpha binding to its 3’ flanking region, Gene, 409, 100, 10.1016\u002Fj.gene.2007.11.015",{"doi":3440},"10.1016\u002Fj.gene.2007.11.015",{"id":26,"text":3442,"url":26,"identifiers":3443},"Raspaglio, 2010, HuR regulates beta-tubulin isotype expression in ovarian cancer, Cancer Res, 70, 5891, 10.1158\u002F0008-5472.CAN-09-4656",{"doi":3444},"10.1158\u002F0008-5472.CAN-09-4656",{"id":26,"text":3446,"url":26,"identifiers":3447},"Masuda, 2009, RNA-binding proteins implicated in the hypoxic response, J Cell Mol Med, 13, 2759, 10.1111\u002Fj.1582-4934.2009.00842.x",{"doi":3448},"10.1111\u002Fj.1582-4934.2009.00842.x",{"id":26,"text":3450,"url":26,"identifiers":3451},"Schwarz, 1998, Beta-tubulin isotypes purified from bovine brain have different relative stabilities, Biochemistry, 37, 4687, 10.1021\u002Fbi972763d",{"doi":3452},"10.1021\u002Fbi972763d",{"id":26,"text":3454,"url":26,"identifiers":3455},"Boekelheide, 1992, Cis-diamminedichloroplatinum (ii) (cisplatin) alters microtubule assembly dynamics, Toxicol Appl Pharmacol, 116, 146, 10.1016\u002F0041-008X(92)90156-M",{"doi":3456},"10.1016\u002F0041-008X(92)90156-M",{"id":26,"text":3458,"url":26,"identifiers":3459},"Gan, 2010, Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of beta III-tubulin, Mol Cancer Ther, 9, 1339, 10.1158\u002F1535-7163.MCT-09-0679",{"doi":3460},"10.1158\u002F1535-7163.MCT-09-0679",{"id":26,"text":3462,"url":26,"identifiers":3463},"Kumar, 1981, Preferential action of a brain detyrosinolating carboxypeptidase on polymerized tubulin, J Biol Chem, 256, 7678, 10.1016\u002FS0021-9258(19)69014-9",{"doi":3464},"10.1016\u002FS0021-9258(19)69014-9",{"id":26,"text":3466,"url":26,"identifiers":3467},"Peris, 2009, Motor-dependent microtubule disassembly driven by tubulin tyrosination, J Cell Biol, 185, 1159, 10.1083\u002Fjcb.200902142",{"doi":3468},"10.1083\u002Fjcb.200902142",{"id":26,"text":3470,"url":26,"identifiers":3471},"Soucek, 2006, Normal and prostate cancer cells display distinct molecular profiles of α-tubulin posttranslational modifications, Prostate, 66, 954, 10.1002\u002Fpros.20416",{"doi":3472},"10.1002\u002Fpros.20416",{"id":26,"text":3474,"url":26,"identifiers":3475},"Mialhe, 2001, Tubulin detyrosination is a frequent occurrence in breast cancers of poor prognosis, Cancer Res, 61, 5024",{},{"id":26,"text":3477,"url":26,"identifiers":3478},"Lafanechere, 1998, Suppression of tubulin tyrosine ligase during tumor growth, J Cell Sci, 111, 171, 10.1242\u002Fjcs.111.2.171",{"doi":3479},"10.1242\u002Fjcs.111.2.171",{"id":26,"text":3481,"url":26,"identifiers":3482},"Kato, 2004, Low expression of human tubulin tyrosine ligase and suppressed tubulin tyrosination\u002Fdetyrosination cycle are associated with impaired neuronal differentiation in neuroblastomas with poor prognosis, Int J Cancer, 112, 365, 10.1002\u002Fijc.20431",{"doi":3483},"10.1002\u002Fijc.20431",{"id":26,"text":3485,"url":26,"identifiers":3486},"Whipple, 2010, Epithelial-to-mesenchymal transition promotes tubulin detyrosination and microtentacles that enhance endothelial engagement, Cancer Res, 70, 8127, 10.1158\u002F0008-5472.CAN-09-4613",{"doi":3487},"10.1158\u002F0008-5472.CAN-09-4613",{"id":26,"text":3489,"url":26,"identifiers":3490},"Giustiniani, 2009, Tubulin acetylation favors Hsp90 recruitment to microtubules and stimulates the signaling function of the Hsp90 clients Akt\u002FPKB and p53, Cell Signal, 21, 529, 10.1016\u002Fj.cellsig.2008.12.004",{"doi":3491},"10.1016\u002Fj.cellsig.2008.12.004",{"id":26,"text":3493,"url":26,"identifiers":3494},"Zhang, 2004, HDAC6 expression is correlated with better survival in breast cancer, Clin Cancer Res, 10, 6962, 10.1158\u002F1078-0432.CCR-04-0455",{"doi":3495},"10.1158\u002F1078-0432.CCR-04-0455",{"id":26,"text":3497,"url":26,"identifiers":3498},"Li, 2007, Sirtuin 2, a mammalian homolog of yeast silent information regulator-2 longevity regulator, is an oligodendroglial protein that decelerates cell differentiation through deacetylating alpha-tubulin, J Neurosci, 27, 2606, 10.1523\u002FJNEUROSCI.4181-06.2007",{"doi":3499},"10.1523\u002FJNEUROSCI.4181-06.2007",{"id":26,"text":3501,"url":26,"identifiers":3502},"Ng, 2013, Sirtuins’ modulation of autophagy, J Cell Physiol, 228, 2262, 10.1002\u002Fjcp.24399",{"doi":3503},"10.1002\u002Fjcp.24399",{"id":26,"text":3505,"url":26,"identifiers":3506},"Tran, 2007, HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions, J Cell Sci, 120, 1469, 10.1242\u002Fjcs.03431",{"doi":3507},"10.1242\u002Fjcs.03431",{"id":26,"text":3509,"url":26,"identifiers":3510},"Gao, 2010, The microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation, J Biol Chem, 285, 11219, 10.1074\u002Fjbc.M109.042754",{"doi":3511},"10.1074\u002Fjbc.M109.042754",{"id":26,"text":3513,"url":26,"identifiers":3514},"Friedman, 2010, ER sliding dynamics and ER-mitochondrial contacts occur on acetylated microtubules, J Cell Biol, 190, 363, 10.1083\u002Fjcb.200911024",{"doi":3515},"10.1083\u002Fjcb.200911024",{"id":26,"text":3517,"url":26,"identifiers":3518},"Daire, 2009, Kinesin-1 regulates microtubule dynamics via a c-Jun N-terminal kinase-dependent mechanism, J Biol Chem, 284, 31992, 10.1074\u002Fjbc.M109.007906",{"doi":3519},"10.1074\u002Fjbc.M109.007906",{"id":26,"text":3521,"url":26,"identifiers":3522},"Miller, 2008, Increased levels of a unique post-translationally modified βIVb-tubulin isotype in liver cancer, Biochemistry, 47, 7572, 10.1021\u002Fbi8005225",{"doi":3523},"10.1021\u002Fbi8005225",{"id":26,"text":3525,"url":26,"identifiers":3526},"Wasylyk, 2010, Tubulin tyrosine ligase like 12 links to prostate cancer through tubulin posttranslational modification and chromosome ploidy, Int J Cancer, 127, 2542, 10.1002\u002Fijc.25261",{"doi":3527},"10.1002\u002Fijc.25261",{"id":26,"text":3529,"url":26,"identifiers":3530},"Bhat, 2007, Microtubule-associated proteins as targets in cancer chemotherapy, Clin Cancer Res, 13, 2849, 10.1158\u002F1078-0432.CCR-06-3040",{"doi":3531},"10.1158\u002F1078-0432.CCR-06-3040",{"id":26,"text":3533,"url":26,"identifiers":3534},"Rouzier, 2005, Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer, Proc Natl Acad Sci U S A, 102, 8315, 10.1073\u002Fpnas.0408974102",{"doi":3535},"10.1073\u002Fpnas.0408974102",{"id":26,"text":3537,"url":26,"identifiers":3538},"Soltani, 2005, Microtubule-associated protein 2, a marker of neuronal differentiation, induces mitotic defects, inhibits growth of melanoma cells, and predicts metastatic potential of cutaneous melanoma, Am J Pathol, 166, 1841, 10.1016\u002FS0002-9440(10)62493-5",{"doi":3539},"10.1016\u002FS0002-9440(10)62493-5",{"id":26,"text":3541,"url":26,"identifiers":3542},"Song, 2010, Increased expression of MAP2 inhibits melanoma cell proliferation, invasion and tumor growth in vitro and in vivo, Exp Dermatol, 19, 958, 10.1111\u002Fj.1600-0625.2009.01020.x",{"doi":3543},"10.1111\u002Fj.1600-0625.2009.01020.x",{"id":26,"text":3545,"url":26,"identifiers":3546},"Verrills, 2003, Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions, Chem Biol, 10, 597, 10.1016\u002FS1074-5521(03)00141-8",{"doi":3547},"10.1016\u002FS1074-5521(03)00141-8",{"id":26,"text":3549,"url":26,"identifiers":3550},"Sun, 2012, Microtubule-binding protein CLIP-170 is a mediator of paclitaxel sensitivity, J Pathol, 226, 666, 10.1002\u002Fpath.3026",{"doi":3551},"10.1002\u002Fpath.3026",{"id":26,"text":3553,"url":26,"identifiers":3554},"Byrne, 2014, RNAi-mediated stathmin suppression reduces lung metastasis in an orthotopic neuroblastoma mouse model, Oncogene, 33, 882, 10.1038\u002Fonc.2013.11",{"doi":3555},"10.1038\u002Fonc.2013.11",{"id":26,"text":3557,"url":26,"identifiers":3558},"Rath, 2012, Kinesins and cancer, Nat Rev Cancer, 12, 527, 10.1038\u002Fnrc3310",{"doi":3559},"10.1038\u002Fnrc3310",{"id":26,"text":3561,"url":26,"identifiers":3562},"Sirajuddin, 2014, Regulation of microtubule motors by tubulin isotypes and post-translational modifications, Nat Cell Biol, 16, 335, 10.1038\u002Fncb2920",{"doi":3563},"10.1038\u002Fncb2920",{"id":26,"text":3565,"url":26,"identifiers":3566},"LaPointe, 2013, Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy, Neurotoxicology, 37, 231, 10.1016\u002Fj.neuro.2013.05.008",{"doi":3567},"10.1016\u002Fj.neuro.2013.05.008",{"id":26,"text":3569,"url":26,"identifiers":3570},"Dhillon, 2007, MAP kinase signalling pathways in cancer, Oncogene, 26, 3279, 10.1038\u002Fsj.onc.1210421",{"doi":3571},"10.1038\u002Fsj.onc.1210421",{"id":26,"text":3573,"url":26,"identifiers":3574},"Reszka, 1995, Association of mitogen-activated protein-kinase with the microtubule cytoskeleton, Proc Natl Acad Sci U S A, 92, 8881, 10.1073\u002Fpnas.92.19.8881",{"doi":3575},"10.1073\u002Fpnas.92.19.8881",{"id":26,"text":3577,"url":26,"identifiers":3578},"Zhou, 2002, Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine, J Biol Chem, 277, 39777, 10.1074\u002Fjbc.M203927200",{"doi":3579},"10.1074\u002Fjbc.M203927200",{"id":26,"text":3581,"url":26,"identifiers":3582},"Wang, 1999, Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells, J Biol Chem, 274, 8208, 10.1074\u002Fjbc.274.12.8208",{"doi":3583},"10.1074\u002Fjbc.274.12.8208",{"id":26,"text":3585,"url":26,"identifiers":3586},"Seidman, 2001, The role of ERK 1\u002F2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells, Exp Cell Res, 268, 84, 10.1006\u002Fexcr.2001.5262",{"doi":3587},"10.1006\u002Fexcr.2001.5262",{"id":26,"text":3589,"url":26,"identifiers":3590},"Geeraert, 2010, Starvation-induced hyperacetylation of tubulin is required for the stimulation of autophagy by nutrient deprivation, J Biol Chem, 285, 24184, 10.1074\u002Fjbc.M109.091553",{"doi":3591},"10.1074\u002Fjbc.M109.091553",{"id":26,"text":3593,"url":26,"identifiers":3594},"Tararuk, 2006, JNK1 phosphorylation of SCG10 determines microtubule dynamics and axodendritic length, J Cell Biol, 173, 265, 10.1083\u002Fjcb.200511055",{"doi":3595},"10.1083\u002Fjcb.200511055",{"id":26,"text":3597,"url":26,"identifiers":3598},"Chang, 2003, JNK1 is required for maintenance of neuronal microtubules and controls phosphorylation of microtubule-associated proteins, Dev Cell, 4, 521, 10.1016\u002FS1534-5807(03)00094-7",{"doi":3599},"10.1016\u002FS1534-5807(03)00094-7",{"id":26,"text":3601,"url":26,"identifiers":3602},"Fan, 2001, Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy, Drug Resist Updat, 4, 253, 10.1054\u002Fdrup.2001.0214",{"doi":3603},"10.1054\u002Fdrup.2001.0214",{"id":26,"text":3605,"url":26,"identifiers":3606},"Brantley-Finley, 2003, The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide, Biochem Pharmacol, 66, 459, 10.1016\u002FS0006-2952(03)00255-7",{"doi":3607},"10.1016\u002FS0006-2952(03)00255-7",{"id":26,"text":3609,"url":26,"identifiers":3610},"Kolomeichuk, 2008, Distinct signaling pathways of microtubule inhibitors – vinblastine and taxol induce JNK-dependent cell death but through AP-1-dependent and AP-1-independent mechanisms, respectively, FEBS J, 275, 1889, 10.1111\u002Fj.1742-4658.2008.06349.x",{"doi":3611},"10.1111\u002Fj.1742-4658.2008.06349.x",{"id":26,"text":3613,"url":26,"identifiers":3614},"Hoshi, 1992, Mitogen-activated-protein-kinase-catalyzed phosphorylation of microtubule-associated proteins, microtubule-associated protein-2 and microtubule-associated protein-4, induces an alteration in their function, Eur J Biochem, 203, 43, 10.1111\u002Fj.1432-1033.1992.tb19825.x",{"doi":3615},"10.1111\u002Fj.1432-1033.1992.tb19825.x",{"id":26,"text":3617,"url":26,"identifiers":3618},"Reszka, 1997, Mitogen-activated protein kinase extracellular signal-regulated kinase 2 regulates cytoskeletal organization and chemotaxis via catalytic and microtubule-specific interactions, Mol Biol Cell, 8, 1219, 10.1091\u002Fmbc.8.7.1219",{"doi":3619},"10.1091\u002Fmbc.8.7.1219",{"id":26,"text":3621,"url":26,"identifiers":3622},"Hu, 2010, The p38\u002FMAPK pathway regulates microtubule polymerization through phosphorylation of MAP4 and Op18 in hypoxic cells, Cell Mol Life Sci, 67, 321, 10.1007\u002Fs00018-009-0187-z",{"doi":3623},"10.1007\u002Fs00018-009-0187-z",{"id":26,"text":3625,"url":26,"identifiers":3626},"Liu, 2001, Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells, Br J Cancer, 85, 1403, 10.1054\u002Fbjoc.2001.1910",{"doi":3627},"10.1054\u002Fbjoc.2001.1910",{"id":26,"text":3629,"url":26,"identifiers":3630},"Giannakakou, 2002, Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics, Proc Natl Acad Sci U S A, 99, 10855, 10.1073\u002Fpnas.132275599",{"doi":3631},"10.1073\u002Fpnas.132275599",{"id":26,"text":3633,"url":26,"identifiers":3634},"Galigniana, 2004, Hsp90-binding immunophilins link p53 to dynein during p53 transport to the nucleus, J Biol Chem, 279, 22483, 10.1074\u002Fjbc.M402223200",{"doi":3635},"10.1074\u002Fjbc.M402223200",{"id":26,"text":3637,"url":26,"identifiers":3638},"Giannakakou, 2000, p53 Is associated with cellular microtubules and is transported to the nucleus by dynein, Nat Cell Biol, 2, 709, 10.1038\u002F35036335",{"doi":3639},"10.1038\u002F35036335",{"id":26,"text":3641,"url":26,"identifiers":3642},"Peng, 2001, Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization, J Biol Chem, 276, 40583, 10.1074\u002Fjbc.M102817200",{"doi":3643},"10.1074\u002Fjbc.M102817200",{"id":26,"text":3645,"url":26,"identifiers":3646},"Kim, 2013, p53 Acetylation enhances taxol-induced apoptosis in human cancer cells, Apoptosis, 18, 110, 10.1007\u002Fs10495-012-0772-8",{"doi":3647},"10.1007\u002Fs10495-012-0772-8",{"id":26,"text":3649,"url":26,"identifiers":3650},"Lee, 2008, Microtubule-associated protein 1B light chain (MAP1B-LC1) negatively regulates the activity of tumor suppressor p53 in neuroblastoma cells, FEBS Lett, 582, 2826, 10.1016\u002Fj.febslet.2008.07.021",{"doi":3651},"10.1016\u002Fj.febslet.2008.07.021",{"id":26,"text":3653,"url":26,"identifiers":3654},"Galmarini, 2003, Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics, Br J Cancer, 88, 1793, 10.1038\u002Fsj.bjc.6600960",{"doi":3655},"10.1038\u002Fsj.bjc.6600960",{"id":26,"text":3657,"url":26,"identifiers":3658},"Mabjeesh, 2003, 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF, Cancer Cell, 3, 363, 10.1016\u002FS1535-6108(03)00077-1",{"doi":3659},"10.1016\u002FS1535-6108(03)00077-1",{"id":26,"text":3661,"url":26,"identifiers":3662},"Obacz, 2013, Cross-talk between HIF and p53 as mediators of molecular responses to physiological and genotoxic stresses, Mol Cancer, 12, 93, 10.1186\u002F1476-4598-12-93",{"doi":3663},"10.1186\u002F1476-4598-12-93",{"id":26,"text":3665,"url":26,"identifiers":3666},"Ivan, 2001, HIF alpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O-2 sensing, Science, 292, 464, 10.1126\u002Fscience.1059817",{"doi":3667},"10.1126\u002Fscience.1059817",{"id":26,"text":3669,"url":26,"identifiers":3670},"Fang, 2011, MAP4 mechanism that stabilizes mitochondrial permeability transition in hypoxia: microtubule enhancement and DYNLT1 interaction with VDAC1, PLoS One, 6, e28052, 10.1371\u002Fjournal.pone.0028052",{"doi":3671},"10.1371\u002Fjournal.pone.0028052",{"id":26,"text":3673,"url":26,"identifiers":3674},"Yoon, 2005, Hypoxia stimulates carcinoma invasion by stabilizing microtubules and promoting the Rab11 trafficking of the alpha 6 beta 4 integrin, Cancer Res, 65, 2761, 10.1158\u002F0008-5472.CAN-04-4122",{"doi":3675},"10.1158\u002F0008-5472.CAN-04-4122",{"id":26,"text":3677,"url":26,"identifiers":3678},"Xu, 2013, Phosphorylation of DYNLT1 at serine 82 regulates microtubule stability and mitochondrial permeabilization in hypoxia, Mol Cells, 36, 322, 10.1007\u002Fs10059-013-0114-x",{"doi":3679},"10.1007\u002Fs10059-013-0114-x",{"id":26,"text":3681,"url":26,"identifiers":3682},"Hinman, 2008, Diverse molecular functions of Hu proteins, Cell Mol Life Sci, 65, 3168, 10.1007\u002Fs00018-008-8252-6",{"doi":3683},"10.1007\u002Fs00018-008-8252-6",{"id":26,"text":3685,"url":26,"identifiers":3686},"Katsetos, 2001, Aberrant localization of the neuronal class III beta-tubulin in astrocytomas – a marker for anaplastic potential, Arch Pathol Lab Med, 125, 613, 10.5858\u002F2001-125-0613-ALOTNC",{"doi":3687},"10.5858\u002F2001-125-0613-ALOTNC",{"id":26,"text":3689,"url":26,"identifiers":3690},"Frew, 2013, Genetic deletion of the long isoform of the von Hippel-Lindau tumour suppressor gene product alters microtubule dynamics, Eur J Cancer, 49, 2433, 10.1016\u002Fj.ejca.2013.02.024",{"doi":3691},"10.1016\u002Fj.ejca.2013.02.024",{"id":26,"text":3693,"url":26,"identifiers":3694},"Carbonaro, 2012, Microtubules regulate hypoxia-inducible factor-1 alpha protein trafficking and activity implications for taxane therapy, J Biol Chem, 287, 11859, 10.1074\u002Fjbc.M112.345587",{"doi":3695},"10.1074\u002Fjbc.M112.345587",{"id":26,"text":3697,"url":26,"identifiers":3698},"Carbonaro, 2011, Microtubule disruption targets HIF-1 alpha mRNA to cytoplasmic P-bodies for translational repression, J Cell Biol, 192, 83, 10.1083\u002Fjcb.201004145",{"doi":3699},"10.1083\u002Fjcb.201004145",{"id":26,"text":3701,"url":26,"identifiers":3702},"Al-Mehdi, 2012, Perinuclear mitochondrial clustering creates an oxidant-rich nuclear domain required for hypoxia-induced transcription, Sci Signal, 5, ra47, 10.1126\u002Fscisignal.2002712",{"doi":3703},"10.1126\u002Fscisignal.2002712",{"id":26,"text":3705,"url":26,"identifiers":3706},"Gorrini, 2013, Modulation of oxidative stress as an anticancer strategy, Nat Rev Drug Discov, 12, 931, 10.1038\u002Fnrd4002",{"doi":3707},"10.1038\u002Fnrd4002",{"id":26,"text":3709,"url":26,"identifiers":3710},"Cicchillitti, 2008, Proteomic characterization of cytoskeletal and mitochondrial class III beta-tubulin, Mol Cancer Ther, 7, 2070, 10.1158\u002F1535-7163.MCT-07-2370",{"doi":3711},"10.1158\u002F1535-7163.MCT-07-2370",{"id":26,"text":3713,"url":26,"identifiers":3714},"Azuma, 2009, Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel, Lung Cancer, 64, 326, 10.1016\u002Fj.lungcan.2008.09.002",{"doi":3715},"10.1016\u002Fj.lungcan.2008.09.002",{"id":26,"text":3717,"url":26,"identifiers":3718},"Joe, 2008, The roles of cys124 and ser239 in the functional properties of human beta III tubulin, Cell Motil Cytoskeleton, 65, 476, 10.1002\u002Fcm.20274",{"doi":3719},"10.1002\u002Fcm.20274",{"id":26,"text":3721,"url":26,"identifiers":3722},"Eiserich, 1999, Microtubule dysfunction by posttranslational nitrotyrosination of alpha-tubulin: a nitric oxide-dependent mechanism of cellular injury, Proc Natl Acad Sci U S A, 96, 6365, 10.1073\u002Fpnas.96.11.6365",{"doi":3723},"10.1073\u002Fpnas.96.11.6365",{"id":26,"text":3725,"url":26,"identifiers":3726},"Bisig, 2002, Incorporation of 3-nitrotyrosine into the C-terminus of alpha-tubulin is reversible and not detrimental to dividing cells, Eur J Biochem, 269, 5037, 10.1046\u002Fj.1432-1033.2002.03220.x",{"doi":3727},"10.1046\u002Fj.1432-1033.2002.03220.x",{"id":26,"text":3729,"url":26,"identifiers":3730},"Cappelletti, 2006, Protein tyrosine nitration is associated with cold- and drug-resistant microtubules in neuronal-like PC 12 cells, Neurosci Lett, 401, 159, 10.1016\u002Fj.neulet.2006.03.009",{"doi":3731},"10.1016\u002Fj.neulet.2006.03.009",{"id":26,"text":3733,"url":26,"identifiers":3734},"Fiore, 2006, Tubulin nitration in human gliomas, Neurosci Lett, 394, 57, 10.1016\u002Fj.neulet.2005.10.011",{"doi":3735},"10.1016\u002Fj.neulet.2005.10.011",{"id":26,"text":3737,"url":26,"identifiers":3738},"Kim, 2008, Reactive oxygen species-dependent EndoG release mediates cisplatin-induced caspase-independent apoptosis in human head and neck squamous carcinoma cells, Int J Cancer, 122, 672, 10.1002\u002Fijc.23158",{"doi":3739},"10.1002\u002Fijc.23158",{"id":26,"text":3741,"url":26,"identifiers":3742},"Selimovic, 2008, Taxol-induced mitochondrial stress in melanoma cells is mediated by activation of c-Jun N-terminal kinase (JNK) and p38 pathways via uncoupling protein 2, Cell Signal, 20, 311, 10.1016\u002Fj.cellsig.2007.10.015",{"doi":3743},"10.1016\u002Fj.cellsig.2007.10.015",{"id":26,"text":3745,"url":26,"identifiers":3746},"Alexandre, 2007, Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species, Cancer Res, 67, 3512, 10.1158\u002F0008-5472.CAN-06-3914",{"doi":3747},"10.1158\u002F0008-5472.CAN-06-3914",{"id":26,"text":3749,"url":26,"identifiers":3750},"Putnam, 2003, External mechanical strain regulates membrane targeting of Rho GTPases by controlling microtubule assembly, Am J Physiol Cell Physiol, 284, C627, 10.1152\u002Fajpcell.00137.2002",{"doi":3751},"10.1152\u002Fajpcell.00137.2002",{"id":26,"text":3753,"url":26,"identifiers":3754},"Cheng, 2006, Nox1-dependent reactive oxygen generation is regulated by Rac1, J Biol Chem, 281, 17718, 10.1074\u002Fjbc.M512751200",{"doi":3755},"10.1074\u002Fjbc.M512751200",{"id":26,"text":3757,"url":26,"identifiers":3758},"Roediger, 2003, Oxidative stress induces axonal beading in cultured human brain tissue, Neurobiol Dis, 13, 222, 10.1016\u002FS0969-9961(03)00038-X",{"doi":3759},"10.1016\u002FS0969-9961(03)00038-X",{"id":26,"text":3761,"url":26,"identifiers":3762},"Valen, 1999, Hydrogen peroxide induces endothelial cell atypia and cytoskeleton depolymerization, Free Radic Biol Med, 26, 1480, 10.1016\u002FS0891-5849(99)00009-X",{"doi":3763},"10.1016\u002FS0891-5849(99)00009-X",{"id":26,"text":3765,"url":26,"identifiers":3766},"Hinshaw, 1993, A cellular-model of oxidant-mediated neuronal injury, Brain Res, 615, 13, 10.1016\u002F0006-8993(93)91110-E",{"doi":3767},"10.1016\u002F0006-8993(93)91110-E",{"id":26,"text":3769,"url":26,"identifiers":3770},"Stewart, 2007, Residue-specific adduction of tubulin by 4-hydroxynonenal and 4-oxononenal causes cross-linking and inhibits polymerization, Chem Res Toxicol, 20, 1111, 10.1021\u002Ftx700106v",{"doi":3771},"10.1021\u002Ftx700106v",{"id":26,"text":3773,"url":26,"identifiers":3774},"Neely, 2005, Mechanisms of 4-hydroxynonenal-induced neuronal microtubule dysfunction, Brain Res, 1037, 90, 10.1016\u002Fj.brainres.2004.12.027",{"doi":3775},"10.1016\u002Fj.brainres.2004.12.027",{"id":26,"text":3777,"url":26,"identifiers":3778},"Kokubo, 2008, Mechanism of destruction of microtubule structures by 4-hydroxy-2-nonenal, Cell Struct Funct, 33, 51, 10.1247\u002Fcsf.07038",{"doi":3779},"10.1247\u002Fcsf.07038",{"id":26,"text":3781,"url":26,"identifiers":3782},"Divinski, 2006, Peptide neuroprotection through specific interaction with brain tubulin, J Neurochem, 98, 973, 10.1111\u002Fj.1471-4159.2006.03936.x",{"doi":3783},"10.1111\u002Fj.1471-4159.2006.03936.x",{"id":26,"text":3785,"url":26,"identifiers":3786},"Stamer, 2002, Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress, J Cell Biol, 156, 1051, 10.1083\u002Fjcb.200108057",{"doi":3787},"10.1083\u002Fjcb.200108057",{"id":26,"text":3789,"url":26,"identifiers":3790},"Altman, 2012, Metabolic stress in autophagy and cell death pathways, Cold Spring Harb Perspect Biol, 4, a008763, 10.1101\u002Fcshperspect.a008763",{"doi":3791},"10.1101\u002Fcshperspect.a008763",{"id":26,"text":3793,"url":26,"identifiers":3794},"Saks, 1995, Control of cellular respiration in-vivo by mitochondrial outer-membrane and by creatine-kinase – a new speculative hypothesis – possible involvement of mitochondrial-cytoskeleton interactions, J Mol Cell Cardiol, 27, 625, 10.1016\u002FS0022-2828(08)80056-9",{"doi":3795},"10.1016\u002FS0022-2828(08)80056-9",{"id":26,"text":3797,"url":26,"identifiers":3798},"Bershadsky, 1981, ATP-dependent regulation of cytoplasmic microtubule disassembly, Proc Natl Acad Sci U S A, 78, 3610, 10.1073\u002Fpnas.78.6.3610",{"doi":3799},"10.1073\u002Fpnas.78.6.3610",{"id":26,"text":3801,"url":26,"identifiers":3802},"Infante, 2000, Detyrosinated (Glu) microtubules are stabilized by an ATP-sensitive plus-end cap, J Cell Sci, 113, 3907, 10.1242\u002Fjcs.113.22.3907",{"doi":3803},"10.1242\u002Fjcs.113.22.3907",{"id":26,"text":3805,"url":26,"identifiers":3806},"Marcussen, 1996, Cell cycle-dependent regulation of cellular ATP concentration, and depolymerization of the interphase microtubular network induced by elevated cellular ATP concentration in whole fibroblasts, Cell Motil Cytoskeleton, 35, 94, 10.1002\u002F(SICI)1097-0169(1996)35:294::AID-CM23.0.CO;2-I",{"doi":3807},"10.1002\u002F(SICI)1097-0169(1996)35:294::AID-CM23.0.CO;2-I",{"id":26,"text":3809,"url":26,"identifiers":3810},"Nakano, 2010, AMPK controls the speed of microtubule polymerization and directional cell migration through CLIP-170 phosphorylation, Nat Cell Biol, 12, 583, 10.1038\u002Fncb2060",{"doi":3811},"10.1038\u002Fncb2060",{"id":26,"text":3813,"url":26,"identifiers":3814},"Williams, 2011, AMP-activated protein kinase (AMPK) activity is not required for neuronal development but regulates axogenesis during metabolic stress, Proc Natl Acad Sci U S A, 108, 5849, 10.1073\u002Fpnas.1013660108",{"doi":3815},"10.1073\u002Fpnas.1013660108",{"id":26,"text":3817,"url":26,"identifiers":3818},"Tuerk, 2007, New candidate targets of AMP-activated protein kinase in murine brain revealed by a novel multidimensional substrate-screen for protein kinases, J Proteome Res, 6, 3266, 10.1021\u002Fpr070160a",{"doi":3819},"10.1021\u002Fpr070160a",{"id":26,"text":3821,"url":26,"identifiers":3822},"Sheldon, 2011, Phosphorylation of voltage-dependent anion channel by serine\u002Fthreonine kinases governs its interaction with tubulin, PLoS One, 6, e25539, 10.1371\u002Fjournal.pone.0025539",{"doi":3823},"10.1371\u002Fjournal.pone.0025539",{"id":26,"text":3825,"url":26,"identifiers":3826},"Rostovtseva, 2008, Tubulin binding blocks mitochondrial voltage-dependent anion channel and regulates respiration, Proc Natl Acad Sci U S A, 105, 18746, 10.1073\u002Fpnas.0806303105",{"doi":3827},"10.1073\u002Fpnas.0806303105",{"id":26,"text":3829,"url":26,"identifiers":3830},"Carre, 2002, Tubulin is an inherent component of mitochondrial membranes that interacts with the voltage-dependent anion channel, J Biol Chem, 277, 33664, 10.1074\u002Fjbc.M203834200",{"doi":3831},"10.1074\u002Fjbc.M203834200",{"id":26,"text":3833,"url":26,"identifiers":3834},"Maldonado, 2013, Voltage-dependent anion channels modulate mitochondrial metabolism in cancer cells: regulation by free tubulin and erastin, J Biol Chem, 288, 11920, 10.1074\u002Fjbc.M112.433847",{"doi":3835},"10.1074\u002Fjbc.M112.433847",{"id":26,"text":3837,"url":26,"identifiers":3838},"Vertessy, 1999, Pyruvate kinase as a microtubule destabilizing factor in vitro, Biochem Biophys Res Commun, 254, 430, 10.1006\u002Fbbrc.1998.9957",{"doi":3839},"10.1006\u002Fbbrc.1998.9957",{"id":26,"text":3841,"url":26,"identifiers":3842},"Orosz, 1999, Phosphofructokinase from Dictyostelium discoideum is a potent inhibitor of tubulin polymerization, Biochemistry, 38, 1857, 10.1021\u002Fbi981350p",{"doi":3843},"10.1021\u002Fbi981350p",{"id":26,"text":3845,"url":26,"identifiers":3846},"Marmillot, 1994, Effect of tubulin on the activity of the muscle isoenzyme of lactate-dehydrogenase, Arch Biochem Biophys, 315, 467, 10.1006\u002Fabbi.1994.1526",{"doi":3847},"10.1006\u002Fabbi.1994.1526",{"id":26,"text":3849,"url":26,"identifiers":3850},"Volker, 1997, A glycolytic enzyme binding domain on tubulin, Arch Biochem Biophys, 338, 237, 10.1006\u002Fabbi.1996.9819",{"doi":3851},"10.1006\u002Fabbi.1996.9819",{"id":26,"text":3853,"url":26,"identifiers":3854},"Muronetz, 1994, Binding constants and stoichiometries of glyceraldehyde-3-phosphate dehydrogenase-tubulin complexes, Arch Biochem Biophys, 313, 253, 10.1006\u002Fabbi.1994.1385",{"doi":3855},"10.1006\u002Fabbi.1994.1385",{"id":26,"text":3857,"url":26,"identifiers":3858},"Durrieu, 1987, Microtubules bind glyceraldehyde-3-phosphate dehydrogenase and modulate its enzyme-activity and quaternary structure, Arch Biochem Biophys, 252, 32, 10.1016\u002F0003-9861(87)90005-1",{"doi":3859},"10.1016\u002F0003-9861(87)90005-1",{"id":26,"text":3861,"url":26,"identifiers":3862},"Tisdale, 2004, Glyceraldehyde-3-phosphate dehydrogenase interacts with Rab2 and plays an essential role in endoplasmic reticulum to Golgi transport exclusive of its glycolytic activity, J Biol Chem, 279, 54046, 10.1074\u002Fjbc.M409472200",{"doi":3863},"10.1074\u002Fjbc.M409472200",{"id":26,"text":3865,"url":26,"identifiers":3866},"Aon, 2002, Coherent and robust modulation of a metabolic network by cytoskeletal organization and dynamics, Biophys Chem, 97, 213, 10.1016\u002FS0301-4622(02)00056-X",{"doi":3867},"10.1016\u002FS0301-4622(02)00056-X",{"id":26,"text":3869,"url":26,"identifiers":3870},"Zala, 2013, Vesicular glycolysis provides on-board energy for fast axonal transport, Cell, 152, 479, 10.1016\u002Fj.cell.2012.12.029",{"doi":3871},"10.1016\u002Fj.cell.2012.12.029",{"id":26,"text":3873,"url":26,"identifiers":3874},"Glaser, 2002, Tubulin is the endogenous inhibitor of the glyceraldehyde 3-phosphate dehydrogenase isoform that catalyzes membrane fusion: implications for the coordinated regulation of glycolysis and membrane fusion, Proc Natl Acad Sci U S A, 99, 14104, 10.1073\u002Fpnas.222542999",{"doi":3875},"10.1073\u002Fpnas.222542999",{"id":26,"text":3877,"url":26,"identifiers":3878},"Tisdale, 2009, Rab2 utilizes glyceraldehyde-3-phosphate dehydrogenase and protein kinase c iota to associate with microtubules and to recruit dynein, J Biol Chem, 284, 5876, 10.1074\u002Fjbc.M807756200",{"doi":3879},"10.1074\u002Fjbc.M807756200",{"id":26,"text":3881,"url":26,"identifiers":3882},"Cueille, 2007, Microtubule-associated protein 1B binds glyceraldehyde-3-phosphate dehydrogenase, J Proteome Res, 6, 2640, 10.1021\u002Fpr070081z",{"doi":3883},"10.1021\u002Fpr070081z",{"id":26,"text":3885,"url":26,"identifiers":3886},"Kovacs, 2003, Phosphoenolpyruvate-dependent tubulin-pyruvate kinase interaction at different organizational levels, J Biol Chem, 278, 7126, 10.1074\u002Fjbc.M210244200",{"doi":3887},"10.1074\u002Fjbc.M210244200",{"id":26,"text":3889,"url":26,"identifiers":3890},"Brinkley, 1974, Rotenone inhibition of spindle microtubule assembly in mammalian-cells, Exp Cell Res, 85, 41, 10.1016\u002F0014-4827(74)90210-9",{"doi":3891},"10.1016\u002F0014-4827(74)90210-9",{"id":26,"text":3893,"url":26,"identifiers":3894},"Dodson, 2013, Cellular metabolic and autophagic pathways: traffic control by redox signaling, Free Radic Biol Med, 63, 207, 10.1016\u002Fj.freeradbiomed.2013.05.014",{"doi":3895},"10.1016\u002Fj.freeradbiomed.2013.05.014",{"id":26,"text":3897,"url":26,"identifiers":3898},"Jin, 2007, Role of autophagy in cancer – management of metabolic stress, Autophagy, 3, 28, 10.4161\u002Fauto.3269",{"doi":3899},"10.4161\u002Fauto.3269",{"id":26,"text":3901,"url":26,"identifiers":3902},"Xie, 2011, Autophagy enhanced by microtubule- and mitochondrion-associated MAP1S suppresses genome instability and hepatocarcinogenesis, Cancer Res, 71, 7537, 10.1158\u002F0008-5472.CAN-11-2170",{"doi":3903},"10.1158\u002F0008-5472.CAN-11-2170",{"id":26,"text":3905,"url":26,"identifiers":3906},"Guo, 2013, Autophagy-mediated tumor promotion, Cell, 155, 1216, 10.1016\u002Fj.cell.2013.11.019",{"doi":3907},"10.1016\u002Fj.cell.2013.11.019",{"id":26,"text":3909,"url":26,"identifiers":3910},"Sui, 2013, Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment, Cell Death Dis, 4, e838, 10.1038\u002Fcddis.2013.350",{"doi":3911},"10.1038\u002Fcddis.2013.350",{"id":26,"text":3913,"url":26,"identifiers":3914},"Macintosh, 2013, Autophagy in tumour cell death, Semin Cancer Biol, 23, 344, 10.1016\u002Fj.semcancer.2013.05.006",{"doi":3915},"10.1016\u002Fj.semcancer.2013.05.006",{"id":26,"text":3917,"url":26,"identifiers":3918},"Amenta, 1977, Effect of microtubular or translational inhibitors on general cell protein degradation – evidence for a dual catabolic pathway, Biochem J, 168, 223, 10.1042\u002Fbj1680223",{"doi":3919},"10.1042\u002Fbj1680223",{"id":26,"text":3921,"url":26,"identifiers":3922},"Fass, 2006, Microtubules support production of starvation-induced autophagosomes but not their targeting and fusion with lysosomes, J Biol Chem, 281, 36303, 10.1074\u002Fjbc.M607031200",{"doi":3923},"10.1074\u002Fjbc.M607031200",{"id":26,"text":3925,"url":26,"identifiers":3926},"Fengsrud, 1995, Ultrastructural and immunocytochemical characterization of autophagic vacuoles in isolated hepatocytes – effects of vinblastine and asparagine on vacuole distributions, Exp Cell Res, 221, 504, 10.1006\u002Fexcr.1995.1402",{"doi":3927},"10.1006\u002Fexcr.1995.1402",{"id":26,"text":3929,"url":26,"identifiers":3930},"Kochl, 2006, Microtubules facilitate autophagosome formation and fusion of autophagosomes with endosomes, Traffic, 7, 129, 10.1111\u002Fj.1600-0854.2005.00368.x",{"doi":3931},"10.1111\u002Fj.1600-0854.2005.00368.x",{"id":26,"text":3933,"url":26,"identifiers":3934},"Webb, 2004, Microtubule disruption inhibits autophagosome-lysosome fusion: implications for studying the roles of aggresomes in polyglutamine diseases, Int J Biochem Cell Biol, 36, 2541, 10.1016\u002Fj.biocel.2004.02.003",{"doi":3935},"10.1016\u002Fj.biocel.2004.02.003",{"id":26,"text":3937,"url":26,"identifiers":3938},"Acharya, 2011, The microtubule depolymerizing agent naphthazarin induces both apoptosis and autophagy in A549 lung cancer cells, Apoptosis, 16, 924, 10.1007\u002Fs10495-011-0613-1",{"doi":3939},"10.1007\u002Fs10495-011-0613-1",{"id":26,"text":3941,"url":26,"identifiers":3942},"Viola, 2012, MG-2477, a new tubulin inhibitor, induces autophagy through inhibition of the Akt\u002FmTOR pathway and delayed apoptosis in A549 cells, Biochem Pharmacol, 83, 16, 10.1016\u002Fj.bcp.2011.09.017",{"doi":3943},"10.1016\u002Fj.bcp.2011.09.017",{"id":26,"text":3945,"url":26,"identifiers":3946},"Kouno, 2005, Solution structure of microtubule-associated protein light chain 3 and identification of its functional subdomains, J Biol Chem, 280, 24610, 10.1074\u002Fjbc.M413565200",{"doi":3947},"10.1074\u002Fjbc.M413565200",{"id":26,"text":3949,"url":26,"identifiers":3950},"Liu, 2012, MAP1S enhances autophagy to suppress tumorigenesis, Autophagy, 8, 278, 10.4161\u002Fauto.8.2.18939",{"doi":3951},"10.4161\u002Fauto.8.2.18939",{"id":26,"text":3953,"url":26,"identifiers":3954},"Xie, 2011, Microtubule-associated protein 1S (MAP1S) bridges autophagic components with microtubules and mitochondria to affect autophagosomal biogenesis and degradation, J Biol Chem, 286, 10367, 10.1074\u002Fjbc.M110.206532",{"doi":3955},"10.1074\u002Fjbc.M110.206532",{"id":26,"text":3957,"url":26,"identifiers":3958},"Di Bartolomeo, 2010, The dynamic interaction of AMBRA1 with the dynein motor complex regulates mammalian autophagy, J Cell Biol, 191, 155, 10.1083\u002Fjcb.201002100",{"doi":3959},"10.1083\u002Fjcb.201002100",{"id":26,"text":3961,"url":26,"identifiers":3962},"Luo, 2012, Bim inhibits autophagy by recruiting beclin 1 to microtubules, Mol Cell, 47, 359, 10.1016\u002Fj.molcel.2012.05.040",{"doi":3963},"10.1016\u002Fj.molcel.2012.05.040",{"id":26,"text":3965,"url":26,"identifiers":3966},"Chen, 2013, Induction of autophagy by TOCP in differentiated human neuroblastoma cells lead to degradation of cytoskeletal components and inhibition of neurite outgrowth, Toxicology, 310, 92, 10.1016\u002Fj.tox.2013.05.012",{"doi":3967},"10.1016\u002Fj.tox.2013.05.012",{"id":26,"text":3969,"url":26,"identifiers":3970},"Sancak, 2010, Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids, Cell, 141, 290, 10.1016\u002Fj.cell.2010.02.024",{"doi":3971},"10.1016\u002Fj.cell.2010.02.024",{"id":26,"text":3973,"url":26,"identifiers":3974},"Korolchuk, 2011, Lysosomal positioning coordinates cellular nutrient responses, Nat Cell Biol, 13, 453, 10.1038\u002Fncb2204",{"doi":3975},"10.1038\u002Fncb2204",{"id":26,"text":3977,"url":26,"identifiers":3978},"Wei, 2008, JNK1-mediated phosphorylation of BcI-2 regulates starvation-induced autophagy, Mol Cell, 30, 678, 10.1016\u002Fj.molcel.2008.06.001",{"doi":3979},"10.1016\u002Fj.molcel.2008.06.001",{"id":26,"text":3981,"url":26,"identifiers":3982},"Mochizuki, 2013, Phosphatidylinositol 3-phosphatase myotubularin-related protein 6 (MTMR6) is regulated by small GTPase Rab1B in the early secretory and autophagic pathways, J Biol Chem, 288, 1009, 10.1074\u002Fjbc.M112.395087",{"doi":3983},"10.1074\u002Fjbc.M112.395087",{"id":26,"text":3985,"url":26,"identifiers":3986},"Yang, 2013, Bit-by-bit autophagic removal of parkin-labelled mitochondria, Nat Commun, 4, 2428, 10.1038\u002Fncomms3428",{"doi":3987},"10.1038\u002Fncomms3428",{"id":26,"text":3989,"url":26,"identifiers":3990},"Appaix, 2003, Possible role of cytoskeleton in intracellular arrangement and regulation of mitochondria, Exp Physiol, 88, 175, 10.1113\u002Feph8802511",{"doi":3991},"10.1113\u002Feph8802511",{"id":26,"text":3993,"url":26,"identifiers":3994},"Terasaki, 1986, Microtubules and the endoplasmic-reticulum are highly interdependent structures, J Cell Biol, 103, 1557, 10.1083\u002Fjcb.103.4.1557",{"doi":3995},"10.1083\u002Fjcb.103.4.1557",{"id":26,"text":3997,"url":26,"identifiers":3998},"Aplin, 1992, Cytoskeletal elements are required for the formation and maturation of autophagic vacuoles, J Cell Physiol, 152, 458, 10.1002\u002Fjcp.1041520304",{"doi":3999},"10.1002\u002Fjcp.1041520304",{"id":26,"text":4001,"url":26,"identifiers":4002},"Reunanen, 1988, Effects of griseofulvin and nocodazole on the accumulation of autophagic vacuoles in ehrlich ascites tumor-cells, Exp Mol Pathol, 48, 97, 10.1016\u002F0014-4800(88)90048-2",{"doi":4003},"10.1016\u002F0014-4800(88)90048-2",{"id":26,"text":4005,"url":26,"identifiers":4006},"Kimura, 2008, Dynein-dependent movement of autophagosomes mediates efficient encounters with lysosomes, Cell Struct Funct, 33, 109, 10.1247\u002Fcsf.08005",{"doi":4007},"10.1247\u002Fcsf.08005",{"id":26,"text":4009,"url":26,"identifiers":4010},"Luo, 2013, The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies, Oncogene, 32, 805, 10.1038\u002Fonc.2012.130",{"doi":4011},"10.1038\u002Fonc.2012.130",{"id":26,"text":4013,"url":26,"identifiers":4014},"Ma, 2004, The role of the unfolded protein response in tumour development: friend or foe?, Nat Rev Cancer, 4, 966, 10.1038\u002Fnrc1505",{"doi":4015},"10.1038\u002Fnrc1505",{"id":26,"text":4017,"url":26,"identifiers":4018},"Dong, 2008, Critical role of the stress chaperone GRP78\u002FBiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development, Cancer Res, 68, 498, 10.1158\u002F0008-5472.CAN-07-2950",{"doi":4019},"10.1158\u002F0008-5472.CAN-07-2950",{"id":26,"text":4021,"url":26,"identifiers":4022},"Reddy, 2003, Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors – role of ATP binding site in suppression of caspase-7 activation, J Biol Chem, 278, 20915, 10.1074\u002Fjbc.M212328200",{"doi":4023},"10.1074\u002Fjbc.M212328200",{"id":26,"text":4025,"url":26,"identifiers":4026},"Sun, 2013, Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways, Neuro Oncol, 15, 562, 10.1093\u002Fneuonc\u002Fnot005",{"doi":4027},"10.1093\u002Fneuonc\u002Fnot005",{"id":26,"text":4029,"url":26,"identifiers":4030},"Yamada, 1999, Cellular sensitization to cisplatin and carboplatin with decreased removal of platinum-DNA adduct by glucose-regulated stress, Cancer Chemother Pharmacol, 44, 59, 10.1007\u002Fs002800050945",{"doi":4031},"10.1007\u002Fs002800050945",{"id":26,"text":4033,"url":26,"identifiers":4034},"Chatterjee, 1997, Hypersensitivity to DNA cross-linking agents associated with up-regulation of glucose-regulated stress protein GRP78, Cancer Res, 57, 5112",{},{"id":26,"text":4036,"url":26,"identifiers":4037},"Luvsandagva, 2012, GRP78 induced by estrogen plays a role in the chemosensitivity of endometrial cancer, Gynecol Oncol, 126, 132, 10.1016\u002Fj.ygyno.2012.04.025",{"doi":4038},"10.1016\u002Fj.ygyno.2012.04.025",{"id":26,"text":4040,"url":26,"identifiers":4041},"Li, 2006, Stress induction of GRP78\u002FBiP and its role in cancer, Curr Mol Med, 6, 45, 10.2174\u002F156652406775574523",{"doi":4042},"10.2174\u002F156652406775574523",{"id":26,"text":4044,"url":26,"identifiers":4045},"Liu, 2011, FPTB, a novel CA-4 derivative, induces cell apoptosis of human chondrosarcoma cells through mitochondrial dysfunction and endoplasmic reticulum stress pathways, J Cell Biochem, 112, 453, 10.1002\u002Fjcb.22927",{"doi":4046},"10.1002\u002Fjcb.22927",{"id":26,"text":4048,"url":26,"identifiers":4049},"Bett, 2013, The P-body component USP52\u002FPAN2 is a novel regulator of HIF1A mRNA stability, Biochem J, 451, 185, 10.1042\u002FBJ20130026",{"doi":4050},"10.1042\u002FBJ20130026",{"id":26,"text":4052,"url":26,"identifiers":4053},"Chernov, 2009, Role of microtubules in stress granule assembly-microtubule dynamical instability favors the formation of micrometric stress granules in cells, J Biol Chem, 284, 36569, 10.1074\u002Fjbc.M109.042879",{"doi":4054},"10.1074\u002Fjbc.M109.042879",{"id":26,"text":4056,"url":26,"identifiers":4057},"Anderson, 2006, RNA granules, J Cell Biol, 172, 803, 10.1083\u002Fjcb.200512082",{"doi":4058},"10.1083\u002Fjcb.200512082",{"id":26,"text":4060,"url":26,"identifiers":4061},"Sriburi, 2004, XBP1: a link between the unfolded protein response, lipid biosynthesis, and biogenesis of the endoplasmic reticulum, J Cell Biol, 167, 35, 10.1083\u002Fjcb.200406136",{"doi":4062},"10.1083\u002Fjcb.200406136",{"id":26,"text":4064,"url":26,"identifiers":4065},"Schuck, 2009, Membrane expansion alleviates endoplasmic reticulum stress independently of the unfolded protein response, J Cell Biol, 187, 525, 10.1083\u002Fjcb.200907074",{"doi":4066},"10.1083\u002Fjcb.200907074",{"id":26,"text":4068,"url":26,"identifiers":4069},"Goyal, 2013, Untangling the web: mechanisms underlying ER network formation, Biochim Biophys Acta, 1833, 2492, 10.1016\u002Fj.bbamcr.2013.04.009",{"doi":4070},"10.1016\u002Fj.bbamcr.2013.04.009",{"id":26,"text":4072,"url":26,"identifiers":4073},"Waterman-Storer, 1997, Microtubule dynamics: treadmilling comes around again, Curr Biol, 7, R369, 10.1016\u002FS0960-9822(06)00177-1",{"doi":4074},"10.1016\u002FS0960-9822(06)00177-1",{"id":26,"text":4076,"url":26,"identifiers":4077},"Lee, 1988, Dynamic behavior of endoplasmic-reticulum in living cells, Cell, 54, 37, 10.1016\u002F0092-8674(88)90177-8",{"doi":4078},"10.1016\u002F0092-8674(88)90177-8",{"id":26,"text":4080,"url":26,"identifiers":4081},"Ogburn, 2006, Cytoskeleton\u002Fendoplasmic reticulum collapse induced by prostaglandin J2 parallels centrosomal deposition of ubiquitinated protein aggregates, J Biol Chem, 281, 23274, 10.1074\u002Fjbc.M600635200",{"doi":4082},"10.1074\u002Fjbc.M600635200",{"id":26,"text":4084,"url":26,"identifiers":4085},"Wettstein, 2012, Small heat shock proteins and the cytoskeleton: an essential interplay for cell integrity?, Int J Biochem Cell Biol, 44, 1680, 10.1016\u002Fj.biocel.2012.05.024",{"doi":4086},"10.1016\u002Fj.biocel.2012.05.024",{"id":26,"text":4088,"url":26,"identifiers":4089},"Ghosh, 2007, Interactive domains in the molecular chaperone human alpha B crystallin modulate microtubule assembly and disassembly, PLoS One, 2, e498, 10.1371\u002Fjournal.pone.0000498",{"doi":4090},"10.1371\u002Fjournal.pone.0000498",{"id":26,"text":4092,"url":26,"identifiers":4093},"Houck, 2010, Dynamic subunit exchange and the regulation of microtubule assembly by the stress response protein human alpha B crystallin, PLoS One, 5, e11795, 10.1371\u002Fjournal.pone.0011795",{"doi":4094},"10.1371\u002Fjournal.pone.0011795",{"id":26,"text":4096,"url":26,"identifiers":4097},"Fujita, 2004, Alpha B-crystallin-coated MAP microtubule resists nocodazole and calcium-induced disassembly, J Cell Sci, 117, 1719, 10.1242\u002Fjcs.01021",{"doi":4098},"10.1242\u002Fjcs.01021",{"id":26,"text":4100,"url":26,"identifiers":4101},"Hino, 2000, Small heat shock protein 27 (HSP27) associates with tubulin\u002Fmicrotubules in HeLa cells, Biochem Biophys Res Commun, 271, 164, 10.1006\u002Fbbrc.2000.2553",{"doi":4102},"10.1006\u002Fbbrc.2000.2553",{"id":26,"text":4104,"url":26,"identifiers":4105},"Almeida-Souza, 2013, HSPB1 facilitates the formation of non-centrosomal microtubules, PLoS One, 8, e66541, 10.1371\u002Fjournal.pone.0066541",{"doi":4106},"10.1371\u002Fjournal.pone.0066541",{"id":26,"text":4108,"url":26,"identifiers":4109},"Casado, 2007, Characterization of HSP27 phosphorylation induced by microtubule interfering agents: implication of p38 signalling pathway, Arch Biochem Biophys, 461, 123, 10.1016\u002Fj.abb.2007.01.027",{"doi":4110},"10.1016\u002Fj.abb.2007.01.027",{"id":26,"text":4112,"url":26,"identifiers":4113},"Sanchez, 1994, Binding of heat-shock protein-70 (hsp70) to tubulin, Arch Biochem Biophys, 310, 428, 10.1006\u002Fabbi.1994.1188",{"doi":4114},"10.1006\u002Fabbi.1994.1188",{"id":26,"text":4116,"url":26,"identifiers":4117},"Welch, 1985, The mammalian stress response and the cytoskeleton – alterations in intermediate filaments, Ann N Y Acad Sci, 455, 57, 10.1111\u002Fj.1749-6632.1985.tb50403.x",{"doi":4118},"10.1111\u002Fj.1749-6632.1985.tb50403.x",{"id":26,"text":4120,"url":26,"identifiers":4121},"Selimovic, 2013, Vinblastine-induced apoptosis of melanoma cells is mediated by Ras homologous A protein (Rho A) via mitochondrial and non-mitochondrial-dependent mechanisms, Apoptosis, 18, 980, 10.1007\u002Fs10495-013-0844-4",{"doi":4122},"10.1007\u002Fs10495-013-0844-4",{"id":26,"text":4124,"url":26,"identifiers":4125},"Guo, 2007, Heat shock protein 70 regulates cellular redox status by modulating glutathione-related enzyme activities, Cell Stress Chaperones, 12, 245, 10.1379\u002FCSC-265.1",{"doi":4126},"10.1379\u002FCSC-265.1",{"id":26,"text":4128,"url":26,"identifiers":4129},"Quintá, 2011, Management of cytoskeleton architecture by molecular chaperones and immunophilins, Cell Signal, 23, 1907, 10.1016\u002Fj.cellsig.2011.07.023",{"doi":4130},"10.1016\u002Fj.cellsig.2011.07.023",{"id":26,"text":4132,"url":26,"identifiers":4133},"Hong, 2013, Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions, Cancer Treat Rev, 39, 375, 10.1016\u002Fj.ctrv.2012.10.001",{"doi":4134},"10.1016\u002Fj.ctrv.2012.10.001",{"id":26,"text":4136,"url":26,"identifiers":4137},"Weis, 2010, The 90-kDa heat Shock protein Hsp90 protects tubulin against thermal denaturation, J Biol Chem, 285, 9525, 10.1074\u002Fjbc.M109.096586",{"doi":4138},"10.1074\u002Fjbc.M109.096586",{"id":26,"text":4140,"url":26,"identifiers":4141},"Pratt, 2003, Regulation of signaling protein function and trafficking by the hsp90\u002Fhsp70-based chaperone machinery, Exp Biol Med, 228, 111, 10.1177\u002F153537020322800201",{"doi":4142},"10.1177\u002F153537020322800201",{"id":26,"text":4144,"url":26,"identifiers":4145},"Pratt, 2010, Proposal for a role of the Hsp90\u002FHsp70-based chaperone machinery in making triage decisions when proteins undergo oxidative and toxic damage, Exp Biol Med, 235, 278, 10.1258\u002Febm.2009.009250",{"doi":4146},"10.1258\u002Febm.2009.009250",{"id":26,"text":4148,"url":26,"identifiers":4149},"Rovini, 2011, Microtubule-targeted agents: when mitochondria become essential to chemotherapy, Biochim Biophys Acta, 1807, 679, 10.1016\u002Fj.bbabio.2011.01.001",{"doi":4150},"10.1016\u002Fj.bbabio.2011.01.001",{"id":26,"text":4152,"url":26,"identifiers":4153},"Ren, 2003, Parkin binds to alpha\u002Fbeta tubulin and increases their ubiquitination and degradation, J Neurosci, 23, 3316, 10.1523\u002FJNEUROSCI.23-08-03316.2003",{"doi":4154},"10.1523\u002FJNEUROSCI.23-08-03316.2003",{"id":26,"text":4156,"url":26,"identifiers":4157},"Jung, 1993, Interaction of brain mitochondria with microtubules reconstituted from brain tubulin and MAP2 or Tau, Cell Motil Cytoskeleton, 24, 245, 10.1002\u002Fcm.970240405",{"doi":4158},"10.1002\u002Fcm.970240405",{"id":26,"text":4160,"url":26,"identifiers":4161},"Maldonado, 2010, Free tubulin modulates mitochondrial membrane potential in cancer cells, Cancer Res, 70, 10192, 10.1158\u002F0008-5472.CAN-10-2429",{"doi":4162},"10.1158\u002F0008-5472.CAN-10-2429",{"id":26,"text":4164,"url":26,"identifiers":4165},"Guzun, 2011, Mitochondria-cytoskeleton interaction: distribution of beta-tubulins in cardiomyocytes and HL-1 cells, Biochim Biophys Acta, 1807, 458, 10.1016\u002Fj.bbabio.2011.01.010",{"doi":4166},"10.1016\u002Fj.bbabio.2011.01.010",{"id":26,"text":4168,"url":26,"identifiers":4169},"Andre, 2000, Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells, Cancer Res, 60, 5349",{},{"id":26,"text":4171,"url":26,"identifiers":4172},"Ferlini, 2003, Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance, Mol Pharmacol, 64, 51, 10.1124\u002Fmol.64.1.51",{"doi":4173},"10.1124\u002Fmol.64.1.51",{"id":26,"text":4175,"url":26,"identifiers":4176},"Gajate, 2000, Induction of apoptosis in leukemic cells by the reversible microtubule-disrupting agent 2-methoxy-5-(2’,3’,4’-trimethoxyphenyl)-2,4,6-cycloheptatrien-1-one: protection by bcl-2 and bcl-x(L) and cell cycle arrest, Cancer Res, 60, 2651",{},{"id":26,"text":4178,"url":26,"identifiers":4179},"Ibrado, 1997, Bcl-x(L) overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells, Cancer Res, 57, 1109",{},{"id":26,"text":4181,"url":26,"identifiers":4182},"Esteve, 2006, Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine, Mol Cancer Ther, 5, 2824, 10.1158\u002F1535-7163.MCT-06-0277",{"doi":4183},"10.1158\u002F1535-7163.MCT-06-0277",{"id":26,"text":4185,"url":26,"identifiers":4186},"Knipling, 2006, Direct interaction of Bcl-2 proteins with tubulin, Biochem Biophys Res Commun, 341, 433, 10.1016\u002Fj.bbrc.2005.12.201",{"doi":4187},"10.1016\u002Fj.bbrc.2005.12.201",{"id":26,"text":4189,"url":26,"identifiers":4190},"Puthalakath, 1999, The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex, Mol Cell, 3, 287, 10.1016\u002FS1097-2765(00)80456-6",{"doi":4191},"10.1016\u002FS1097-2765(00)80456-6",{"id":26,"text":4193,"url":26,"identifiers":4194},"Giodini, 2002, Regulation of microtubule stability and mitotic progression by survivin, Cancer Res, 62, 2462",{},{"id":26,"text":4196,"url":26,"identifiers":4197},"Prislei, 2008, From plasma membrane to cytoskeleton: a novel function for semaphorin 6A, Mol Cancer Ther, 7, 233, 10.1158\u002F1535-7163.MCT-07-0390",{"doi":4198},"10.1158\u002F1535-7163.MCT-07-0390",{"id":26,"text":4200,"url":26,"identifiers":4201},"Srivastava, 1998, Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase, Mol Cell Biol, 18, 3509, 10.1128\u002FMCB.18.6.3509",{"doi":4202},"10.1128\u002FMCB.18.6.3509",{"id":26,"text":4204,"url":26,"identifiers":4205},"Ling, 1998, Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis, J Biol Chem, 273, 18984, 10.1074\u002Fjbc.273.30.18984",{"doi":4206},"10.1074\u002Fjbc.273.30.18984",{"id":26,"text":4208,"url":26,"identifiers":4209},"Verdier-Pinard, 2009, Tubulin proteomics: towards breaking the code, Anal Biochem, 384, 197, 10.1016\u002Fj.ab.2008.09.020",{"doi":4210},"10.1016\u002Fj.ab.2008.09.020",{"id":26,"text":4212,"url":26,"identifiers":4213},"Hasegawa, 2003, Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers, Clin Cancer Res, 9, 2992",{},{"id":26,"text":4215,"url":26,"identifiers":4216},"Zhang, 2012, Association between class III beta-tubulin expression and response to paclitaxel\u002Fvinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis, Lung Cancer, 77, 9, 10.1016\u002Fj.lungcan.2012.01.005",{"doi":4217},"10.1016\u002Fj.lungcan.2012.01.005",{"id":26,"text":4219,"url":26,"identifiers":4220},"Sève, 2007, Class III β-tubulin expression and benefit from adjuvant cisplatin\u002Fvinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10, Clin Cancer Res, 13, 994, 10.1158\u002F1078-0432.CCR-06-1503",{"doi":4221},"10.1158\u002F1078-0432.CCR-06-1503",{"id":26,"text":4223,"url":26,"identifiers":4224},"Reiman, 2012, Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials, Ann Oncol, 23, 86, 10.1093\u002Fannonc\u002Fmdr033",{"doi":4225},"10.1093\u002Fannonc\u002Fmdr033",{"id":26,"text":4227,"url":26,"identifiers":4228},"Seve, 2005, Expression of class III beta-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy, Clin Cancer Res, 11, 5481, 10.1158\u002F1078-0432.CCR-05-0285",{"doi":4229},"10.1158\u002F1078-0432.CCR-05-0285",{"id":26,"text":4231,"url":26,"identifiers":4232},"Ohishi, 2007, Expression of beta-tubulin isotypes in human primary ovarian carcinoma, Gynecol Oncol, 105, 586, 10.1016\u002Fj.ygyno.2007.01.044",{"doi":4233},"10.1016\u002Fj.ygyno.2007.01.044",{"id":26,"text":4235,"url":26,"identifiers":4236},"Kavallaris, 1997, Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes, J Clin Invest, 100, 1282, 10.1172\u002FJCI119642",{"doi":4237},"10.1172\u002FJCI119642",{"id":26,"text":4239,"url":26,"identifiers":4240},"De Donato, 2012, Class III beta-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer, J Cell Physiol, 227, 1034, 10.1002\u002Fjcp.22813",{"doi":4241},"10.1002\u002Fjcp.22813",{"id":26,"text":4243,"url":26,"identifiers":4244},"Su, 2009, Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel, Cancer, 115, 2453, 10.1002\u002Fcncr.24282",{"doi":4245},"10.1002\u002Fcncr.24282",{"id":26,"text":4247,"url":26,"identifiers":4248},"Aoki, 2009, Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma, Clin Cancer Res, 15, 1473, 10.1158\u002F1078-0432.CCR-08-1274",{"doi":4249},"10.1158\u002F1078-0432.CCR-08-1274",{"id":26,"text":4251,"url":26,"identifiers":4252},"Paradiso, 2005, Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer, Ann Oncol, 16, 14, 10.1093\u002Fannonc\u002Fmdi902",{"doi":4253},"10.1093\u002Fannonc\u002Fmdi902",{"id":26,"text":4255,"url":26,"identifiers":4256},"Portyanko, 2009, Beta(III)-tubulin at the invasive margin of colorectal cancer: possible link to invasion, Virchows Arch, 454, 541, 10.1007\u002Fs00428-009-0764-4",{"doi":4257},"10.1007\u002Fs00428-009-0764-4",{"id":26,"text":4259,"url":26,"identifiers":4260},"Roque, 2013, Tubulin-beta-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum\u002Ftaxane chemotherapy and sensitivity to epothilones, Cancer, 119, 2582, 10.1002\u002Fcncr.28017",{"doi":4261},"10.1002\u002Fcncr.28017",{"id":26,"text":4263,"url":26,"identifiers":4264},"Hwang, 2013, Class III beta-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer, BMC Cancer, 13, 431, 10.1186\u002F1471-2407-13-431",{"doi":4265},"10.1186\u002F1471-2407-13-431",{"id":26,"text":4267,"url":26,"identifiers":4268},"Ploussard, 2010, Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy, Cancer Res, 70, 9253, 10.1158\u002F0008-5472.CAN-10-1447",{"doi":4269},"10.1158\u002F0008-5472.CAN-10-1447",{"id":26,"text":4271,"url":26,"identifiers":4272},"Terry, 2009, Increased expression of class III beta-tubulin in castration-resistant human prostate cancer, Br J Cancer, 101, 951, 10.1038\u002Fsj.bjc.6605245",{"doi":4273},"10.1038\u002Fsj.bjc.6605245",{"id":26,"text":4275,"url":26,"identifiers":4276},"Bernard-Marty, 2002, Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study, Clin Breast Cancer, 3, 341, 10.3816\u002FCBC.2002.n.037",{"doi":4277},"10.3816\u002FCBC.2002.n.037",{"id":26,"text":4279,"url":26,"identifiers":4280},"Christoph, 2012, BetaV-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancer, Br J Cancer, 107, 823, 10.1038\u002Fbjc.2012.324",{"doi":4281},"10.1038\u002Fbjc.2012.324",{"id":26,"text":4283,"url":26,"identifiers":4284},"Lu, 2013, Increased alpha-tubulin1b expression indicates poor prognosis and resistance to chemotherapy in hepatocellular carcinoma, Dig Dis Sci, 58, 2713, 10.1007\u002Fs10620-013-2692-z",{"doi":4285},"10.1007\u002Fs10620-013-2692-z",{"id":26,"text":4287,"url":26,"identifiers":4288},"Caracciolo, 2010, Differential expression and cellular distribution of gamma-tubulin and beta III-tubulin in medulloblastomas and human medulloblastoma cell lines, J Cell Physiol, 223, 519, 10.1002\u002Fjcp.22077",{"doi":4289},"10.1002\u002Fjcp.22077",{"id":4291,"createTime":4292,"updateTime":4292,"relativeEntities":4293,"slug":4294,"properties":4295,"entityType":772,"verifyStatus":25,"verifyTime":4310,"verifyNote":773,"syncStatus":28,"languages":4311,"translateLanguages":26,"viewCount":36,"primaryUrl":4312,"fullTextUrl":26,"authors":4313,"publicationType":843,"publisherRelationship":4351,"citationCount":621,"citationInfo":4384,"publishDate":26,"publishYear":26,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":4386,"isForceReanalyzing":1390},"749c4341-16ad-40c5-ae8c-ef61d62737e5","2024-09-02T04:10:27.413+00:00",[],"Altered-Tumor-Cell-Glycosylation-Promotes-Metastasis",{"mag":4296,"keywords":4298,"pmc":4299,"openalex":4301,"abstract":4303,"title":4304,"pm":4306,"doi":4308},{"VOID":4297},"2134294354",{},{"VOID":4300},"3923139",{"VOID":4302},"W2134294354",{},{"EN":4305},"Altered Tumor-Cell Glycosylation Promotes Metastasis",{"VOID":4307},"24592356",{"VOID":4309},"10.3389\u002Ffonc.2014.00028","2024-09-02T04:10:27.412+00:00",[102],"http:\u002F\u002Fjournal.frontiersin.org\u002Farticle\u002F10.3389\u002Ffonc.2014.00028\u002Fabstract",[4314,4336],{"id":4315,"sortIndex":115,"researcher":26,"roles":4316,"affiliations":4317,"properties":4329},"67f71baf-93ca-45d0-8132-e6ba2b69fee0",[],[4318],{"id":4319,"sortIndex":36,"affiliation":4320,"properties":26},"c7a8cc11-9722-44af-804e-91afa06db5ec",{"id":4321,"createTime":4322,"updateTime":4323,"relativeEntities":4324,"slug":4325,"properties":4326,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"05edbc7b-113c-48cb-93cf-0ccf51515a4e","2024-09-02T04:10:27.437+00:00","2025-06-11T19:03:23.358+00:00",[],"Institute-of-Physiology-University-of-Zurich-Winterthurerstrasse-190-Zurich-8057-Switzerland",{"title":4327},{"EN":4328},"Institute of Physiology, University of Zurich, Winterthurerstrasse 190, Zurich, 8057, Switzerland",{"openalex":4330,"orcid":4332,"title":4334},{"VOID":4331},"A5047132606",{"VOID":4333},"https:\u002F\u002Forcid.org\u002F0000-0003-2263-9545",{"EN":4335},"Lubor Borsig",{"id":4337,"sortIndex":36,"researcher":26,"roles":4338,"affiliations":4339,"properties":4346},"13cace81-9cd7-4ffa-9fd7-3ed91ddcc1e2",[],[4340],{"id":4341,"sortIndex":36,"affiliation":4342,"properties":26},"12aa2864-676c-4953-882c-ba6caf41ea82",{"id":4321,"createTime":4322,"updateTime":4323,"relativeEntities":4343,"slug":4325,"properties":4344,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":4345},{"EN":4328},{"openalex":4347,"title":4349},{"VOID":4348},"A5084054644",{"EN":4350},"Irina Häuselmann",{"url":26,"publisher":4352,"properties":4382},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":4353,"slug":663,"properties":4354,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":4360,"manageAffiliations":4361,"indexDatabases":4362,"url":742,"thumbnailPath":26,"statistic":4377,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"country":4355,"issn":4356,"introduce":4357,"eissn":4358,"title":4359},{"VOID":666},{"VOID":668},{"EN":670},{"VOID":668},{"EN":673},[],[],[4363,4370],{"id":704,"indexDatabase":4364,"url":719,"indexYears":26,"academicFieldIds":4369,"indexDatabaseRanking":26},{"id":706,"createTime":707,"updateTime":708,"relativeEntities":4365,"label":4366,"description":4367,"key":715,"publicationTags":4368,"standard":26},[],{"EN":711,"VI":711},{"VI":713,"EN":714},[717,718],[721],{"id":723,"indexDatabase":4371,"url":736,"indexYears":737,"academicFieldIds":4376,"indexDatabaseRanking":741},{"id":725,"createTime":726,"updateTime":727,"relativeEntities":4372,"label":4373,"description":4374,"key":733,"publicationTags":4375,"standard":26},[],{"EN":730,"VI":730},{"EN":730,"VI":732},[735],[739,740],{"impactFactor":36,"impactFactorByYear":4378,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":115,"totalPublicationByYear":4379,"totalCitation":158,"totalCitationByYear":4380,"totalCitationPerPublication":158,"totalCitationPerPublicationByYear":4381,"hindexLast5Year":115,"hindex":115},{},{"2021":115},{"2021":158},{"2021":158},{"volume":4383},{"VOID":3285},{"total":621,"publishYear":26,"statisticByYear":4385},{"2014":103,"2015":244,"2016":168,"2017":396,"2018":159,"2019":244,"2020":159,"2021":396,"2022":79,"2023":124,"2024":53},[],{"id":4388,"createTime":4389,"updateTime":4389,"relativeEntities":4390,"slug":4391,"properties":4392,"entityType":772,"verifyStatus":25,"verifyTime":4389,"verifyNote":773,"syncStatus":28,"languages":4407,"translateLanguages":26,"viewCount":36,"primaryUrl":4408,"fullTextUrl":26,"authors":4409,"publicationType":843,"publisherRelationship":4481,"citationCount":4514,"citationInfo":4515,"publishDate":26,"publishYear":26,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":4517,"isForceReanalyzing":1390},"3e620ad3-b313-465c-9e31-935181801f14","2024-12-01T02:44:00.455+00:00",[],"Fluorescence-Guided-Surgery",{"mag":4393,"keywords":4395,"pmc":4396,"openalex":4398,"abstract":4400,"title":4401,"pm":4403,"doi":4405},{"VOID":4394},"2776736539",{},{"VOID":4397},"5743791",{"VOID":4399},"W2776736539",{},{"EN":4402},"Fluorescence-Guided Surgery",{"VOID":4404},"29312886",{"VOID":4406},"10.3389\u002Ffonc.2017.00314",[102],"http:\u002F\u002Fjournal.frontiersin.org\u002Farticle\u002F10.3389\u002Ffonc.2017.00314\u002Ffull",[4410,4430,4447,4464],{"id":4411,"sortIndex":115,"researcher":26,"roles":4412,"affiliations":4413,"properties":4425},"b64aab78-c4f8-4ca3-8ad4-e2586376d2dc",[],[4414],{"id":4415,"sortIndex":36,"affiliation":4416,"properties":26},"f59f3b3d-179e-41d7-a5da-ab07407b6017",{"id":4417,"createTime":4418,"updateTime":4419,"relativeEntities":4420,"slug":4421,"properties":4422,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"31e985da-b6a6-46a9-85b8-31af4556bb11","2024-01-17T05:44:05.006+00:00","2024-12-01T02:44:00.474+00:00",[],"Molecular-Imaging-Program-Center-for-Cancer-Research-National-Cancer-Institute-National-Institutes-of-Health-Bethesda-MD-United-States",{"title":4423},{"VI":4424},"Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States",{"openalex":4426,"title":4428},{"VOID":4427},"A5103607436",{"EN":4429},"Yu Nakamura",{"id":4431,"sortIndex":59,"researcher":26,"roles":4432,"affiliations":4433,"properties":4440},"7eabde28-0938-48e7-96a1-c9455417bac6",[],[4434],{"id":4435,"sortIndex":36,"affiliation":4436,"properties":26},"dce7da18-2943-4bb7-a31f-55f8d37cbbb6",{"id":4417,"createTime":4418,"updateTime":4419,"relativeEntities":4437,"slug":4421,"properties":4438,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":4439},{"VI":4424},{"openalex":4441,"orcid":4443,"title":4445},{"VOID":4442},"A5090173640",{"VOID":4444},"https:\u002F\u002Forcid.org\u002F0000-0003-1019-4112",{"EN":4446},"Hisataka Kobayashi",{"id":4448,"sortIndex":114,"researcher":26,"roles":4449,"affiliations":4450,"properties":4457},"02da70d5-b40e-4520-9bdd-db83b06d0864",[],[4451],{"id":4452,"sortIndex":36,"affiliation":4453,"properties":26},"dbc0e8be-e22d-4288-b21e-1c20bede3c65",{"id":4417,"createTime":4418,"updateTime":4419,"relativeEntities":4454,"slug":4421,"properties":4455,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":4456},{"VI":4424},{"openalex":4458,"orcid":4460,"title":4462},{"VOID":4459},"A5082080836",{"VOID":4461},"https:\u002F\u002Forcid.org\u002F0000-0003-1086-8826",{"EN":4463},"Peter L. Choyke",{"id":4465,"sortIndex":36,"researcher":26,"roles":4466,"affiliations":4467,"properties":4474},"80c00996-673f-4d56-b0de-5643c4f87e83",[],[4468],{"id":4469,"sortIndex":36,"affiliation":4470,"properties":26},"f12b4fbd-0b72-4ffd-9e92-edf8a2daefe6",{"id":4417,"createTime":4418,"updateTime":4419,"relativeEntities":4471,"slug":4421,"properties":4472,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":4473},{"VI":4424},{"openalex":4475,"orcid":4477,"title":4479},{"VOID":4476},"A5075595526",{"VOID":4478},"https:\u002F\u002Forcid.org\u002F0000-0002-0091-8343",{"EN":4480},"Tadanobu Nagaya",{"url":26,"publisher":4482,"properties":4512},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":4483,"slug":663,"properties":4484,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":4490,"manageAffiliations":4491,"indexDatabases":4492,"url":742,"thumbnailPath":26,"statistic":4507,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"country":4485,"issn":4486,"introduce":4487,"eissn":4488,"title":4489},{"VOID":666},{"VOID":668},{"EN":670},{"VOID":668},{"EN":673},[],[],[4493,4500],{"id":704,"indexDatabase":4494,"url":719,"indexYears":26,"academicFieldIds":4499,"indexDatabaseRanking":26},{"id":706,"createTime":707,"updateTime":708,"relativeEntities":4495,"label":4496,"description":4497,"key":715,"publicationTags":4498,"standard":26},[],{"EN":711,"VI":711},{"VI":713,"EN":714},[717,718],[721],{"id":723,"indexDatabase":4501,"url":736,"indexYears":737,"academicFieldIds":4506,"indexDatabaseRanking":741},{"id":725,"createTime":726,"updateTime":727,"relativeEntities":4502,"label":4503,"description":4504,"key":733,"publicationTags":4505,"standard":26},[],{"EN":730,"VI":730},{"EN":730,"VI":732},[735],[739,740],{"impactFactor":36,"impactFactorByYear":4508,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":115,"totalPublicationByYear":4509,"totalCitation":158,"totalCitationByYear":4510,"totalCitationPerPublication":158,"totalCitationPerPublicationByYear":4511,"hindexLast5Year":115,"hindex":115},{},{"2021":115},{"2021":158},{"2021":158},{"volume":4513},{"VOID":1643},306,{"total":4514,"publishYear":26,"statisticByYear":4516},{"2016":115,"2018":116,"2019":396,"2020":282,"2021":402,"2022":44,"2023":281,"2024":286},[4518,4522,4526,4530,4534,4538,4542,4546,4550,4554,4558,4562,4566,4570,4574,4578,4582,4586,4590,4594,4598,4602,4606,4610,4614,4618,4622,4626,4630,4634,4638,4642,4646,4650,4654,4658,4662,4666,4670,4674,4678,4682,4686,4690,4694,4698,4702,4706,4710,4714,4718,4722,4726,4730,4734,4738,4742,4746,4750,4754,4758,4762,4766,4770,4774,4778,4782,4786,4790,4794,4798,4802,4806,4810,4814,4818,4822,4826,4830,4834,4838,4842,4846,4850,4854,4858,4862,4866,4870,4874,4878,4882,4886,4890,4894,4898,4902,4906,4910,4914,4918,4922,4926,4930,4934,4938,4942,4946,4950,4954,4958,4962,4966,4970,4974,4978,4982,4986,4990,4994,4998,5002,5006,5010,5014,5018,5022,5026,5029,5033,5037,5041,5045,5049,5053,5057,5061,5065,5069,5073,5077,5081,5085,5089,5093,5097,5101,5105,5109,5113,5117,5121,5125,5129,5133,5137,5141,5145,5149,5153,5157,5161,5165,5169,5173,5177,5181,5185,5189,5193,5196,5200,5204,5208,5212,5216,5220,5224,5228,5232,5236,5240,5244,5248,5252,5256,5260,5264,5268,5272,5276,5280,5284,5287,5291,5295,5299,5303,5307,5311,5315,5319,5323,5327,5331,5335,5339,5343,5347,5351,5355,5359,5363,5367,5371,5375,5379,5383,5387,5391,5395,5399,5402,5406,5410,5414,5418,5422,5426],{"id":26,"text":4519,"url":26,"identifiers":4520},"DeSantis, 2014, Cancer treatment and survivorship statistics, 2014, CA Cancer J Clin, 64, 252, 10.3322\u002Fcaac.21235",{"doi":4521},"10.3322\u002Fcaac.21235",{"id":26,"text":4523,"url":26,"identifiers":4524},"Haque, 2006, Surgical margins and survival after head and neck cancer surgery, BMC Ear Nose Throat Disord, 6, 2, 10.1186\u002F1472-6815-6-2",{"doi":4525},"10.1186\u002F1472-6815-6-2",{"id":26,"text":4527,"url":26,"identifiers":4528},"Singletary, 2002, Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy, Am J Surg, 184, 383, 10.1016\u002FS0002-9610(02)01012-7",{"doi":4529},"10.1016\u002FS0002-9610(02)01012-7",{"id":26,"text":4531,"url":26,"identifiers":4532},"Meric, 2003, Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy, Cancer, 97, 926, 10.1002\u002Fcncr.11222",{"doi":4533},"10.1002\u002Fcncr.11222",{"id":26,"text":4535,"url":26,"identifiers":4536},"Snijder, 1998, Survival in resected stage I lung cancer with residual tumor at the bronchial resection margin, Ann Thorac Surg, 65, 212, 10.1016\u002FS0003-4975(97)01114-4",{"doi":4537},"10.1016\u002FS0003-4975(97)01114-4",{"id":26,"text":4539,"url":26,"identifiers":4540},"Nagtegaal, 2008, What is the role for the circumferential margin in the modern treatment of rectal cancer?, J Clin Oncol, 26, 303, 10.1200\u002Fjco.2007.12.7027",{"doi":4541},"10.1200\u002Fjco.2007.12.7027",{"id":26,"text":4543,"url":26,"identifiers":4544},"Dotan, 2007, Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival, J Urol, 178, 2308, 10.1016\u002Fj.juro.2007.08.023",{"doi":4545},"10.1016\u002Fj.juro.2007.08.023",{"id":26,"text":4547,"url":26,"identifiers":4548},"Wieder, 1998, Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer, J Urol, 160, 299, 10.1097\u002F00005392-199808000-00003",{"doi":4549},"10.1097\u002F00005392-199808000-00003",{"id":26,"text":4551,"url":26,"identifiers":4552},"Rosenthal, 2015, The status of contemporary image-guided modalities in oncologic surgery, Ann Surg, 261, 46, 10.1097\u002Fsla.0000000000000622",{"doi":4553},"10.1097\u002Fsla.0000000000000622",{"id":26,"text":4555,"url":26,"identifiers":4556},"Ravasz, 1991, The status of the resection margin as a prognostic factor in the treatment of head and neck carcinoma, J Craniomaxillofac Surg, 19, 314, 10.1016\u002FS1010-5182(05)80339-7",{"doi":4557},"10.1016\u002FS1010-5182(05)80339-7",{"id":26,"text":4559,"url":26,"identifiers":4560},"Choti, 2002, Trends in long-term survival following liver resection for hepatic colorectal metastases, Ann Surg, 235, 759, 10.1097\u002F00000658-200206000-00002",{"doi":4561},"10.1097\u002F00000658-200206000-00002",{"id":26,"text":4563,"url":26,"identifiers":4564},"McMahon, 2003, Influence of condition of surgical margins on local recurrence and disease-specific survival in oral and oropharyngeal cancer, Br J Oral Maxillofac Surg, 41, 224, 10.1016\u002FS0266-4356(03)00119-0",{"doi":4565},"10.1016\u002FS0266-4356(03)00119-0",{"id":26,"text":4567,"url":26,"identifiers":4568},"Woolgar, 2005, A histopathological appraisal of surgical margins in oral and oropharyngeal cancer resection specimens, Oral Oncol, 41, 1034, 10.1016\u002Fj.oraloncology.2005.06.008",{"doi":4569},"10.1016\u002Fj.oraloncology.2005.06.008",{"id":26,"text":4571,"url":26,"identifiers":4572},"Iczkowski, 2011, Frequency of positive surgical margin at prostatectomy and its effect on patient outcome, Prostate Cancer, 2011, 673021, 10.1155\u002F2011\u002F673021",{"doi":4573},"10.1155\u002F2011\u002F673021",{"id":26,"text":4575,"url":26,"identifiers":4576},"Atkins, 2012, Positive margin rates following breast-conserving surgery for stage I-III breast cancer: palpable versus nonpalpable tumors, J Surg Res, 177, 109, 10.1016\u002Fj.jss.2012.03.045",{"doi":4577},"10.1016\u002Fj.jss.2012.03.045",{"id":26,"text":4579,"url":26,"identifiers":4580},"Chagpar, 2015, Cavity shave margins in breast cancer, N Engl J Med, 373, 2187, 10.1056\u002FNEJMc1511344",{"doi":4581},"10.1056\u002FNEJMc1511344",{"id":26,"text":4583,"url":26,"identifiers":4584},"Rosenthal, 2016, Successful translation of fluorescence navigation during oncologic surgery: a consensus report, J Nucl Med, 57, 144, 10.2967\u002Fjnumed.115.158915",{"doi":4585},"10.2967\u002Fjnumed.115.158915",{"id":26,"text":4587,"url":26,"identifiers":4588},"Kubben, 2011, Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review, Lancet Oncol, 12, 1062, 10.1016\u002Fs1470-2045(11)70130-9",{"doi":4589},"10.1016\u002Fs1470-2045(11)70130-9",{"id":26,"text":4591,"url":26,"identifiers":4592},"Li, 2012, Individualized treatment of craniovertebral junction malformation guided by intraoperative computed tomography, J Spinal Disord Tech, 25, 77, 10.1097\u002FBSD.0b013e31820f8afb",{"doi":4593},"10.1097\u002FBSD.0b013e31820f8afb",{"id":26,"text":4595,"url":26,"identifiers":4596},"Singh, 2017, Endoscopic endonasal odontoid resection with real-time intraoperative image-guided computed tomography: report of 4 cases, J Neurosurg, 1, 10.3171\u002F2017.1.jns162601",{"doi":4597},"10.3171\u002F2017.1.jns162601",{"id":26,"text":4599,"url":26,"identifiers":4600},"Moore, 1948, The clinical use of fluorescein in neurosurgery; the localization of brain tumors, J Neurosurg, 5, 392, 10.3171\u002Fjns.1948.5.4.0392",{"doi":4601},"10.3171\u002Fjns.1948.5.4.0392",{"id":26,"text":4603,"url":26,"identifiers":4604},"Nguyen, 2013, Fluorescence-guided surgery with live molecular navigation – a new cutting edge, Nat Rev Cancer, 13, 653, 10.1038\u002Fnrc3566",{"doi":4605},"10.1038\u002Fnrc3566",{"id":26,"text":4607,"url":26,"identifiers":4608},"Vahrmeijer, 2013, Image-guided cancer surgery using near-infrared fluorescence, Nat Rev Clin Oncol, 10, 507, 10.1038\u002Fnrclinonc.2013.123",{"doi":4609},"10.1038\u002Fnrclinonc.2013.123",{"id":26,"text":4611,"url":26,"identifiers":4612},"DeLong, 2016, Current status and future perspectives of fluorescence-guided surgery for cancer, Expert Rev Anticancer Ther, 16, 71, 10.1586\u002F14737140.2016.1121109",{"doi":4613},"10.1586\u002F14737140.2016.1121109",{"id":26,"text":4615,"url":26,"identifiers":4616},"Alander, 2012, A review of indocyanine green fluorescent imaging in surgery, Int J Biomed Imaging, 2012, 940585, 10.1155\u002F2012\u002F940585",{"doi":4617},"10.1155\u002F2012\u002F940585",{"id":26,"text":4619,"url":26,"identifiers":4620},"Xi, 2016, Image-guided surgery using multimodality strategy and molecular probes, Wiley Interdiscip Rev Nanomed Nanobiotechnol, 8, 46, 10.1002\u002Fwnan.1352",{"doi":4621},"10.1002\u002Fwnan.1352",{"id":26,"text":4623,"url":26,"identifiers":4624},"AV, 2016, Review of fluorescence guided surgery systems: identification of key performance capabilities beyond indocyanine green imaging, J Biomed Opt, 21, 80901, 10.1117\u002F1.jbo.21.8.080901",{"doi":4625},"10.1117\u002F1.jbo.21.8.080901",{"id":26,"text":4627,"url":26,"identifiers":4628},"van Dam, 2011, Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results, Nat Med, 17, 1315, 10.1038\u002Fnm.2472",{"doi":4629},"10.1038\u002Fnm.2472",{"id":26,"text":4631,"url":26,"identifiers":4632},"Aldave, 2013, Prognostic value of residual fluorescent tissue in glioblastoma patients after gross total resection in 5-aminolevulinic acid-guided surgery, Neurosurgery, 72, 915, 10.1227\u002FNEU.0b013e31828c3974",{"doi":4633},"10.1227\u002FNEU.0b013e31828c3974",{"id":26,"text":4635,"url":26,"identifiers":4636},"Hussain, 2014, Molecular imaging for cancer diagnosis and surgery, Adv Drug Deliv Rev, 66, 90, 10.1016\u002Fj.addr.2013.09.007",{"doi":4637},"10.1016\u002Fj.addr.2013.09.007",{"id":26,"text":4639,"url":26,"identifiers":4640},"de Boer, 2015, Optical innovations in surgery, Br J Surg, 102, e56, 10.1002\u002Fbjs.9713",{"doi":4641},"10.1002\u002Fbjs.9713",{"id":26,"text":4643,"url":26,"identifiers":4644},"Lee, 2010, The FLARE intraoperative near-infrared fluorescence imaging system: a first-in-human clinical trial in perforator flap breast reconstruction, Plast Reconstr Surg, 126, 1472, 10.1097\u002FPRS.0b013e3181f059c7",{"doi":4645},"10.1097\u002FPRS.0b013e3181f059c7",{"id":26,"text":4647,"url":26,"identifiers":4648},"Hill, 2016, Image-guided tumor surgery: will there be a role for fluorescent nanoparticles?, Wiley Interdiscip Rev Nanomed Nanobiotechnol, 8, 498, 10.1002\u002Fwnan.1381",{"doi":4649},"10.1002\u002Fwnan.1381",{"id":26,"text":4651,"url":26,"identifiers":4652},"Motomura, 1999, Sentinel node biopsy guided by indocyanine green dye in breast cancer patients, Jpn J Clin Oncol, 29, 604, 10.1093\u002Fjjco\u002F29.12.604",{"doi":4653},"10.1093\u002Fjjco\u002F29.12.604",{"id":26,"text":4655,"url":26,"identifiers":4656},"Kitai, 2005, Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer, Breast Cancer, 12, 211, 10.2325\u002Fjbcs.12.211",{"doi":4657},"10.2325\u002Fjbcs.12.211",{"id":26,"text":4659,"url":26,"identifiers":4660},"Tagaya, 2008, Intraoperative identification of sentinel lymph nodes by near-infrared fluorescence imaging in patients with breast cancer, Am J Surg, 195, 850, 10.1016\u002Fj.amjsurg.2007.02.032",{"doi":4661},"10.1016\u002Fj.amjsurg.2007.02.032",{"id":26,"text":4663,"url":26,"identifiers":4664},"Murawa, 2009, Sentinel lymph node biopsy in breast cancer guided by indocyanine green fluorescence, Br J Surg, 96, 1289, 10.1002\u002Fbjs.6721",{"doi":4665},"10.1002\u002Fbjs.6721",{"id":26,"text":4667,"url":26,"identifiers":4668},"Zakaria, 2008, Safety and technical success of methylene blue dye for lymphatic mapping in breast cancer, Am J Surg, 196, 228, 10.1016\u002Fj.amjsurg.2007.08.060",{"doi":4669},"10.1016\u002Fj.amjsurg.2007.08.060",{"id":26,"text":4671,"url":26,"identifiers":4672},"Peek, 2017, Blue dye for identification of sentinel nodes in breast cancer and malignant melanoma: a systematic review and meta-analysis, Future Oncol, 13, 455, 10.2217\u002Ffon-2016-0255",{"doi":4673},"10.2217\u002Ffon-2016-0255",{"id":26,"text":4675,"url":26,"identifiers":4676},"Fujiwara, 2009, Sentinel lymph node detection in skin cancer patients using real-time fluorescence navigation with indocyanine green: preliminary experience, J Plast Reconstr Aesthet Surg, 62, e373, 10.1016\u002Fj.bjps.2007.12.074",{"doi":4677},"10.1016\u002Fj.bjps.2007.12.074",{"id":26,"text":4679,"url":26,"identifiers":4680},"Tanaka, 2009, Sentinel lymph node detection in skin cancer using fluorescence navigation with indocyanine green, J Dermatol, 36, 468, 10.1111\u002Fj.1346-8138.2009.00679.x",{"doi":4681},"10.1111\u002Fj.1346-8138.2009.00679.x",{"id":26,"text":4683,"url":26,"identifiers":4684},"Bredell, 2010, Sentinel lymph node mapping by indocyanin green fluorescence imaging in oropharyngeal cancer – preliminary experience, Head Neck Oncol, 2, 31, 10.1186\u002F1758-3284-2-31",{"doi":4685},"10.1186\u002F1758-3284-2-31",{"id":26,"text":4687,"url":26,"identifiers":4688},"Yamashita, 2011, Video-assisted thoracoscopic indocyanine green fluorescence imaging system shows sentinel lymph nodes in non-small-cell lung cancer, J Thorac Cardiovasc Surg, 141, 141, 10.1016\u002Fj.jtcvs.2010.01.028",{"doi":4689},"10.1016\u002Fj.jtcvs.2010.01.028",{"id":26,"text":4691,"url":26,"identifiers":4692},"Yuasa, 2012, Sentinel lymph node biopsy using intraoperative indocyanine green fluorescence imaging navigated with preoperative CT lymphography for superficial esophageal cancer, Ann Surg Oncol, 19, 486, 10.1245\u002Fs10434-011-1922-x",{"doi":4693},"10.1245\u002Fs10434-011-1922-x",{"id":26,"text":4695,"url":26,"identifiers":4696},"Kubota, 2013, Application of the HyperEye Medical System for esophageal cancer surgery: a preliminary report, Surg Today, 43, 215, 10.1007\u002Fs00595-012-0251-4",{"doi":4697},"10.1007\u002Fs00595-012-0251-4",{"id":26,"text":4699,"url":26,"identifiers":4700},"Nimura, 2004, Infrared ray electronic endoscopy combined with indocyanine green injection for detection of sentinel nodes of patients with gastric cancer, Br J Surg, 91, 575, 10.1002\u002Fbjs.4470",{"doi":4701},"10.1002\u002Fbjs.4470",{"id":26,"text":4703,"url":26,"identifiers":4704},"Kusano, 2008, Sentinel node mapping guided by indocyanine green fluorescence imaging: a new method for sentinel node navigation surgery in gastrointestinal cancer, Dig Surg, 25, 103, 10.1159\u002F000121905",{"doi":4705},"10.1159\u002F000121905",{"id":26,"text":4707,"url":26,"identifiers":4708},"Noura, 2010, Feasibility of a lateral region sentinel node biopsy of lower rectal cancer guided by indocyanine green using a near-infrared camera system, Ann Surg Oncol, 17, 144, 10.1245\u002Fs10434-009-0711-2",{"doi":4709},"10.1245\u002Fs10434-009-0711-2",{"id":26,"text":4711,"url":26,"identifiers":4712},"Hirche, 2010, Sentinel node biopsy by indocyanine green retention fluorescence detection for inguinal lymph node staging of anal cancer: preliminary experience, Ann Surg Oncol, 17, 2357, 10.1245\u002Fs10434-010-1010-7",{"doi":4713},"10.1245\u002Fs10434-010-1010-7",{"id":26,"text":4715,"url":26,"identifiers":4716},"Jeschke, 2012, Visualisation of the lymph node pathway in real time by laparoscopic radioisotope- and fluorescence-guided sentinel lymph node dissection in prostate cancer staging, Urology, 80, 1080, 10.1016\u002Fj.urology.2012.05.050",{"doi":4717},"10.1016\u002Fj.urology.2012.05.050",{"id":26,"text":4719,"url":26,"identifiers":4720},"Polom, 2014, Usage of invisible near infrared light (NIR) fluorescence with indocyanine green (ICG) and methylene blue (MB) in urological oncology. Part 1, Cent European J Urol, 67, 142, 10.5173\u002Fceju.2014.02.art5",{"doi":4721},"10.5173\u002Fceju.2014.02.art5",{"id":26,"text":4723,"url":26,"identifiers":4724},"Polom, 2014, Use of invisible near infrared light fluorescence with indocyanine green and methylene blue in urology. Part 2, Cent European J Urol, 67, 310, 10.5173\u002Fceju.2014.03.art19",{"doi":4725},"10.5173\u002Fceju.2014.03.art19",{"id":26,"text":4727,"url":26,"identifiers":4728},"Ogata, 2007, Intraoperative lymphography using indocyanine green dye for near-infrared fluorescence labeling in lymphedema, Ann Plast Surg, 59, 180, 10.1097\u002F01.sap.0000253341.70866.54",{"doi":4729},"10.1097\u002F01.sap.0000253341.70866.54",{"id":26,"text":4731,"url":26,"identifiers":4732},"Unno, 2007, Preliminary experience with a novel fluorescence lymphography using indocyanine green in patients with secondary lymphedema, J Vasc Surg, 45, 1016, 10.1016\u002Fj.jvs.2007.01.023",{"doi":4733},"10.1016\u002Fj.jvs.2007.01.023",{"id":26,"text":4735,"url":26,"identifiers":4736},"Chang, 2013, A prospective analysis of 100 consecutive lymphovenous bypass cases for treatment of extremity lymphedema, Plast Reconstr Surg, 132, 1305, 10.1097\u002FPRS.0b013e3182a4d626",{"doi":4737},"10.1097\u002FPRS.0b013e3182a4d626",{"id":26,"text":4739,"url":26,"identifiers":4740},"Kuroda, 2013, Intra-arterial injection fluorescein videoangiography in aneurysm surgery, Neurosurgery, 72, ons141, 10.1227\u002FNEU.0b013e3182752f32",{"doi":4741},"10.1227\u002FNEU.0b013e3182752f32",{"id":26,"text":4743,"url":26,"identifiers":4744},"Ichikawa, 2014, Intra-arterial fluorescence angiography with injection of fluorescein sodium from the superficial temporal artery during aneurysm surgery: technical notes, Neurol Med Chir (Tokyo), 54, 490, 10.2176\u002Fnmc.tn.2013-0232",{"doi":4745},"10.2176\u002Fnmc.tn.2013-0232",{"id":26,"text":4747,"url":26,"identifiers":4748},"Ichikawa, 2016, Development of and clinical experience with a simple device for performing intraoperative fluorescein fluorescence cerebral angiography: technical notes, Neurol Med Chir (Tokyo), 56, 141, 10.2176\u002Fnmc.tn.2015-0188",{"doi":4749},"10.2176\u002Fnmc.tn.2015-0188",{"id":26,"text":4751,"url":26,"identifiers":4752},"Yamamoto, 2011, Assessing intraoperative blood flow in cardiovascular surgery, Surg Today, 41, 1467, 10.1007\u002Fs00595-010-4553-0",{"doi":4753},"10.1007\u002Fs00595-010-4553-0",{"id":26,"text":4755,"url":26,"identifiers":4756},"Yamamoto, 2015, Efficacy of intraoperative HyperEye Medical System angiography for coronary artery bypass grafting, Surg Today, 45, 966, 10.1007\u002Fs00595-014-1015-0",{"doi":4757},"10.1007\u002Fs00595-014-1015-0",{"id":26,"text":4759,"url":26,"identifiers":4760},"Yamamoto, 2012, Indocyanine green angiography for intra-operative assessment in vascular surgery, Eur J Vasc Endovasc Surg, 43, 426, 10.1016\u002Fj.ejvs.2011.12.030",{"doi":4761},"10.1016\u002Fj.ejvs.2011.12.030",{"id":26,"text":4763,"url":26,"identifiers":4764},"Jafari, 2013, The use of indocyanine green fluorescence to assess anastomotic perfusion during robotic assisted laparoscopic rectal surgery, Surg Endosc, 27, 3003, 10.1007\u002Fs00464-013-2832-8",{"doi":4765},"10.1007\u002Fs00464-013-2832-8",{"id":26,"text":4767,"url":26,"identifiers":4768},"Pacheco, 2013, The novel use of intraoperative laser-induced fluorescence of indocyanine green tissue angiography for evaluation of the gastric conduit in esophageal reconstructive surgery, Am J Surg, 205, 349, 10.1016\u002Fj.amjsurg.2012.11.005",{"doi":4769},"10.1016\u002Fj.amjsurg.2012.11.005",{"id":26,"text":4771,"url":26,"identifiers":4772},"Yamaguchi, 2004, The “perfusion map” of the unipedicled TRAM flap to reduce postoperative partial necrosis, Ann Plast Surg, 53, 205, 10.1097\u002F01.sap.0000116284.51679.ea",{"doi":4773},"10.1097\u002F01.sap.0000116284.51679.ea",{"id":26,"text":4775,"url":26,"identifiers":4776},"Giunta, 2005, Prediction of flap necrosis with laser induced indocyanine green fluorescence in a rat model, Br J Plast Surg, 58, 695, 10.1016\u002Fj.bjps.2005.02.018",{"doi":4777},"10.1016\u002Fj.bjps.2005.02.018",{"id":26,"text":4779,"url":26,"identifiers":4780},"Holm, 2008, Interindividual variability of the SIEA angiosome: effects on operative strategies in breast reconstruction, Plast Reconstr Surg, 122, 1612, 10.1097\u002FPRS.0b013e31818a9a3f",{"doi":4781},"10.1097\u002FPRS.0b013e31818a9a3f",{"id":26,"text":4783,"url":26,"identifiers":4784},"Lamby, 2008, Evaluation of the vascular integrity of free flaps based on microcirculation imaging techniques, Clin Hemorheol Microcirc, 39, 253, 10.3233\u002FCH-2008-1094",{"doi":4785},"10.3233\u002FCH-2008-1094",{"id":26,"text":4787,"url":26,"identifiers":4788},"Newman, 2009, The application of laser-assisted indocyanine green fluorescent dye angiography in microsurgical breast reconstruction, J Reconstr Microsurg, 25, 21, 10.1055\u002Fs-0028-1090617",{"doi":4789},"10.1055\u002Fs-0028-1090617",{"id":26,"text":4791,"url":26,"identifiers":4792},"Pestana, 2009, Early experience with fluorescent angiography in free-tissue transfer reconstruction, Plast Reconstr Surg, 123, 1239, 10.1097\u002FPRS.0b013e31819e67c1",{"doi":4793},"10.1097\u002FPRS.0b013e31819e67c1",{"id":26,"text":4795,"url":26,"identifiers":4796},"Komorowska-Timek, 2010, Intraoperative perfusion mapping with laser-assisted indocyanine green imaging can predict and prevent complications in immediate breast reconstruction, Plast Reconstr Surg, 125, 1065, 10.1097\u002FPRS.0b013e3181d17f80",{"doi":4797},"10.1097\u002FPRS.0b013e3181d17f80",{"id":26,"text":4799,"url":26,"identifiers":4800},"Ishizawa, 2010, Fluorescent cholangiography illuminating the biliary tree during laparoscopic cholecystectomy, Br J Surg, 97, 1369, 10.1002\u002Fbjs.7125",{"doi":4801},"10.1002\u002Fbjs.7125",{"id":26,"text":4803,"url":26,"identifiers":4804},"Boni, 2015, Clinical applications of indocyanine green (ICG) enhanced fluorescence in laparoscopic surgery, Surg Endosc, 29, 2046, 10.1007\u002Fs00464-014-3895-x",{"doi":4805},"10.1007\u002Fs00464-014-3895-x",{"id":26,"text":4807,"url":26,"identifiers":4808},"Winer, 2010, Intraoperative localization of insulinoma and normal pancreas using invisible near-infrared fluorescent light, Ann Surg Oncol, 17, 1094, 10.1245\u002Fs10434-009-0868-8",{"doi":4809},"10.1245\u002Fs10434-009-0868-8",{"id":26,"text":4811,"url":26,"identifiers":4812},"Wada, 2015, Pancreas-targeted NIR fluorophores for dual-channel image-guided abdominal surgery, Theranostics, 5, 1, 10.7150\u002Fthno.10259",{"doi":4813},"10.7150\u002Fthno.10259",{"id":26,"text":4815,"url":26,"identifiers":4816},"Verbeek, 2013, Intraoperative near infrared fluorescence guided identification of the ureters using low dose methylene blue: a first in human experience, J Urol, 190, 574, 10.1016\u002Fj.juro.2013.02.3187",{"doi":4817},"10.1016\u002Fj.juro.2013.02.3187",{"id":26,"text":4819,"url":26,"identifiers":4820},"Whitney, 2011, Fluorescent peptides highlight peripheral nerves during surgery in mice, Nat Biotechnol, 29, 352, 10.1038\u002Fnbt.1764",{"doi":4821},"10.1038\u002Fnbt.1764",{"id":26,"text":4823,"url":26,"identifiers":4824},"Wu, 2011, Improved facial nerve identification with novel fluorescently labeled probe, Laryngoscope, 121, 805, 10.1002\u002Flary.21411",{"doi":4825},"10.1002\u002Flary.21411",{"id":26,"text":4827,"url":26,"identifiers":4828},"Hyun, 2015, Structure-inherent targeting of near-infrared fluorophores for parathyroid and thyroid gland imaging, Nat Med, 21, 192, 10.1038\u002Fnm.3728",{"doi":4829},"10.1038\u002Fnm.3728",{"id":26,"text":4831,"url":26,"identifiers":4832},"Owens, 2015, Correlating molecular character of NIR imaging agents with tissue-specific uptake, J Med Chem, 58, 4348, 10.1021\u002Facs.jmedchem.5b00475",{"doi":4833},"10.1021\u002Facs.jmedchem.5b00475",{"id":26,"text":4835,"url":26,"identifiers":4836},"Ashitate, 2016, Endocrine-specific NIR fluorophores for adrenal gland targeting, Chem Commun (Camb), 52, 10305, 10.1039\u002Fc6cc03845j",{"doi":4837},"10.1039\u002Fc6cc03845j",{"id":26,"text":4839,"url":26,"identifiers":4840},"Owens, 2016, Near-infrared illumination of native tissues for image-guided surgery, J Med Chem, 59, 5311, 10.1021\u002Facs.jmedchem.6b00038",{"doi":4841},"10.1021\u002Facs.jmedchem.6b00038",{"id":26,"text":4843,"url":26,"identifiers":4844},"Stummer, 1998, Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence, Neurosurgery, 42, 518, 10.1097\u002F00006123-199803000-00017",{"doi":4845},"10.1097\u002F00006123-199803000-00017",{"id":26,"text":4847,"url":26,"identifiers":4848},"Stummer, 2006, Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial, Lancet Oncol, 7, 392, 10.1016\u002Fs1470-2045(06)70665-9",{"doi":4849},"10.1016\u002Fs1470-2045(06)70665-9",{"id":26,"text":4851,"url":26,"identifiers":4852},"Roberts, 2011, Coregistered fluorescence-enhanced tumor resection of malignant glioma: relationships between delta-aminolevulinic acid-induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. Clinical article, J Neurosurg, 114, 595, 10.3171\u002F2010.2.jns091322",{"doi":4853},"10.3171\u002F2010.2.jns091322",{"id":26,"text":4855,"url":26,"identifiers":4856},"Colditz, 2012, Aminolevulinic acid (ALA)-protoporphyrin IX fluorescence guided tumour resection. Part 1: clinical, radiological and pathological studies, J Clin Neurosci, 19, 1471, 10.1016\u002Fj.jocn.2012.03.009",{"doi":4857},"10.1016\u002Fj.jocn.2012.03.009",{"id":26,"text":4859,"url":26,"identifiers":4860},"Colditz, 2012, Aminolevulinic acid (ALA)-protoporphyrin IX fluorescence guided tumour resection. Part 2: theoretical, biochemical and practical aspects, J Clin Neurosci, 19, 1611, 10.1016\u002Fj.jocn.2012.03.013",{"doi":4861},"10.1016\u002Fj.jocn.2012.03.013",{"id":26,"text":4863,"url":26,"identifiers":4864},"Kuroiwa, 1998, Development of a fluorescein operative microscope for use during malignant glioma surgery: a technical note and preliminary report, Surg Neurol, 50, 41, 10.1016\u002FS0090-3019(98)00055-X",{"doi":4865},"10.1016\u002FS0090-3019(98)00055-X",{"id":26,"text":4867,"url":26,"identifiers":4868},"Shinoda, 2003, Fluorescence-guided resection of glioblastoma multiforme by using high-dose fluorescein sodium. Technical note, J Neurosurg, 99, 597, 10.3171\u002Fjns.2003.99.3.0597",{"doi":4869},"10.3171\u002Fjns.2003.99.3.0597",{"id":26,"text":4871,"url":26,"identifiers":4872},"Okuda, 2012, Fluorescence-guided surgery for glioblastoma multiforme using high-dose fluorescein sodium with excitation and barrier filters, J Clin Neurosci, 19, 1719, 10.1016\u002Fj.jocn.2011.12.034",{"doi":4873},"10.1016\u002Fj.jocn.2011.12.034",{"id":26,"text":4875,"url":26,"identifiers":4876},"Butte, 2014, Near-infrared imaging of brain tumors using the Tumor Paint BLZ-100 to achieve near-complete resection of brain tumors, Neurosurg Focus, 36, E1, 10.3171\u002F2013.11.focus13497",{"doi":4877},"10.3171\u002F2013.11.focus13497",{"id":26,"text":4879,"url":26,"identifiers":4880},"Cutter, 2012, Topical application of activity-based probes for visualization of brain tumor tissue, PLoS One, 7, e33060, 10.1371\u002Fjournal.pone.0033060",{"doi":4881},"10.1371\u002Fjournal.pone.0033060",{"id":26,"text":4883,"url":26,"identifiers":4884},"Okuda, 2007, Metastatic brain tumor surgery using fluorescein sodium: technical note, Minim Invasive Neurosurg, 50, 382, 10.1055\u002Fs-2007-993200",{"doi":4885},"10.1055\u002Fs-2007-993200",{"id":26,"text":4887,"url":26,"identifiers":4888},"Okuda, 2010, Fluorescence-guided surgery of metastatic brain tumors using fluorescein sodium, J Clin Neurosci, 17, 118, 10.1016\u002Fj.jocn.2009.06.033",{"doi":4889},"10.1016\u002Fj.jocn.2009.06.033",{"id":26,"text":4891,"url":26,"identifiers":4892},"de Boer, 2015, In vivo fluorescence immunohistochemistry: localization of fluorescently labeled cetuximab in squamous cell carcinomas, Sci Rep, 5, 10169, 10.1038\u002Fsrep10169",{"doi":4893},"10.1038\u002Fsrep10169",{"id":26,"text":4895,"url":26,"identifiers":4896},"Rosenthal, 2015, Safety and tumor specificity of cetuximab-IRDye800 for surgical navigation in head and neck cancer, Clin Cancer Res, 21, 3658, 10.1158\u002F1078-0432.ccr-14-3284",{"doi":4897},"10.1158\u002F1078-0432.ccr-14-3284",{"id":26,"text":4899,"url":26,"identifiers":4900},"Mitsunaga, 2011, Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules, Nat Med, 17, 1685, 10.1038\u002Fnm.2554",{"doi":4901},"10.1038\u002Fnm.2554",{"id":26,"text":4903,"url":26,"identifiers":4904},"Cherrick, 1960, Indocyanine green: observations on its physical properties, plasma decay, and hepatic extraction, J Clin Invest, 39, 592, 10.1172\u002Fjci104072",{"doi":4905},"10.1172\u002Fjci104072",{"id":26,"text":4907,"url":26,"identifiers":4908},"Gotoh, 2009, A novel image-guided surgery of hepatocellular carcinoma by indocyanine green fluorescence imaging navigation, J Surg Oncol, 100, 75, 10.1002\u002Fjso.21272",{"doi":4909},"10.1002\u002Fjso.21272",{"id":26,"text":4911,"url":26,"identifiers":4912},"Ishizawa, 2009, Real-time identification of liver cancers by using indocyanine green fluorescent imaging, Cancer, 115, 2491, 10.1002\u002Fcncr.24291",{"doi":4913},"10.1002\u002Fcncr.24291",{"id":26,"text":4915,"url":26,"identifiers":4916},"Uchiyama, 2010, Combined use of contrast-enhanced intraoperative ultrasonography and a fluorescence navigation system for identifying hepatic metastases, World J Surg, 34, 2953, 10.1007\u002Fs00268-010-0764-1",{"doi":4917},"10.1007\u002Fs00268-010-0764-1",{"id":26,"text":4919,"url":26,"identifiers":4920},"Tummers, 2014, Real-time intraoperative detection of breast cancer using near-infrared fluorescence imaging and methylene blue, Eur J Surg Oncol, 40, 850, 10.1016\u002Fj.ejso.2014.02.225",{"doi":4921},"10.1016\u002Fj.ejso.2014.02.225",{"id":26,"text":4923,"url":26,"identifiers":4924},"Tipirneni, 2017, Oncologic procedures amenable to fluorescence-guided surgery, Ann Surg, 266, 36, 10.1097\u002Fsla.0000000000002127",{"doi":4925},"10.1097\u002Fsla.0000000000002127",{"id":26,"text":4927,"url":26,"identifiers":4928},"Whitley, 2016, A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer, Sci Transl Med, 8, 320ra324, 10.1126\u002Fscitranslmed.aad0293",{"doi":4929},"10.1126\u002Fscitranslmed.aad0293",{"id":26,"text":4931,"url":26,"identifiers":4932},"Unkart, 2017, Intraoperative tumor detection using a ratiometric activatable fluorescent peptide: a first-in-human phase 1 study, Ann Surg Oncol, 3167, 10.1245\u002Fs10434-017-5991-3",{"doi":4933},"10.1245\u002Fs10434-017-5991-3",{"id":26,"text":4935,"url":26,"identifiers":4936},"Holt, 2014, Intraoperative near-infrared imaging can distinguish cancer from normal tissue but not inflammation, PLoS One, 9, e103342, 10.1371\u002Fjournal.pone.0103342",{"doi":4937},"10.1371\u002Fjournal.pone.0103342",{"id":26,"text":4939,"url":26,"identifiers":4940},"Okusanya, 2015, Intraoperative molecular imaging can identify lung adenocarcinomas during pulmonary resection, J Thorac Cardiovasc Surg, 150, 28, 10.1016\u002Fj.jtcvs.2015.05.014",{"doi":4941},"10.1016\u002Fj.jtcvs.2015.05.014",{"id":26,"text":4943,"url":26,"identifiers":4944},"Predina, 2017, Standardization and optimization of intraoperative molecular imaging for identifying primary pulmonary adenocarcinomas, Mol Imaging Biol, 10.1007\u002Fs11307-017-1076-8",{"doi":4945},"10.1007\u002Fs11307-017-1076-8",{"id":26,"text":4947,"url":26,"identifiers":4948},"Predina, 2017, Intraoperative molecular imaging combined with positron emission tomography improves surgical management of peripheral malignant pulmonary nodules, Ann Surg, 266, 479, 10.1097\u002Fsla.0000000000002382",{"doi":4949},"10.1097\u002Fsla.0000000000002382",{"id":26,"text":4951,"url":26,"identifiers":4952},"Tummers, 2015, The value of intraoperative near-infrared fluorescence imaging based on enhanced permeability and retention of indocyanine green: feasibility and false-positives in ovarian cancer, PLoS One, 10, e0129766, 10.1371\u002Fjournal.pone.0129766",{"doi":4953},"10.1371\u002Fjournal.pone.0129766",{"id":26,"text":4955,"url":26,"identifiers":4956},"Tummers, 2016, Intraoperative imaging of folate receptor alpha positive ovarian and breast cancer using the tumor specific agent EC17, Oncotarget, 7, 32144, 10.18632\u002Foncotarget.8282",{"doi":4957},"10.18632\u002Foncotarget.8282",{"id":26,"text":4959,"url":26,"identifiers":4960},"Hoogstins, 2016, A novel tumor-specific agent for intraoperative near-infrared fluorescence imaging: a translational study in healthy volunteers and patients with ovarian cancer, Clin Cancer Res, 22, 2929, 10.1158\u002F1078-0432.ccr-15-2640",{"doi":4961},"10.1158\u002F1078-0432.ccr-15-2640",{"id":26,"text":4963,"url":26,"identifiers":4964},"Urano, 2011, Rapid cancer detection by topically spraying a gamma-glutamyltranspeptidase-activated fluorescent probe, Sci Transl Med, 3, 110ra119, 10.1126\u002Fscitranslmed.3002823",{"doi":4965},"10.1126\u002Fscitranslmed.3002823",{"id":26,"text":4967,"url":26,"identifiers":4968},"Kaushal, 2008, Fluorophore-conjugated anti-CEA antibody for the intraoperative imaging of pancreatic and colorectal cancer, J Gastrointest Surg, 12, 1938, 10.1007\u002Fs11605-008-0581-0",{"doi":4969},"10.1007\u002Fs11605-008-0581-0",{"id":26,"text":4971,"url":26,"identifiers":4972},"McElroy, 2008, Imaging of primary and metastatic pancreatic cancer using a fluorophore-conjugated anti-CA19-9 antibody for surgical navigation, World J Surg, 32, 1057, 10.1007\u002Fs00268-007-9452-1",{"doi":4973},"10.1007\u002Fs00268-007-9452-1",{"id":26,"text":4975,"url":26,"identifiers":4976},"van der Vorst, 2012, Near-infrared fluorescence imaging of a solitary fibrous tumor of the pancreas using methylene blue, World J Gastrointest Surg, 4, 180, 10.4240\u002Fwjgs.v4.i7.180",{"doi":4977},"10.4240\u002Fwjgs.v4.i7.180",{"id":26,"text":4979,"url":26,"identifiers":4980},"Guzzo, 2016, Intraoperative molecular diagnostic imaging can identify renal cell carcinoma, J Urol, 195, 748, 10.1016\u002Fj.juro.2015.09.093",{"doi":4981},"10.1016\u002Fj.juro.2015.09.093",{"id":26,"text":4983,"url":26,"identifiers":4984},"Jichlinski, 1997, Clinical evaluation of a method for detecting superficial surgical transitional cell carcinoma of the bladder by light-induced fluorescence of protoporphyrin IX following the topical application of 5-aminolevulinic acid: preliminary results, Lasers Surg Med, 20, 402, 10.1002\u002F(SICI)1096-9101(1997)20:4\u003C402::AID-LSM5>3.0.CO;2-U",{"doi":4985},"10.1002\u002F(SICI)1096-9101(1997)20:4\u003C402::AID-LSM5>3.0.CO;2-U",{"id":26,"text":4987,"url":26,"identifiers":4988},"Jichlinski, 2003, Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer – a multicenter study, J Urol, 170, 226, 10.1097\u002F01.ju.0000060782.52358.04",{"doi":4989},"10.1097\u002F01.ju.0000060782.52358.04",{"id":26,"text":4991,"url":26,"identifiers":4992},"Stenzl, 2010, Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer, J Urol, 184, 1907, 10.1016\u002Fj.juro.2010.06.148",{"doi":4993},"10.1016\u002Fj.juro.2010.06.148",{"id":26,"text":4995,"url":26,"identifiers":4996},"Rink, 2013, Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature, Eur Urol, 64, 624, 10.1016\u002Fj.eururo.2013.07.007",{"doi":4997},"10.1016\u002Fj.eururo.2013.07.007",{"id":26,"text":4999,"url":26,"identifiers":5000},"Nakajima, 2011, Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate, Bioconjug Chem, 22, 1700, 10.1021\u002Fbc2002715",{"doi":5001},"10.1021\u002Fbc2002715",{"id":26,"text":5003,"url":26,"identifiers":5004},"Fukuhara, 2015, Performance of 5-aminolevulinic-acid-based photodynamic diagnosis for radical prostatectomy, BMC Urol, 15, 78, 10.1186\u002Fs12894-015-0073-y",{"doi":5005},"10.1186\u002Fs12894-015-0073-y",{"id":26,"text":5007,"url":26,"identifiers":5008},"Iseki, 2000, Effectiveness of the near-infrared electronic endoscope for diagnosis of the depth of involvement of gastric cancers, Gastrointest Endosc, 52, 755, 10.1067\u002Fmge.2000.110455",{"doi":5009},"10.1067\u002Fmge.2000.110455",{"id":26,"text":5011,"url":26,"identifiers":5012},"Mataki, 2003, Clinical usefulness of a new infrared videoendoscope system for diagnosis of early stage gastric cancer, Gastrointest Endosc, 57, 336, 10.1067\u002Fmge.2003.133",{"doi":5013},"10.1067\u002Fmge.2003.133",{"id":26,"text":5015,"url":26,"identifiers":5016},"Kimura, 2007, Infrared fluorescence endoscopy for the diagnosis of superficial gastric tumors, Gastrointest Endosc, 66, 37, 10.1016\u002Fj.gie.2007.01.009",{"doi":5017},"10.1016\u002Fj.gie.2007.01.009",{"id":26,"text":5019,"url":26,"identifiers":5020},"Gong, 2017, A 3E8.scFv.Cys-IR800 conjugate targeting TAG-72 in an orthotopic colorectal cancer model, Mol Imaging Biol, 10.1007\u002Fs11307-017-1096-4",{"doi":5021},"10.1007\u002Fs11307-017-1096-4",{"id":26,"text":5023,"url":26,"identifiers":5024},"Mitsunaga, 2013, Fluorescence endoscopic detection of murine colitis-associated colon cancer by topically applied enzymatically rapid-activatable probe, Gut, 62, 1179, 10.1136\u002Fgutjnl-2011-301795",{"doi":5025},"10.1136\u002Fgutjnl-2011-301795",{"id":26,"text":5027,"url":26,"identifiers":5028},"Alkalay, 2008, Fluorescence imaging for the demarcation of basal cell carcinoma tumor borders, J Drugs Dermatol, 7, 1033",{},{"id":26,"text":5030,"url":26,"identifiers":5031},"Walker, 2017, Rapid visualization of nonmelanoma skin cancer, J Am Acad Dermatol, 76, 209, 10.1016\u002Fj.jaad.2016.09.008",{"doi":5032},"10.1016\u002Fj.jaad.2016.09.008",{"id":26,"text":5034,"url":26,"identifiers":5035},"van der Vorst, 2014, Intraoperative near-infrared fluorescence imaging of parathyroid adenomas with use of low-dose methylene blue, Head Neck, 36, 853, 10.1002\u002Fhed.23384",{"doi":5036},"10.1002\u002Fhed.23384",{"id":26,"text":5038,"url":26,"identifiers":5039},"Tobis, 2011, Near infrared fluorescence imaging with robotic assisted laparoscopic partial nephrectomy: initial clinical experience for renal cortical tumors, J Urol, 186, 47, 10.1016\u002Fj.juro.2011.02.2701",{"doi":5040},"10.1016\u002Fj.juro.2011.02.2701",{"id":26,"text":5042,"url":26,"identifiers":5043},"Morita, 2014, Application of indocyanine green-fluorescence imaging to full-thickness cholecystectomy, Asian J Endosc Surg, 7, 193, 10.1111\u002Fases.12083",{"doi":5044},"10.1111\u002Fases.12083",{"id":26,"text":5046,"url":26,"identifiers":5047},"Schlottmann, 2017, Evaluation of gastric conduit perfusion during esophagectomy with indocyanine green fluorescence imaging, J Laparoendosc Adv Surg Tech A, 27, 1305, 10.1089\u002Flap.2017.0359",{"doi":5048},"10.1089\u002Flap.2017.0359",{"id":26,"text":5050,"url":26,"identifiers":5051},"Kim, 2017, Real-time vessel navigation using indocyanine green fluorescence during robotic or laparoscopic gastrectomy for gastric cancer, J Gastric Cancer, 17, 145, 10.5230\u002Fjgc.2017.17.e17",{"doi":5052},"10.5230\u002Fjgc.2017.17.e17",{"id":26,"text":5054,"url":26,"identifiers":5055},"Manny, 2013, Robotic partial adrenalectomy using indocyanine green dye with near-infrared imaging: the initial clinical experience, Urology, 82, 738, 10.1016\u002Fj.urology.2013.03.074",{"doi":5056},"10.1016\u002Fj.urology.2013.03.074",{"id":26,"text":5058,"url":26,"identifiers":5059},"Colvin, 2016, The utility of indocyanine green fluorescence imaging during robotic adrenalectomy, J Surg Oncol, 114, 153, 10.1002\u002Fjso.24296",{"doi":5060},"10.1002\u002Fjso.24296",{"id":26,"text":5062,"url":26,"identifiers":5063},"Nishiyama, 2012, Endoscopic indocyanine green video angiography in aneurysm surgery: an innovative method for intraoperative assessment of blood flow in vasculature hidden from microscopic view, J Neurosurg, 117, 302, 10.3171\u002F2012.5.jns112300",{"doi":5064},"10.3171\u002F2012.5.jns112300",{"id":26,"text":5066,"url":26,"identifiers":5067},"Bruneau, 2013, Endoscope-integrated ICG technology: first application during intracranial aneurysm surgery, Neurosurg Rev, 36, 77, 10.1007\u002Fs10143-012-0419-9",{"doi":5068},"10.1007\u002Fs10143-012-0419-9",{"id":26,"text":5070,"url":26,"identifiers":5071},"Mielke, 2014, Comparison of intraoperative microscopic and endoscopic ICG angiography in aneurysm surgery, Neurosurgery, 10, 418, 10.1227\u002Fneu.0000000000000345",{"doi":5072},"10.1227\u002Fneu.0000000000000345",{"id":26,"text":5074,"url":26,"identifiers":5075},"Litvack, 2012, Indocyanine green fluorescence endoscopy for visual differentiation of pituitary tumor from surrounding structures, J Neurosurg, 116, 935, 10.3171\u002F2012.1.jns11601",{"doi":5076},"10.3171\u002F2012.1.jns11601",{"id":26,"text":5078,"url":26,"identifiers":5079},"Hide, 2015, Usefulness of the indocyanine green fluorescence endoscope in endonasal transsphenoidal surgery, J Neurosurg, 122, 1185, 10.3171\u002F2014.9.jns14599",{"doi":5080},"10.3171\u002F2014.9.jns14599",{"id":26,"text":5082,"url":26,"identifiers":5083},"Simal Julian, 2016, Endo ICG videoangiography: localizing the carotid artery in skull-base endonasal approaches, Acta Neurochir (Wien), 158, 1351, 10.1007\u002Fs00701-016-2830-4",{"doi":5084},"10.1007\u002Fs00701-016-2830-4",{"id":26,"text":5086,"url":26,"identifiers":5087},"Wachter, 2013, Indocyanine green angiography in endoscopic third ventriculostomy, Neurosurgery, 73, ons67, 10.1227\u002FNEU.0b013e318285b846",{"doi":5088},"10.1227\u002FNEU.0b013e318285b846",{"id":26,"text":5090,"url":26,"identifiers":5091},"Foersch, 2012, Confocal laser endomicroscopy for diagnosis and histomorphologic imaging of brain tumors in vivo, PLoS One, 7, e41760, 10.1371\u002Fjournal.pone.0041760",{"doi":5092},"10.1371\u002Fjournal.pone.0041760",{"id":26,"text":5094,"url":26,"identifiers":5095},"Tsuzuki, 2014, Application of indocyanine green (ICG) fluorescence for endoscopic biopsy of intraventricular tumors, Childs Nerv Syst, 30, 723, 10.1007\u002Fs00381-013-2266-6",{"doi":5096},"10.1007\u002Fs00381-013-2266-6",{"id":26,"text":5098,"url":26,"identifiers":5099},"Schmidt, 2017, Feasibility of real-time near-infrared indocyanine green fluorescence endoscopy for the evaluation of mucosal head and neck lesions, Head Neck, 39, 234, 10.1002\u002Fhed.24570",{"doi":5100},"10.1002\u002Fhed.24570",{"id":26,"text":5102,"url":26,"identifiers":5103},"Lee, 2000, Randomized comparative study of indocyanine green and India ink for colonic tattooing: an animal survival study, J Clin Gastroenterol, 31, 233, 10.1097\u002F00004836-200010000-00010",{"doi":5104},"10.1097\u002F00004836-200010000-00010",{"id":26,"text":5106,"url":26,"identifiers":5107},"Miyoshi, 2009, Surgical usefulness of indocyanine green as an alternative to India ink for endoscopic marking, Surg Endosc, 23, 347, 10.1007\u002Fs00464-008-9938-4",{"doi":5108},"10.1007\u002Fs00464-008-9938-4",{"id":26,"text":5110,"url":26,"identifiers":5111},"Watanabe, 2009, Colonic tattooing using fluorescence imaging with light-emitting diode-activated indocyanine green: a feasibility study, Surg Today, 39, 214, 10.1007\u002Fs00595-008-3849-9",{"doi":5112},"10.1007\u002Fs00595-008-3849-9",{"id":26,"text":5114,"url":26,"identifiers":5115},"Gray, 2012, Compact fluorescence and white light imaging system for intraoperative visualization of nerves, Proc SPIE Int Soc Opt Eng, 8207, 10.1117\u002F12.905354",{"doi":5116},"10.1117\u002F12.905354",{"id":26,"text":5118,"url":26,"identifiers":5119},"Keereweer, 2012, Dual wavelength tumor targeting for detection of hypopharyngeal cancer using near-infrared optical imaging in an animal model, Int J Cancer, 131, 1633, 10.1002\u002Fijc.27430",{"doi":5120},"10.1002\u002Fijc.27430",{"id":26,"text":5122,"url":26,"identifiers":5123},"Wapnir, 2014, Intraoperative imaging of nipple perfusion patterns and ischemic complications in nipple-sparing mastectomies, Ann Surg Oncol, 21, 100, 10.1245\u002Fs10434-013-3214-0",{"doi":5124},"10.1245\u002Fs10434-013-3214-0",{"id":26,"text":5126,"url":26,"identifiers":5127},"Richards-Kortum, 1996, Quantitative optical spectroscopy for tissue diagnosis, Annu Rev Phys Chem, 47, 555, 10.1146\u002Fannurev.physchem.47.1.555",{"doi":5128},"10.1146\u002Fannurev.physchem.47.1.555",{"id":26,"text":5130,"url":26,"identifiers":5131},"Hilderbrand, 2010, Near-infrared fluorescence: application to in vivo molecular imaging, Curr Opin Chem Biol, 14, 71, 10.1016\u002Fj.cbpa.2009.09.029",{"doi":5132},"10.1016\u002Fj.cbpa.2009.09.029",{"id":26,"text":5134,"url":26,"identifiers":5135},"Kobayashi, 2010, New strategies for fluorescent probe design in medical diagnostic imaging, Chem Rev, 110, 2620, 10.1021\u002Fcr900263j",{"doi":5136},"10.1021\u002Fcr900263j",{"id":26,"text":5138,"url":26,"identifiers":5139},"Chance, 1998, Near-infrared images using continuous, phase-modulated, and pulsed light with quantitation of blood and blood oxygenation, Ann N Y Acad Sci, 838, 29, 10.1111\u002Fj.1749-6632.1998.tb08185.x",{"doi":5140},"10.1111\u002Fj.1749-6632.1998.tb08185.x",{"id":26,"text":5142,"url":26,"identifiers":5143},"Bouvet, 2011, Glowing tumors make for better detection and resection, Sci Transl Med, 3, 110fs110, 10.1126\u002Fscitranslmed.3003375",{"doi":5144},"10.1126\u002Fscitranslmed.3003375",{"id":26,"text":5146,"url":26,"identifiers":5147},"Moody, 1999, Non-covalent labeling of human serum albumin with indocyanine green: a study by capillary electrophoresis with diode laser-induced fluorescence detection, J Chromatogr B Biomed Sci Appl, 729, 55, 10.1016\u002FS0378-4347(99)00121-8",{"doi":5148},"10.1016\u002FS0378-4347(99)00121-8",{"id":26,"text":5150,"url":26,"identifiers":5151},"Ogawa, 2009, In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green, Cancer Res, 69, 1268, 10.1158\u002F0008-5472.can-08-3116",{"doi":5152},"10.1158\u002F0008-5472.can-08-3116",{"id":26,"text":5154,"url":26,"identifiers":5155},"Tanaka, 2009, Real-time assessment of cardiac perfusion, coronary angiography, and acute intravascular thrombi using dual-channel near-infrared fluorescence imaging, J Thorac Cardiovasc Surg, 138, 133, 10.1016\u002Fj.jtcvs.2008.09.082",{"doi":5156},"10.1016\u002Fj.jtcvs.2008.09.082",{"id":26,"text":5158,"url":26,"identifiers":5159},"Deja, 2010, Changes in hepatic blood flow during whole body hyperthermia, Int J Hyperthermia, 26, 95, 10.3109\u002F02656730903250574",{"doi":5160},"10.3109\u002F02656730903250574",{"id":26,"text":5162,"url":26,"identifiers":5163},"Kang, 2009, Polypoidal choroidal vasculopathy and late geographic hyperfluorescence on indocyanine green angiography, Br J Ophthalmol, 93, 759, 10.1136\u002Fbjo.2008.145862",{"doi":5164},"10.1136\u002Fbjo.2008.145862",{"id":26,"text":5166,"url":26,"identifiers":5167},"Alford, 2009, Toxicity of organic fluorophores used in molecular imaging: literature review, Mol Imaging, 8, 341, 10.2310\u002F7290.2009.00031",{"doi":5168},"10.2310\u002F7290.2009.00031",{"id":26,"text":5170,"url":26,"identifiers":5171},"Kudszus, 2010, Intraoperative laser fluorescence angiography in colorectal surgery: a noninvasive analysis to reduce the rate of anastomotic leakage, Langenbecks Arch Surg, 395, 1025, 10.1007\u002Fs00423-010-0699-x",{"doi":5172},"10.1007\u002Fs00423-010-0699-x",{"id":26,"text":5174,"url":26,"identifiers":5175},"Schaafsma, 2011, The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for image-guided oncologic surgery, J Surg Oncol, 104, 323, 10.1002\u002Fjso.21943",{"doi":5176},"10.1002\u002Fjso.21943",{"id":26,"text":5178,"url":26,"identifiers":5179},"Shimizu, 1995, New method for measuring ICG Rmax with a clearance meter, World J Surg, 19, 113, 10.1007\u002FBF00316992",{"doi":5180},"10.1007\u002FBF00316992",{"id":26,"text":5182,"url":26,"identifiers":5183},"Kung, 2017, Current concepts in the surgical management of lymphedema, Plast Reconstr Surg, 139, 1003e, 10.1097\u002Fprs.0000000000003218",{"doi":5184},"10.1097\u002Fprs.0000000000003218",{"id":26,"text":5186,"url":26,"identifiers":5187},"Champagne, 2004, Outcome of aggressive surveillance colonoscopy in ruptured abdominal aortic aneurysm, J Vasc Surg, 39, 792, 10.1016\u002Fj.jvs.2003.12.002",{"doi":5188},"10.1016\u002Fj.jvs.2003.12.002",{"id":26,"text":5190,"url":26,"identifiers":5191},"Schirmer, 2011, Lest we forget you – methylene blue…, Neurobiol Aging, 32, 2325.e7, 10.1016\u002Fj.neurobiolaging.2010.12.012",{"doi":5192},"10.1016\u002Fj.neurobiolaging.2010.12.012",{"id":26,"text":5194,"url":26,"identifiers":5195},"Ashurst, 2011, Methemoglobinemia: a systematic review of the pathophysiology, detection, and treatment, Del Med J, 83, 203",{},{"id":26,"text":5197,"url":26,"identifiers":5198},"Richards, 2011, Evaluation of methylene blue, thiamine, and\u002For albumin in the prevention of ifosfamide-related neurotoxicity, J Oncol Pharm Pract, 17, 372, 10.1177\u002F1078155210385159",{"doi":5199},"10.1177\u002F1078155210385159",{"id":26,"text":5201,"url":26,"identifiers":5202},"Ginimuge, 2010, Methylene blue: revisited, J Anaesthesiol Clin Pharmacol, 26, 517, 10.4103\u002F0970-9185.74599",{"doi":5203},"10.4103\u002F0970-9185.74599",{"id":26,"text":5205,"url":26,"identifiers":5206},"Melo, 1986, The physicochemical state of protoporphyrin IX in aqueous solution investigated by fluorescence and light scattering, Biophys Chem, 25, 99, 10.1016\u002F0301-4622(86)85070-0",{"doi":5207},"10.1016\u002F0301-4622(86)85070-0",{"id":26,"text":5209,"url":26,"identifiers":5210},"Montcel, 2013, Two-peaked 5-ALA-induced PpIX fluorescence emission spectrum distinguishes glioblastomas from low grade gliomas and infiltrative component of glioblastomas, Biomed Opt Express, 4, 548, 10.1364\u002Fboe.4.000548",{"doi":5211},"10.1364\u002Fboe.4.000548",{"id":26,"text":5213,"url":26,"identifiers":5214},"Acerbi, 2013, Fluorescein-guided surgery for grade IV gliomas with a dedicated filter on the surgical microscope: preliminary results in 12 cases, Acta Neurochir (Wien), 155, 1277, 10.1007\u002Fs00701-013-1734-9",{"doi":5215},"10.1007\u002Fs00701-013-1734-9",{"id":26,"text":5217,"url":26,"identifiers":5218},"Acerbi, 2014, Is fluorescein-guided technique able to help in resection of high-grade gliomas?, Neurosurg Focus, 36, E5, 10.3171\u002F2013.11.focus13487",{"doi":5219},"10.3171\u002F2013.11.focus13487",{"id":26,"text":5221,"url":26,"identifiers":5222},"Diaz, 2015, Study of the biodistribution of fluorescein in glioma-infiltrated mouse brain and histopathological correlation of intraoperative findings in high-grade gliomas resected under fluorescein fluorescence guidance, J Neurosurg, 122, 1360, 10.3171\u002F2015.2.jns132507",{"doi":5223},"10.3171\u002F2015.2.jns132507",{"id":26,"text":5225,"url":26,"identifiers":5226},"Schwake, 2015, Simultaneous fluorescein sodium and 5-ALA in fluorescence-guided glioma surgery, Acta Neurochir (Wien), 157, 877, 10.1007\u002Fs00701-015-2401-0",{"doi":5227},"10.1007\u002Fs00701-015-2401-0",{"id":26,"text":5229,"url":26,"identifiers":5230},"Moore, 1947, Fluorescein as an agent in the differentiation of normal and malignant tissues, Science, 106, 130, 10.1126\u002Fscience.106.2745.130-a",{"doi":5231},"10.1126\u002Fscience.106.2745.130-a",{"id":26,"text":5233,"url":26,"identifiers":5234},"Te Velde, 2010, The use of fluorescent dyes and probes in surgical oncology, Eur J Surg Oncol, 36, 6, 10.1016\u002Fj.ejso.2009.10.014",{"doi":5235},"10.1016\u002Fj.ejso.2009.10.014",{"id":26,"text":5237,"url":26,"identifiers":5238},"Gioux, 2010, Image-guided surgery using invisible near-infrared light: fundamentals of clinical translation, Mol Imaging, 9, 237, 10.2310\u002F7290.2010.00034",{"doi":5239},"10.2310\u002F7290.2010.00034",{"id":26,"text":5241,"url":26,"identifiers":5242},"Terwisscha van Scheltinga, 2011, Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies, J Nucl Med, 52, 1778, 10.2967\u002Fjnumed.111.092833",{"doi":5243},"10.2967\u002Fjnumed.111.092833",{"id":26,"text":5245,"url":26,"identifiers":5246},"Sano, 2012, In vivo breast cancer characterization imaging using two monoclonal antibodies activatably labeled with near infrared fluorophores, Breast Cancer Res, 14, R61, 10.1186\u002Fbcr3167",{"doi":5247},"10.1186\u002Fbcr3167",{"id":26,"text":5249,"url":26,"identifiers":5250},"Oliveira, 2012, Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody, Mol Imaging, 11, 33, 10.2310\u002F7290.2011.00025",{"doi":5251},"10.2310\u002F7290.2011.00025",{"id":26,"text":5253,"url":26,"identifiers":5254},"Blum, 2007, Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes, Nat Chem Biol, 3, 668, 10.1038\u002Fnchembio.2007.26",{"doi":5255},"10.1038\u002Fnchembio.2007.26",{"id":26,"text":5257,"url":26,"identifiers":5258},"Blum, 2009, Comparative assessment of substrates and activity based probes as tools for non-invasive optical imaging of cysteine protease activity, PLoS One, 4, e6374, 10.1371\u002Fjournal.pone.0006374",{"doi":5259},"10.1371\u002Fjournal.pone.0006374",{"id":26,"text":5261,"url":26,"identifiers":5262},"Olson, 2010, Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases, Proc Natl Acad Sci U S A, 107, 4311, 10.1073\u002Fpnas.0910283107",{"doi":5263},"10.1073\u002Fpnas.0910283107",{"id":26,"text":5265,"url":26,"identifiers":5266},"Deu, 2012, New approaches for dissecting protease functions to improve probe development and drug discovery, Nat Struct Mol Biol, 19, 9, 10.1038\u002Fnsmb.2203",{"doi":5267},"10.1038\u002Fnsmb.2203",{"id":26,"text":5269,"url":26,"identifiers":5270},"Olson, 2012, In vivo fluorescence imaging of atherosclerotic plaques with activatable cell-penetrating peptides targeting thrombin activity, Integr Biol (Camb), 4, 595, 10.1039\u002Fc2ib00161f",{"doi":5271},"10.1039\u002Fc2ib00161f",{"id":26,"text":5273,"url":26,"identifiers":5274},"Lu, 2002, Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors, Cancer Immunol Immunother, 51, 153, 10.1007\u002Fs00262-002-0266-6",{"doi":5275},"10.1007\u002Fs00262-002-0266-6",{"id":26,"text":5277,"url":26,"identifiers":5278},"Leamon, 1991, Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis, Proc Natl Acad Sci U S A, 88, 5572, 10.1073\u002Fpnas.88.13.5572",{"doi":5279},"10.1073\u002Fpnas.88.13.5572",{"id":26,"text":5281,"url":26,"identifiers":5282},"Low, 2008, Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases, Acc Chem Res, 41, 120, 10.1021\u002Far7000815",{"doi":5283},"10.1021\u002Far7000815",{"id":26,"text":5285,"url":26,"identifiers":5286},"Weitman, 1992, Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues, Cancer Res, 52, 3396",{},{"id":26,"text":5288,"url":26,"identifiers":5289},"O’Shannessy, 2012, Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance, Oncotarget, 3, 414, 10.18632\u002Foncotarget.489",{"doi":5290},"10.18632\u002Foncotarget.489",{"id":26,"text":5292,"url":26,"identifiers":5293},"Ogawa, 2009, H-type dimer formation of fluorophores: a mechanism for activatable, in vivo optical molecular imaging, ACS Chem Biol, 4, 535, 10.1021\u002Fcb900089j",{"doi":5294},"10.1021\u002Fcb900089j",{"id":26,"text":5296,"url":26,"identifiers":5297},"Ogawa, 2009, Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer metastases, Mol Pharm, 6, 386, 10.1021\u002Fmp800115t",{"doi":5298},"10.1021\u002Fmp800115t",{"id":26,"text":5300,"url":26,"identifiers":5301},"Ogawa, 2009, In vivo target-specific activatable near-infrared optical labeling of humanized monoclonal antibodies, Mol Cancer Ther, 8, 232, 10.1158\u002F1535-7163.mct-08-0862",{"doi":5302},"10.1158\u002F1535-7163.mct-08-0862",{"id":26,"text":5304,"url":26,"identifiers":5305},"Hanaoka, 2015, Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy, Mol Pharm, 12, 2151, 10.1021\u002Facs.molpharmaceut.5b00132",{"doi":5306},"10.1021\u002Facs.molpharmaceut.5b00132",{"id":26,"text":5308,"url":26,"identifiers":5309},"Sato, 2015, Near infrared photoimmunotherapy in the treatment of pleural disseminated NSCLC: preclinical experience, Theranostics, 5, 698, 10.7150\u002Fthno.11559",{"doi":5310},"10.7150\u002Fthno.11559",{"id":26,"text":5312,"url":26,"identifiers":5313},"Nagaya, 2016, Near infrared photoimmunotherapy of B-cell lymphoma, Mol Oncol, 10, 1404, 10.1016\u002Fj.molonc.2016.07.010",{"doi":5314},"10.1016\u002Fj.molonc.2016.07.010",{"id":26,"text":5316,"url":26,"identifiers":5317},"Nagaya, 2016, Near infrared photoimmunotherapy with an anti-mesothelin antibody, Oncotarget, 7, 23361, 10.18632\u002Foncotarget.8025",{"doi":5318},"10.18632\u002Foncotarget.8025",{"id":26,"text":5320,"url":26,"identifiers":5321},"Nagaya, 2017, Near-infrared photoimmunotherapy targeting prostate cancer with prostate-specific membrane antigen (PSMA) antibody, Mol Cancer Res, 15, 1153, 10.1158\u002F1541-7786.mcr-17-0164",{"doi":5322},"10.1158\u002F1541-7786.mcr-17-0164",{"id":26,"text":5324,"url":26,"identifiers":5325},"Kobayashi, 2011, Target-cancer-cell-specific activatable fluorescence imaging probes: rational design and in vivo applications, Acc Chem Res, 44, 83, 10.1021\u002Far1000633",{"doi":5326},"10.1021\u002Far1000633",{"id":26,"text":5328,"url":26,"identifiers":5329},"Chi, 2015, Increased precision of orthotopic and metastatic breast cancer surgery guided by matrix metalloproteinase-activatable near-infrared fluorescence probes, Sci Rep, 5, 14197, 10.1038\u002Fsrep14197",{"doi":5330},"10.1038\u002Fsrep14197",{"id":26,"text":5332,"url":26,"identifiers":5333},"Weissleder, 2001, A clearer vision for in vivo imaging, Nat Biotechnol, 19, 316, 10.1038\u002F86684",{"doi":5334},"10.1038\u002F86684",{"id":26,"text":5336,"url":26,"identifiers":5337},"Sheth, 2009, Improved detection of ovarian cancer metastases by intraoperative quantitative fluorescence protease imaging in a pre-clinical model, Gynecol Oncol, 112, 616, 10.1016\u002Fj.ygyno.2008.11.018",{"doi":5338},"10.1016\u002Fj.ygyno.2008.11.018",{"id":26,"text":5340,"url":26,"identifiers":5341},"Urano, 2009, Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes, Nat Med, 15, 104, 10.1038\u002Fnm.1854",{"doi":5342},"10.1038\u002Fnm.1854",{"id":26,"text":5344,"url":26,"identifiers":5345},"Mieog, 2011, Image-guided tumor resection using real-time near-infrared fluorescence in a syngeneic rat model of primary breast cancer, Breast Cancer Res Treat, 128, 679, 10.1007\u002Fs10549-010-1130-6",{"doi":5346},"10.1007\u002Fs10549-010-1130-6",{"id":26,"text":5348,"url":26,"identifiers":5349},"Ogawa, 2009, Dual-modality molecular imaging using antibodies labeled with activatable fluorescence and a radionuclide for specific and quantitative targeted cancer detection, Bioconjug Chem, 20, 2177, 10.1021\u002Fbc900362k",{"doi":5350},"10.1021\u002Fbc900362k",{"id":26,"text":5352,"url":26,"identifiers":5353},"Kobayashi, 2016, Monoclonal antibody-based optical molecular imaging probes; considerations and caveats in chemistry, biology and pharmacology, Curr Opin Chem Biol, 33, 32, 10.1016\u002Fj.cbpa.2016.05.015",{"doi":5354},"10.1016\u002Fj.cbpa.2016.05.015",{"id":26,"text":5356,"url":26,"identifiers":5357},"Hama, 2007, A target cell-specific activatable fluorescence probe for in vivo molecular imaging of cancer based on a self-quenched avidin-rhodamine conjugate, Cancer Res, 67, 2791, 10.1158\u002F0008-5472.can-06-3315",{"doi":5358},"10.1158\u002F0008-5472.can-06-3315",{"id":26,"text":5360,"url":26,"identifiers":5361},"Mahmood, 1999, Near-infrared optical imaging of protease activity for tumor detection, Radiology, 213, 866, 10.1148\u002Fradiology.213.3.r99dc14866",{"doi":5362},"10.1148\u002Fradiology.213.3.r99dc14866",{"id":26,"text":5364,"url":26,"identifiers":5365},"Tung, 1999, Preparation of a cathepsin D sensitive near-infrared fluorescence probe for imaging, Bioconjug Chem, 10, 892, 10.1021\u002Fbc990052h",{"doi":5366},"10.1021\u002Fbc990052h",{"id":26,"text":5368,"url":26,"identifiers":5369},"Urano, 2012, Novel live imaging techniques of cellular functions and in vivo tumors based on precise design of small molecule-based ‘activatable’ fluorescence probes, Curr Opin Chem Biol, 16, 602, 10.1016\u002Fj.cbpa.2012.10.023",{"doi":5370},"10.1016\u002Fj.cbpa.2012.10.023",{"id":26,"text":5372,"url":26,"identifiers":5373},"Lotan, 1988, Lectins in cancer cells, Ann N Y Acad Sci, 551, 385, 10.1111\u002Fj.1749-6632.1988.tb22372.x",{"doi":5374},"10.1111\u002Fj.1749-6632.1988.tb22372.x",{"id":26,"text":5376,"url":26,"identifiers":5377},"Ang, 2014, “Turn-on” fluorescence probe integrated polymer nanoparticles for sensing biological thiol molecules, Sci Rep, 4, 7057, 10.1038\u002Fsrep07057",{"doi":5378},"10.1038\u002Fsrep07057",{"id":26,"text":5380,"url":26,"identifiers":5381},"Shimizu, 2014, Micelle-based activatable probe for in vivo near-infrared optical imaging of cancer biomolecules, Nanomedicine, 10, 187, 10.1016\u002Fj.nano.2013.06.009",{"doi":5382},"10.1016\u002Fj.nano.2013.06.009",{"id":26,"text":5384,"url":26,"identifiers":5385},"Feng, 2016, Dual-responsive carbon dots for tumor extracellular microenvironment triggered targeting and enhanced anticancer drug delivery, ACS Appl Mater Interfaces, 8, 18732, 10.1021\u002Facsami.6b06695",{"doi":5386},"10.1021\u002Facsami.6b06695",{"id":26,"text":5388,"url":26,"identifiers":5389},"Johansson, 2003, Intramolecular dimers: a new design strategy for fluorescence-quenched probes, Chemistry, 9, 3466, 10.1002\u002Fchem.200304941",{"doi":5390},"10.1002\u002Fchem.200304941",{"id":26,"text":5392,"url":26,"identifiers":5393},"Urano, 2005, Evolution of fluorescein as a platform for finely tunable fluorescence probes, J Am Chem Soc, 127, 4888, 10.1021\u002Fja043919h",{"doi":5394},"10.1021\u002Fja043919h",{"id":26,"text":5396,"url":26,"identifiers":5397},"Mohamed, 2006, Cysteine cathepsins: multifunctional enzymes in cancer, Nat Rev Cancer, 6, 764, 10.1038\u002Fnrc1949",{"doi":5398},"10.1038\u002Fnrc1949",{"id":26,"text":5400,"url":26,"identifiers":5401},"Tung, 2000, In vivo imaging of proteolytic enzyme activity using a novel molecular reporter, Cancer Res, 60, 4953",{},{"id":26,"text":5403,"url":26,"identifiers":5404},"Chen, 2005, Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction, Circulation, 111, 1800, 10.1161\u002F01.cir.0000160936.91849.9f",{"doi":5405},"10.1161\u002F01.cir.0000160936.91849.9f",{"id":26,"text":5407,"url":26,"identifiers":5408},"Sato, 2015, A pilot study of fluorescent imaging of colorectal tumors using a gamma-glutamyl-transpeptidase-activatable fluorescent probe, Digestion, 91, 70, 10.1159\u002F000369367",{"doi":5409},"10.1159\u002F000369367",{"id":26,"text":5411,"url":26,"identifiers":5412},"Ueo, 2015, Rapid intraoperative visualization of breast lesions with gamma-glutamyl hydroxymethyl rhodamine green, Sci Rep, 5, 12080, 10.1038\u002Fsrep12080",{"doi":5413},"10.1038\u002Fsrep12080",{"id":26,"text":5415,"url":26,"identifiers":5416},"Kawakubo, 2016, Feasibility of using an enzymatically activatable fluorescence probe for the rapid evaluation of pancreatic tissue obtained using endoscopic ultrasound-guided fine needle aspiration: a pilot study, Mol Imaging Biol, 18, 463, 10.1007\u002Fs11307-015-0898-5",{"doi":5417},"10.1007\u002Fs11307-015-0898-5",{"id":26,"text":5419,"url":26,"identifiers":5420},"Asanuma, 2015, Sensitive beta-galactosidase-targeting fluorescence probe for visualizing small peritoneal metastatic tumours in vivo, Nat Commun, 6, 6463, 10.1038\u002Fncomms7463",{"doi":5421},"10.1038\u002Fncomms7463",{"id":26,"text":5423,"url":26,"identifiers":5424},"Sakabe, 2013, Rational design of highly sensitive fluorescence probes for protease and glycosidase based on precisely controlled spirocyclization, J Am Chem Soc, 135, 409, 10.1021\u002Fja309688m",{"doi":5425},"10.1021\u002Fja309688m",{"id":26,"text":5427,"url":26,"identifiers":5428},"Shen, 2017, A near-infrared, wavelength-shiftable, turn-on fluorescent probe for the detection and imaging of cancer tumor cells, ACS Chem Biol, 12, 1121, 10.1021\u002Facschembio.6b01094",{"doi":5429},"10.1021\u002Facschembio.6b01094",{"id":5431,"createTime":5432,"updateTime":5432,"relativeEntities":5433,"slug":5434,"properties":5435,"entityType":772,"verifyStatus":25,"verifyTime":5432,"verifyNote":773,"syncStatus":28,"languages":5450,"translateLanguages":26,"viewCount":36,"primaryUrl":5451,"fullTextUrl":26,"authors":5452,"publicationType":843,"publisherRelationship":5541,"citationCount":5574,"citationInfo":5575,"publishDate":26,"publishYear":26,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":5577,"isForceReanalyzing":1390},"f2f90c5c-52bb-4922-99c4-7c9f00d05e51","2024-10-03T00:53:20.659+00:00",[],"The-Role-of-the-Extracellular-Matrix-and-Its-Molecular-and-Cellular-Regulators-in-Cancer-Cell-Plasticity",{"mag":5436,"keywords":5438,"pmc":5439,"openalex":5441,"abstract":5443,"title":5444,"pm":5446,"doi":5448},{"VOID":5437},"2897285216",{},{"VOID":5440},"6189298",{"VOID":5442},"W2897285216",{},{"EN":5445},"The Role of the Extracellular Matrix and Its Molecular and Cellular Regulators in Cancer Cell Plasticity",{"VOID":5447},"30356678",{"VOID":5449},"10.3389\u002Ffonc.2018.00431",[102],"https:\u002F\u002Fwww.frontiersin.org\u002Farticle\u002F10.3389\u002Ffonc.2018.00431\u002Ffull",[5453,5484,5501,5518],{"id":5454,"sortIndex":114,"researcher":26,"roles":5455,"affiliations":5456,"properties":5477},"10784eb2-0fba-4413-bae2-d8d2bbc71fc8",[],[5457,5467],{"id":5458,"sortIndex":36,"affiliation":5459,"properties":26},"4e2a7421-2d12-4fc1-af4c-2da273d0a087",{"id":5460,"createTime":5461,"updateTime":5461,"relativeEntities":5462,"slug":5463,"properties":5464,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"6f22c8b8-c1c8-415f-a5ea-c1ac904dbb48","2024-10-03T00:53:20.696+00:00",[],"Adelaide-Medical-School-Faculty-of-Health-Sciences-University-of-Adelaide-Australia",{"title":5465},{"EN":5466},"Adelaide Medical School, Faculty of Health Sciences, University of Adelaide, Australia",{"id":5468,"sortIndex":115,"affiliation":5469,"properties":26},"a6626f5a-96ff-4bda-a3c2-993ee2e6a0de",{"id":5470,"createTime":5471,"updateTime":5471,"relativeEntities":5472,"slug":5473,"properties":5474,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"d1465f9e-5df4-47f1-879c-33fe94501a6b","2024-10-03T00:53:20.676+00:00",[],"Centre-for-Cancer-Biology-SA-Pathology-and-University-of-South-Australia-Australia",{"title":5475},{"EN":5476},"Centre for Cancer Biology, SA Pathology and University of South Australia, Australia",{"openalex":5478,"orcid":5480,"title":5482},{"VOID":5479},"A5032213369",{"VOID":5481},"https:\u002F\u002Forcid.org\u002F0000-0002-9527-2740",{"EN":5483},"Stuart M. Pitson",{"id":5485,"sortIndex":36,"researcher":26,"roles":5486,"affiliations":5487,"properties":5494},"251b0d76-1f6d-465e-ac68-8160a0d65c58",[],[5488],{"id":5489,"sortIndex":36,"affiliation":5490,"properties":26},"67e37c0b-9343-4d53-9f62-8853352385e5",{"id":5470,"createTime":5471,"updateTime":5471,"relativeEntities":5491,"slug":5473,"properties":5492,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":5493},{"EN":5476},{"openalex":5495,"orcid":5497,"title":5499},{"VOID":5496},"A5063301691",{"VOID":5498},"https:\u002F\u002Forcid.org\u002F0000-0003-1976-7765",{"EN":5500},"Valentina Poltavets",{"id":5502,"sortIndex":115,"researcher":26,"roles":5503,"affiliations":5504,"properties":5511},"ab029a72-a1ff-4c8b-b039-fc4bded9d946",[],[5505],{"id":5506,"sortIndex":36,"affiliation":5507,"properties":26},"a4aeb615-a135-447f-b8fc-1e416a446426",{"id":5470,"createTime":5471,"updateTime":5471,"relativeEntities":5508,"slug":5473,"properties":5509,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":5510},{"EN":5476},{"openalex":5512,"orcid":5514,"title":5516},{"VOID":5513},"A5077160235",{"VOID":5515},"https:\u002F\u002Forcid.org\u002F0000-0002-0599-7378",{"EN":5517},"Marina Kochetkova",{"id":5519,"sortIndex":59,"researcher":26,"roles":5520,"affiliations":5521,"properties":5534},"722e7df5-bf79-427f-acad-d790ea7956a3",[],[5522,5528],{"id":5523,"sortIndex":115,"affiliation":5524,"properties":26},"0019bd11-39ca-4b92-a1e3-e1e238c879e7",{"id":5470,"createTime":5471,"updateTime":5471,"relativeEntities":5525,"slug":5473,"properties":5526,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":5527},{"EN":5476},{"id":5529,"sortIndex":36,"affiliation":5530,"properties":26},"631396b1-13f7-44c0-9567-98fed81b51e6",{"id":5460,"createTime":5461,"updateTime":5461,"relativeEntities":5531,"slug":5463,"properties":5532,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":5533},{"EN":5466},{"openalex":5535,"orcid":5537,"title":5539},{"VOID":5536},"A5050393309",{"VOID":5538},"https:\u002F\u002Forcid.org\u002F0000-0001-7880-6379",{"EN":5540},"Michael S. Samuel",{"url":26,"publisher":5542,"properties":5572},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":5543,"slug":663,"properties":5544,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":5550,"manageAffiliations":5551,"indexDatabases":5552,"url":742,"thumbnailPath":26,"statistic":5567,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"country":5545,"issn":5546,"introduce":5547,"eissn":5548,"title":5549},{"VOID":666},{"VOID":668},{"EN":670},{"VOID":668},{"EN":673},[],[],[5553,5560],{"id":704,"indexDatabase":5554,"url":719,"indexYears":26,"academicFieldIds":5559,"indexDatabaseRanking":26},{"id":706,"createTime":707,"updateTime":708,"relativeEntities":5555,"label":5556,"description":5557,"key":715,"publicationTags":5558,"standard":26},[],{"EN":711,"VI":711},{"VI":713,"EN":714},[717,718],[721],{"id":723,"indexDatabase":5561,"url":736,"indexYears":737,"academicFieldIds":5566,"indexDatabaseRanking":741},{"id":725,"createTime":726,"updateTime":727,"relativeEntities":5562,"label":5563,"description":5564,"key":733,"publicationTags":5565,"standard":26},[],{"EN":730,"VI":730},{"EN":730,"VI":732},[735],[739,740],{"impactFactor":36,"impactFactorByYear":5568,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":115,"totalPublicationByYear":5569,"totalCitation":158,"totalCitationByYear":5570,"totalCitationPerPublication":158,"totalCitationPerPublicationByYear":5571,"hindexLast5Year":115,"hindex":115},{},{"2021":115},{"2021":158},{"2021":158},{"volume":5573},{"VOID":877},304,{"total":5574,"publishYear":26,"statisticByYear":5576},{"2018":59,"2019":241,"2020":623,"2021":254,"2022":249,"2023":1547,"2024":237},[5578,5582,5586,5590,5594,5598,5602,5606,5610,5614,5618,5622,5626,5630,5634,5638,5642,5646,5650,5654,5658,5662,5666,5670,5674,5678,5682,5686,5690,5694,5698,5702,5706,5710,5714,5718,5722,5726,5730,5734,5738,5742,5746,5750,5754,5758,5762,5766,5770,5774,5778,5782,5786,5790,5794,5798,5802,5806,5810,5814,5818,5822,5826,5830,5834,5838,5842,5846,5850,5854,5858,5862,5866,5870,5874,5878,5882,5886,5890,5894,5898,5902,5906,5910,5914,5918,5922,5926,5930,5934,5938,5942,5946,5950,5954,5958,5962,5966,5970,5974,5978,5982,5986,5990,5994,5998,6002,6006,6010,6014,6018,6022,6026,6030,6034,6038,6042,6046,6050,6054,6058,6062,6066,6070,6074,6078,6082,6086,6090,6094,6098,6102,6106,6110,6114,6118,6122,6126,6130,6134,6137,6141,6145,6149,6153,6157,6161,6165,6169,6173,6177,6181,6185,6189,6193,6197,6201,6205,6209,6213,6217,6221,6225,6229,6233,6237,6240,6244,6248,6252,6256,6260,6264,6268,6272,6276,6280,6284,6288,6292,6296,6300,6304,6308,6312,6316,6320,6324,6328,6332,6336,6340,6344,6348,6352,6356,6360,6364,6367,6371,6375,6379,6383,6387,6391,6395,6399,6403,6407,6411,6415,6419,6423,6427,6431,6435,6439,6443,6447,6451,6455,6459,6463,6467,6471],{"id":26,"text":5579,"url":26,"identifiers":5580},"Bacac, 2008, Metastatic cancer cell, Annu Rev Pathol, 3, 221, 10.1146\u002Fannurev.pathmechdis.3.121806.151523",{"doi":5581},"10.1146\u002Fannurev.pathmechdis.3.121806.151523",{"id":26,"text":5583,"url":26,"identifiers":5584},"Quail, 2013, Microenvironmental regulation of tumor progression and metastasis, Nat Med, 19, 1423, 10.1038\u002Fnm.3394",{"doi":5585},"10.1038\u002Fnm.3394",{"id":26,"text":5587,"url":26,"identifiers":5588},"Tsai, 2013, Epithelial-mesenchymal plasticity in carcinoma metastasis, Genes Dev., 27, 2192, 10.1101\u002Fgad.225334.113",{"doi":5589},"10.1101\u002Fgad.225334.113",{"id":26,"text":5591,"url":26,"identifiers":5592},"Orkin, 2008, Hematopoiesis: an evolving paradigm for stem cell biology, Cell, 132, 631, 10.1016\u002Fj.cell.2008.01.025",{"doi":5593},"10.1016\u002Fj.cell.2008.01.025",{"id":26,"text":5595,"url":26,"identifiers":5596},"Marusyk, 2014, Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity, Nature, 514, 54, 10.1038\u002Fnature13556",{"doi":5597},"10.1038\u002Fnature13556",{"id":26,"text":5599,"url":26,"identifiers":5600},"Nassar, 2016, Cancer stem cells: basic concepts and therapeutic implications, Annu Rev Pathol., 11, 47, 10.1146\u002Fannurev-pathol-012615-044438",{"doi":5601},"10.1146\u002Fannurev-pathol-012615-044438",{"id":26,"text":5603,"url":26,"identifiers":5604},"Batlle, 2017, Cancer stem cells revisited, Nat Med., 23, 1124, 10.1038\u002Fnm.4409",{"doi":5605},"10.1038\u002Fnm.4409",{"id":26,"text":5607,"url":26,"identifiers":5608},"Villa-Diaz, 2016, Inhibition of focal adhesion kinase signaling by integrin alpha6beta1 supports human pluripotent stem cell self-renewal, Stem Cells, 34, 1753, 10.1002\u002Fstem.2349",{"doi":5609},"10.1002\u002Fstem.2349",{"id":26,"text":5611,"url":26,"identifiers":5612},"Cattavarayane, 2015, alpha6beta1- and alphaV-integrins are required for long-term self-renewal of murine embryonic stem cells in the absence of LIF, BMC Cell Biol., 16, 3, 10.1186\u002Fs12860-015-0051-y",{"doi":5613},"10.1186\u002Fs12860-015-0051-y",{"id":26,"text":5615,"url":26,"identifiers":5616},"Popov, 2011, Integrins alpha2beta1 and alpha11beta1 regulate the survival of mesenchymal stem cells on collagen I, Cell Death Dis., 2, e186, 10.1038\u002Fcddis.2011.71",{"doi":5617},"10.1038\u002Fcddis.2011.71",{"id":26,"text":5619,"url":26,"identifiers":5620},"Plaks, 2015, The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?, Cell Stem Cell, 16, 225, 10.1016\u002Fj.stem.2015.02.015",{"doi":5621},"10.1016\u002Fj.stem.2015.02.015",{"id":26,"text":5623,"url":26,"identifiers":5624},"Kumar, 2009, Mechanics, malignancy, and metastasis: the force journey of a tumor cell, Cancer Metastasis Rev., 28, 113, 10.1007\u002Fs10555-008-9173-4",{"doi":5625},"10.1007\u002Fs10555-008-9173-4",{"id":26,"text":5627,"url":26,"identifiers":5628},"Malik, 2015, Biomechanical and biochemical remodeling of stromal extracellular matrix in cancer, Trends Biotechnol., 33, 230, 10.1016\u002Fj.tibtech.2015.01.004",{"doi":5629},"10.1016\u002Fj.tibtech.2015.01.004",{"id":26,"text":5631,"url":26,"identifiers":5632},"Venning, 2015, Targeting ECM disrupts cancer progression, Front Oncol., 5, 224, 10.3389\u002Ffonc.2015.00224",{"doi":5633},"10.3389\u002Ffonc.2015.00224",{"id":26,"text":5635,"url":26,"identifiers":5636},"El-Haibi, 2012, Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy, Proc Natl Acad Sci USA., 109, 17460, 10.1073\u002Fpnas.1206653109",{"doi":5637},"10.1073\u002Fpnas.1206653109",{"id":26,"text":5639,"url":26,"identifiers":5640},"Singleton, 2014, Hyaluronan regulation of endothelial barrier function in cancer, Adv Cancer Res., 123, 191, 10.1016\u002FB978-0-12-800092-2.00007-1",{"doi":5641},"10.1016\u002FB978-0-12-800092-2.00007-1",{"id":26,"text":5643,"url":26,"identifiers":5644},"Nikitovic, 2015, Cancer microenvironment and inflammation: role of hyaluronan, Front Immunol., 6, 169, 10.3389\u002Ffimmu.2015.00169",{"doi":5645},"10.3389\u002Ffimmu.2015.00169",{"id":26,"text":5647,"url":26,"identifiers":5648},"Alexander, 2008, Dynamic imaging of cancer growth and invasion: a modified skin-fold chamber model, Histochem Cell Biol., 130, 1147, 10.1007\u002Fs00418-008-0529-1",{"doi":5649},"10.1007\u002Fs00418-008-0529-1",{"id":26,"text":5651,"url":26,"identifiers":5652},"Egeblad, 2010, Dynamic interplay between the collagen scaffold and tumor evolution, Curr Opin Cell Biol., 22, 697, 10.1016\u002Fj.ceb.2010.08.015",{"doi":5653},"10.1016\u002Fj.ceb.2010.08.015",{"id":26,"text":5655,"url":26,"identifiers":5656},"Samuel, 2011, Actomyosin-mediated cellular tension drives increased tissue stiffness and beta-catenin activation to induce epidermal hyperplasia and tumor growth, Cancer Cell, 19, 776, 10.1016\u002Fj.ccr.2011.05.008",{"doi":5657},"10.1016\u002Fj.ccr.2011.05.008",{"id":26,"text":5659,"url":26,"identifiers":5660},"Guo, 2004, Integrin signalling during tumour progression, Nat Rev Mol Cell Biol., 5, 816, 10.1038\u002Fnrm1490",{"doi":5661},"10.1038\u002Fnrm1490",{"id":26,"text":5663,"url":26,"identifiers":5664},"Bainbridge, 2013, Wound healing and the role of fibroblasts, J Wound Care, 22, 407, 10.12968\u002Fjowc.2013.22.8.407",{"doi":5665},"10.12968\u002Fjowc.2013.22.8.407",{"id":26,"text":5667,"url":26,"identifiers":5668},"Kular, 2015, A negative regulatory mechanism involving 14–3-3zeta limits signaling downstream of ROCK to regulate tissue stiffness in epidermal homeostasis, Dev Cell, 35, 759, 10.1016\u002Fj.devcel.2015.11.026",{"doi":5669},"10.1016\u002Fj.devcel.2015.11.026",{"id":26,"text":5671,"url":26,"identifiers":5672},"Trapani, 2017, Role of the ECM in notochord formation, function and disease, J Cell Sci., 130, 3203, 10.1242\u002Fjcs.175950",{"doi":5673},"10.1242\u002Fjcs.175950",{"id":26,"text":5675,"url":26,"identifiers":5676},"Nagy, 2018, Collagen 18 and agrin are secreted by neural crest cells to remodel their microenvironment and regulate their migration during enteric nervous system development, Development, 10.1242\u002Fdev.160317",{"doi":5677},"10.1242\u002Fdev.160317",{"id":26,"text":5679,"url":26,"identifiers":5680},"Ishii, 2016, Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment, Adv Drug Deliv Rev., 99, 186, 10.1016\u002Fj.addr.2015.07.007",{"doi":5681},"10.1016\u002Fj.addr.2015.07.007",{"id":26,"text":5683,"url":26,"identifiers":5684},"Kalluri, 2016, The biology and function of fibroblasts in cancer, Nat Rev Cancer, 16, 582, 10.1038\u002Fnrc.2016.73",{"doi":5685},"10.1038\u002Fnrc.2016.73",{"id":26,"text":5687,"url":26,"identifiers":5688},"Dvorak, 1986, Tumors: wounds that do not heal, N Engl J Med., 315, 1650, 10.1056\u002FNEJM198612253152606",{"doi":5689},"10.1056\u002FNEJM198612253152606",{"id":26,"text":5691,"url":26,"identifiers":5692},"Coussens, 2002, Inflammation and cancer, Nature, 420, 860, 10.1038\u002Fnature01322",{"doi":5693},"10.1038\u002Fnature01322",{"id":26,"text":5695,"url":26,"identifiers":5696},"Augsten, 2014, Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment, Front Oncol., 4, 62, 10.3389\u002Ffonc.2014.00062",{"doi":5697},"10.3389\u002Ffonc.2014.00062",{"id":26,"text":5699,"url":26,"identifiers":5700},"Yu, 2014, Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-beta signalling, Br J Cancer, 110, 724, 10.1038\u002Fbjc.2013.768",{"doi":5701},"10.1038\u002Fbjc.2013.768",{"id":26,"text":5703,"url":26,"identifiers":5704},"Fiaschi, 2013, Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells, Cell Cycle, 12, 1791, 10.4161\u002Fcc.24902",{"doi":5705},"10.4161\u002Fcc.24902",{"id":26,"text":5707,"url":26,"identifiers":5708},"Giannoni, 2010, Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness, Cancer Res., 70, 6945, 10.1158\u002F0008-5472.CAN-10-0785",{"doi":5709},"10.1158\u002F0008-5472.CAN-10-0785",{"id":26,"text":5711,"url":26,"identifiers":5712},"Gattazzo, 2014, Extracellular matrix: a dynamic microenvironment for stem cell niche, Biochim Biophys Acta, 1840, 2506, 10.1016\u002Fj.bbagen.2014.01.010",{"doi":5713},"10.1016\u002Fj.bbagen.2014.01.010",{"id":26,"text":5715,"url":26,"identifiers":5716},"Meran, 2017, Intestinal stem cell Niche: the extracellular matrix and cellular components, Stem Cells Int, 2017, 7970385, 10.1155\u002F2017\u002F7970385",{"doi":5717},"10.1155\u002F2017\u002F7970385",{"id":26,"text":5719,"url":26,"identifiers":5720},"Malanchi, 2012, Interactions between cancer stem cells and their niche govern metastatic colonization, Nature, 481, 85, 10.1038\u002Fnature10694",{"doi":5721},"10.1038\u002Fnature10694",{"id":26,"text":5723,"url":26,"identifiers":5724},"Cazet, 2018, Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer, Nat Commun., 9, 2897, 10.1038\u002Fs41467-018-05220-6",{"doi":5725},"10.1038\u002Fs41467-018-05220-6",{"id":26,"text":5727,"url":26,"identifiers":5728},"Shimoda, 2014, Loss of the Timp gene family is sufficient for the acquisition of the CAF-like cell state, Nat Cell Biol., 16, 889, 10.1038\u002Fncb3021",{"doi":5729},"10.1038\u002Fncb3021",{"id":26,"text":5731,"url":26,"identifiers":5732},"Vermeulen, 2010, Wnt activity defines colon cancer stem cells and is regulated by the microenvironment, Nat Cell Biol., 12, 468, 10.1038\u002Fncb2048",{"doi":5733},"10.1038\u002Fncb2048",{"id":26,"text":5735,"url":26,"identifiers":5736},"Chen, 2014, Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling, Nat Commun., 5, 3472, 10.1038\u002Fncomms4472",{"doi":5737},"10.1038\u002Fncomms4472",{"id":26,"text":5739,"url":26,"identifiers":5740},"Van Helvert, 2018, Mechanoreciprocity in cell migration, Nat Cell Biol., 20, 8, 10.1038\u002Fs41556-017-0012-0",{"doi":5741},"10.1038\u002Fs41556-017-0012-0",{"id":26,"text":5743,"url":26,"identifiers":5744},"De Wever, 2004, Tenascin-C and SF\u002FHGF produced by myofibroblasts in vitro provide convergent proinvasive signals to human colon cancer cells through RhoA and Rac, FASEB J., 18, 1016, 10.1096\u002Ffj.03-1110fje",{"doi":5745},"10.1096\u002Ffj.03-1110fje",{"id":26,"text":5747,"url":26,"identifiers":5748},"Calvo, 2013, Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts, Nat Cell Biol., 15, 637, 10.1038\u002Fncb2756",{"doi":5749},"10.1038\u002Fncb2756",{"id":26,"text":5751,"url":26,"identifiers":5752},"Sanz-Moreno, 2011, ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma, Cancer Cell, 20, 229, 10.1016\u002Fj.ccr.2011.06.018",{"doi":5753},"10.1016\u002Fj.ccr.2011.06.018",{"id":26,"text":5755,"url":26,"identifiers":5756},"Qian, 2010, Macrophage diversity enhances tumor progression and metastasis, Cell, 141, 39, 10.1016\u002Fj.cell.2010.03.014",{"doi":5757},"10.1016\u002Fj.cell.2010.03.014",{"id":26,"text":5759,"url":26,"identifiers":5760},"Wynn, 2013, Macrophage biology in development, homeostasis and disease, Nature, 496, 445, 10.1038\u002Fnature12034",{"doi":5761},"10.1038\u002Fnature12034",{"id":26,"text":5763,"url":26,"identifiers":5764},"Pollard, 2009, Trophic macrophages in development and disease, Nat Rev Immunol., 9, 259, 10.1038\u002Fnri2528",{"doi":5765},"10.1038\u002Fnri2528",{"id":26,"text":5767,"url":26,"identifiers":5768},"Sica, 2012, Macrophage plasticity and polarization: in vivo veritas, J Clin Invest, 122, 787, 10.1172\u002FJCI59643",{"doi":5769},"10.1172\u002FJCI59643",{"id":26,"text":5771,"url":26,"identifiers":5772},"Xue, 2014, Transcriptome-based network analysis reveals a spectrum model of human macrophage activation, Immunity, 40, 274, 10.1016\u002Fj.immuni.2014.01.006",{"doi":5773},"10.1016\u002Fj.immuni.2014.01.006",{"id":26,"text":5775,"url":26,"identifiers":5776},"Aras, 2017, TAMeless traitors: macrophages in cancer progression and metastasis, Br J Cancer, 117, 1583, 10.1038\u002Fbjc.2017.356",{"doi":5777},"10.1038\u002Fbjc.2017.356",{"id":26,"text":5779,"url":26,"identifiers":5780},"Wyckoff, 2004, A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors, Cancer Res., 64, 7022, 10.1158\u002F0008-5472.CAN-04-1449",{"doi":5781},"10.1158\u002F0008-5472.CAN-04-1449",{"id":26,"text":5783,"url":26,"identifiers":5784},"Murdoch, 2007, Expression of Tie-2 by human monocytes and their responses to angiopoietin-2, J Immunol., 178, 7405, 10.4049\u002Fjimmunol.178.11.7405",{"doi":5785},"10.4049\u002Fjimmunol.178.11.7405",{"id":26,"text":5787,"url":26,"identifiers":5788},"Qian, 2011, CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis, Nature, 475, 222, 10.1038\u002Fnature10138",{"doi":5789},"10.1038\u002Fnature10138",{"id":26,"text":5791,"url":26,"identifiers":5792},"Dwyer, 2017, Promotion of tumor invasion by tumor-associated macrophages: the role of CSF-1-activated phosphatidylinositol 3 kinase and Src family kinase motility signaling, Cancers (Basel), 9, E68, 10.3390\u002Fcancers9060068",{"doi":5793},"10.3390\u002Fcancers9060068",{"id":26,"text":5795,"url":26,"identifiers":5796},"Boyle, 2015, The chemokine receptor CCR6 facilitates the onset of mammary neoplasia in the MMTV-PyMT mouse model via recruitment of tumor-promoting macrophages, Mol Cancer, 14, 115, 10.1186\u002Fs12943-015-0394-1",{"doi":5797},"10.1186\u002Fs12943-015-0394-1",{"id":26,"text":5799,"url":26,"identifiers":5800},"Bohrer, 2012, Macrophages promote fibroblast growth factor receptor-driven tumor cell migration and invasion in a CXCR2-dependent manner, Mol Cancer Res., 10, 1294, 10.1158\u002F1541-7786.MCR-12-0275",{"doi":5801},"10.1158\u002F1541-7786.MCR-12-0275",{"id":26,"text":5803,"url":26,"identifiers":5804},"Baghel, 2016, Macrophages promote matrix protrusive and invasive function of breast cancer cells via MIP-1 beta dependent upregulation of MYO3A gene in breast cancer cells, Oncoimmunology, 10.1080\u002F2162402X.2016.1196299",{"doi":5805},"10.1080\u002F2162402X.2016.1196299",{"id":26,"text":5807,"url":26,"identifiers":5808},"Lin, 2007, Tumor-associated macrophages press the angiogenic switch in breast cancer, Cancer Res., 67, 5064, 10.1158\u002F0008-5472.CAN-07-0912",{"doi":5809},"10.1158\u002F0008-5472.CAN-07-0912",{"id":26,"text":5811,"url":26,"identifiers":5812},"Goswami, 2005, Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1\u002Fepidermal growth factor paracrine loop, Cancer Res., 65, 5278, 10.1158\u002F0008-5472.CAN-04-1853",{"doi":5813},"10.1158\u002F0008-5472.CAN-04-1853",{"id":26,"text":5815,"url":26,"identifiers":5816},"Linde, 2012, Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages, J Pathol., 227, 17, 10.1002\u002Fpath.3989",{"doi":5817},"10.1002\u002Fpath.3989",{"id":26,"text":5819,"url":26,"identifiers":5820},"Sica, 2000, Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages, J Immunol., 164, 762, 10.4049\u002Fjimmunol.164.2.762",{"doi":5821},"10.4049\u002Fjimmunol.164.2.762",{"id":26,"text":5823,"url":26,"identifiers":5824},"Bonde, 2012, Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors, BMC Cancer, 12, 35, 10.1186\u002F1471-2407-12-35",{"doi":5825},"10.1186\u002F1471-2407-12-35",{"id":26,"text":5827,"url":26,"identifiers":5828},"Wyckoff, 2007, Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors, Cancer Res., 67, 2649, 10.1158\u002F0008-5472.CAN-06-1823",{"doi":5829},"10.1158\u002F0008-5472.CAN-06-1823",{"id":26,"text":5831,"url":26,"identifiers":5832},"Liguori, 2011, Tumor-associated macrophages as incessant builders and destroyers of the cancer stroma, Cancers (Basel), 3, 3740, 10.3390\u002Fcancers3043740",{"doi":5833},"10.3390\u002Fcancers3043740",{"id":26,"text":5835,"url":26,"identifiers":5836},"Afik, 2016, Tumor macrophages are pivotal constructors of tumor collagenous matrix, J Exp Med., 213, 2315, 10.1084\u002Fjem.20151193",{"doi":5837},"10.1084\u002Fjem.20151193",{"id":26,"text":5839,"url":26,"identifiers":5840},"Condeelis, 2006, Macrophages: obligate partners for tumor cell migration, invasion, and metastasis, Cell, 124, 263, 10.1016\u002Fj.cell.2006.01.007",{"doi":5841},"10.1016\u002Fj.cell.2006.01.007",{"id":26,"text":5843,"url":26,"identifiers":5844},"Chen, 2011, CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3, Cancer Cell, 19, 541, 10.1016\u002Fj.ccr.2011.02.006",{"doi":5845},"10.1016\u002Fj.ccr.2011.02.006",{"id":26,"text":5847,"url":26,"identifiers":5848},"Felbor, 2000, Secreted cathepsin L generates endostatin from collagen XVIII, EMBO J., 19, 1187, 10.1093\u002Femboj\u002F19.6.1187",{"doi":5849},"10.1093\u002Femboj\u002F19.6.1187",{"id":26,"text":5851,"url":26,"identifiers":5852},"Liu, 2013, M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4\u002FIL-10 signaling pathway, Lab Invest., 93, 844, 10.1038\u002Flabinvest.2013.69",{"doi":5853},"10.1038\u002Flabinvest.2013.69",{"id":26,"text":5855,"url":26,"identifiers":5856},"Su, 2014, A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis, Cancer Cell, 25, 605, 10.1016\u002Fj.ccr.2014.03.021",{"doi":5857},"10.1016\u002Fj.ccr.2014.03.021",{"id":26,"text":5859,"url":26,"identifiers":5860},"Raggi, 2016, Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies, Oncogene, 35, 671, 10.1038\u002Fonc.2015.132",{"doi":5861},"10.1038\u002Fonc.2015.132",{"id":26,"text":5863,"url":26,"identifiers":5864},"Fan, 2014, Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma, Cancer Lett., 352, 160, 10.1016\u002Fj.canlet.2014.05.008",{"doi":5865},"10.1016\u002Fj.canlet.2014.05.008",{"id":26,"text":5867,"url":26,"identifiers":5868},"Kolaczkowska, 2013, Neutrophil recruitment and function in health and inflammation, Nat Rev Immunol., 13, 159, 10.1038\u002Fnri3399",{"doi":5869},"10.1038\u002Fnri3399",{"id":26,"text":5871,"url":26,"identifiers":5872},"Coffelt, 2016, Neutrophils in cancer: neutral no more, Nat Rev Cancer, 16, 431, 10.1038\u002Fnrc.2016.52",{"doi":5873},"10.1038\u002Fnrc.2016.52",{"id":26,"text":5875,"url":26,"identifiers":5876},"Martins, 2010, The multifaceted effects of granulocyte colony-stimulating factor in immunomodulation and potential roles in intestinal immune homeostasis, IUBMB Life, 62, 611, 10.1002\u002Fiub.361",{"doi":5877},"10.1002\u002Fiub.361",{"id":26,"text":5879,"url":26,"identifiers":5880},"Houghton, 2010, Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth, Nat Med., 16, 219, 10.1038\u002Fnm.2084",{"doi":5881},"10.1038\u002Fnm.2084",{"id":26,"text":5883,"url":26,"identifiers":5884},"Gong, 2013, Promoting effect of neutrophils on lung tumorigenesis is mediated by CXCR2 and neutrophil elastase, Mol Cancer, 12, 154, 10.1186\u002F1476-4598-12-154",{"doi":5885},"10.1186\u002F1476-4598-12-154",{"id":26,"text":5887,"url":26,"identifiers":5888},"Deryugina, 2014, Tissue-infiltrating neutrophils constitute the major in vivo source of angiogenesis-inducing MMP-9 in the tumor microenvironment, Neoplasia, 16, 771, 10.1016\u002Fj.neo.2014.08.013",{"doi":5889},"10.1016\u002Fj.neo.2014.08.013",{"id":26,"text":5891,"url":26,"identifiers":5892},"Fridlender, 2009, Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN, Cancer Cell, 16, 183, 10.1016\u002Fj.ccr.2009.06.017",{"doi":5893},"10.1016\u002Fj.ccr.2009.06.017",{"id":26,"text":5895,"url":26,"identifiers":5896},"Moore, 1999, Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis, Nat Med., 5, 828, 10.1038\u002F10552",{"doi":5897},"10.1038\u002F10552",{"id":26,"text":5899,"url":26,"identifiers":5900},"Zhou, 2012, Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma, Hepatology, 56, 2242, 10.1002\u002Fhep.25907",{"doi":5901},"10.1002\u002Fhep.25907",{"id":26,"text":5903,"url":26,"identifiers":5904},"Coussens, 2000, MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis, Cell, 103, 481, 10.1016\u002FS0092-8674(00)00139-2",{"doi":5905},"10.1016\u002FS0092-8674(00)00139-2",{"id":26,"text":5907,"url":26,"identifiers":5908},"Bekes, 2011, Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation, Am J Pathol., 179, 1455, 10.1016\u002Fj.ajpath.2011.05.031",{"doi":5909},"10.1016\u002Fj.ajpath.2011.05.031",{"id":26,"text":5911,"url":26,"identifiers":5912},"Grosse-Steffen, 2012, Epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma and pancreatic tumor cell lines: the role of neutrophils and neutrophil-derived elastase, Clin Dev Immunol., 2012, 720768, 10.1155\u002F2012\u002F720768",{"doi":5913},"10.1155\u002F2012\u002F720768",{"id":26,"text":5915,"url":26,"identifiers":5916},"Freisinger, 2014, Live imaging and gene expression analysis in zebrafish identifies a link between neutrophils and epithelial to mesenchymal transition, PLoS ONE, 9, e112183, 10.1371\u002Fjournal.pone.0112183",{"doi":5917},"10.1371\u002Fjournal.pone.0112183",{"id":26,"text":5919,"url":26,"identifiers":5920},"Jamieson, 2012, Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis, J Clin Invest., 122, 3127, 10.1172\u002FJCI61067",{"doi":5921},"10.1172\u002FJCI61067",{"id":26,"text":5923,"url":26,"identifiers":5924},"He, 2012, Neutrophil-mediated experimental metastasis is enhanced by VEGFR inhibition in a zebrafish xenograft model, J Pathol., 227, 431, 10.1002\u002Fpath.4013",{"doi":5925},"10.1002\u002Fpath.4013",{"id":26,"text":5927,"url":26,"identifiers":5928},"Glogauer, 2015, Neutrophils increase oral squamous cell carcinoma invasion through an invadopodia-dependent pathway, Cancer Immunol Res., 3, 1218, 10.1158\u002F2326-6066.CIR-15-0017",{"doi":5929},"10.1158\u002F2326-6066.CIR-15-0017",{"id":26,"text":5931,"url":26,"identifiers":5932},"Garcia-Mendoza, 2016, Neutrophils drive accelerated tumor progression in the collagen-dense mammary tumor microenvironment, Breast Cancer Res., 18, 49, 10.1186\u002Fs13058-016-0703-7",{"doi":5933},"10.1186\u002Fs13058-016-0703-7",{"id":26,"text":5935,"url":26,"identifiers":5936},"Cools-Lartigue, 2014, Neutrophil extracellular traps in cancer progression, Cell Mol Life Sci., 71, 4179, 10.1007\u002Fs00018-014-1683-3",{"doi":5937},"10.1007\u002Fs00018-014-1683-3",{"id":26,"text":5939,"url":26,"identifiers":5940},"Erpenbeck, 2017, Neutrophil extracellular traps: protagonists of cancer progression?, Oncogene, 36, 2483, 10.1038\u002Fonc.2016.406",{"doi":5941},"10.1038\u002Fonc.2016.406",{"id":26,"text":5943,"url":26,"identifiers":5944},"Cools-Lartigue, 2013, Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis, J Clin Invest., 123, 3446, 10.1172\u002FJCI67484",{"doi":5945},"10.1172\u002FJCI67484",{"id":26,"text":5947,"url":26,"identifiers":5948},"Monti, 2017, Integrin-dependent cell adhesion to neutrophil extracellular traps through engagement of fibronectin in neutrophil-like cells, PLoS ONE, 12, e0171362, 10.1371\u002Fjournal.pone.0171362",{"doi":5949},"10.1371\u002Fjournal.pone.0171362",{"id":26,"text":5951,"url":26,"identifiers":5952},"Sethi, 2007, Thematic review series: adipocyte biology, J Lipid Res., 48, 1253, 10.1194\u002Fjlr.R700005-JLR200",{"doi":5953},"10.1194\u002Fjlr.R700005-JLR200",{"id":26,"text":5955,"url":26,"identifiers":5956},"Nieman, 2013, Adipose tissue and adipocytes support tumorigenesis and metastasis, Biochim Biophys Acta, 1831, 1533, 10.1016\u002Fj.bbalip.2013.02.010",{"doi":5957},"10.1016\u002Fj.bbalip.2013.02.010",{"id":26,"text":5959,"url":26,"identifiers":5960},"Duong, 2017, The fat and the bad: Mature adipocytes, key actors in tumor progression and resistance, Oncotarget, 8, 57622, 10.18632\u002Foncotarget.18038",{"doi":5961},"10.18632\u002Foncotarget.18038",{"id":26,"text":5963,"url":26,"identifiers":5964},"Rodeheffer, 2008, Identification of white adipocyte progenitor cells in vivo, Cell, 135, 240, 10.1016\u002Fj.cell.2008.09.036",{"doi":5965},"10.1016\u002Fj.cell.2008.09.036",{"id":26,"text":5967,"url":26,"identifiers":5968},"Tang, 2012, Adipogenesis: from stem cell to adipocyte, Annu Rev Biochem., 81, 715, 10.1146\u002Fannurev-biochem-052110-115718",{"doi":5969},"10.1146\u002Fannurev-biochem-052110-115718",{"id":26,"text":5971,"url":26,"identifiers":5972},"Tomiyama, 2008, Characterization of transplanted green fluorescent protein+ bone marrow cells into adipose tissue, Stem Cells, 26, 330, 10.1634\u002Fstemcells.2007-0567",{"doi":5973},"10.1634\u002Fstemcells.2007-0567",{"id":26,"text":5975,"url":26,"identifiers":5976},"Sera, 2009, Hematopoietic stem cell origin of adipocytes, Exp Hematol., 37, 1108, 10.1016\u002Fj.exphem.2009.06.008",{"doi":5977},"10.1016\u002Fj.exphem.2009.06.008",{"id":26,"text":5979,"url":26,"identifiers":5980},"Dirat, 2011, Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion, Cancer Res., 71, 2455, 10.1158\u002F0008-5472.CAN-10-3323",{"doi":5981},"10.1158\u002F0008-5472.CAN-10-3323",{"id":26,"text":5983,"url":26,"identifiers":5984},"Bochet, 2013, Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer, Cancer Res., 73, 5657, 10.1158\u002F0008-5472.CAN-13-0530",{"doi":5985},"10.1158\u002F0008-5472.CAN-13-0530",{"id":26,"text":5987,"url":26,"identifiers":5988},"Carter, 2012, Mature breast adipocytes promote breast cancer cell motility, Exp Mol Pathol., 92, 312, 10.1016\u002Fj.yexmp.2012.03.005",{"doi":5989},"10.1016\u002Fj.yexmp.2012.03.005",{"id":26,"text":5991,"url":26,"identifiers":5992},"Nieman, 2011, Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth, Nat Med., 17, 1498, 10.1038\u002Fnm.2492",{"doi":5993},"10.1038\u002Fnm.2492",{"id":26,"text":5995,"url":26,"identifiers":5996},"Park, 2014, Obesity and cancer–mechanisms underlying tumour progression and recurrence, Nat Rev Endocrinol., 10, 455, 10.1038\u002Fnrendo.2014.94",{"doi":5997},"10.1038\u002Fnrendo.2014.94",{"id":26,"text":5999,"url":26,"identifiers":6000},"Donohoe, 2017, Emerging concepts linking obesity with the hallmarks of cancer, Trends Endocrinol Metab., 28, 46, 10.1016\u002Fj.tem.2016.08.004",{"doi":6001},"10.1016\u002Fj.tem.2016.08.004",{"id":26,"text":6003,"url":26,"identifiers":6004},"Incio, 2016, Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy, Cancer Discov., 6, 852, 10.1158\u002F2159-8290.CD-15-1177",{"doi":6005},"10.1158\u002F2159-8290.CD-15-1177",{"id":26,"text":6007,"url":26,"identifiers":6008},"Seo, 2015, Obesity-dependent changes in interstitial ECM mechanics promote breast tumorigenesis, Sci Transl Med., 10.1126\u002Fscitranslmed.3010467",{"doi":6009},"10.1126\u002Fscitranslmed.3010467",{"id":26,"text":6011,"url":26,"identifiers":6012},"Ribeiro, 2012, Tumor cell-educated periprostatic adipose tissue acquires an aggressive cancer-promoting secretory profile, Cell Physiol Biochem., 29, 233, 10.1159\u002F000337604",{"doi":6013},"10.1159\u002F000337604",{"id":26,"text":6015,"url":26,"identifiers":6016},"Iyengar, 2005, Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor\u002Fstroma microenvironment, J Clin Invest., 115, 1163, 10.1172\u002FJCI23424",{"doi":6017},"10.1172\u002FJCI23424",{"id":26,"text":6019,"url":26,"identifiers":6020},"Park, 2012, Adipocyte-derived endotrophin promotes malignant tumor progression, J Clin Invest., 122, 4243, 10.1172\u002FJCI63930",{"doi":6021},"10.1172\u002FJCI63930",{"id":26,"text":6023,"url":26,"identifiers":6024},"Campo-Verde-Arbocco, 2017, Human renal adipose tissue induces the invasion and progression of renal cell carcinoma, Oncotarget, 8, 94223, 10.18632\u002Foncotarget.21666",{"doi":6025},"10.18632\u002Foncotarget.21666",{"id":26,"text":6027,"url":26,"identifiers":6028},"De Visser, 2006, Paradoxical roles of the immune system during cancer development, Nat Rev Cancer, 6, 24, 10.1038\u002Fnrc1782",{"doi":6029},"10.1038\u002Fnrc1782",{"id":26,"text":6031,"url":26,"identifiers":6032},"Sasada, 2011, Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance, Immunotherapy, 3, 1235, 10.2217\u002Fimt.11.106",{"doi":6033},"10.2217\u002Fimt.11.106",{"id":26,"text":6035,"url":26,"identifiers":6036},"Wakita, 2010, Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis, Eur J Immunol., 40, 1927, 10.1002\u002Feji.200940157",{"doi":6037},"10.1002\u002Feji.200940157",{"id":26,"text":6039,"url":26,"identifiers":6040},"Coffelt, 2015, IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis, Nature, 522, 345, 10.1038\u002Fnature14282",{"doi":6041},"10.1038\u002Fnature14282",{"id":26,"text":6043,"url":26,"identifiers":6044},"Denardo, 2009, CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages, Cancer Cell, 16, 91, 10.1016\u002Fj.ccr.2009.06.018",{"doi":6045},"10.1016\u002Fj.ccr.2009.06.018",{"id":26,"text":6047,"url":26,"identifiers":6048},"Smyth, 2006, CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer, J Immunol., 176, 1582, 10.4049\u002Fjimmunol.176.3.1582",{"doi":6049},"10.4049\u002Fjimmunol.176.3.1582",{"id":26,"text":6051,"url":26,"identifiers":6052},"Facciabene, 2011, Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells, Nature, 475, 226, 10.1038\u002Fnature10169",{"doi":6053},"10.1038\u002Fnature10169",{"id":26,"text":6055,"url":26,"identifiers":6056},"De Visser, 2005, De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent, Cancer Cell, 7, 411, 10.1016\u002Fj.ccr.2005.04.014",{"doi":6057},"10.1016\u002Fj.ccr.2005.04.014",{"id":26,"text":6059,"url":26,"identifiers":6060},"Ammirante, 2010, B-cell-derived lymphotoxin promotes castration-resistant prostate cancer, Nature, 464, 302, 10.1038\u002Fnature08782",{"doi":6061},"10.1038\u002Fnature08782",{"id":26,"text":6063,"url":26,"identifiers":6064},"Yang, 2013, B cells promote tumor progression via STAT3 regulated-angiogenesis, PLoS ONE, 8, e64159, 10.1371\u002Fjournal.pone.0064159",{"doi":6065},"10.1371\u002Fjournal.pone.0064159",{"id":26,"text":6067,"url":26,"identifiers":6068},"Edsparr, 2011, Matrix metalloproteinases in cytotoxic lymphocytes impact on tumour infiltration and immunomodulation, Cancer Microenviron., 4, 351, 10.1007\u002Fs12307-010-0057-0",{"doi":6069},"10.1007\u002Fs12307-010-0057-0",{"id":26,"text":6071,"url":26,"identifiers":6072},"Johnatty, 1997, Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes, J Immunol., 158, 2327, 10.4049\u002Fjimmunol.158.5.2327",{"doi":6073},"10.4049\u002Fjimmunol.158.5.2327",{"id":26,"text":6075,"url":26,"identifiers":6076},"Segarra, 2005, Dual function of focal adhesion kinase in regulating integrin-induced MMP-2 and MMP-9 release by human T lymphoid cells, FASEB J., 19, 1875, 10.1096\u002Ffj.04-3574fje",{"doi":6077},"10.1096\u002Ffj.04-3574fje",{"id":26,"text":6079,"url":26,"identifiers":6080},"Owen, 2003, Up-regulation of matrix metalloproteinase-9 in T lymphocytes of mammary tumor bearers: role of vascular endothelial growth factor, J Immunol., 171, 4340, 10.4049\u002Fjimmunol.171.8.4340",{"doi":6081},"10.4049\u002Fjimmunol.171.8.4340",{"id":26,"text":6083,"url":26,"identifiers":6084},"Mach, 1999, T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation, Am J Pathol., 154, 229, 10.1016\u002FS0002-9440(10)65269-8",{"doi":6085},"10.1016\u002FS0002-9440(10)65269-8",{"id":26,"text":6087,"url":26,"identifiers":6088},"Aoudjit, 1997, Gelatinase B (MMP-9) production and expression by stromal cells in the normal and adult thymus and experimental thymic lymphoma, Int J Cancer, 71, 71, 10.1002\u002F(SICI)1097-0215(19970328)71:1\u003C71::AID-IJC13>3.0.CO;2-C",{"doi":6089},"10.1002\u002F(SICI)1097-0215(19970328)71:1\u003C71::AID-IJC13>3.0.CO;2-C",{"id":26,"text":6091,"url":26,"identifiers":6092},"Casey, 2009, Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer, Breast Cancer Res Treat, 114, 47, 10.1007\u002Fs10549-008-9982-8",{"doi":6093},"10.1007\u002Fs10549-008-9982-8",{"id":26,"text":6095,"url":26,"identifiers":6096},"Naba, 2012, The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices, Mol Cell Proteomics, 10.1074\u002Fmcp.M111.014647",{"doi":6097},"10.1074\u002Fmcp.M111.014647",{"id":26,"text":6099,"url":26,"identifiers":6100},"Naba, 2014, Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters, Elife, 3, e01308, 10.7554\u002FeLife.01308",{"doi":6101},"10.7554\u002FeLife.01308",{"id":26,"text":6103,"url":26,"identifiers":6104},"Denko, 2003, Investigating hypoxic tumor physiology through gene expression patterns, Oncogene, 22, 5907, 10.1038\u002Fsj.onc.1206703",{"doi":6105},"10.1038\u002Fsj.onc.1206703",{"id":26,"text":6107,"url":26,"identifiers":6108},"Erler, 2006, Lysyl oxidase is essential for hypoxia-induced metastasis, Nature, 440, 1222, 10.1038\u002Fnature04695",{"doi":6109},"10.1038\u002Fnature04695",{"id":26,"text":6111,"url":26,"identifiers":6112},"Levental, 2009, Matrix crosslinking forces tumor progression by enhancing integrin signaling, Cell, 139, 891, 10.1016\u002Fj.cell.2009.10.027",{"doi":6113},"10.1016\u002Fj.cell.2009.10.027",{"id":26,"text":6115,"url":26,"identifiers":6116},"Boyle, 2016, Mechano-reciprocity is maintained between physiological boundaries by tuning signal flux through the Rho-associated protein kinase, Small GTPases, 7, 139, 10.1080\u002F21541248.2016.1173771",{"doi":6117},"10.1080\u002F21541248.2016.1173771",{"id":26,"text":6119,"url":26,"identifiers":6120},"Boyle, 2018, Acute compressive stress activates RHO\u002FROCK-mediated cellular processes, Small GTPases, 17, 1, 10.1080\u002F21541248.2017.1413496",{"doi":6121},"10.1080\u002F21541248.2017.1413496",{"id":26,"text":6123,"url":26,"identifiers":6124},"Gilkes, 2014, Hypoxia and the extracellular matrix: drivers of tumour metastasis, Nat Rev Cancer, 14, 430, 10.1038\u002Fnrc3726",{"doi":6125},"10.1038\u002Fnrc3726",{"id":26,"text":6127,"url":26,"identifiers":6128},"Gilkes, 2013, Collagen prolyl hydroxylases are essential for breast cancer metastasis, Cancer Res., 73, 3285, 10.1158\u002F0008-5472.CAN-12-3963",{"doi":6129},"10.1158\u002F0008-5472.CAN-12-3963",{"id":26,"text":6131,"url":26,"identifiers":6132},"Gilkes, 2013, Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis, Mol Cancer Res., 11, 456, 10.1158\u002F1541-7786.MCR-12-0629",{"doi":6133},"10.1158\u002F1541-7786.MCR-12-0629",{"id":26,"text":6135,"url":26,"identifiers":6136},"Krishnamachary, 2003, Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1, Cancer Res., 63, 1138",{},{"id":26,"text":6138,"url":26,"identifiers":6139},"Munoz-Najar, 2006, Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation, Oncogene, 25, 2379, 10.1038\u002Fsj.onc.1209273",{"doi":6140},"10.1038\u002Fsj.onc.1209273",{"id":26,"text":6142,"url":26,"identifiers":6143},"Wolf, 2007, Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion, Nat Cell Biol., 9, 893, 10.1038\u002Fncb1616",{"doi":6144},"10.1038\u002Fncb1616",{"id":26,"text":6146,"url":26,"identifiers":6147},"Ota, 2009, Induction of a MT1-MMP and MT2-MMP-dependent basement membrane transmigration program in cancer cells by Snail1, Proc Natl Acad Sci USA., 106, 20318, 10.1073\u002Fpnas.0910962106",{"doi":6148},"10.1073\u002Fpnas.0910962106",{"id":26,"text":6150,"url":26,"identifiers":6151},"Radisky, 2010, Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer, J Mammary Gland Biol Neoplasia, 15, 201, 10.1007\u002Fs10911-010-9177-x",{"doi":6152},"10.1007\u002Fs10911-010-9177-x",{"id":26,"text":6154,"url":26,"identifiers":6155},"Rath, 2017, ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth, EMBO Mol Med., 9, 198, 10.15252\u002Femmm.201606743",{"doi":6156},"10.15252\u002Femmm.201606743",{"id":26,"text":6158,"url":26,"identifiers":6159},"Clancy, 2015, Regulated delivery of molecular cargo to invasive tumour-derived microvesicles, Nat Commun., 6, 6919, 10.1038\u002Fncomms7919",{"doi":6160},"10.1038\u002Fncomms7919",{"id":26,"text":6162,"url":26,"identifiers":6163},"Bordeleau, 2016, Microvesicles released from tumor cells disrupt epithelial cell morphology and contractility, J Biomech., 49, 1272, 10.1016\u002Fj.jbiomech.2015.10.003",{"doi":6164},"10.1016\u002Fj.jbiomech.2015.10.003",{"id":26,"text":6166,"url":26,"identifiers":6167},"Tkach, 2016, Communication by extracellular vesicles: where we are and where we need to go, Cell, 164, 1226, 10.1016\u002Fj.cell.2016.01.043",{"doi":6168},"10.1016\u002Fj.cell.2016.01.043",{"id":26,"text":6170,"url":26,"identifiers":6171},"Mcniven, 2013, Breaking away: matrix remodeling from the leading edge, Trends Cell Biol., 23, 16, 10.1016\u002Fj.tcb.2012.08.009",{"doi":6172},"10.1016\u002Fj.tcb.2012.08.009",{"id":26,"text":6174,"url":26,"identifiers":6175},"Albiges-Rizo, 2009, Actin machinery and mechanosensitivity in invadopodia, podosomes and focal adhesions, J Cell Sci., 122, 3037, 10.1242\u002Fjcs.052704",{"doi":6176},"10.1242\u002Fjcs.052704",{"id":26,"text":6178,"url":26,"identifiers":6179},"Geiger, 2011, Molecular architecture and function of matrix adhesions, Cold Spring Harb Perspect Biol., 3, a005033, 10.1101\u002Fcshperspect.a005033",{"doi":6180},"10.1101\u002Fcshperspect.a005033",{"id":26,"text":6182,"url":26,"identifiers":6183},"Wang, 2012, Invasive matrix degradation at focal adhesions occurs via protease recruitment by a FAK-p130Cas complex, J Cell Biol., 196, 375, 10.1083\u002Fjcb.201105153",{"doi":6184},"10.1083\u002Fjcb.201105153",{"id":26,"text":6186,"url":26,"identifiers":6187},"Jacob, 2015, The regulation of MMP targeting to invadopodia during cancer metastasis, Front Cell Dev Biol., 3, 4, 10.3389\u002Ffcell.2015.00004",{"doi":6188},"10.3389\u002Ffcell.2015.00004",{"id":26,"text":6190,"url":26,"identifiers":6191},"Leong, 2014, Invadopodia are required for cancer cell extravasation and are a therapeutic target for metastasis, Cell Rep., 8, 1558, 10.1016\u002Fj.celrep.2014.07.050",{"doi":6192},"10.1016\u002Fj.celrep.2014.07.050",{"id":26,"text":6194,"url":26,"identifiers":6195},"Goetz, 2011, Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis, Cell, 146, 148, 10.1016\u002Fj.cell.2011.05.040",{"doi":6196},"10.1016\u002Fj.cell.2011.05.040",{"id":26,"text":6198,"url":26,"identifiers":6199},"Scott, 2010, LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells, J Cell Biol., 191, 169, 10.1083\u002Fjcb.201002041",{"doi":6200},"10.1083\u002Fjcb.201002041",{"id":26,"text":6202,"url":26,"identifiers":6203},"Boire, 2005, PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells, Cell, 120, 303, 10.1016\u002Fj.cell.2004.12.018",{"doi":6204},"10.1016\u002Fj.cell.2004.12.018",{"id":26,"text":6206,"url":26,"identifiers":6207},"Gocheva, 2010, IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion, Genes Dev., 24, 241, 10.1101\u002Fgad.1874010",{"doi":6208},"10.1101\u002Fgad.1874010",{"id":26,"text":6210,"url":26,"identifiers":6211},"Faurobert, 2015, Microenvironment, tumor cell plasticity, and cancer, Curr Opin Oncol., 27, 64, 10.1097\u002FCCO.0000000000000154",{"doi":6212},"10.1097\u002FCCO.0000000000000154",{"id":26,"text":6214,"url":26,"identifiers":6215},"Massague, 2012, TGF-beta control of stem cell differentiation genes, FEBS Lett., 586, 1953, 10.1016\u002Fj.febslet.2012.03.023",{"doi":6216},"10.1016\u002Fj.febslet.2012.03.023",{"id":26,"text":6218,"url":26,"identifiers":6219},"Heldin, 1997, TGF-beta signalling from cell membrane to nucleus through SMAD proteins, Nature, 390, 465, 10.1038\u002F37284",{"doi":6220},"10.1038\u002F37284",{"id":26,"text":6222,"url":26,"identifiers":6223},"Shi, 2003, Mechanisms of TGF-beta signaling from cell membrane to the nucleus, Cell, 113, 685, 10.1016\u002FS0092-8674(03)00432-X",{"doi":6224},"10.1016\u002FS0092-8674(03)00432-X",{"id":26,"text":6226,"url":26,"identifiers":6227},"Sun, 1995, The cystine-knot growth-factor superfamily, Annu Rev Biophys Biomol Struct., 24, 269, 10.1146\u002Fannurev.bb.24.060195.001413",{"doi":6228},"10.1146\u002Fannurev.bb.24.060195.001413",{"id":26,"text":6230,"url":26,"identifiers":6231},"Assoian, 1987, Expression and secretion of type beta transforming growth factor by activated human macrophages, Proc Natl Acad Sci USA., 84, 6020, 10.1073\u002Fpnas.84.17.6020",{"doi":6232},"10.1073\u002Fpnas.84.17.6020",{"id":26,"text":6234,"url":26,"identifiers":6235},"Schultz-Cherry, 1993, Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism, J Cell Biol., 122, 923, 10.1083\u002Fjcb.122.4.923",{"doi":6236},"10.1083\u002Fjcb.122.4.923",{"id":26,"text":6238,"url":26,"identifiers":6239},"Kelley, 1991, Cytokine signaling in lung: transforming growth factor-beta secretion by lung fibroblasts, Am J Physiol., 260, L123",{},{"id":26,"text":6241,"url":26,"identifiers":6242},"Massague, 2012, TGFbeta signalling in context, Nat Rev Mol Cell Biol., 13, 616, 10.1038\u002Fnrm3434",{"doi":6243},"10.1038\u002Fnrm3434",{"id":26,"text":6245,"url":26,"identifiers":6246},"Cui, 1996, TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice, Cell, 86, 531, 10.1016\u002FS0092-8674(00)80127-0",{"doi":6247},"10.1016\u002FS0092-8674(00)80127-0",{"id":26,"text":6249,"url":26,"identifiers":6250},"Oft, 1998, TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis, Curr Biol., 8, 1243, 10.1016\u002FS0960-9822(07)00533-7",{"doi":6251},"10.1016\u002FS0960-9822(07)00533-7",{"id":26,"text":6253,"url":26,"identifiers":6254},"Muraoka, 2002, Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases, J Clin Invest., 109, 1551, 10.1172\u002FJCI0215234",{"doi":6255},"10.1172\u002FJCI0215234",{"id":26,"text":6257,"url":26,"identifiers":6258},"Ischenko, 2014, Transforming growth factor-beta signaling network regulates plasticity and lineage commitment of lung cancer cells, Cell Death Differ., 21, 1218, 10.1038\u002Fcdd.2014.38",{"doi":6259},"10.1038\u002Fcdd.2014.38",{"id":26,"text":6261,"url":26,"identifiers":6262},"Taylor, 2011, Lysyl oxidase contributes to mechanotransduction-mediated regulation of transforming growth factor-beta signaling in breast cancer cells, Neoplasia, 13, 406, 10.1593\u002Fneo.101086",{"doi":6263},"10.1593\u002Fneo.101086",{"id":26,"text":6265,"url":26,"identifiers":6266},"Cox, 2013, LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis, Cancer Res., 73, 1721, 10.1158\u002F0008-5472.CAN-12-2233",{"doi":6267},"10.1158\u002F0008-5472.CAN-12-2233",{"id":26,"text":6269,"url":26,"identifiers":6270},"Taipale, 1994, Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein, J Cell Biol., 124, 171, 10.1083\u002Fjcb.124.1.171",{"doi":6271},"10.1083\u002Fjcb.124.1.171",{"id":26,"text":6273,"url":26,"identifiers":6274},"Babic, 1999, Fisp12\u002Fmouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo, Mol Cell Biol., 19, 2958, 10.1128\u002FMCB.19.4.2958",{"doi":6275},"10.1128\u002FMCB.19.4.2958",{"id":26,"text":6277,"url":26,"identifiers":6278},"Abreu, 2002, Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta, Nat Cell Biol., 4, 599, 10.1038\u002Fncb826",{"doi":6279},"10.1038\u002Fncb826",{"id":26,"text":6281,"url":26,"identifiers":6282},"Chang, 2013, Connective tissue growth factor activates pluripotency genes and mesenchymal-epithelial transition in head and neck cancer cells, Cancer Res., 73, 4147, 10.1158\u002F0008-5472.CAN-12-4085",{"doi":6283},"10.1158\u002F0008-5472.CAN-12-4085",{"id":26,"text":6285,"url":26,"identifiers":6286},"Zeng, 2017, Connective tissue growth factor promotes temozolomide resistance in glioblastoma through TGF-beta1-dependent activation of Smad\u002FERK signaling, Cell Death Dis., 8, e2885, 10.1038\u002Fcddis.2017.248",{"doi":6287},"10.1038\u002Fcddis.2017.248",{"id":26,"text":6289,"url":26,"identifiers":6290},"Finger, 2014, CTGF is a therapeutic target for metastatic melanoma, Oncogene, 33, 1093, 10.1038\u002Fonc.2013.47",{"doi":6291},"10.1038\u002Fonc.2013.47",{"id":26,"text":6293,"url":26,"identifiers":6294},"Tamai, 2000, LDL-receptor-related proteins in Wnt signal transduction, Nature, 407, 530, 10.1038\u002F35035117",{"doi":6295},"10.1038\u002F35035117",{"id":26,"text":6297,"url":26,"identifiers":6298},"Bhanot, 1996, A new member of the frizzled family from Drosophila functions as a Wingless receptor, Nature, 382, 225, 10.1038\u002F382225a0",{"doi":6299},"10.1038\u002F382225a0",{"id":26,"text":6301,"url":26,"identifiers":6302},"Itoh, 1998, Axis determination in Xenopus involves biochemical interactions of axin, glycogen synthase kinase 3 and beta-catenin, Curr Biol., 8, 591, 10.1016\u002FS0960-9822(98)70229-5",{"doi":6303},"10.1016\u002FS0960-9822(98)70229-5",{"id":26,"text":6305,"url":26,"identifiers":6306},"Kishida, 1999, DIX domains of Dvl and axin are necessary for protein interactions and their ability to regulate beta-catenin stability, Mol Cell Biol., 19, 4414, 10.1128\u002FMCB.19.6.4414",{"doi":6307},"10.1128\u002FMCB.19.6.4414",{"id":26,"text":6309,"url":26,"identifiers":6310},"Smalley, 1999, Interaction of axin and Dvl-2 proteins regulates Dvl-2-stimulated TCF-dependent transcription, Embo J., 18, 2823, 10.1093\u002Femboj\u002F18.10.2823",{"doi":6311},"10.1093\u002Femboj\u002F18.10.2823",{"id":26,"text":6313,"url":26,"identifiers":6314},"Rubinfeld, 1996, Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly, Science, 272, 1023, 10.1126\u002Fscience.272.5264.1023",{"doi":6315},"10.1126\u002Fscience.272.5264.1023",{"id":26,"text":6317,"url":26,"identifiers":6318},"Yost, 1996, The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3, Genes Dev., 10, 1443, 10.1101\u002Fgad.10.12.1443",{"doi":6319},"10.1101\u002Fgad.10.12.1443",{"id":26,"text":6321,"url":26,"identifiers":6322},"Hart, 1998, Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta, Curr Biol., 8, 573, 10.1016\u002FS0960-9822(98)70226-X",{"doi":6323},"10.1016\u002FS0960-9822(98)70226-X",{"id":26,"text":6325,"url":26,"identifiers":6326},"Yamamoto, 1999, Phosphorylation of axin, a Wnt signal negative regulator, by glycogen synthase kinase-3beta regulates its stability, J Biol Chem., 274, 10681, 10.1074\u002Fjbc.274.16.10681",{"doi":6327},"10.1074\u002Fjbc.274.16.10681",{"id":26,"text":6329,"url":26,"identifiers":6330},"Aberle, 1997, beta-catenin is a target for the ubiquitin-proteasome pathway, Embo J., 16, 3797, 10.1093\u002Femboj\u002F16.13.3797",{"doi":6331},"10.1093\u002Femboj\u002F16.13.3797",{"id":26,"text":6333,"url":26,"identifiers":6334},"Marikawa, 1998, beta-TrCP is a negative regulator of Wnt\u002Fbeta-catenin signaling pathway and dorsal axis formation in Xenopus embryos, Mech Dev., 77, 75, 10.1016\u002FS0925-4773(98)00134-8",{"doi":6335},"10.1016\u002FS0925-4773(98)00134-8",{"id":26,"text":6337,"url":26,"identifiers":6338},"Behrens, 1996, Functional interaction of beta-catenin with the transcription factor LEF-1, Nature, 382, 638, 10.1038\u002F382638a0",{"doi":6339},"10.1038\u002F382638a0",{"id":26,"text":6341,"url":26,"identifiers":6342},"Roose, 1998, The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors, Nature, 395, 608, 10.1038\u002F26989",{"doi":6343},"10.1038\u002F26989",{"id":26,"text":6345,"url":26,"identifiers":6346},"Waltzer, 1998, Drosophila CBP represses the transcription factor TCF to antagonize Wingless signalling, Nature, 395, 521, 10.1038\u002F26785",{"doi":6347},"10.1038\u002F26785",{"id":26,"text":6349,"url":26,"identifiers":6350},"Brannon, 1999, XCtBP is a XTcf-3 co-repressor with roles throughout Xenopus development, Development, 126, 3159, 10.1242\u002Fdev.126.14.3159",{"doi":6351},"10.1242\u002Fdev.126.14.3159",{"id":26,"text":6353,"url":26,"identifiers":6354},"Brantjes, 2001, All Tcf HMG box transcription factors interact with Groucho-related co-repressors, Nucleic Acids Res., 29, 1410, 10.1093\u002Fnar\u002F29.7.1410",{"doi":6355},"10.1093\u002Fnar\u002F29.7.1410",{"id":26,"text":6357,"url":26,"identifiers":6358},"Yook, 2006, A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells, Nat Cell Biol., 8, 1398, 10.1038\u002Fncb1508",{"doi":6359},"10.1038\u002Fncb1508",{"id":26,"text":6361,"url":26,"identifiers":6362},"Conacci-Sorrell, 2003, Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of beta-catenin signaling, Slug, and MAPK, J Cell Biol., 163, 847, 10.1083\u002Fjcb.200308162",{"doi":6363},"10.1083\u002Fjcb.200308162",{"id":26,"text":6365,"url":26,"identifiers":6366},"Howe, 2003, Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation, Cancer Res., 63, 1906",{},{"id":26,"text":6368,"url":26,"identifiers":6369},"Dimeo, 2009, A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer, Cancer Res., 69, 5364, 10.1158\u002F0008-5472.CAN-08-4135",{"doi":6370},"10.1158\u002F0008-5472.CAN-08-4135",{"id":26,"text":6372,"url":26,"identifiers":6373},"Xu, 2015, Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt\u002Fbeta-catenin signaling pathway, Cancer Lett., 356, 613, 10.1016\u002Fj.canlet.2014.10.008",{"doi":6374},"10.1016\u002Fj.canlet.2014.10.008",{"id":26,"text":6376,"url":26,"identifiers":6377},"Gujral, 2014, A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis, Cell, 159, 844, 10.1016\u002Fj.cell.2014.10.032",{"doi":6378},"10.1016\u002Fj.cell.2014.10.032",{"id":26,"text":6380,"url":26,"identifiers":6381},"Pinto, 2003, Canonical Wnt signals are essential for homeostasis of the intestinal epithelium, Genes Dev., 17, 1709, 10.1101\u002Fgad.267103",{"doi":6382},"10.1101\u002Fgad.267103",{"id":26,"text":6384,"url":26,"identifiers":6385},"Bastide, 2007, Sox9 regulates cell proliferation and is required for Paneth cell differentiation in the intestinal epithelium, J Cell Biol., 178, 635, 10.1083\u002Fjcb.200704152",{"doi":6386},"10.1083\u002Fjcb.200704152",{"id":26,"text":6388,"url":26,"identifiers":6389},"Goessling, 2009, Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration, Cell, 136, 1136, 10.1016\u002Fj.cell.2009.01.015",{"doi":6390},"10.1016\u002Fj.cell.2009.01.015",{"id":26,"text":6392,"url":26,"identifiers":6393},"Du, 2016, Extracellular matrix stiffness dictates Wnt expression through integrin pathway, Sci Rep., 6, 20395, 10.1038\u002Fsrep20395",{"doi":6394},"10.1038\u002Fsrep20395",{"id":26,"text":6396,"url":26,"identifiers":6397},"Etienne-Manneville, 2002, Rho GTPases in cell biology, Nature, 420, 629, 10.1038\u002Fnature01148",{"doi":6398},"10.1038\u002Fnature01148",{"id":26,"text":6400,"url":26,"identifiers":6401},"Samuel, 2018, ROCK, Encyclopedia of Signaling Molecules., 4746, 10.1007\u002F978-3-319-67199-4_328",{"doi":6402},"10.1007\u002F978-3-319-67199-4_328",{"id":26,"text":6404,"url":26,"identifiers":6405},"Leung, 1995, A novel serine\u002Fthreonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes, J Biol Chem., 270, 29051, 10.1074\u002Fjbc.270.49.29051",{"doi":6406},"10.1074\u002Fjbc.270.49.29051",{"id":26,"text":6408,"url":26,"identifiers":6409},"Ishizaki, 1996, The small GTP-binding protein Rho binds to and activates a 160 kDa Ser\u002FThr protein kinase homologous to myotonic dystrophy kinase, Embo J., 15, 1885, 10.1002\u002Fj.1460-2075.1996.tb00539.x",{"doi":6410},"10.1002\u002Fj.1460-2075.1996.tb00539.x",{"id":26,"text":6412,"url":26,"identifiers":6413},"Matsui, 1996, Rho-associated kinase, a novel serine\u002Fthreonine kinase, as a putative target for small GTP binding protein Rho, Embo J., 15, 2208, 10.1002\u002Fj.1460-2075.1996.tb00574.x",{"doi":6414},"10.1002\u002Fj.1460-2075.1996.tb00574.x",{"id":26,"text":6416,"url":26,"identifiers":6417},"Scott, 2007, LIM kinases: function, regulation and association with human disease, J Mol Med (Berl)., 85, 555, 10.1007\u002Fs00109-007-0165-6",{"doi":6418},"10.1007\u002Fs00109-007-0165-6",{"id":26,"text":6420,"url":26,"identifiers":6421},"Croft, 2011, p53-mediated transcriptional regulation and activation of the actin cytoskeleton regulatory RhoC to LIMK2 signaling pathway promotes cell survival, Cell Res., 21, 666, 10.1038\u002Fcr.2010.154",{"doi":6422},"10.1038\u002Fcr.2010.154",{"id":26,"text":6424,"url":26,"identifiers":6425},"Olson, 2009, The actin cytoskeleton in cancer cell motility, Clin Exp Meta., 26, 273, 10.1007\u002Fs10585-008-9174-2",{"doi":6426},"10.1007\u002Fs10585-008-9174-2",{"id":26,"text":6428,"url":26,"identifiers":6429},"Narumiya, 2009, Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion, Cancer Metastasis Rev., 28, 65, 10.1007\u002Fs10555-008-9170-7",{"doi":6430},"10.1007\u002Fs10555-008-9170-7",{"id":26,"text":6432,"url":26,"identifiers":6433},"Woodcock, 2015, Destabilisation of dimeric 14–3-3 proteins as a novel approach to anti-cancer therapeutics, Oncotarget, 6, 14522, 10.18632\u002Foncotarget.3995",{"doi":6434},"10.18632\u002Foncotarget.3995",{"id":26,"text":6436,"url":26,"identifiers":6437},"Harvey, 2003, The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis, Cell, 114, 457, 10.1016\u002FS0092-8674(03)00557-9",{"doi":6438},"10.1016\u002FS0092-8674(03)00557-9",{"id":26,"text":6440,"url":26,"identifiers":6441},"Vassilev, 2001, TEAD\u002FTEF transcription factors utilize the activation domain of YAP65, a Src\u002FYes-associated protein localized in the cytoplasm, Genes Dev., 15, 1229, 10.1101\u002Fgad.888601",{"doi":6442},"10.1101\u002Fgad.888601",{"id":26,"text":6444,"url":26,"identifiers":6445},"Dupont, 2011, Role of YAP\u002FTAZ in mechanotransduction, Nature, 474, 179, 10.1038\u002Fnature10137",{"doi":6446},"10.1038\u002Fnature10137",{"id":26,"text":6448,"url":26,"identifiers":6449},"Panciera, 2017, Mechanobiology of YAP and TAZ in physiology and disease, Nat Rev Mol Cell Biol., 18, 758, 10.1038\u002Fnrm.2017.87",{"doi":6450},"10.1038\u002Fnrm.2017.87",{"id":26,"text":6452,"url":26,"identifiers":6453},"Diepenbruck, 2014, Tead2 expression levels control the subcellular distribution of Yap and Taz, zyxin expression and epithelial-mesenchymal transition, J Cell Sci., 127, 1523, 10.1242\u002Fjcs.139865",{"doi":6454},"10.1242\u002Fjcs.139865",{"id":26,"text":6456,"url":26,"identifiers":6457},"Kim, 2017, Hippo signaling interactions with Wnt\u002Fbeta-catenin and Notch signaling repress liver tumorigenesis, J Clin Invest., 127, 137, 10.1172\u002FJCI88486",{"doi":6458},"10.1172\u002FJCI88486",{"id":26,"text":6460,"url":26,"identifiers":6461},"Campos, 2006, Notch, epidermal growth factor receptor, and beta1-integrin pathways are coordinated in neural stem cells, J Biol Chem., 281, 5300, 10.1074\u002Fjbc.M511886200",{"doi":6462},"10.1074\u002Fjbc.M511886200",{"id":26,"text":6464,"url":26,"identifiers":6465},"Quail, 2012, Microenvironmental regulation of cancer stem cell phenotypes, Curr Stem Cell Res Ther., 7, 197, 10.2174\u002F157488812799859838",{"doi":6466},"10.2174\u002F157488812799859838",{"id":26,"text":6468,"url":26,"identifiers":6469},"Shirakihara, 2011, TGF-beta regulates isoform switching of FGF receptors and epithelial-mesenchymal transition, EMBO J., 30, 783, 10.1038\u002Femboj.2010.351",{"doi":6470},"10.1038\u002Femboj.2010.351",{"id":26,"text":6472,"url":26,"identifiers":6473},"Spina, 2015, HGF\u002Fc-MET axis in tumor microenvironment and metastasis formation, Biomedicines, 3, 71, 10.3390\u002Fbiomedicines3010071",{"doi":6474},"10.3390\u002Fbiomedicines3010071",{"id":6476,"createTime":6477,"updateTime":6477,"relativeEntities":6478,"slug":6479,"properties":6480,"entityType":772,"verifyStatus":25,"verifyTime":6477,"verifyNote":773,"syncStatus":28,"languages":6495,"translateLanguages":26,"viewCount":36,"primaryUrl":6496,"fullTextUrl":26,"authors":6497,"publicationType":843,"publisherRelationship":6620,"citationCount":6654,"citationInfo":6655,"publishDate":26,"publishYear":26,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":6658,"isForceReanalyzing":1390},"01562a3c-ef84-41d3-9090-6a5731a01a1f","2024-10-13T14:20:05.224+00:00",[],"Signal-Transducer-and-Activator-of-Transcription-STATs-Proteins-in-Cancer-and-Inflammation-Functions-and-Therapeutic-Implication",{"mag":6481,"keywords":6483,"pmc":6484,"openalex":6486,"abstract":6488,"title":6489,"pm":6491,"doi":6493},{"VOID":6482},"2917410143",{},{"VOID":6485},"6393348",{"VOID":6487},"W2917410143",{},{"EN":6490},"Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication",{"VOID":6492},"30847297",{"VOID":6494},"10.3389\u002Ffonc.2019.00048",[102],"https:\u002F\u002Fwww.frontiersin.org\u002Farticle\u002F10.3389\u002Ffonc.2019.00048\u002Ffull",[6498,6520,6542,6564,6583,6605],{"id":6499,"sortIndex":162,"researcher":26,"roles":6500,"affiliations":6501,"properties":6513},"05668612-7556-4703-bee9-0c1aa20f865c",[],[6502],{"id":6503,"sortIndex":36,"affiliation":6504,"properties":26},"f2625a2d-87db-487a-b856-9c3f1a787bc2",{"id":6505,"createTime":6506,"updateTime":6507,"relativeEntities":6508,"slug":6509,"properties":6510,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"9de6299f-216a-435e-8298-25ee1aeae48a","2024-01-05T12:50:23.370+00:00","2024-10-13T14:20:05.246+00:00",[],"School-of-Biosciences-Faculty-of-Health-and-Medical-Sciences-Taylor-s-University-Subang-Jaya-Malaysia",{"title":6511},{"VI":6512},"School of Biosciences, Faculty of Health and Medical Sciences, Taylor’s University, Subang Jaya, Malaysia",{"openalex":6514,"orcid":6516,"title":6518},{"VOID":6515},"A5053135777",{"VOID":6517},"https:\u002F\u002Forcid.org\u002F0000-0002-4830-3495",{"EN":6519},"Chung Yeng Looi",{"id":6521,"sortIndex":115,"researcher":26,"roles":6522,"affiliations":6523,"properties":6535},"93ce5005-49aa-48df-8250-8f5265ac5650",[],[6524],{"id":6525,"sortIndex":36,"affiliation":6526,"properties":26},"3fe3717e-c385-4cfe-9f0b-7b67373cea41",{"id":6527,"createTime":6528,"updateTime":6529,"relativeEntities":6530,"slug":6531,"properties":6532,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"068ea55d-fa22-4a03-a8ed-fd94a19db530","2023-12-06T05:50:35.399+00:00","2025-06-11T19:37:29.724+00:00",[],"School-of-Medicine-Faculty-of-Health-and-Medical-Sciences-Taylor-s-University-Subang-Jaya-Malaysia",{"title":6533},{"VI":6534},"School of Medicine, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya, Malaysia",{"openalex":6536,"orcid":6538,"title":6540},{"VOID":6537},"A5019325995",{"VOID":6539},"https:\u002F\u002Forcid.org\u002F0000-0002-8747-3462",{"EN":6541},"Aditya Arya",{"id":6543,"sortIndex":59,"researcher":26,"roles":6544,"affiliations":6545,"properties":6557},"8392591e-6d4a-4621-bb51-12ae102e4d02",[],[6546],{"id":6547,"sortIndex":36,"affiliation":6548,"properties":26},"24b876dd-7501-4811-82f4-61c9c8d007fa",{"id":6549,"createTime":6550,"updateTime":6551,"relativeEntities":6552,"slug":6553,"properties":6554,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"98ede796-f606-4b14-9a99-d129a8e4c101","2024-01-04T06:07:33.620+00:00","2024-10-17T08:58:17.614+00:00",[],"Department-of-Medical-Microbiology-Faculty-of-Medicine-University-of-Malaya-Kuala-Lumpur-Malaysia",{"title":6555},{"VI":6556},"Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia",{"openalex":6558,"orcid":6560,"title":6562},{"VOID":6559},"A5027392490",{"VOID":6561},"https:\u002F\u002Forcid.org\u002F0000-0003-1082-1956",{"EN":6563},"Won Fen Wong",{"id":6565,"sortIndex":114,"researcher":26,"roles":6566,"affiliations":6567,"properties":6578},"9bbb1c2d-0ffe-4410-8297-528f2fe2fe71",[],[6568],{"id":6569,"sortIndex":36,"affiliation":6570,"properties":26},"da7180e8-a6e7-48a9-8279-4bc409f3f477",{"id":6571,"createTime":6572,"updateTime":6572,"relativeEntities":6573,"slug":6574,"properties":6575,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"275121c7-99c3-4022-9b7f-1d1fb727b50e","2024-10-13T14:20:05.267+00:00",[],"Center-of-Biotechnology-Researches-University-of-Al-Nahrain-Baghdad-Iraq",{"title":6576},{"EN":6577},"Center of Biotechnology Researches, University of Al-Nahrain, Baghdad, Iraq",{"openalex":6579,"title":6581},{"VOID":6580},"A5026384763",{"EN":6582},"Ahmed Fadhil Naema",{"id":6584,"sortIndex":111,"researcher":26,"roles":6585,"affiliations":6586,"properties":6598},"a65a2997-e4da-4875-96aa-3926cded5818",[],[6587],{"id":6588,"sortIndex":36,"affiliation":6589,"properties":26},"6f539fe8-77f5-4f25-92af-aec2c6f70628",{"id":6590,"createTime":6591,"updateTime":6592,"relativeEntities":6593,"slug":6594,"properties":6595,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"4786704c-3bb0-4cbc-873d-5246a3f4790d","2023-12-11T06:22:31.031+00:00","2024-10-13T14:20:05.289+00:00",[],"Department-of-Pharmacology-Yong-Loo-Lin-School-of-Medicine-National-University-of-Singapore-Singapore-Singapore",{"title":6596},{"VI":6597},"Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore",{"openalex":6599,"orcid":6601,"title":6603},{"VOID":6600},"A5034304968",{"VOID":6602},"https:\u002F\u002Forcid.org\u002F0000-0002-8677-8475",{"EN":6604},"Gautam Sethi",{"id":6606,"sortIndex":36,"researcher":26,"roles":6607,"affiliations":6608,"properties":6615},"b8991d92-af67-462e-b1f6-c53189a4829e",[],[6609],{"id":6610,"sortIndex":36,"affiliation":6611,"properties":26},"d8e05e01-8b29-4a58-9477-7ebad0bf5ffb",{"id":6505,"createTime":6506,"updateTime":6507,"relativeEntities":6612,"slug":6509,"properties":6613,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":6614},{"VI":6512},{"openalex":6616,"title":6618},{"VOID":6617},"A5064818278",{"EN":6619},"Choy-Theng Loh",{"url":26,"publisher":6621,"properties":6651},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":6622,"slug":663,"properties":6623,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":6629,"manageAffiliations":6630,"indexDatabases":6631,"url":742,"thumbnailPath":26,"statistic":6646,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"country":6624,"issn":6625,"introduce":6626,"eissn":6627,"title":6628},{"VOID":666},{"VOID":668},{"EN":670},{"VOID":668},{"EN":673},[],[],[6632,6639],{"id":704,"indexDatabase":6633,"url":719,"indexYears":26,"academicFieldIds":6638,"indexDatabaseRanking":26},{"id":706,"createTime":707,"updateTime":708,"relativeEntities":6634,"label":6635,"description":6636,"key":715,"publicationTags":6637,"standard":26},[],{"EN":711,"VI":711},{"VI":713,"EN":714},[717,718],[721],{"id":723,"indexDatabase":6640,"url":736,"indexYears":737,"academicFieldIds":6645,"indexDatabaseRanking":741},{"id":725,"createTime":726,"updateTime":727,"relativeEntities":6641,"label":6642,"description":6643,"key":733,"publicationTags":6644,"standard":26},[],{"EN":730,"VI":730},{"EN":730,"VI":732},[735],[739,740],{"impactFactor":36,"impactFactorByYear":6647,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":115,"totalPublicationByYear":6648,"totalCitation":158,"totalCitationByYear":6649,"totalCitationPerPublication":158,"totalCitationPerPublicationByYear":6650,"hindexLast5Year":115,"hindex":115},{},{"2021":115},{"2021":158},{"2021":158},{"volume":6652},{"VOID":6653},"9",298,{"total":6654,"publishYear":26,"statisticByYear":6656},{"2019":516,"2020":281,"2021":6657,"2022":358,"2023":253,"2024":168},61,[6659,6663,6667,6671,6675,6678,6682,6686,6690,6694,6698,6702,6706,6710,6714,6718,6722,6726,6730,6734,6738,6742,6746,6750,6754,6758,6762,6766,6770,6774,6778,6782,6786,6790,6794,6798,6802,6806,6810,6814,6818,6822,6826,6830,6834,6838,6842,6846,6850,6854,6858,6862,6866,6870,6874,6878,6882,6886,6890,6894,6898,6902,6906,6910,6914,6918,6922,6926,6930,6934,6938,6942,6946,6950,6954,6958,6962,6966,6970,6974,6978,6982,6986,6990,6994,6998,7002,7006,7010,7014,7018,7022,7026,7030,7034,7038,7042,7046,7050,7054,7058,7062,7066,7070,7074,7078,7082,7086,7090,7094,7098,7102,7106,7110,7114,7118,7122,7126,7129,7133,7137,7141,7145,7149,7153,7157,7161,7165,7169,7173,7177,7181,7185,7189,7193,7197,7201,7205,7209,7213,7217,7221,7225,7229,7233,7237,7241,7245,7249,7253,7257,7261,7265,7269,7273,7277,7281,7285,7289,7293,7297,7301,7305,7309,7313,7317,7321,7325,7329,7333,7337,7341,7345,7349,7353,7357,7361,7365,7369,7373,7377,7381,7385,7389,7393,7397,7401,7405,7409,7413,7417,7421,7425,7429],{"id":26,"text":6660,"url":26,"identifiers":6661},"Catlett-Falcone, 1999, Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells, Immunity, 10, 105, 10.1016\u002FS1074-7613(00)80011-4",{"doi":6662},"10.1016\u002FS1074-7613(00)80011-4",{"id":26,"text":6664,"url":26,"identifiers":6665},"Grandis, 1998, Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth in vitro, J Clin Invest., 102, 1385, 10.1172\u002FJCI3785",{"doi":6666},"10.1172\u002FJCI3785",{"id":26,"text":6668,"url":26,"identifiers":6669},"Lou, 2000, Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway, Prostate, 42, 239, 10.1002\u002F(SICI)1097-0045(20000215)42:3\u003C239::AID-PROS10>3.0.CO;2-G",{"doi":6670},"10.1002\u002F(SICI)1097-0045(20000215)42:3\u003C239::AID-PROS10>3.0.CO;2-G",{"id":26,"text":6672,"url":26,"identifiers":6673},"Zhang, 2002, Requirement of Stat3 signaling for HGF\u002FSF-Met mediated tumorigenesis, Oncogene, 21, 217, 10.1038\u002Fsj.onc.1205004",{"doi":6674},"10.1038\u002Fsj.onc.1205004",{"id":26,"text":6676,"url":26,"identifiers":6677},"Kaido, 2004, Interleukin-6 augments hepatocyte growth factor-induced liver regeneration; involvement of STAT3 activation, Hepatogastroenterology, 51, 1667",{},{"id":26,"text":6679,"url":26,"identifiers":6680},"Hung, 2001, Co-operative effect of c-Src tyrosine kinase and Stat3 in activation of hepatocyte growth factor expression in mammary carcinoma cells, J Biol Chem., 276, 12395, 10.1074\u002Fjbc.M010715200",{"doi":6681},"10.1074\u002Fjbc.M010715200",{"id":26,"text":6683,"url":26,"identifiers":6684},"Garcia, 2001, Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells, Oncogene, 20, 2499, 10.1038\u002Fsj.onc.1204349",{"doi":6685},"10.1038\u002Fsj.onc.1204349",{"id":26,"text":6687,"url":26,"identifiers":6688},"Bowman, 2000, STATs in oncogenesis, Oncogene, 19, 2474, 10.1038\u002Fsj.onc.1203527",{"doi":6689},"10.1038\u002Fsj.onc.1203527",{"id":26,"text":6691,"url":26,"identifiers":6692},"Lin, 2000, STAT signaling in the pathogenesis and treatment of leukemias, Oncogene, 19, 2496, 10.1038\u002Fsj.onc.1203486",{"doi":6693},"10.1038\u002Fsj.onc.1203486",{"id":26,"text":6695,"url":26,"identifiers":6696},"Schwaller, 2000, Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL\u002FJAK2, Mol Cell, 6, 693, 10.1016\u002FS1097-2765(00)00067-8",{"doi":6697},"10.1016\u002FS1097-2765(00)00067-8",{"id":26,"text":6699,"url":26,"identifiers":6700},"Bromberg, 1996, Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma, Proc Natl Acad Sci USA., 93, 7673, 10.1073\u002Fpnas.93.15.7673",{"doi":6701},"10.1073\u002Fpnas.93.15.7673",{"id":26,"text":6703,"url":26,"identifiers":6704},"Shankaran, 2001, IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity, Nature, 410, 1107, 10.1038\u002F35074122",{"doi":6705},"10.1038\u002F35074122",{"id":26,"text":6707,"url":26,"identifiers":6708},"Gao, 2007, Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas, J Clin Invest., 117, 3846, 10.1172\u002FJCI31871",{"doi":6709},"10.1172\u002FJCI31871",{"id":26,"text":6711,"url":26,"identifiers":6712},"Ernst, 2008, STAT3 and STAT1 mediate IL-11–dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice, J Clin Invest., 118, 1727, 10.1172\u002FJCI34944",{"doi":6713},"10.1172\u002FJCI34944",{"id":26,"text":6715,"url":26,"identifiers":6716},"Arredondo, 2006, Receptor-mediated tobacco toxicity: cooperation of the Ras\u002FRaf-1\u002FMEK1\u002FERK and JAK-2\u002FSTAT-3 pathways downstream of α7 nicotinic receptor in oral keratinocytes, FASEB J., 20, 2093, 10.1096\u002Ffj.06-6191com",{"doi":6717},"10.1096\u002Ffj.06-6191com",{"id":26,"text":6719,"url":26,"identifiers":6720},"Sano, 2005, Signal transducer and activator of transcription 3 is a key regulator of keratinocyte survival and proliferation following UV irradiation, Cancer Res., 65, 5720, 10.1158\u002F0008-5472.CAN-04-4359",{"doi":6721},"10.1158\u002F0008-5472.CAN-04-4359",{"id":26,"text":6723,"url":26,"identifiers":6724},"O'shea, 2012, JAK and STAT signaling molecules in immunoregulation and immune-mediated disease, Immunity, 36, 542, 10.1016\u002Fj.immuni.2012.03.014",{"doi":6725},"10.1016\u002Fj.immuni.2012.03.014",{"id":26,"text":6727,"url":26,"identifiers":6728},"Rauch, 2013, The regulation of inflammation by interferons and their STATs, JAKSTAT, 2, e23820, 10.4161\u002Fjkst.23820",{"doi":6729},"10.4161\u002Fjkst.23820",{"id":26,"text":6731,"url":26,"identifiers":6732},"Rani, 2016, STAT5 in cancer and immunity, J Interferon Cytokine Res., 36, 226, 10.1089\u002Fjir.2015.0054",{"doi":6733},"10.1089\u002Fjir.2015.0054",{"id":26,"text":6735,"url":26,"identifiers":6736},"Glosson, 2012, Wheezing and itching: the requirement for STAT proteins in allergic inflammation, JAKSTAT, 1, 3, 10.4161\u002Fjkst.19086",{"doi":6737},"10.4161\u002Fjkst.19086",{"id":26,"text":6739,"url":26,"identifiers":6740},"O'shea, 2011, Genomic views of STAT function in CD4+ T helper cell differentiation, Nat Rev Immunol., 11, 239, 10.1038\u002Fnri2958",{"doi":6741},"10.1038\u002Fnri2958",{"id":26,"text":6743,"url":26,"identifiers":6744},"Stritesky, 2011, Changing the STATus quo in T helper cells, Transcription, 2, 179, 10.4161\u002Ftrns.2.4.16614",{"doi":6745},"10.4161\u002Ftrns.2.4.16614",{"id":26,"text":6747,"url":26,"identifiers":6748},"Aggarwal, 2006, Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution, Ann N Y Acad Sci., 1091, 151, 10.1196\u002Fannals.1378.063",{"doi":6749},"10.1196\u002Fannals.1378.063",{"id":26,"text":6751,"url":26,"identifiers":6752},"Chai, 2016, Targeting transcription factor STAT3 for cancer prevention and therapy, Pharmacol Ther., 162, 86, 10.1016\u002Fj.pharmthera.2015.10.004",{"doi":6753},"10.1016\u002Fj.pharmthera.2015.10.004",{"id":26,"text":6755,"url":26,"identifiers":6756},"Subramaniam, 2014, Possible involvement of signal transducer and activator of transcription-3 (STAT3) signaling pathway in the initiation and progression of hepatocellular carcinoma, Perspectives in Cancer Prevention-Translational Cancer Research, 73, 10.1007\u002F978-81-322-1533-2_6",{"doi":6757},"10.1007\u002F978-81-322-1533-2_6",{"id":26,"text":6759,"url":26,"identifiers":6760},"Wong, 2017, Do STAT3 inhibitors have potential in the future for cancer therapy?, Expert Opin Investig Drugs, 26, 883, 10.1080\u002F13543784.2017.1351941",{"doi":6761},"10.1080\u002F13543784.2017.1351941",{"id":26,"text":6763,"url":26,"identifiers":6764},"Wingelhofer, 2018, Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer, Leukemia, 32, 1713, 10.1038\u002Fs41375-018-0117-x",{"doi":6765},"10.1038\u002Fs41375-018-0117-x",{"id":26,"text":6767,"url":26,"identifiers":6768},"Able, 2017, STAT5-interacting proteins: a synopsis of proteins that regulate STAT5 activity, Biology (Basel), 6, 20, 10.3390\u002Fbiology6010020",{"doi":6769},"10.3390\u002Fbiology6010020",{"id":26,"text":6771,"url":26,"identifiers":6772},"Hennighausen, 2008, Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B, Genes Dev., 22, 711, 10.1101\u002Fgad.1643908",{"doi":6773},"10.1101\u002Fgad.1643908",{"id":26,"text":6775,"url":26,"identifiers":6776},"Ihle, 2001, The Stat family in cytokine signaling, Curr Opin Cell Biol., 13, 211, 10.1016\u002FS0955-0674(00)00199-X",{"doi":6777},"10.1016\u002FS0955-0674(00)00199-X",{"id":26,"text":6779,"url":26,"identifiers":6780},"Lee, 2017, Capsazepine inhibits JAK\u002FSTAT3 signaling, tumor growth, and cell survival in prostate cancer, Oncotarget, 8, 17700, 10.18632\u002Foncotarget.10775",{"doi":6781},"10.18632\u002Foncotarget.10775",{"id":26,"text":6783,"url":26,"identifiers":6784},"Darnell, 1997, STATs and gene regulation, Science, 277, 1630, 10.1126\u002Fscience.277.5332.1630",{"doi":6785},"10.1126\u002Fscience.277.5332.1630",{"id":26,"text":6787,"url":26,"identifiers":6788},"Zhang, 2016, Nimbolide-induced oxidative stress abrogates STAT3 signaling cascade and inhibits tumor growth in transgenic adenocarcinoma of mouse prostate model, Antioxid Redox Signal., 24, 575, 10.1089\u002Fars.2015.6418",{"doi":6789},"10.1089\u002Fars.2015.6418",{"id":26,"text":6791,"url":26,"identifiers":6792},"Kim, 2018, Formononetin-induced oxidative stress abrogates the activation of STAT3\u002F5 signaling axis and suppresses the tumor growth in multiple myeloma preclinical model, Cancer Lett., 431, 123, 10.1016\u002Fj.canlet.2018.05.038",{"doi":6793},"10.1016\u002Fj.canlet.2018.05.038",{"id":26,"text":6795,"url":26,"identifiers":6796},"Lee, 2015, Brassinin inhibits STAT3 signaling pathway through modulation of PIAS-3 and SOCS-3 expression and sensitizes human lung cancer xenograft in nude mice to paclitaxel, Oncotarget, 6, 6386, 10.18632\u002Foncotarget.3443",{"doi":6797},"10.18632\u002Foncotarget.3443",{"id":26,"text":6799,"url":26,"identifiers":6800},"Rajendran, 2012, Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3\u002FJAK2 signaling cascade in vitro and in vivo, Cancer Prev Res., 5, 631, 10.1158\u002F1940-6207.CAPR-11-0420",{"doi":6801},"10.1158\u002F1940-6207.CAPR-11-0420",{"id":26,"text":6803,"url":26,"identifiers":6804},"Tormo, 2012, IL-6 activates STAT5 in T cells, Cytokine, 60, 575, 10.1016\u002Fj.cyto.2012.07.002",{"doi":6805},"10.1016\u002Fj.cyto.2012.07.002",{"id":26,"text":6807,"url":26,"identifiers":6808},"Leonard, 1998, Jaks and STATs: biological implications, Annu Rev Immunol., 16, 293, 10.1146\u002Fannurev.immunol.16.1.293",{"doi":6809},"10.1146\u002Fannurev.immunol.16.1.293",{"id":26,"text":6811,"url":26,"identifiers":6812},"Stark, 1998, How Cells Respond to Interferons, 10.1146\u002Fannurev.biochem.67.1.227",{"doi":6813},"10.1146\u002Fannurev.biochem.67.1.227",{"id":26,"text":6815,"url":26,"identifiers":6816},"Xue, 2002, Serine phosphorylation of Stat5 proteins in lymphocytes stimulated with IL-2, Int Immunol., 14, 1263, 10.1093\u002Fintimm\u002Fdxf101",{"doi":6817},"10.1093\u002Fintimm\u002Fdxf101",{"id":26,"text":6819,"url":26,"identifiers":6820},"Scheel, 2011, Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast, Cell, 145, 926, 10.1016\u002Fj.cell.2011.04.029",{"doi":6821},"10.1016\u002Fj.cell.2011.04.029",{"id":26,"text":6823,"url":26,"identifiers":6824},"Zhang, 2017, Cardamonin represses proliferation, invasion, and causes apoptosis through the modulation of signal transducer and activator of transcription 3 pathway in prostate cancer, Apoptosis, 22, 158, 10.1007\u002Fs10495-016-1313-7",{"doi":6825},"10.1007\u002Fs10495-016-1313-7",{"id":26,"text":6827,"url":26,"identifiers":6828},"Liu, 2010, IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells, Cell Cycle, 9, 3423, 10.4161\u002Fcc.9.17.12946",{"doi":6829},"10.4161\u002Fcc.9.17.12946",{"id":26,"text":6831,"url":26,"identifiers":6832},"Mohan, 2014, Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo, J Biol Chem., 289, 34296, 10.1074\u002Fjbc.M114.601104",{"doi":6833},"10.1074\u002Fjbc.M114.601104",{"id":26,"text":6835,"url":26,"identifiers":6836},"Baek, 2016, Resveratrol inhibits STAT3 signaling pathway through the induction of SOCS-1: role in apoptosis induction and radiosensitization in head and neck tumor cells, Phytomedicine, 23, 566, 10.1016\u002Fj.phymed.2016.02.011",{"doi":6837},"10.1016\u002Fj.phymed.2016.02.011",{"id":26,"text":6839,"url":26,"identifiers":6840},"Subramaniam, 2013, Potential role of signal transducer and activator of transcription (STAT) 3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma, Biochim Biophys Acta, 1835, 46, 10.1016\u002Fj.bbcan.2012.10.002",{"doi":6841},"10.1016\u002Fj.bbcan.2012.10.002",{"id":26,"text":6843,"url":26,"identifiers":6844},"Kim, 2014, β-caryophyllene oxide inhibits constitutive and inducible STAT3 signaling pathway through induction of the SHP-1 protein tyrosine phosphatase, Mol Carcinog., 53, 793, 10.1002\u002Fmc.22035",{"doi":6845},"10.1002\u002Fmc.22035",{"id":26,"text":6847,"url":26,"identifiers":6848},"Leaman, 1996, Regulation of STAT-dependent pathways by growth factors and cytokines, FASEB J., 10, 1578, 10.1096\u002Ffasebj.10.14.9002549",{"doi":6849},"10.1096\u002Ffasebj.10.14.9002549",{"id":26,"text":6851,"url":26,"identifiers":6852},"Hirano, 2000, Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors, Oncogene, 19, 2548, 10.1038\u002Fsj.onc.1203551",{"doi":6853},"10.1038\u002Fsj.onc.1203551",{"id":26,"text":6855,"url":26,"identifiers":6856},"Kim, 2015, 6-Shogaol exerts anti-proliferative and pro-apoptotic effects through the modulation of STAT3 and MAPKs signaling pathways, Mol Carcinog., 54, 1132, 10.1002\u002Fmc.22184",{"doi":6857},"10.1002\u002Fmc.22184",{"id":26,"text":6859,"url":26,"identifiers":6860},"Baek, 2017, Ginkgolic acid C 17: 1, derived from Ginkgo biloba leaves, suppresses constitutive and inducible STAT3 activation through induction of PTEN and SHP-1 tyrosine phosphatase, Molecules, 22, 276, 10.3390\u002Fmolecules22020276",{"doi":6861},"10.3390\u002Fmolecules22020276",{"id":26,"text":6863,"url":26,"identifiers":6864},"Haura, 2005, Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer, Nat Rev Clin Oncol., 2, 315, 10.1038\u002Fncponc0195",{"doi":6865},"10.1038\u002Fncponc0195",{"id":26,"text":6867,"url":26,"identifiers":6868},"Shanmugam, 2015, Abrogation of STAT3 signaling cascade by zerumbone inhibits proliferation and induces apoptosis in renal cell carcinoma xenograft mouse model, Mol Carcinog., 54, 971, 10.1002\u002Fmc.22166",{"doi":6869},"10.1002\u002Fmc.22166",{"id":26,"text":6871,"url":26,"identifiers":6872},"Ma, 2006, Regulation of Stat3 nuclear import by importin α5 and importin α7 via two different functional sequence elements, Cell Signal., 18, 1117, 10.1016\u002Fj.cellsig.2005.06.016",{"doi":6873},"10.1016\u002Fj.cellsig.2005.06.016",{"id":26,"text":6875,"url":26,"identifiers":6876},"Sethi, 2014, Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo, Mol Cancer, 13, 66, 10.1186\u002F1476-4598-13-66",{"doi":6877},"10.1186\u002F1476-4598-13-66",{"id":26,"text":6879,"url":26,"identifiers":6880},"Jing, 2005, Targeting Stat3 in cancer therapy, Anticancer Drugs, 16, 601, 10.1097\u002F00001813-200507000-00002",{"doi":6881},"10.1097\u002F00001813-200507000-00002",{"id":26,"text":6883,"url":26,"identifiers":6884},"Lee, 2014, Capillarisin inhibits constitutive and inducible STAT3 activation through induction of SHP-1 and SHP-2 tyrosine phosphatases, Cancer Lett., 345, 140, 10.1016\u002Fj.canlet.2013.12.008",{"doi":6885},"10.1016\u002Fj.canlet.2013.12.008",{"id":26,"text":6887,"url":26,"identifiers":6888},"Siveen, 2014, Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors, Biochim Biophys Acta, 1845, 136, 10.1016\u002Fj.bbcan.2013.12.005",{"doi":6889},"10.1016\u002Fj.bbcan.2013.12.005",{"id":26,"text":6891,"url":26,"identifiers":6892},"Li, 2010, Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells, Cancer Lett., 292, 197, 10.1016\u002Fj.canlet.2009.12.003",{"doi":6893},"10.1016\u002Fj.canlet.2009.12.003",{"id":26,"text":6895,"url":26,"identifiers":6896},"Kannaiyan, 2011, Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-κB and STAT3 regulated gene products in multiple myeloma cells, Br J Pharmacol., 164, 1506, 10.1111\u002Fj.1476-5381.2011.01449.x",{"doi":6897},"10.1111\u002Fj.1476-5381.2011.01449.x",{"id":26,"text":6899,"url":26,"identifiers":6900},"Wen, 1997, JE, Nucleic Acids Res., 25, 2062, 10.1093\u002Fnar\u002F25.11.2062",{"doi":6901},"10.1093\u002Fnar\u002F25.11.2062",{"id":26,"text":6903,"url":26,"identifiers":6904},"Kazansky, 1999, Differential effects of prolactin andsrc\u002Fabl kinases on the nuclear translocation of STAT5B and STAT5A, J Biol Chem., 274, 22484, 10.1074\u002Fjbc.274.32.22484",{"doi":6905},"10.1074\u002Fjbc.274.32.22484",{"id":26,"text":6907,"url":26,"identifiers":6908},"Rajendran, 2011, γ-Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, pro-apoptotic and chemosensitizing agent, Br J Pharmacol., 163, 283, 10.1111\u002Fj.1476-5381.2010.01187.x",{"doi":6909},"10.1111\u002Fj.1476-5381.2010.01187.x",{"id":26,"text":6911,"url":26,"identifiers":6912},"Turkson, 2000, STAT proteins: novel molecular targets for cancer drug discovery, Oncogene, 19, 6613, 10.1038\u002Fsj.onc.1204086",{"doi":6913},"10.1038\u002Fsj.onc.1204086",{"id":26,"text":6915,"url":26,"identifiers":6916},"Li, 2013, Garcinol, a polyisoprenylated benzophenone modulates multiple pro-inflammatory signaling cascades leading to suppression of growth and survival of head and neck carcinoma, Cancer Prev Res., 6, 843, 10.1158\u002F1940-6207.CAPR-13-0070",{"doi":6917},"10.1158\u002F1940-6207.CAPR-13-0070",{"id":26,"text":6919,"url":26,"identifiers":6920},"Silva, 2004, Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis, Oncogene, 23, 8017, 10.1038\u002Fsj.onc.1208159",{"doi":6921},"10.1038\u002Fsj.onc.1208159",{"id":26,"text":6923,"url":26,"identifiers":6924},"Yamashita, 1998, Differential control of the phosphorylation state of proline-juxtaposed serine residues Ser725 of Stat5a and Ser730 of Stat5b in prolactin-sensitive cells, J Biol Chem., 273, 30218, 10.1074\u002Fjbc.273.46.30218",{"doi":6925},"10.1074\u002Fjbc.273.46.30218",{"id":26,"text":6927,"url":26,"identifiers":6928},"Wang, 2003, Essential functions of p21-activated kinase 1 in morphogenesis and differentiation of mammary glands, J Cell Biol., 161, 583, 10.1083\u002Fjcb.200212066",{"doi":6929},"10.1083\u002Fjcb.200212066",{"id":26,"text":6931,"url":26,"identifiers":6932},"Park, 2001, Serine phosphorylation of GH-activated signal transducer and activator of transcription 5a (STAT5a) and STAT5b: impact on STAT5 transcriptional activity, Mol Endocrinol., 15, 2157, 10.1210\u002Fmend.15.12.0746",{"doi":6933},"10.1210\u002Fmend.15.12.0746",{"id":26,"text":6935,"url":26,"identifiers":6936},"Shanmugam, 2011, Ursolic acid inhibits multiple cell survival pathways leading to suppression of growth of prostate cancer xenograft in nude mice, J Mol Med., 89, 713, 10.1007\u002Fs00109-011-0746-2",{"doi":6937},"10.1007\u002Fs00109-011-0746-2",{"id":26,"text":6939,"url":26,"identifiers":6940},"Rajendran, 2011, Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo, Clin Cancer Res., 17, 1425, 10.1158\u002F1078-0432.CCR-10-1123",{"doi":6941},"10.1158\u002F1078-0432.CCR-10-1123",{"id":26,"text":6943,"url":26,"identifiers":6944},"Xiong, 2009, Inhibition of STAT5 induces G1 cell cycle arrest and reduces tumor cell invasion in human colorectal cancer cells, Lab Invest., 89, 717, 10.1038\u002Flabinvest.2009.11",{"doi":6945},"10.1038\u002Flabinvest.2009.11",{"id":26,"text":6947,"url":26,"identifiers":6948},"Coffer, 2000, The role of STATs in myeloid differentiation and leukemia, Oncogene, 19, 2511, 10.1038\u002Fsj.onc.1203479",{"doi":6949},"10.1038\u002Fsj.onc.1203479",{"id":26,"text":6951,"url":26,"identifiers":6952},"Ito, 2004, Oncogenic potential of the RUNX gene family: ‘overview’, Oncogene, 23, 4198, 10.1038\u002Fsj.onc.1207755",{"doi":6953},"10.1038\u002Fsj.onc.1207755",{"id":26,"text":6955,"url":26,"identifiers":6956},"Cameron, 2004, The RUNX genes: lineage-specific oncogenes and tumor suppressors, Oncogene, 23, 4308, 10.1038\u002Fsj.onc.1207130",{"doi":6957},"10.1038\u002Fsj.onc.1207130",{"id":26,"text":6959,"url":26,"identifiers":6960},"Osato, 2004, Point mutations in the RUNX1\u002FAML1 gene: another actor in RUNX leukemia, Oncogene, 23, 4284, 10.1038\u002Fsj.onc.1207779",{"doi":6961},"10.1038\u002Fsj.onc.1207779",{"id":26,"text":6963,"url":26,"identifiers":6964},"Pratap, 2011, Metastatic bone disease: role of transcription factors and future targets, Bone, 48, 30, 10.1016\u002Fj.bone.2010.05.035",{"doi":6965},"10.1016\u002Fj.bone.2010.05.035",{"id":26,"text":6967,"url":26,"identifiers":6968},"Thomas, 2004, Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma, J Cell Biol., 167, 925, 10.1083\u002Fjcb.200409187",{"doi":6969},"10.1083\u002Fjcb.200409187",{"id":26,"text":6971,"url":26,"identifiers":6972},"Ito, 2005, RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization, Cancer Res., 65, 7743, 10.1158\u002F0008-5472.CAN-05-0743",{"doi":6973},"10.1158\u002F0008-5472.CAN-05-0743",{"id":26,"text":6975,"url":26,"identifiers":6976},"Ulloa, 1999, Inhibition of transforming growth factor-β\u002FSMAD signalling by the interferon-γ\u002FSTAT pathway, Nature, 397, 710, 10.1038\u002F17826",{"doi":6977},"10.1038\u002F17826",{"id":26,"text":6979,"url":26,"identifiers":6980},"Li, 2002, Causal relationship between the loss of RUNX3 expression and gastric cancer, Cell, 109, 113, 10.1016\u002FS0092-8674(02)00690-6",{"doi":6981},"10.1016\u002FS0092-8674(02)00690-6",{"id":26,"text":6983,"url":26,"identifiers":6984},"Yano, 2006, The RUNX3 tumor suppressor upregulates bim in gastric epithelial cells undergoing transforming growth factorβ-induced apoptosis, Mol Cell Biol., 26, 4474, 10.1128\u002FMCB.01926-05",{"doi":6985},"10.1128\u002FMCB.01926-05",{"id":26,"text":6987,"url":26,"identifiers":6988},"Zheng, 2018, DNA methylation affects metastasis of renal cancer and is associated with TGF-β\u002FRUNX3 inhibition, Cancer Cell Int., 18, 56, 10.1186\u002Fs12935-018-0554-7",{"doi":6989},"10.1186\u002Fs12935-018-0554-7",{"id":26,"text":6991,"url":26,"identifiers":6992},"Nakashima, 1999, Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300, Science, 284, 479, 10.1126\u002Fscience.284.5413.479",{"doi":6993},"10.1126\u002Fscience.284.5413.479",{"id":26,"text":6995,"url":26,"identifiers":6996},"Kim, 2003, Stat1 functions as a cytoplasmic attenuator of Runx2 in the transcriptional program of osteoblast differentiation, Genes Dev., 17, 1979, 10.1101\u002Fgad.1119303",{"doi":6997},"10.1101\u002Fgad.1119303",{"id":26,"text":6999,"url":26,"identifiers":7000},"Miyazono, 2004, Coordinate regulation of cell growth and differentiation by TGF-β superfamily and RUNX proteins, Oncogene, 23, 4232, 10.1038\u002Fsj.onc.1207131",{"doi":7001},"10.1038\u002Fsj.onc.1207131",{"id":26,"text":7003,"url":26,"identifiers":7004},"Levine, 1991, The p53 tumour suppressor gene, Nature, 351, 453, 10.1038\u002F351453a0",{"doi":7005},"10.1038\u002F351453a0",{"id":26,"text":7007,"url":26,"identifiers":7008},"Niu, 2005, Role of Stat3 in regulating p53 expression and function, Mol Cell Biol., 25, 7432, 10.1128\u002FMCB.25.17.7432-7440.2005",{"doi":7009},"10.1128\u002FMCB.25.17.7432-7440.2005",{"id":26,"text":7011,"url":26,"identifiers":7012},"Chin, 1996, Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21WAF1\u002FCIP1 mediated by STAT1, Science, 272, 719, 10.1126\u002Fscience.272.5262.719",{"doi":7013},"10.1126\u002Fscience.272.5262.719",{"id":26,"text":7015,"url":26,"identifiers":7016},"Macleod, 1995, p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage, Genes Dev., 9, 935, 10.1101\u002Fgad.9.8.935",{"doi":7017},"10.1101\u002Fgad.9.8.935",{"id":26,"text":7019,"url":26,"identifiers":7020},"Townsend, 2004, STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis, J Biol Chem., 279, 5811, 10.1074\u002Fjbc.M302637200",{"doi":7021},"10.1074\u002Fjbc.M302637200",{"id":26,"text":7023,"url":26,"identifiers":7024},"Kaplan, 1998, Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice, Proc Natl Acad Sci USA., 95, 7556, 10.1073\u002Fpnas.95.13.7556",{"doi":7025},"10.1073\u002Fpnas.95.13.7556",{"id":26,"text":7027,"url":26,"identifiers":7028},"Haupt, 1997, Mdm2 promotes the rapid degradation of p53, Nature, 387, 296, 10.1038\u002F387296a0",{"doi":7029},"10.1038\u002F387296a0",{"id":26,"text":7031,"url":26,"identifiers":7032},"Baran-Marszak, 2004, Differential roles of STAT1α and STAT1β in fludarabine-induced cell cycle arrest and apoptosis in human B cells, Blood, 104, 2475, 10.1182\u002Fblood-2003-10-3508",{"doi":7033},"10.1182\u002Fblood-2003-10-3508",{"id":26,"text":7035,"url":26,"identifiers":7036},"Youlyouz-Marfak, 2008, Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents, Cell Death Differ., 15, 376, 10.1038\u002Fsj.cdd.4402270",{"doi":7037},"10.1038\u002Fsj.cdd.4402270",{"id":26,"text":7039,"url":26,"identifiers":7040},"Gamero, 2018, p53 inactivation and STAT2 cooperate to enhance migration and metastasis of colon tumor cells, AACR, 10.1158\u002F1538-7445.AM2018-3157",{"doi":7041},"10.1158\u002F1538-7445.AM2018-3157",{"id":26,"text":7043,"url":26,"identifiers":7044},"Mantovani, 2008, Cancer-related inflammation, Nature, 454, 436, 10.1038\u002Fnature07205",{"doi":7045},"10.1038\u002Fnature07205",{"id":26,"text":7047,"url":26,"identifiers":7048},"Karin, 2005, NF-κB: linking inflammation and immunity to cancer development and progression, Nat Rev Immunol., 5, 749, 10.1038\u002Fnri1703",{"doi":7049},"10.1038\u002Fnri1703",{"id":26,"text":7051,"url":26,"identifiers":7052},"Baud, 2009, Is NF-κB a good target for cancer therapy?, Nature Rev Drug Discov., 8, 33, 10.1038\u002Fnrd2781",{"doi":7053},"10.1038\u002Fnrd2781",{"id":26,"text":7055,"url":26,"identifiers":7056},"Bollrath, 2009, gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis, Cancer Cell, 15, 91, 10.1016\u002Fj.ccr.2009.01.002",{"doi":7057},"10.1016\u002Fj.ccr.2009.01.002",{"id":26,"text":7059,"url":26,"identifiers":7060},"Grivennikov, 2009, IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer, Cancer Cell, 15, 103, 10.1016\u002Fj.ccr.2009.01.001",{"doi":7061},"10.1016\u002Fj.ccr.2009.01.001",{"id":26,"text":7063,"url":26,"identifiers":7064},"Lee, 2009, Persistently activated Stat3 maintains constitutive NF-κB activity in tumors, Cancer Cell, 15, 283, 10.1016\u002Fj.ccr.2009.02.015",{"doi":7065},"10.1016\u002Fj.ccr.2009.02.015",{"id":26,"text":7067,"url":26,"identifiers":7068},"Yang, 2007, Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFκB, Genes Dev., 21, 1396, 10.1101\u002Fgad.1553707",{"doi":7069},"10.1101\u002Fgad.1553707",{"id":26,"text":7071,"url":26,"identifiers":7072},"Bromberg, 1999, Stat3 as an oncogene, Cell, 98, 295, 10.1016\u002FS0092-8674(00)81959-5",{"doi":7073},"10.1016\u002FS0092-8674(00)81959-5",{"id":26,"text":7075,"url":26,"identifiers":7076},"Yu, 2007, Tumour immunology: crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment, Nat Rev Immunol., 7, 41, 10.1038\u002Fnri1995",{"doi":7077},"10.1038\u002Fnri1995",{"id":26,"text":7079,"url":26,"identifiers":7080},"Basseres, 2006, Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression, Oncogene, 25, 6817, 10.1038\u002Fsj.onc.1209942",{"doi":7081},"10.1038\u002Fsj.onc.1209942",{"id":26,"text":7083,"url":26,"identifiers":7084},"Zhong, 1994, Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6, Science, 264, 95, 10.1126\u002Fscience.8140422",{"doi":7085},"10.1126\u002Fscience.8140422",{"id":26,"text":7087,"url":26,"identifiers":7088},"Yu, 2004, The STATs of cancer—new molecular targets come of age, Nat Rev Cancer, 4, 97, 10.1038\u002Fnrc1275",{"doi":7089},"10.1038\u002Fnrc1275",{"id":26,"text":7091,"url":26,"identifiers":7092},"Ogura, 2008, Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction, Immunity, 29, 628, 10.1016\u002Fj.immuni.2008.07.018",{"doi":7093},"10.1016\u002Fj.immuni.2008.07.018",{"id":26,"text":7095,"url":26,"identifiers":7096},"Pandurangan, 2014, Signal transducer and activator of transcription 3-a promising target in colitis-associated cancer, Asian Pac J Cancer Prev., 15, 551, 10.7314\u002Fapjcp.2014.15.2.551",{"doi":7097},"10.7314\u002Fapjcp.2014.15.2.551",{"id":26,"text":7099,"url":26,"identifiers":7100},"Murone, 2016, Debio 0617B inhibits growth of STAT3-driven solid tumors through combined inhibition of JAK, SRC, and class III\u002FV receptor tyrosine kinases, Mol Cancer Ther., 15, 2334, 10.1158\u002F1535-7163.MCT-15-0974",{"doi":7101},"10.1158\u002F1535-7163.MCT-15-0974",{"id":26,"text":7103,"url":26,"identifiers":7104},"Wu, 2015, FDA-approved small-molecule kinase inhibitors, Trends Pharmacol Sci., 36, 422, 10.1016\u002Fj.tips.2015.04.005",{"doi":7105},"10.1016\u002Fj.tips.2015.04.005",{"id":26,"text":7107,"url":26,"identifiers":7108},"Pei, 2018, Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis, Sci Rep., 8, 5273, 10.1038\u002Fs41598-018-23569-y",{"doi":7109},"10.1038\u002Fs41598-018-23569-y",{"id":26,"text":7111,"url":26,"identifiers":7112},"Ghoreschi, 2009, Janus kinases in immune cell signaling, Immunol Rev., 228, 273, 10.1111\u002Fj.1600-065X.2008.00754.x",{"doi":7113},"10.1111\u002Fj.1600-065X.2008.00754.x",{"id":26,"text":7115,"url":26,"identifiers":7116},"Gehringer, 2014, Novel Hinge-binding motifs for janus kinase 3 inhibitors: a comprehensive structure–activity relationship study on tofacitinib bioisosteres, ChemMedChem, 9, 2516, 10.1002\u002Fcmdc.201402252",{"doi":7117},"10.1002\u002Fcmdc.201402252",{"id":26,"text":7119,"url":26,"identifiers":7120},"Winthrop, 2017, The emerging safety profile of JAK inhibitors in rheumatic disease, Nat Rev Rheumatol., 13, 234, 10.1038\u002Fnrrheum.2017.23",{"doi":7121},"10.1038\u002Fnrrheum.2017.23",{"id":26,"text":7123,"url":26,"identifiers":7124},"Lavecchia, 2011, STAT-3 inhibitors: state of the art and new horizons for cancer treatment, Curr Med Chem., 18, 2359, 10.2174\u002F092986711795843218",{"doi":7125},"10.2174\u002F092986711795843218",{"id":26,"text":7127,"url":26,"identifiers":7128},"Buettner, 2002, Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention, Clin Cancer Res., 8, 945",{},{"id":26,"text":7130,"url":26,"identifiers":7131},"Furqan, 2013, STAT inhibitors for cancer therapy, J Hematol Oncol., 6, 90, 10.1186\u002F1756-8722-6-90",{"doi":7132},"10.1186\u002F1756-8722-6-90",{"id":26,"text":7134,"url":26,"identifiers":7135},"Wingelhofer, 2018, Pharmacologic inhibition of STAT5 in acute myeloid leukemia, Leukemia, 32, 1135, 10.1038\u002Fs41375-017-0005-9",{"doi":7136},"10.1038\u002Fs41375-017-0005-9",{"id":26,"text":7138,"url":26,"identifiers":7139},"Nelson, 2011, The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors, Blood, 117, 3421, 10.1182\u002Fblood-2009-11-255232",{"doi":7140},"10.1182\u002Fblood-2009-11-255232",{"id":26,"text":7142,"url":26,"identifiers":7143},"Arora, 2018, The role of signal transducer and activator of transcription 3 (STAT3) and its targeted inhibition in hematological malignancies, Cancers (Basel), 10, 327, 10.3390\u002Fcancers10090327",{"doi":7144},"10.3390\u002Fcancers10090327",{"id":26,"text":7146,"url":26,"identifiers":7147},"Shin, 2009, Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells, Cancer Res., 69, 193, 10.1158\u002F0008-5472.CAN-08-2575",{"doi":7148},"10.1158\u002F0008-5472.CAN-08-2575",{"id":26,"text":7150,"url":26,"identifiers":7151},"Bhutani, 2007, Capsaicin is a novel blocker of constitutive and interleukin-6–inducible STAT3 activation, Clin Cancer Res., 13, 3024, 10.1158\u002F1078-0432.CCR-06-2575",{"doi":7152},"10.1158\u002F1078-0432.CCR-06-2575",{"id":26,"text":7154,"url":26,"identifiers":7155},"Bharti, 2003, Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells, J Immunol., 171, 3863, 10.4049\u002Fjimmunol.171.7.3863",{"doi":7156},"10.4049\u002Fjimmunol.171.7.3863",{"id":26,"text":7158,"url":26,"identifiers":7159},"Oi, 2016, STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma, Int J Oncol., 49, 2275, 10.3892\u002Fijo.2016.3757",{"doi":7160},"10.3892\u002Fijo.2016.3757",{"id":26,"text":7162,"url":26,"identifiers":7163},"Amit-Vazina, 2005, Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells, Br J Cancer, 93, 70, 10.1038\u002Fsj.bjc.6602637",{"doi":7164},"10.1038\u002Fsj.bjc.6602637",{"id":26,"text":7166,"url":26,"identifiers":7167},"Pinz, 2014, The natural chemopreventive agent sulforaphane inhibits STAT5 activity, PLoS ONE, 9, e99391, 10.1371\u002Fjournal.pone.0099391",{"doi":7168},"10.1371\u002Fjournal.pone.0099391",{"id":26,"text":7170,"url":26,"identifiers":7171},"Alshamsan, 2010, The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine, Biomaterials, 31, 1420, 10.1016\u002Fj.biomaterials.2009.11.003",{"doi":7172},"10.1016\u002Fj.biomaterials.2009.11.003",{"id":26,"text":7174,"url":26,"identifiers":7175},"Turkson, 2004, STAT proteins as novel targets for cancer drug discovery, Expert Opin Ther Targets, 8, 409, 10.1517\u002F14728222.8.5.409",{"doi":7176},"10.1517\u002F14728222.8.5.409",{"id":26,"text":7178,"url":26,"identifiers":7179},"Anastasov, 2009, Efficient shRNA delivery into B and T lymphoma cells using lentiviral vector-mediated transfer, J Hematopathol., 2, 9, 10.1007\u002Fs12308-008-0020-x",{"doi":7180},"10.1007\u002Fs12308-008-0020-x",{"id":26,"text":7182,"url":26,"identifiers":7183},"Peer, 2011, Special delivery: targeted therapy with small RNAs, Gene Ther., 18, 1127, 10.1038\u002Fgt.2011.56",{"doi":7184},"10.1038\u002Fgt.2011.56",{"id":26,"text":7186,"url":26,"identifiers":7187},"Weinstein, 2016, Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies, Proc Natl Acad Sci USA., 113, E16, 10.1073\u002Fpnas.1519273113",{"doi":7188},"10.1073\u002Fpnas.1519273113",{"id":26,"text":7190,"url":26,"identifiers":7191},"de Fougerolles, 2007, Interfering with disease: a progress report on siRNA-based therapeutics, Nat Rev Drug Discov., 6, 443, 10.1038\u002Fnrd2310",{"doi":7192},"10.1038\u002Fnrd2310",{"id":26,"text":7194,"url":26,"identifiers":7195},"Paddison, 2002, Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells, Genes Dev., 16, 948, 10.1101\u002Fgad.981002",{"doi":7196},"10.1101\u002Fgad.981002",{"id":26,"text":7198,"url":26,"identifiers":7199},"Konnikova, 2003, Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells, BMC Cancer, 3, 23, 10.1186\u002F1471-2407-3-23",{"doi":7200},"10.1186\u002F1471-2407-3-23",{"id":26,"text":7202,"url":26,"identifiers":7203},"Konnikova, 2005, Signal transducer and activator of transcription 3 (STAT3) regulates human telomerase reverse transcriptase (hTERT) expression in human cancer and primary cells, Cancer Res., 65, 6516, 10.1158\u002F0008-5472.CAN-05-0924",{"doi":7204},"10.1158\u002F0008-5472.CAN-05-0924",{"id":26,"text":7206,"url":26,"identifiers":7207},"Cao, 2011, STAT5 regulates glioma cell invasion by pathways dependent and independent of STAT5 DNA binding, Neurosci Lett., 487, 228, 10.1016\u002Fj.neulet.2010.10.028",{"doi":7208},"10.1016\u002Fj.neulet.2010.10.028",{"id":26,"text":7210,"url":26,"identifiers":7211},"Gu, 2010, Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo, Endocr Relat Cancer, 17, 481, 10.1677\u002FERC-09-0328",{"doi":7212},"10.1677\u002FERC-09-0328",{"id":26,"text":7214,"url":26,"identifiers":7215},"Choi, 2011, Granulocyte macrophage-colony stimulating factor shows anti-apoptotic activity in neural progenitor cells via JAK\u002FSTAT5-Bcl-2 pathway, Apoptosis, 16, 127, 10.1007\u002Fs10495-010-0552-2",{"doi":7216},"10.1007\u002Fs10495-010-0552-2",{"id":26,"text":7218,"url":26,"identifiers":7219},"Gao, 2005, Inhibition of STAT3 expression by siRNA suppresses growth and induces apoptosis in laryngeal cancer cells, Acta Pharmacol Sin., 26, 377, 10.1111\u002Fj.1745-7254.2005.00053.x",{"doi":7220},"10.1111\u002Fj.1745-7254.2005.00053.x",{"id":26,"text":7222,"url":26,"identifiers":7223},"Jin, 2010, The effect of STAT5 silenced by siRNA on proliferation, apoptosis and invasion of esophageal carcinoma cell line EC9706, Chinese German J Clin Oncol., 9, 692, 10.1007\u002Fs10330-010-0717-z",{"doi":7224},"10.1007\u002Fs10330-010-0717-z",{"id":26,"text":7226,"url":26,"identifiers":7227},"Kunigal, 2009, Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo in breast cancer, Int J Oncol., 34, 1209, 10.3892\u002Fijo_00000249",{"doi":7228},"10.3892\u002Fijo_00000249",{"id":26,"text":7230,"url":26,"identifiers":7231},"Xiong, 2012, Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition, J Biol Chem., 287, 5819, 10.1074\u002Fjbc.M111.295964",{"doi":7232},"10.1074\u002Fjbc.M111.295964",{"id":26,"text":7234,"url":26,"identifiers":7235},"Xu, 2013, The upregulation of signal transducer and activator of transcription 5-dependent microRNA-182 and microRNA-96 promotes ovarian cancer cell proliferation by targeting forkhead box O3 upon leptin stimulation, Int J Biochem Cell Biol., 45, 536, 10.1016\u002Fj.biocel.2012.12.010",{"doi":7236},"10.1016\u002Fj.biocel.2012.12.010",{"id":26,"text":7238,"url":26,"identifiers":7239},"Zhang, 2016, SENP1 regulates hepatocyte growth factor-induced migration and epithelial-mesenchymal transition of hepatocellular carcinoma, Tumour Biol., 37, 7741, 10.1007\u002Fs13277-015-4406-y",{"doi":7240},"10.1007\u002Fs13277-015-4406-y",{"id":26,"text":7242,"url":26,"identifiers":7243},"Tatiparti, 2017, siRNA delivery strategies: a comprehensive review of recent developments, Nanomaterials, 7, 77, 10.3390\u002Fnano7040077",{"doi":7244},"10.3390\u002Fnano7040077",{"id":26,"text":7246,"url":26,"identifiers":7247},"Guven, 2005, Efficient gene transfer into primary human natural killer cells by retroviral transduction, Exp Hematol., 33, 1320, 10.1016\u002Fj.exphem.2005.07.006",{"doi":7248},"10.1016\u002Fj.exphem.2005.07.006",{"id":26,"text":7250,"url":26,"identifiers":7251},"Yang, 2009, Lentivirus-mediated shRNA interference targeting STAT3 inhibits human pancreatic cancer cell invasion, World J Gastroenterol., 15, 3757, 10.3748\u002Fwjg.15.3757",{"doi":7252},"10.3748\u002Fwjg.15.3757",{"id":26,"text":7254,"url":26,"identifiers":7255},"Emeagi, 2013, Downregulation of Stat3 in melanoma: reprogramming the immune microenvironment as an anticancer therapeutic strategy, Gene Ther., 20, 1085, 10.1038\u002Fgt.2013.35",{"doi":7256},"10.1038\u002Fgt.2013.35",{"id":26,"text":7258,"url":26,"identifiers":7259},"Wang, 2012, Delivery of interferons and siRNA targeting STAT3 using lentiviral vectors suppresses the growth of murine melanoma, Cancer Gene Ther., 19, 822, 10.1038\u002Fcgt.2012.65",{"doi":7260},"10.1038\u002Fcgt.2012.65",{"id":26,"text":7262,"url":26,"identifiers":7263},"Cao, 2011, EGF stimulates cyclooxygenase-2 expression through the STAT5 signaling pathway in human lung adenocarcinoma A549 cells, Int J Oncol., 39, 383, 10.3892\u002Fijo.2011.1053",{"doi":7264},"10.3892\u002Fijo.2011.1053",{"id":26,"text":7266,"url":26,"identifiers":7267},"Zhang, 2007, Cationic lipids and polymers mediated vectors for delivery of siRNA, J Control Release, 123, 1, 10.1016\u002Fj.jconrel.2007.07.016",{"doi":7268},"10.1016\u002Fj.jconrel.2007.07.016",{"id":26,"text":7270,"url":26,"identifiers":7271},"Zhao, 2015, Knockdown of STAT3 expression in SKOV3 cells by biodegradable siRNA–PLGA\u002FCSO conjugate micelles, Colloids Surf B Biointerfaces, 127, 155, 10.1016\u002Fj.colsurfb.2015.01.034",{"doi":7272},"10.1016\u002Fj.colsurfb.2015.01.034",{"id":26,"text":7274,"url":26,"identifiers":7275},"Hou, 2013, Melittin derived peptides for nanoparticle based siRNA transfection, Biomaterials, 34, 3110, 10.1016\u002Fj.biomaterials.2013.01.037",{"doi":7276},"10.1016\u002Fj.biomaterials.2013.01.037",{"id":26,"text":7278,"url":26,"identifiers":7279},"Soenen, 2009, Addressing the problem of cationic lipid-mediated toxicity: the magnetoliposome model, Biomaterials, 30, 3691, 10.1016\u002Fj.biomaterials.2009.03.040",{"doi":7280},"10.1016\u002Fj.biomaterials.2009.03.040",{"id":26,"text":7282,"url":26,"identifiers":7283},"Ballarín-González, 2012, Polycation-based nanoparticle delivery of RNAi therapeutics: adverse effects and solutions, Adv Drug Deliv Rev., 64, 1717, 10.1016\u002Fj.addr.2012.07.004",{"doi":7284},"10.1016\u002Fj.addr.2012.07.004",{"id":26,"text":7286,"url":26,"identifiers":7287},"Forti, 2016, A bridge to silencing: Co-assembling anionic nanoparticles of siRNA and hyaluronan sulfate via calcium ion bridges, J Control Release, 232, 215, 10.1016\u002Fj.jconrel.2016.04.033",{"doi":7288},"10.1016\u002Fj.jconrel.2016.04.033",{"id":26,"text":7290,"url":26,"identifiers":7291},"Lv, 2006, Toxicity of cationic lipids and cationic polymers in gene delivery, J Control Release, 114, 100, 10.1016\u002Fj.jconrel.2006.04.014",{"doi":7292},"10.1016\u002Fj.jconrel.2006.04.014",{"id":26,"text":7294,"url":26,"identifiers":7295},"Alshamsan, 2008, Formulation and delivery of siRNA by oleic acid and stearic acid modified polyethylenimine, Mol Pharma., 6, 121, 10.1021\u002Fmp8000815",{"doi":7296},"10.1021\u002Fmp8000815",{"id":26,"text":7298,"url":26,"identifiers":7299},"Das, 2014, Assessment of drug delivery and anticancer potentials of nanoparticles-loaded siRNA targeting STAT3 in lung cancer, in vitro and in vivo, Toxicol Lett., 225, 454, 10.1016\u002Fj.toxlet.2014.01.009",{"doi":7300},"10.1016\u002Fj.toxlet.2014.01.009",{"id":26,"text":7302,"url":26,"identifiers":7303},"Su, 2012, PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells, Int J Nanomed., 7, 4269, 10.2147\u002FIJN.S33666",{"doi":7304},"10.2147\u002FIJN.S33666",{"id":26,"text":7306,"url":26,"identifiers":7307},"Yin, 2013, Functional graphene oxide as a plasmid-based Stat3 siRNA carrier inhibits mouse malignant melanoma growth in vivo, Nanotechnology, 24, 105102, 10.1088\u002F0957-4484\u002F24\u002F10\u002F105102",{"doi":7308},"10.1088\u002F0957-4484\u002F24\u002F10\u002F105102",{"id":26,"text":7310,"url":26,"identifiers":7311},"Yuan, 2011, Recent advances of siRNA delivery by nanoparticles, Expert Opin Drug Deliv., 8, 521, 10.1517\u002F17425247.2011.559223",{"doi":7312},"10.1517\u002F17425247.2011.559223",{"id":26,"text":7314,"url":26,"identifiers":7315},"Heo, 2014, Programmed nanoparticles for combined immunomodulation, antigen presentation and tracking of immunotherapeutic cells, Biomaterials, 35, 590, 10.1016\u002Fj.biomaterials.2013.10.009",{"doi":7316},"10.1016\u002Fj.biomaterials.2013.10.009",{"id":26,"text":7318,"url":26,"identifiers":7319},"Molavi, 2010, Development of a poly (d, l-lactic-co-glycolic acid) nanoparticle formulation of STAT3 inhibitor JSI-124: implication for cancer immunotherapy, Mol Pharma., 7, 364, 10.1021\u002Fmp900145g",{"doi":7320},"10.1021\u002Fmp900145g",{"id":26,"text":7322,"url":26,"identifiers":7323},"Labala, 2017, Effective melanoma cancer suppression by iontophoretic co-delivery of STAT3 siRNA and imatinib using gold nanoparticles, Int J Pharma., 525, 407, 10.1016\u002Fj.ijpharm.2017.03.087",{"doi":7324},"10.1016\u002Fj.ijpharm.2017.03.087",{"id":26,"text":7326,"url":26,"identifiers":7327},"Labala, 2016, Transcutaneous iontophoretic delivery of STAT3 siRNA using layer-by-layer chitosan coated gold nanoparticles to treat melanoma, Colloids Surf B Biointerfaces, 146, 188, 10.1016\u002Fj.colsurfb.2016.05.076",{"doi":7328},"10.1016\u002Fj.colsurfb.2016.05.076",{"id":26,"text":7330,"url":26,"identifiers":7331},"Tan, 2005, Surface modification of gold and quantum dot nanoparticles with chitosan for bioapplications, J Biomed Mater Res A, 75, 56, 10.1002\u002Fjbm.a.30410",{"doi":7332},"10.1002\u002Fjbm.a.30410",{"id":26,"text":7334,"url":26,"identifiers":7335},"Liang, 2011, Plasmid-based Stat3 siRNA delivered by hydroxyapatite nanoparticles suppresses mouse prostate tumour growth in vivo, Asian J Androl., 13, 481, 10.1038\u002Faja.2010.167",{"doi":7336},"10.1038\u002Faja.2010.167",{"id":26,"text":7338,"url":26,"identifiers":7339},"Shi, 2018, Inorganic kernel-Supported asymmetric hybrid vesicles for targeting delivery of STAT3-decoy oligonucleotides to overcome anti-HER2 therapeutic resistance of BT474R, J Control Release, 279, 53, 10.1016\u002Fj.jconrel.2018.04.023",{"doi":7340},"10.1016\u002Fj.jconrel.2018.04.023",{"id":26,"text":7342,"url":26,"identifiers":7343},"Luo, 2015, Nanovaccine loaded with poly I: C and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo, Biomaterials, 38, 50, 10.1016\u002Fj.biomaterials.2014.10.050",{"doi":7344},"10.1016\u002Fj.biomaterials.2014.10.050",{"id":26,"text":7346,"url":26,"identifiers":7347},"Ou, 2018, Regulatory T cell-targeted hybrid nanoparticles combined with immuno-checkpoint blockage for cancer immunotherapy, J Control Release, 281, 84, 10.1016\u002Fj.jconrel.2018.05.018",{"doi":7348},"10.1016\u002Fj.jconrel.2018.05.018",{"id":26,"text":7350,"url":26,"identifiers":7351},"Larmonier, 2008, Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL− tumors, J Immunol., 181, 6955, 10.4049\u002Fjimmunol.181.10.6955",{"doi":7352},"10.4049\u002Fjimmunol.181.10.6955",{"id":26,"text":7354,"url":26,"identifiers":7355},"Kim, 2012, Nanoparticle delivery of a peptide targeting EGFR signaling, J Control Release, 157, 279, 10.1016\u002Fj.jconrel.2011.08.014",{"doi":7356},"10.1016\u002Fj.jconrel.2011.08.014",{"id":26,"text":7358,"url":26,"identifiers":7359},"Liu, 2013, Curcumin ameliorates dextran sulfate sodium-induced experimental colitis by blocking STAT3 signaling pathway, Int Immunopharmacol., 17, 314, 10.1016\u002Fj.intimp.2013.06.020",{"doi":7360},"10.1016\u002Fj.intimp.2013.06.020",{"id":26,"text":7362,"url":26,"identifiers":7363},"Rathore, 2008, Simultaneous determination of hydrazinocurcumin and phenol red in samples from rat intestinal permeability studies: HPLC method development and validation, J Pharma Biomed Anal., 46, 374, 10.1016\u002Fj.jpba.2007.09.019",{"doi":7364},"10.1016\u002Fj.jpba.2007.09.019",{"id":26,"text":7366,"url":26,"identifiers":7367},"Zhang, 2013, Hydrazinocurcumin encapsuled nanoparticles “re-educate” tumor-associated macrophages and exhibit anti-tumor effects on breast cancer following STAT3 suppression, PLoS ONE, 8, e65896, 10.1371\u002Fjournal.pone.0065896",{"doi":7368},"10.1371\u002Fjournal.pone.0065896",{"id":26,"text":7370,"url":26,"identifiers":7371},"Liao, 2011, Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity, Nanomedicine, 7, 665, 10.1016\u002Fj.nano.2011.03.001",{"doi":7372},"10.1016\u002Fj.nano.2011.03.001",{"id":26,"text":7374,"url":26,"identifiers":7375},"Guorgui, 2018, Curcumin formulated in solid lipid nanoparticles has enhanced efficacy in Hodgkin's lymphoma in mice, Arch Biochem Biophys., 648, 12, 10.1016\u002Fj.abb.2018.04.012",{"doi":7376},"10.1016\u002Fj.abb.2018.04.012",{"id":26,"text":7378,"url":26,"identifiers":7379},"Ma, 2015, STAT3 decoy oligodeoxynucleotides-loaded solid lipid nanoparticles induce cell death and inhibit invasion in ovarian cancer cells, PLoS ONE, 10, e0124924, 10.1371\u002Fjournal.pone.0124924",{"doi":7380},"10.1371\u002Fjournal.pone.0124924",{"id":26,"text":7382,"url":26,"identifiers":7383},"Kotmakçi, 2017, Preparation and characterization of lipid nanoparticle\u002FpDNA complexes for STAT3 downregulation and overcoming chemotherapy resistance in lung cancer cells, Int J Pharma., 525, 101, 10.1016\u002Fj.ijpharm.2017.04.034",{"doi":7384},"10.1016\u002Fj.ijpharm.2017.04.034",{"id":26,"text":7386,"url":26,"identifiers":7387},"Xu, 2014, A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer, Eur J Surg Oncol., 40, 311, 10.1016\u002Fj.ejso.2013.11.012",{"doi":7388},"10.1016\u002Fj.ejso.2013.11.012",{"id":26,"text":7390,"url":26,"identifiers":7391},"Shahzad, 2011, Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles, Neoplasia, 13, 309, 10.1593\u002Fneo.101372",{"doi":7392},"10.1593\u002Fneo.101372",{"id":26,"text":7394,"url":26,"identifiers":7395},"Ruvinov, 2015, Calcium–siRNA nanocomplexes: what reversibility is all about, J Control Release, 203, 150, 10.1016\u002Fj.jconrel.2015.02.029",{"doi":7396},"10.1016\u002Fj.jconrel.2015.02.029",{"id":26,"text":7398,"url":26,"identifiers":7399},"Bondalapati, 2014, Rapid end-group modification of polysaccharides for biomaterial applications in regenerative medicine, Macromol Rapid Commun., 35, 1754, 10.1002\u002Fmarc.201400354",{"doi":7400},"10.1002\u002Fmarc.201400354",{"id":26,"text":7402,"url":26,"identifiers":7403},"Korin, 2017, GalNAc bio-functionalization of nanoparticles assembled by electrostatic interactions improves siRNA targeting to the liver, J Control Release, 266, 310, 10.1016\u002Fj.jconrel.2017.10.001",{"doi":7404},"10.1016\u002Fj.jconrel.2017.10.001",{"id":26,"text":7406,"url":26,"identifiers":7407},"de Almeida, 2017, Aptamer delivery of siRNA, radiopharmaceutics and chemotherapy agents in cancer, Int J Pharma., 525, 334, 10.1016\u002Fj.ijpharm.2017.03.086",{"doi":7408},"10.1016\u002Fj.ijpharm.2017.03.086",{"id":26,"text":7410,"url":26,"identifiers":7411},"Esposito, 2018, STAT3 gene silencing by aptamer-siRNA chimera as selective therapeutic for glioblastoma, Mol Ther Nucleic Acids, 10, 398, 10.1016\u002Fj.omtn.2017.12.021",{"doi":7412},"10.1016\u002Fj.omtn.2017.12.021",{"id":26,"text":7414,"url":26,"identifiers":7415},"Akhavan, 2013, De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients, Cancer Discov., 3, 534, 10.1158\u002F2159-8290.CD-12-0502",{"doi":7416},"10.1158\u002F2159-8290.CD-12-0502",{"id":26,"text":7418,"url":26,"identifiers":7419},"Najar, 2013, EGFR antisense oligonucleotides encapsulated with nanoparticles decrease EGFR, MAPK1 and STAT5 expression in a human colon cancer cell line, Asian Pac J Cancer Prev., 14, 495, 10.7314\u002Fapjcp.2013.14.1.495",{"doi":7420},"10.7314\u002Fapjcp.2013.14.1.495",{"id":26,"text":7422,"url":26,"identifiers":7423},"Jiang, 2016, Eradication of acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles, Cancer Res., 76, 4470, 10.1158\u002F0008-5472.CAN-15-2949",{"doi":7424},"10.1158\u002F0008-5472.CAN-15-2949",{"id":26,"text":7426,"url":26,"identifiers":7427},"Théry, 2002, Exosomes: composition, biogenesis and function, Nat Rev Immunol., 2, 569, 10.1038\u002Fnri855",{"doi":7428},"10.1038\u002Fnri855",{"id":26,"text":7430,"url":26,"identifiers":7431},"Zhang, 2018, Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation, Nat Cell Biol., 20, 332, 10.1038\u002Fs41556-018-0040-4",{"doi":7432},"10.1038\u002Fs41556-018-0040-4",{"id":7434,"createTime":7435,"updateTime":7435,"relativeEntities":7436,"slug":7437,"properties":7438,"entityType":772,"verifyStatus":25,"verifyTime":7453,"verifyNote":773,"syncStatus":28,"languages":7454,"translateLanguages":26,"viewCount":36,"primaryUrl":7455,"fullTextUrl":26,"authors":7456,"publicationType":843,"publisherRelationship":7493,"citationCount":7527,"citationInfo":7528,"publishDate":26,"publishYear":26,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":7530,"isForceReanalyzing":1390},"eea8e833-2b9e-4ffd-aa35-9694494837ae","2024-10-10T11:01:28.346+00:00",[],"Targeting-Oncogenic-Mutant-p53-for-Cancer-Therapy",{"mag":7439,"keywords":7441,"pmc":7442,"openalex":7444,"abstract":7446,"title":7447,"pm":7449,"doi":7451},{"VOID":7440},"2210624024",{},{"VOID":7443},"4685147",{"VOID":7445},"W2210624024",{},{"EN":7448},"Targeting Oncogenic Mutant p53 for Cancer Therapy",{"VOID":7450},"26732534",{"VOID":7452},"10.3389\u002Ffonc.2015.00288","2024-10-10T11:01:28.345+00:00",[102],"http:\u002F\u002Fjournal.frontiersin.org\u002FArticle\u002F10.3389\u002Ffonc.2015.00288\u002Fabstract",[7457,7478],{"id":7458,"sortIndex":115,"researcher":26,"roles":7459,"affiliations":7460,"properties":7471},"0e3fb55b-4593-4c50-8ca9-ec2547495312",[],[7461],{"id":7462,"sortIndex":36,"affiliation":7463,"properties":26},"a7ec5d9e-8058-4ba1-ae48-5604b1581ede",{"id":7464,"createTime":7465,"updateTime":7465,"relativeEntities":7466,"slug":7467,"properties":7468,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"38ac45dc-5494-4d36-acac-80a5e1cff65b","2024-10-10T11:01:28.364+00:00",[],"Department-of-Cancer-Biology-University-of-Kansas-Medical-Center-USA",{"title":7469},{"EN":7470},"Department of Cancer Biology, University of Kansas Medical Center, USA",{"openalex":7472,"orcid":7474,"title":7476},{"VOID":7473},"A5043198099",{"VOID":7475},"https:\u002F\u002Forcid.org\u002F0000-0001-7249-7958",{"EN":7477},"Tomoo Iwakuma",{"id":7479,"sortIndex":36,"researcher":26,"roles":7480,"affiliations":7481,"properties":7488},"094547aa-6032-4a2d-90b4-ca53ab7c940a",[],[7482],{"id":7483,"sortIndex":36,"affiliation":7484,"properties":26},"7ab12211-f769-41d4-be49-8eb6e64e20ba",{"id":7464,"createTime":7465,"updateTime":7465,"relativeEntities":7485,"slug":7467,"properties":7486,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":7487},{"EN":7470},{"openalex":7489,"title":7491},{"VOID":7490},"A5049433901",{"EN":7492},"Alejandro Parrales",{"url":26,"publisher":7494,"properties":7524},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":7495,"slug":663,"properties":7496,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":7502,"manageAffiliations":7503,"indexDatabases":7504,"url":742,"thumbnailPath":26,"statistic":7519,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"country":7497,"issn":7498,"introduce":7499,"eissn":7500,"title":7501},{"VOID":666},{"VOID":668},{"EN":670},{"VOID":668},{"EN":673},[],[],[7505,7512],{"id":704,"indexDatabase":7506,"url":719,"indexYears":26,"academicFieldIds":7511,"indexDatabaseRanking":26},{"id":706,"createTime":707,"updateTime":708,"relativeEntities":7507,"label":7508,"description":7509,"key":715,"publicationTags":7510,"standard":26},[],{"EN":711,"VI":711},{"VI":713,"EN":714},[717,718],[721],{"id":723,"indexDatabase":7513,"url":736,"indexYears":737,"academicFieldIds":7518,"indexDatabaseRanking":741},{"id":725,"createTime":726,"updateTime":727,"relativeEntities":7514,"label":7515,"description":7516,"key":733,"publicationTags":7517,"standard":26},[],{"EN":730,"VI":730},{"EN":730,"VI":732},[735],[739,740],{"impactFactor":36,"impactFactorByYear":7520,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":115,"totalPublicationByYear":7521,"totalCitation":158,"totalCitationByYear":7522,"totalCitationPerPublication":158,"totalCitationPerPublicationByYear":7523,"hindexLast5Year":115,"hindex":115},{},{"2021":115},{"2021":158},{"2021":158},{"volume":7525},{"VOID":7526},"5",290,{"total":7527,"publishYear":26,"statisticByYear":7529},{"2016":53,"2017":255,"2018":204,"2019":397,"2020":397,"2021":159,"2022":159,"2023":255,"2024":242},[7531,7535,7539,7543,7547,7551,7555,7559,7563,7567,7571,7575,7578,7582,7586,7590,7594,7598,7602,7606,7610,7614,7618,7622,7626,7630,7634,7638,7642,7646,7650,7654,7658,7662,7666,7670,7674,7678,7682,7686,7690,7694,7698,7702,7705,7709,7713,7717,7721,7725,7729,7733,7737,7741,7745,7749,7753,7757,7761,7765,7769,7773,7777,7781,7785,7789,7792,7795,7799,7803,7807,7811,7815,7819,7823,7827,7831,7835,7839,7843,7847,7851,7855,7859,7863,7867,7871,7875,7879,7883,7887,7891,7895,7899,7903,7907,7911,7915,7919,7923,7927,7931,7935,7939,7943,7947,7951,7955,7959,7963,7967,7971,7975,7979,7983,7986,7990,7994,7998,8002,8006,8009,8013,8017,8021,8025,8029,8033,8037,8041,8045,8049],{"id":26,"text":7532,"url":26,"identifiers":7533},"Lane, 2010, p53 Research: the past thirty years and the next thirty years, Cold Spring Harb Perspect Biol, 2, a000893, 10.1101\u002F­cshperspect.a000893",{"doi":7534},"10.1101\u002F­cshperspect.a000893",{"id":26,"text":7536,"url":26,"identifiers":7537},"Levav-Cohen, 2014, The p53-Mdm2 loop: a critical juncture of stress response, Subcell Biochem, 85, 161, 10.1007\u002F978-94-017-9211-0_9",{"doi":7538},"10.1007\u002F978-94-017-9211-0_9",{"id":26,"text":7540,"url":26,"identifiers":7541},"Vaseva, 2009, The mitochondrial p53 pathway, Biochim Biophys Acta, 1787, 414, 10.1016\u002Fj.bbabio.2008.10.005",{"doi":7542},"10.1016\u002Fj.bbabio.2008.10.005",{"id":26,"text":7544,"url":26,"identifiers":7545},"Pant, 2014, Limiting the power of p53 through the ubiquitin proteasome pathway, Genes Dev, 28, 1739, 10.1101\u002Fgad.247452.114",{"doi":7546},"10.1101\u002Fgad.247452.114",{"id":26,"text":7548,"url":26,"identifiers":7549},"Muller, 2013, p53 mutations in cancer, Nat Cell Biol, 15, 2, 10.1038\u002Fncb2641",{"doi":7550},"10.1038\u002Fncb2641",{"id":26,"text":7552,"url":26,"identifiers":7553},"Rivlin, 2011, Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis, Genes Cancer, 2, 466, 10.1177\u002F1947601911408889",{"doi":7554},"10.1177\u002F1947601911408889",{"id":26,"text":7556,"url":26,"identifiers":7557},"Rivlin, 2015, p53 orchestrates between normal differentiation and cancer, Semin Cancer Biol, 32, 10, 10.1016\u002Fj.semcancer.2013.12.006",{"doi":7558},"10.1016\u002Fj.semcancer.2013.12.006",{"id":26,"text":7560,"url":26,"identifiers":7561},"Joerger, 2008, Structural biology of the tumor suppressor p53, Annu Rev Biochem, 77, 557, 10.1146\u002Fannurev.biochem.77.060806.091238",{"doi":7562},"10.1146\u002Fannurev.biochem.77.060806.091238",{"id":26,"text":7564,"url":26,"identifiers":7565},"Goldstein, 2011, Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies, Cancer Gene Ther, 18, 2, 10.1038\u002Fcgt.2010.63",{"doi":7566},"10.1038\u002Fcgt.2010.63",{"id":26,"text":7568,"url":26,"identifiers":7569},"Terzian, 2008, The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss, Genes Dev, 22, 1337, 10.1101\u002Fgad.1662908",{"doi":7570},"10.1101\u002Fgad.1662908",{"id":26,"text":7572,"url":26,"identifiers":7573},"Cavenee, 1991, Molecular genetics of human cancer predisposition and progression, Mutat Res, 247, 199, 10.1016\u002F0027-5107(91)90015-G",{"doi":7574},"10.1016\u002F0027-5107(91)90015-G",{"id":26,"text":7576,"url":26,"identifiers":7577},"Gonzalez, 1995, Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck, Clin Cancer Res, 1, 1043",{},{"id":26,"text":7579,"url":26,"identifiers":7580},"Alexandrova, 2015, Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment, Nature, 523, 352, 10.1038\u002Fnature14430",{"doi":7581},"10.1038\u002Fnature14430",{"id":26,"text":7583,"url":26,"identifiers":7584},"Masciarelli, 2014, Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells, Oncogene, 33, 1601, 10.1038\u002Fonc.2013.106",{"doi":7585},"10.1038\u002Fonc.2013.106",{"id":26,"text":7587,"url":26,"identifiers":7588},"Weisz, 2007, Transcription regulation by mutant p53, Oncogene, 26, 2202, 10.1038\u002Fsj.onc.1210294",{"doi":7589},"10.1038\u002Fsj.onc.1210294",{"id":26,"text":7591,"url":26,"identifiers":7592},"Freed-Pastor, 2012, Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway, Cell, 148, 244, 10.1016\u002Fj.cell.2011.12.017",{"doi":7593},"10.1016\u002Fj.cell.2011.12.017",{"id":26,"text":7595,"url":26,"identifiers":7596},"Foster, 1999, Pharmacological rescue of mutant p53 conformation and function, Science, 286, 2507, 10.1126\u002Fscience.286.5449.2507",{"doi":7597},"10.1126\u002Fscience.286.5449.2507",{"id":26,"text":7599,"url":26,"identifiers":7600},"Zhang, 1994, A temperature-sensitive mutant of human p53, EMBO J, 13, 2535, 10.1002\u002Fj.1460-2075.1994.tb06543.x",{"doi":7601},"10.1002\u002Fj.1460-2075.1994.tb06543.x",{"id":26,"text":7603,"url":26,"identifiers":7604},"Selivanova, 1998, Reactivation of mutant p53: a new strategy for cancer therapy, Semin Cancer Biol, 8, 369, 10.1006\u002Fscbi.1998.0099",{"doi":7605},"10.1006\u002Fscbi.1998.0099",{"id":26,"text":7607,"url":26,"identifiers":7608},"Friedler, 2002, A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants, Proc Natl Acad Sci U S A, 99, 937, 10.1073\u002Fpnas.241629998",{"doi":7609},"10.1073\u002Fpnas.241629998",{"id":26,"text":7611,"url":26,"identifiers":7612},"Selivanova, 1997, Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain, Nat Med, 3, 632, 10.1038\u002Fnm0697-632",{"doi":7613},"10.1038\u002Fnm0697-632",{"id":26,"text":7615,"url":26,"identifiers":7616},"Nikolova, 2000, Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations, EMBO J, 19, 370, 10.1093\u002Femboj\u002F19.3.370",{"doi":7617},"10.1093\u002Femboj\u002F19.3.370",{"id":26,"text":7619,"url":26,"identifiers":7620},"Bykov, 2002, Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound, Nat Med, 8, 282, 10.1038\u002Fnm0302-282",{"doi":7621},"10.1038\u002Fnm0302-282",{"id":26,"text":7623,"url":26,"identifiers":7624},"Liu, 2001, Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein, J Mol Biol, 313, 711, 10.1006\u002Fjmbi.2001.5082",{"doi":7625},"10.1006\u002Fjmbi.2001.5082",{"id":26,"text":7627,"url":26,"identifiers":7628},"Tang, 2007, CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice, J Clin Invest, 117, 3753, 10.1172\u002FJCI32481",{"doi":7629},"10.1172\u002FJCI32481",{"id":26,"text":7631,"url":26,"identifiers":7632},"Tanner, 2004, CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity, J Negat Results Biomed, 3, 5, 10.1186\u002F1477-5751-3-5",{"doi":7633},"10.1186\u002F1477-5751-3-5",{"id":26,"text":7635,"url":26,"identifiers":7636},"Rippin, 2002, Characterization of the p53-rescue drug CP-31398 in vitro and in living cells, Oncogene, 21, 2119, 10.1038\u002Fsj.onc.1205362",{"doi":7637},"10.1038\u002Fsj.onc.1205362",{"id":26,"text":7639,"url":26,"identifiers":7640},"Zache, 2008, Mutant p53 targeting by the low molecular weight compound STIMA-1, Mol Oncol, 2, 70, 10.1016\u002Fj.molonc.2008.02.004",{"doi":7641},"10.1016\u002Fj.molonc.2008.02.004",{"id":26,"text":7643,"url":26,"identifiers":7644},"Lambert, 2009, PRIMA-1 reactivates mutant p53 by covalent binding to the core domain, Cancer Cell, 15, 376, 10.1016\u002Fj.ccr.2009.03.003",{"doi":7645},"10.1016\u002Fj.ccr.2009.03.003",{"id":26,"text":7647,"url":26,"identifiers":7648},"Lambert, 2010, Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis, Oncogene, 29, 1329, 10.1038\u002Fonc.2009.425",{"doi":7649},"10.1038\u002Fonc.2009.425",{"id":26,"text":7651,"url":26,"identifiers":7652},"Bykov, 2005, Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs, J Biol Chem, 280, 30384, 10.1074\u002Fjbc.M501664200",{"doi":7653},"10.1074\u002Fjbc.M501664200",{"id":26,"text":7655,"url":26,"identifiers":7656},"Zhao, 2010, Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA, Cell Cycle, 9, 1847, 10.4161\u002Fcc.9.9.11545",{"doi":7657},"10.4161\u002Fcc.9.9.11545",{"id":26,"text":7659,"url":26,"identifiers":7660},"Burmakin, 2013, Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro, Clin Cancer Res, 19, 5092, 10.1158\u002F1078-0432.CCR-12-2211",{"doi":7661},"10.1158\u002F1078-0432.CCR-12-2211",{"id":26,"text":7663,"url":26,"identifiers":7664},"Blanden, 2015, Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore, Mol Pharmacol, 87, 825, 10.1124\u002Fmol.114.097550",{"doi":7665},"10.1124\u002Fmol.114.097550",{"id":26,"text":7667,"url":26,"identifiers":7668},"Yu, 2012, Allele-specific p53 mutant reactivation, Cancer Cell, 21, 614, 10.1016\u002Fj.ccr.2012.03.042",{"doi":7669},"10.1016\u002Fj.ccr.2012.03.042",{"id":26,"text":7671,"url":26,"identifiers":7672},"Yu, 2014, Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism, Oncotarget, 5, 8879, 10.18632\u002Foncotarget.2432",{"doi":7673},"10.18632\u002Foncotarget.2432",{"id":26,"text":7675,"url":26,"identifiers":7676},"Hiraki, 2015, Small-molecule reactivation of mutant p53 to wild-type-like p53 through the p53-Hsp40 regulatory axis, Chem Biol, 22, 1206, 10.1016\u002Fj.chembiol.2015.07.016",{"doi":7677},"10.1016\u002Fj.chembiol.2015.07.016",{"id":26,"text":7679,"url":26,"identifiers":7680},"Liu, 2013, Small molecule induced reactivation of mutant p53 in cancer cells, Nucleic Acids Res, 41, 6034, 10.1093\u002Fnar\u002Fgkt305",{"doi":7681},"10.1093\u002Fnar\u002Fgkt305",{"id":26,"text":7683,"url":26,"identifiers":7684},"Wassman, 2013, Computational identification of a transiently open L1\u002FS3 pocket for reactivation of mutant p53, Nat Commun, 4, 1407, 10.1038\u002Fncomms2361",{"doi":7685},"10.1038\u002Fncomms2361",{"id":26,"text":7687,"url":26,"identifiers":7688},"Weinmann, 2008, A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L\u002FTRAIL-induced apoptosis, Cell Death Differ, 15, 718, 10.1038\u002Fsj.cdd.4402301",{"doi":7689},"10.1038\u002Fsj.cdd.4402301",{"id":26,"text":7691,"url":26,"identifiers":7692},"Demma, 2010, SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53, J Biol Chem, 285, 10198, 10.1074\u002Fjbc.M109.083469",{"doi":7693},"10.1074\u002Fjbc.M109.083469",{"id":26,"text":7695,"url":26,"identifiers":7696},"Pluquet, 2003, Activation of p53 by the cytoprotective aminothiol WR1065: DNA-damage-independent pathway and redox-dependent modulation of p53 DNA-binding activity, Biochem Pharmacol, 65, 1129, 10.1016\u002FS0006-2952(02)01655-6",{"doi":7697},"10.1016\u002FS0006-2952(02)01655-6",{"id":26,"text":7699,"url":26,"identifiers":7700},"Pluquet, 2003, The cytoprotective aminothiol WR1065 activates p53 through a non-genotoxic signaling pathway involving c-Jun N-terminal kinase, J Biol Chem, 278, 11879, 10.1074\u002Fjbc.M207396200",{"doi":7701},"10.1074\u002Fjbc.M207396200",{"id":26,"text":7703,"url":26,"identifiers":7704},"Shen, 2001, Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs, J Pharmacol Exp Ther, 297, 1067",{},{"id":26,"text":7706,"url":26,"identifiers":7707},"North, 2002, Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1, Mol Carcinog, 33, 181, 10.1002\u002Fmc.10038",{"doi":7708},"10.1002\u002Fmc.10038",{"id":26,"text":7710,"url":26,"identifiers":7711},"Wischhusen, 2003, CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death, Oncogene, 22, 8233, 10.1038\u002Fsj.onc.1207198",{"doi":7712},"10.1038\u002Fsj.onc.1207198",{"id":26,"text":7714,"url":26,"identifiers":7715},"Rao, 2013, Chemopreventive effects of the p53-modulating agents CP-31398 and Prima-1 in tobacco carcinogen-induced lung tumorigenesis in A\u002FJ mice, Neoplasia, 15, 1018, 10.1593\u002Fneo.131256",{"doi":7716},"10.1593\u002Fneo.131256",{"id":26,"text":7718,"url":26,"identifiers":7719},"Zandi, 2011, PRIMA-1Met\u002FAPR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53, Clin Cancer Res, 17, 2830, 10.1158\u002F1078-0432.CCR-10-3168",{"doi":7720},"10.1158\u002F1078-0432.CCR-10-3168",{"id":26,"text":7722,"url":26,"identifiers":7723},"Liang, 2009, PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein, Int J Oncol, 35, 1015, 10.3892\u002Fijo_00000416",{"doi":7724},"10.3892\u002Fijo_00000416",{"id":26,"text":7726,"url":26,"identifiers":7727},"Zache, 2008, PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53, Cell Oncol, 30, 411, 10.3233\u002FCLO-2008-0440",{"doi":7728},"10.3233\u002FCLO-2008-0440",{"id":26,"text":7730,"url":26,"identifiers":7731},"Bykov, 2014, Mutant p53 reactivation by small molecules makes its way to the clinic, FEBS Lett, 588, 2622, 10.1016\u002Fj.febslet.2014.04.017",{"doi":7732},"10.1016\u002Fj.febslet.2014.04.017",{"id":26,"text":7734,"url":26,"identifiers":7735},"Duffy, 2014, p53 as a target for the treatment of cancer, Cancer Treat Rev, 40, 1153, 10.1016\u002Fj.ctrv.2014.10.004",{"doi":7736},"10.1016\u002Fj.ctrv.2014.10.004",{"id":26,"text":7738,"url":26,"identifiers":7739},"Saha, 2014, Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents, Br J Cancer, 110, 2224, 10.1038\u002Fbjc.2014.164",{"doi":7740},"10.1038\u002Fbjc.2014.164",{"id":26,"text":7742,"url":26,"identifiers":7743},"Rivera, 1999, Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines: differential accumulation and metabolism, Biochem Pharmacol, 57, 1283, 10.1016\u002FS0006-2952(99)00046-5",{"doi":7744},"10.1016\u002FS0006-2952(99)00046-5",{"id":26,"text":7746,"url":26,"identifiers":7747},"Nieves-Neira, 1999, DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells, Mol Pharmacol, 56, 478, 10.1124\u002Fmol.56.3.478",{"doi":7748},"10.1124\u002Fmol.56.3.478",{"id":26,"text":7750,"url":26,"identifiers":7751},"Issaeva, 2004, Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors, Nat Med, 10, 1321, 10.1038\u002Fnm1146",{"doi":7752},"10.1038\u002Fnm1146",{"id":26,"text":7754,"url":26,"identifiers":7755},"Grinkevich, 2009, Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis, Cancer Cell, 15, 441, 10.1016\u002Fj.ccr.2009.03.021",{"doi":7756},"10.1016\u002Fj.ccr.2009.03.021",{"id":26,"text":7758,"url":26,"identifiers":7759},"Margalit, 2012, Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function, Int J cancer, 131, E562, 10.1002\u002Fijc.26441",{"doi":7760},"10.1002\u002Fijc.26441",{"id":26,"text":7762,"url":26,"identifiers":7763},"Pintus, 2013, The substitutions G245C and G245D in the Zn(2+)-binding pocket of the p53 protein result in differences of conformational flexibility of the DNA-binding domain, J Biomol Struct Dyn, 31, 78, 10.1080\u002F07391102.2012.691364",{"doi":7764},"10.1080\u002F07391102.2012.691364",{"id":26,"text":7766,"url":26,"identifiers":7767},"Puca, 2011, Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs, Cell Cycle, 10, 1679, 10.4161\u002Fcc.10.10.15642",{"doi":7768},"10.4161\u002Fcc.10.10.15642",{"id":26,"text":7770,"url":26,"identifiers":7771},"Kung, 2004, Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway, Cancer Cell, 6, 33, 10.1016\u002Fj.ccr.2004.06.009",{"doi":7772},"10.1016\u002Fj.ccr.2004.06.009",{"id":26,"text":7774,"url":26,"identifiers":7775},"Staab, 2007, Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells, BMC Cancer, 7, 213, 10.1186\u002F1471-2407-7-213",{"doi":7776},"10.1186\u002F1471-2407-7-213",{"id":26,"text":7778,"url":26,"identifiers":7779},"Kessler, 2010, HIF-1alpha inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression, BMC Cancer, 10, 605, 10.1186\u002F1471-2407-10-605",{"doi":7780},"10.1186\u002F1471-2407-10-605",{"id":26,"text":7782,"url":26,"identifiers":7783},"Boeckler, 2008, Targeted rescue of a destabilized mutant of p53 by an in silico screened drug, Proc Natl Acad Sci U S A, 105, 10360, 10.1073\u002Fpnas.0805326105",{"doi":7784},"10.1073\u002Fpnas.0805326105",{"id":26,"text":7786,"url":26,"identifiers":7787},"Lukashchuk, 2007, Ubiquitination and degradation of mutant p53, Mol Cell Biol, 27, 8284, 10.1128\u002FMCB.00050-07",{"doi":7788},"10.1128\u002FMCB.00050-07",{"id":26,"text":7790,"url":26,"identifiers":7791},"Blagosklonny, 1995, Geldanamycin selectively destabilizes and conformationally alters mutated p53, Oncogene, 11, 933",{},{"id":26,"text":7793,"url":26,"identifiers":7794},"Egorin, 1998, Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations, Cancer Res, 58, 2385",{},{"id":26,"text":7796,"url":26,"identifiers":7797},"Wang, 2003, Phosphorylation and hsp90 binding mediate heat shock stabilization of p53, J Biol Chem, 278, 2066, 10.1074\u002Fjbc.M206697200",{"doi":7798},"10.1074\u002Fjbc.M206697200",{"id":26,"text":7800,"url":26,"identifiers":7801},"Li, 2011, Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells, Mol Cancer Res, 9, 577, 10.1158\u002F1541-7786.MCR-10-0534",{"doi":7802},"10.1158\u002F1541-7786.MCR-10-0534",{"id":26,"text":7804,"url":26,"identifiers":7805},"Blagosklonny, 2005, Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance, Cell Cycle, 4, 1693, 10.4161\u002Fcc.4.12.2259",{"doi":7806},"10.4161\u002Fcc.4.12.2259",{"id":26,"text":7808,"url":26,"identifiers":7809},"Li, 2011, SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis, Cell Death Differ, 18, 1904, 10.1038\u002Fcdd.2011.71",{"doi":7810},"10.1038\u002Fcdd.2011.71",{"id":26,"text":7812,"url":26,"identifiers":7813},"Marks, 2007, Discovery and development of SAHA as an anticancer agent, Oncogene, 26, 1351, 10.1038\u002Fsj.onc.1210204",{"doi":7814},"10.1038\u002Fsj.onc.1210204",{"id":26,"text":7816,"url":26,"identifiers":7817},"Yan, 2011, Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression, J Biol Chem, 286, 17478, 10.1074\u002Fjbc.M111.231639",{"doi":7818},"10.1074\u002Fjbc.M111.231639",{"id":26,"text":7820,"url":26,"identifiers":7821},"Yan, 2014, Arsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligase, PLoS One, 9, e103497, 10.1371\u002Fjournal.pone.0103497",{"doi":7822},"10.1371\u002Fjournal.pone.0103497",{"id":26,"text":7824,"url":26,"identifiers":7825},"Wang, 2011, Gambogic acid-induced degradation of mutant p53 is mediated by proteasome and related to CHIP, J Cell Biochem, 112, 509, 10.1002\u002Fjcb.22941",{"doi":7826},"10.1002\u002Fjcb.22941",{"id":26,"text":7828,"url":26,"identifiers":7829},"Vakifahmetoglu-Norberg, 2013, Chaperone-mediated autophagy degrades mutant p53, Genes Dev, 27, 1718, 10.1101\u002Fgad.220897.113",{"doi":7830},"10.1101\u002Fgad.220897.113",{"id":26,"text":7832,"url":26,"identifiers":7833},"Vakifahmetoglu-Norberg, 2013, A degradative detour for mutant TP53, Autophagy, 9, 2158, 10.4161\u002Fauto.26338",{"doi":7834},"10.4161\u002Fauto.26338",{"id":26,"text":7836,"url":26,"identifiers":7837},"Yi, 2013, Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells, Oncotarget, 4, 984, 10.18632\u002Foncotarget.1070",{"doi":7838},"10.18632\u002Foncotarget.1070",{"id":26,"text":7840,"url":26,"identifiers":7841},"Zhang, 2015, Small-molecule NSC59984 restores p53 pathway signaling and antitumor effects against colorectal cancer via p73 activation and degradation of mutant p53, Cancer Res, 75, 3842, 10.1158\u002F0008-5472.CAN-13-1079",{"doi":7842},"10.1158\u002F0008-5472.CAN-13-1079",{"id":26,"text":7844,"url":26,"identifiers":7845},"Paranjpe, 2013, Degradation of NF-kappaB, p53 and other regulatory redox-sensitive proteins by thiol-conjugating and -nitrosylating drugs in human tumor cells, Carcinogenesis, 34, 990, 10.1093\u002Fcarcin\u002Fbgt032",{"doi":7846},"10.1093\u002Fcarcin\u002Fbgt032",{"id":26,"text":7848,"url":26,"identifiers":7849},"Ramalingam, 2015, A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1), Ann Oncol, 26, 1741, 10.1093\u002Fannonc\u002Fmdv220",{"doi":7850},"10.1093\u002Fannonc\u002Fmdv220",{"id":26,"text":7852,"url":26,"identifiers":7853},"Goyal, 2015, A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma, Invest New Drugs, 33, 128, 10.1007\u002Fs10637-014-0164-8",{"doi":7854},"10.1007\u002Fs10637-014-0164-8",{"id":26,"text":7856,"url":26,"identifiers":7857},"Jhaveri, 2014, A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer, Clin Breast Cancer, 14, 154, 10.1016\u002Fj.clbc.2013.12.012",{"doi":7858},"10.1016\u002Fj.clbc.2013.12.012",{"id":26,"text":7860,"url":26,"identifiers":7861},"Yan, 2013, Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8, Oncogene, 32, 599, 10.1038\u002Fonc.2012.81",{"doi":7862},"10.1038\u002Fonc.2012.81",{"id":26,"text":7864,"url":26,"identifiers":7865},"Beauchamp, 2012, A new era for an ancient drug: arsenic trioxide and Hedgehog signaling, Vitam Horm, 88, 333, 10.1016\u002FB978-0-12-394622-5.00015-8",{"doi":7866},"10.1016\u002FB978-0-12-394622-5.00015-8",{"id":26,"text":7868,"url":26,"identifiers":7869},"Jiang, 2010, Cooperation of tumor-derived HBx mutants and p53-249(ser) mutant in regulating cell proliferation, anchorage-independent growth and aneuploidy in a telomerase-immortalized normal human hepatocyte-derived cell line, Int J Cancer, 127, 1011, 10.1002\u002Fijc.25118",{"doi":7870},"10.1002\u002Fijc.25118",{"id":26,"text":7872,"url":26,"identifiers":7873},"Hughes, 2011, Arsenic exposure and toxicology: a historical perspective, Toxicol Sci, 123, 305, 10.1093\u002Ftoxsci\u002Fkfr184",{"doi":7874},"10.1093\u002Ftoxsci\u002Fkfr184",{"id":26,"text":7876,"url":26,"identifiers":7877},"Gu, 2008, Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells, Mol Cancer Ther, 7, 3298, 10.1158\u002F1535-7163.MCT-08-0212",{"doi":7878},"10.1158\u002F1535-7163.MCT-08-0212",{"id":26,"text":7880,"url":26,"identifiers":7881},"Liu, 2011, Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13, Cell, 147, 223, 10.1016\u002Fj.cell.2011.08.037",{"doi":7882},"10.1016\u002Fj.cell.2011.08.037",{"id":26,"text":7884,"url":26,"identifiers":7885},"Yuan, 2010, USP10 regulates p53 localization and stability by deubiquitinating p53, Cell, 140, 384, 10.1016\u002Fj.cell.2009.12.032",{"doi":7886},"10.1016\u002Fj.cell.2009.12.032",{"id":26,"text":7888,"url":26,"identifiers":7889},"Kong, 2010, A boronic acid chalcone analog of combretastatin A-4 as a potent anti-proliferation agent, Bioorg Med Chem, 18, 971, 10.1016\u002Fj.bmc.2009.11.003",{"doi":7890},"10.1016\u002Fj.bmc.2009.11.003",{"id":26,"text":7892,"url":26,"identifiers":7893},"Kona, 2011, Disulfiram, and disulfiram derivatives as novel potential anticancer drugs targeting the ubiquitin-proteasome system in both preclinical and clinical studies, Curr Cancer Drug Targets, 11, 338, 10.2174\u002F156800911794519798",{"doi":7894},"10.2174\u002F156800911794519798",{"id":26,"text":7896,"url":26,"identifiers":7897},"Nechushtan, 2015, A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer, Oncologist, 20, 366, 10.1634\u002Ftheoncologist.2014-0424",{"doi":7898},"10.1634\u002Ftheoncologist.2014-0424",{"id":26,"text":7900,"url":26,"identifiers":7901},"Petersen, 1992, The pharmacology and toxicology of disulfiram and its metabolites, Acta Psychiatr Scand Suppl, 369, 7, 10.1111\u002Fj.1600-0447.1992.tb03309.x",{"doi":7902},"10.1111\u002Fj.1600-0447.1992.tb03309.x",{"id":26,"text":7904,"url":26,"identifiers":7905},"Mathieu, 2015, Effects of pesticide chemicals on the activity of metabolic enzymes: focus on thiocarbamates, Expert Opin Drug Metab Toxicol, 11, 81, 10.1517\u002F17425255.2015.975691",{"doi":7906},"10.1517\u002F17425255.2015.975691",{"id":26,"text":7908,"url":26,"identifiers":7909},"Davies, 2001, Degradation of oxidized proteins by the 20S proteasome, Biochimie, 83, 301, 10.1016\u002FS0300-9084(01)01250-0",{"doi":7910},"10.1016\u002FS0300-9084(01)01250-0",{"id":26,"text":7912,"url":26,"identifiers":7913},"Velu, 2007, Human p53 is inhibited by glutathionylation of cysteines present in the proximal DNA-binding domain during oxidative stress, Biochemistry, 46, 7765, 10.1021\u002Fbi700425y",{"doi":7914},"10.1021\u002Fbi700425y",{"id":26,"text":7916,"url":26,"identifiers":7917},"Yusuf, 2010, Cys-141 glutathionylation of human p53: studies using specific polyclonal antibodies in cancer samples and cell lines, Free Radic Biol Med, 49, 908, 10.1016\u002Fj.freeradbiomed.2010.06.020",{"doi":7918},"10.1016\u002Fj.freeradbiomed.2010.06.020",{"id":26,"text":7920,"url":26,"identifiers":7921},"Olivier, 2010, TP53 mutations in human cancers: ­origins, consequences, and clinical use, Cold Spring Harb Perspect Biol, 2, a001008, 10.1101\u002Fcshperspect.a001008",{"doi":7922},"10.1101\u002Fcshperspect.a001008",{"id":26,"text":7924,"url":26,"identifiers":7925},"Micale, 2014, Molecular analysis, pathogenic mechanisms, and readthrough therapy on a large cohort of Kabuki syndrome patients, Hum Mutat, 35, 841, 10.1002\u002Fhumu.22547",{"doi":7926},"10.1002\u002Fhumu.22547",{"id":26,"text":7928,"url":26,"identifiers":7929},"Floquet, 2011, Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides, Nucleic Acids Res, 39, 3350, 10.1093\u002Fnar\u002Fgkq1277",{"doi":7930},"10.1093\u002Fnar\u002Fgkq1277",{"id":26,"text":7932,"url":26,"identifiers":7933},"Martin, 2014, Identification and characterization of small molecules that inhibit nonsense-mediated RNA decay and suppress nonsense p53 mutations, Cancer Res, 74, 3104, 10.1158\u002F0008-5472.CAN-13-2235",{"doi":7934},"10.1158\u002F0008-5472.CAN-13-2235",{"id":26,"text":7936,"url":26,"identifiers":7937},"Kanasty, 2013, Delivery materials for siRNA therapeutics, Nat Mater, 12, 967, 10.1038\u002Fnmat3765",{"doi":7938},"10.1038\u002Fnmat3765",{"id":26,"text":7940,"url":26,"identifiers":7941},"Lim, 2009, Mutant p53 mediates survival of breast cancer cells, Br J Cancer, 101, 1606, 10.1038\u002Fsj.bjc.6605335",{"doi":7942},"10.1038\u002Fsj.bjc.6605335",{"id":26,"text":7944,"url":26,"identifiers":7945},"Hui, 2006, Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D, Oncogene, 25, 7305, 10.1038\u002Fsj.onc.1209735",{"doi":7946},"10.1038\u002Fsj.onc.1209735",{"id":26,"text":7948,"url":26,"identifiers":7949},"Zhu, 2011, RNA interference targeting mutant p53 inhibits growth and induces apoptosis in DU145 human prostate cancer cells, Med Oncol, 28, S381, 10.1007\u002Fs12032-010-9679-9",{"doi":7950},"10.1007\u002Fs12032-010-9679-9",{"id":26,"text":7952,"url":26,"identifiers":7953},"Zhu, 2013, Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells, World J Surg Oncol, 11, 22, 10.1186\u002F1477-7819-11-22",{"doi":7954},"10.1186\u002F1477-7819-11-22",{"id":26,"text":7956,"url":26,"identifiers":7957},"Martinez, 2002, Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways, Proc Natl Acad Sci U S A, 99, 14849, 10.1073\u002Fpnas.222406899",{"doi":7958},"10.1073\u002Fpnas.222406899",{"id":26,"text":7960,"url":26,"identifiers":7961},"Kravchenko, 2008, Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway, Proc Natl Acad Sci U S A, 105, 6302, 10.1073\u002Fpnas.0802091105",{"doi":7962},"10.1073\u002Fpnas.0802091105",{"id":26,"text":7964,"url":26,"identifiers":7965},"Shimoyama, 2011, Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers, Cancer Chemother Pharmacol, 67, 729, 10.1007\u002Fs00280-011-1583-2",{"doi":7966},"10.1007\u002Fs00280-011-1583-2",{"id":26,"text":7968,"url":26,"identifiers":7969},"Sorrentino, 2014, Metabolic control of YAP and TAZ by the mevalonate pathway, Nat Cell Biol, 16, 357, 10.1038\u002Fncb2936",{"doi":7970},"10.1038\u002Fncb2936",{"id":26,"text":7972,"url":26,"identifiers":7973},"Kaelin, 2005, The concept of synthetic lethality in the context of anticancer therapy, Nat Rev Cancer, 5, 689, 10.1038\u002Fnrc1691",{"doi":7974},"10.1038\u002Fnrc1691",{"id":26,"text":7976,"url":26,"identifiers":7977},"Wang, 1996, UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53, J Natl Cancer Inst, 88, 956, 10.1093\u002Fjnci\u002F88.14.956",{"doi":7978},"10.1093\u002Fjnci\u002F88.14.956",{"id":26,"text":7980,"url":26,"identifiers":7981},"Sur, 2009, A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53, Proc Natl Acad Sci U S A, 106, 3964, 10.1073\u002Fpnas.0813333106",{"doi":7982},"10.1073\u002Fpnas.0813333106",{"id":26,"text":7984,"url":26,"identifiers":7985},"Wang, 2001, Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator, Cancer Res, 61, 8211",{},{"id":26,"text":7987,"url":26,"identifiers":7988},"Reguart, 2014, Phase I\u002FII trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression, Lung Cancer, 84, 161, 10.1016\u002Fj.lungcan.2014.02.011",{"doi":7989},"10.1016\u002Fj.lungcan.2014.02.011",{"id":26,"text":7991,"url":26,"identifiers":7992},"Krug, 2015, Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial, Lancet Oncol, 16, 447, 10.1016\u002FS1470-2045(15)70056-2",{"doi":7993},"10.1016\u002FS1470-2045(15)70056-2",{"id":26,"text":7995,"url":26,"identifiers":7996},"Yoo, 2014, Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer, Invest New Drugs, 32, 271, 10.1007\u002Fs10637-013-9983-2",{"doi":7997},"10.1007\u002Fs10637-013-9983-2",{"id":26,"text":7999,"url":26,"identifiers":8000},"Yanada, 2013, Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia, Blood, 121, 3095, 10.1182\u002Fblood-2012-11-466862",{"doi":8001},"10.1182\u002Fblood-2012-11-466862",{"id":26,"text":8003,"url":26,"identifiers":8004},"Efficace, 2014, Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes, J Clin Oncol, 32, 3406, 10.1200\u002FJCO.2014.55.3453",{"doi":8005},"10.1200\u002FJCO.2014.55.3453",{"id":26,"text":8007,"url":26,"identifiers":8008},"Qu, 2011, [Multicenter phase II clinical trial of arsenic trioxide injection in the treatment of primary hepatocarcinoma], Zhonghua Zhong Liu Za Zhi, 33, 697",{},{"id":26,"text":8010,"url":26,"identifiers":8011},"Verma, 1990, A randomized phase II study of cisplatin alone versus cisplatin plus disulfiram, Am J Clin Oncol, 13, 119, 10.1097\u002F00000421-199004000-00007",{"doi":8012},"10.1097\u002F00000421-199004000-00007",{"id":26,"text":8014,"url":26,"identifiers":8015},"Karlsson, 2000, Biosensor analysis of drug-target interactions: direct and competitive binding assays for investigation of interactions between thrombin and thrombin inhibitors, Anal Biochem, 278, 1, 10.1006\u002Fabio.1999.4406",{"doi":8016},"10.1006\u002Fabio.1999.4406",{"id":26,"text":8018,"url":26,"identifiers":8019},"Lamos, 2006, Mixed isotope photoaffinity reagents for identification of small-molecule targets by mass spectrometry, Angew Chem Int Ed Engl, 45, 4329, 10.1002\u002Fanie.200600743",{"doi":8020},"10.1002\u002Fanie.200600743",{"id":26,"text":8022,"url":26,"identifiers":8023},"Lomenick, 2009, Target identification using drug affinity responsive target stability (DARTS), Proc Natl Acad Sci U S A, 106, 21984, 10.1073\u002Fpnas.0910040106",{"doi":8024},"10.1073\u002Fpnas.0910040106",{"id":26,"text":8026,"url":26,"identifiers":8027},"Jafari, 2014, The cellular thermal shift assay for evaluating drug target interactions in cells, Nat Protoc, 9, 2100, 10.1038\u002Fnprot.2014.138",{"doi":8028},"10.1038\u002Fnprot.2014.138",{"id":26,"text":8030,"url":26,"identifiers":8031},"Lammens, 2010, Regular surveillance for Li-Fraumeni syndrome: advice, adherence and perceived benefits, Fam Cancer, 9, 647, 10.1007\u002Fs10689-010-9368-z",{"doi":8032},"10.1007\u002Fs10689-010-9368-z",{"id":26,"text":8034,"url":26,"identifiers":8035},"Wang, 2010, Targeting p53 for novel anticancer therapy, Transl Oncol, 3, 1, 10.1593\u002Ftlo.09250",{"doi":8036},"10.1593\u002Ftlo.09250",{"id":26,"text":8038,"url":26,"identifiers":8039},"Khoo, 2014, Drugging the p53 pathway: understanding the route to clinical efficacy, Nat Rev Drug Discov, 13, 217, 10.1038\u002Fnrd4236",{"doi":8040},"10.1038\u002Fnrd4236",{"id":26,"text":8042,"url":26,"identifiers":8043},"Tongyang, 2015, [Synthetic lethal genes to mutant p53], Yi Chuan, 37, 321, 10.16288\u002Fj.yczz.14-277",{"doi":8044},"10.16288\u002Fj.yczz.14-277",{"id":26,"text":8046,"url":26,"identifiers":8047},"Shaheen, 2011, Synthetic lethality: exploiting the addiction of cancer to DNA repair, Blood, 117, 6074, 10.1182\u002Fblood-2011-01-313734",{"doi":8048},"10.1182\u002Fblood-2011-01-313734",{"id":26,"text":8050,"url":26,"identifiers":8051},"Wang, 2013, Identification of potential synthetic lethal genes to p53 using a computational biology approach, BMC Med Genomics, 6, 30, 10.1186\u002F1755-8794-6-30",{"doi":8052},"10.1186\u002F1755-8794-6-30"]